Phase 3, Randomized, Placebo Controlled, Double-blind, Multicenter, Stratified Study of CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients
Phase: PHASE3
Conditions: Covid-19
Sponsor: Corvus Pharmaceuticals, Inc.

Protocol Title: Phase 3, Randomized, Placebo Controlled, Double-blind, Multicenter, 
Stratified Study of CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care 
in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients 
Protocol Number: CPI-006-003 
NCT Number: NCT04734873 
Protocol Version 003 – 23 March 2021 
Protocol Version 002 – 11 January 2021 
Protocol Version 001 – 06 November 2020 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 1 of 114 
Version 003 
 
 
 
Protocol 
 
Protocol Title: 
Phase 3, Randomized, Placebo Controlled, Double-blind, 
Multicenter, Stratified Study of CPI-006 Plus Standard of 
Care Versus Placebo Plus Standard of Care in Mild to 
Moderately Symptomatic Hospitalized Covid-19 Patients 
Protocol Number: 
CPI-006-003 
Regulatory Agency 
Identifier Number(s): 
 
EudraCT: 2020‐005305‐54 
Compound Number: 
CPI-006 
Study Phase: 
3 
Sponsor Name: 
Corvus Pharmaceuticals 
Sponsor Address: 
863 Mitten Rd, Suite 102 
Burlingame, CA 94010, USA 
Version Number: 
003 
Date Final: 
23 March 2021 
 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 3 of 114 
Version 003 
INVESTIGATOR SIGNATURE PAGE 
Protocol Title: 
Phase 3, Randomized, Placebo Controlled, Double-blind, Multicenter, 
Stratified Study of CPI-006 Plus Standard of Care Versus Placebo Plus 
Standard of Care in Mild to Moderately Symptomatic Hospitalized 
Covid-19 Patients 
Protocol Number: CPI-006-003 
Version Number: 003 
 
 
 
I have read and understood the current version of the protocol (as listed above). I agree to 
conduct this trial in accordance with International Council for Harmonisation (ICH) Good 
Clinical Practice (GCP), all applicable regulatory requirements, and the general ethical 
principles outlined in the Declaration of Helsinki.  
I agree to ensure that no deviation from, or changes to the protocol will take place without 
prior agreement from Corvus Pharmaceuticals and documented approval from the 
Institutional Review Board (IRB)/Independent Ethics Committee (IEC), except where 
necessary to eliminate an immediate hazard(s) to the trial participants.  
I will ensure that all staff members under my supervision involved in the conduct of this 
study are informed about the protocol and protocol amendments, the investigational products, 
and their study-related duties and functions.  
I agree not to divulge to anyone, either during or after the termination of the study, any 
confidential information acquired regarding the investigational products and processes or 
methods of Corvus. 
 
 
 
 
Investigator Signatory 
Name: 
Title: 
 
Date 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 4 of 114 
Version 003 
TABLE OF CONTENTS 
Page 
1. 
Protocol Summary ............................................................................................ 12 
1.1. 
Synopsis ............................................................................................................ 12 
1.2. 
Schema ............................................................................................................. 22 
1.3. 
Schedule of Activities (SoA) ............................................................................ 22 
2. 
Introduction ...................................................................................................... 22 
2.1. 
Study Rationale ................................................................................................ 22 
2.2. 
Background ...................................................................................................... 23 
2.3. 
CPI-006 Nonclinical Evaluation ...................................................................... 25 
2.4. 
Summary of Clinical Experience with CPI-006 ............................................... 26 
2.4.1. 
Benefit/Risk Assessment .................................................................................. 27 
3. 
Objectives and Endpoints ................................................................................. 28 
4. 
Study Design .................................................................................................... 31 
4.1. 
Overall Design .................................................................................................. 31 
4.2. 
Scientific Rationale for Study Design .............................................................. 33 
4.3. 
Justification for Dose ........................................................................................ 33 
4.4. 
End of Study Definition ................................................................................... 36 
5. 
Study Population .............................................................................................. 36 
5.1. 
Inclusion Criteria .............................................................................................. 36 
5.2. 
Exclusion Criteria ............................................................................................. 37 
5.3. 
Lifestyle Considerations ................................................................................... 38 
5.3.1. 
Meals and Dietary Restrictions ........................................................................ 38 
5.3.2. 
Activity ............................................................................................................. 38 
5.4. 
Screen Failures ................................................................................................. 38 
6. 
Study Treatment ............................................................................................... 38 
6.1. 
Study Treatment Administered ........................................................................ 38 
6.2. 
Study Treatment: Preparation/Handling/Storage/Accountability .................... 39 
6.2.1. 
Handling and Storage ....................................................................................... 40 
6.2.1.1. 
CPI-006 Injection ............................................................................................. 40 
6.2.1.2. 
Placebo ............................................................................................................. 40 
6.2.2. 
Preparation and Dispensing .............................................................................. 40 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 5 of 114 
Version 003 
6.2.3. 
Administration .................................................................................................. 41 
6.2.4. 
Management of Infusion Reactions .................................................................. 42 
6.3. 
Measures to Minimize Bias: Randomization and Blinding .............................. 44 
6.3.1. 
Randomization .................................................................................................. 44 
6.3.2. 
Blinding ............................................................................................................ 45 
6.3.3. 
Procedures for Unblinding ............................................................................... 45 
6.4. 
Study Treatment Compliance ........................................................................... 45 
6.5. 
Concomitant Therapy ....................................................................................... 46 
6.5.1. 
Rescue Medicine .............................................................................................. 46 
6.5.2. 
Permitted Concomitant Therapy ...................................................................... 46 
6.5.3. 
Prohibited Concomitant Therapy ..................................................................... 47 
6.6. 
Dose Modification ............................................................................................ 48 
6.7. 
Study Treatment After the End of the Study .................................................... 48 
7. 
Discontinuation of Study Treatment and Participant 
Discontinuation/Withdrawal ............................................................................ 48 
7.1. 
Discontinuation of Study Treatment ................................................................ 48 
7.2. 
Participant Discontinuation/Withdrawal from the Study ................................. 48 
7.3. 
Lost to Follow-Up ............................................................................................ 48 
8. 
Study Assessments and Procedures .................................................................. 49 
8.1. 
Screening .......................................................................................................... 50 
8.2. 
Study Assessments and Procedures .................................................................. 50 
8.3. 
Efficacy Assessments ....................................................................................... 50 
8.4. 
Pharmacokinetic and Pharmacodynamic Assessments .................................... 51 
8.5. 
Safety Assessments .......................................................................................... 52 
8.6. 
Adverse Events and Serious Adverse Events ................................................... 52 
8.6.1. 
Time Period and Frequency for Collecting AE and SAE Information ............ 52 
8.6.2. 
Method of Detecting AEs and SAEs ................................................................ 53 
8.6.3. 
Follow-up of AEs and SAEs ............................................................................ 53 
8.6.4. 
Regulatory Reporting Requirements for SAEs ................................................ 53 
8.7. 
Biomarkers ....................................................................................................... 54 
8.7.1. 
Immunogenicity Assessments .......................................................................... 55 
9. 
Statistical Considerations ................................................................................. 55 
9.1. 
Sample Size Determination .............................................................................. 55 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 6 of 114 
Version 003 
9.2. 
Statistical Analyses ........................................................................................... 56 
9.2.1. 
Population for Analyses ................................................................................... 56 
9.2.2. 
General Approach ............................................................................................. 56 
9.2.3. 
Demographic and Participant Characteristics .................................................. 57 
9.2.4. 
Efficacy Analyses ............................................................................................. 57 
9.2.4.1. 
Analysis of Primary and Key Secondary Efficacy Endpoints .......................... 58 
9.2.4.1.1. Analysis of Primary Endpoint: Estimand 1 ...................................................... 58 
9.2.4.1.2. Analysis of Secondary Endpoints: Estimand 2, 3, and 4 .................................. 59 
9.2.4.1.3. Statistical Hypotheses for the Primary and Key Secondary Endpoints ............ 60 
9.2.4.1.4. Parallel Gatekeeping Procedure for Testing Hypotheses ................................. 61 
9.2.5. 
Supportive Secondary and Exploratory Endpoints .......................................... 61 
9.2.6. 
Safety Analyses ................................................................................................ 61 
9.2.7. 
Interim and Final Analyses ............................................................................... 62 
9.2.7.1. 
Efficacy Stopping Criteria ................................................................................ 62 
9.2.8. 
Independent Data Monitoring Committee (iDMC) .......................................... 63 
9.2.8.1. 
Safety Stopping Criteria ................................................................................... 63 
10. 
References ........................................................................................................ 64 
Appendix 1 
Schedule of Activities ..................................................................................... 66 
Appendix 2 
Regulatory, Ethical, and Study Oversight Considerations.............................. 70 
Appendix 3 
Clinical Laboratory Tests ................................................................................ 75 
Appendix 4 
Adverse Events: Definitions and Procedures for Recording, Evaluating, 
Follow-up, and Reporting ............................................................................... 76 
Appendix 5 
Contraceptive Guidance and Collection of Pregnancy Information ............... 84 
Appendix 6 
8-Point Ordinal Scale for Clinical Improvement ............................................ 88 
Appendix 7 
NEWS2 Scoring System ................................................................................. 89 
Appendix 8 
Example of An Assessment of 14 Common Covid-19-Related Symptoms: 
Items and Response Options ........................................................................... 90 
Appendix 9 
Intercurrent Event (ICE) and Estimand Strategy ............................................ 92 
Appendix 10  Efficacy Analysis for the Primary Endpoint ................................................... 99 
Appendix 11  Gatekeeping Strategy for Testing Hypotheses .............................................. 101 
Appendix 12  Futility Criteria and Its Operating Characteristics for Go or No-Go Decisions  
based on Efficacy Data at Interim Analyses 1 and 2 .................................... 105 
Appendix 13  Operating Characteristics of Non-Inferiority Test for Treatment A (or B) 
relative to Treatment C in terms of the Ratio of the Mortality Rates ........... 110 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 7 of 114 
Version 003 
Appendix 14 Protocol Amendment History ....................................................................... 114 
 
LIST OF TABLES 
Table 1 
Population Definitions................................................................................... 20 
Table 2 
Study Treatment ............................................................................................ 38 
Table 3 
CPI-006 Infusion-Related Reaction Management Guidelines ...................... 42 
Table 4 
Population Definitions................................................................................... 56 
Table 5 
Efficacy Endpoints ........................................................................................ 57 
Table 6 
Schedule of Activities ................................................................................... 66 
Table 7 
PK, ADA, and Neutralizing Antibody Sampling Schedule .......................... 69 
Table 8 
Protocol-Required Safety Laboratory Assessments ...................................... 75 
Table 9 
Assessment of Severity of Adverse Events ................................................... 80 
Table 10 
Highly Effective Contraceptive Methodsa .................................................... 85 
Table 11 
Intercurrent Event Types ............................................................................... 92 
Table 12 
Primary and Key Secondary Objectives and Estimands with Rationale for 
Strategies to Address Intercurrent Events ..................................................... 93 
Table 13 
Simulation Scenarios ................................................................................... 106 
Table 14 
Operating Characteristics of the Futility Stopping Criteria at Interim Analysis 
1 with 25% Information .............................................................................. 108 
Table 15 
Operating Characteristics of the Futility Stopping Criteria at Interim Analysis 
2 with 60% Information .............................................................................. 108 
Table 16 
Multiplicative Ratios Between Treatment Mortality Relative to Control 
Mortality ...................................................................................................... 112 
Table 17 
Estimated Power for Non-inferiority of Treatment Relative to Control in 
Terms of Mortality Ratio ............................................................................. 113 
Table 18  
Document History ....................................................................................... 114 
 
LIST OF FIGURES 
Figure 1 
Study Schematic ............................................................................................ 22 
Figure 2 
Testing Strategy Based on the Gatekeeping Procedure .............................. 102 
 
LIST OF APPENDICES 
Appendix 1 
 Schedule of Activities .................................................................................. 66 
Appendix 2 
 Regulatory, Ethical, and Study Oversight Considerations ........................... 70 
Appendix 3 
 Clinical Laboratory Tests ............................................................................. 75 
Appendix 4 
 Adverse Events: Definitions and Procedures for Recording, Evaluating, 
Follow-up, and Reporting ............................................................................ 76 
Appendix 5 
 Contraceptive Guidance and Collection of Pregnancy Information ............ 84 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 8 of 114 
Version 003 
Appendix 6 
 8-Point Ordinal Scale for Clinical Improvement ......................................... 88 
Appendix 7 
 NEWS2 Scoring System .............................................................................. 89 
Appendix 8 
 Example of An Assessment of 14 Common Covid-19-Related Symptoms: 
Items and Response Options ........................................................................ 90 
Appendix 9 
 Intercurrent Event (ICE) and Estimand Strategy ......................................... 92 
Appendix 10   Efficacy Analysis for the Primary Endpoint ................................................ 99 
Appendix 11   Gatekeeping Strategy for Testing Hypotheses ........................................... 101 
Appendix 12   Futility Criteria and Its Operating Characteristics for Go or No-Go Decisions 
based on Efficacy Data at Interim Analyses 1 and 2 ................................. 105 
Appendix 13   Operating Characteristics of Non-Inferiority Test for Treatment A (or B) 
relative to Treatment C in terms of the Ratio of the Mortality Rates ........ 110 
Appendix 14   Protocol Amendment History..................................................................... 114 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 9 of 114 
Version 003 
LIST OF ABBREVIATIONS 
Abbreviation  
Definition 
ACE2 
angiotensin converting enzyme 2 
ADA 
anti-drug antibodies 
AE 
adverse event 
ALT 
alanine aminotransferase 
AMP 
adenosine monophosphate 
ANC 
absolute neutrophil count 
aPTT 
activated partial thromboplastin time 
ARDS 
acute respiratory distress syndrome 
AST 
aspartate aminotransferase 
AUC 
area under the serum or plasma concentration-time curve 
AUC(0-169) 
AUC from the start of infusion to 169 hours after the start of infusion 
AUClast 
AUC from time zero to the time of the last quantifiable concentration 
BCR 
B cell receptor 
C(0) 
the initial CPI-006 concentration measured 30 minutes after completion of the 
infusion 
CBC 
complete blood count 
CCP 
Covid-19 Convalescent Plasma 
CI 
confidence interval 
CKD 
chronic kidney disease 
Cmax 
maximum drug concentration in serum or plasma 
COPD 
chronic obstructive pulmonary disease 
CRF 
case report form 
CRO 
contract research organization 
CRP 
C-reactive protein 
CT 
computed tomography 
DLT 
dose-limiting toxicity 
ELISA 
enzyme-linked immunosorbent assay 
Fc 
fragment crystallizable 
FDA 
U.S. Food and Drug Administration 
GCP 
Good Clinical Practice 
GLP 
Good Laboratory Practice 
HIPAA 
United States Health Insurance Portability and Accountability Act 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 10 of 114 
Version 003 
Abbreviation  
Definition 
HLA-DR 
human leukocyte antigen – DR isotype  
IC50 
concentration required for 50% inhibition 
ICF 
informed consent form 
ICH 
International Council for Harmonisation 
ICU 
intensive care unit 
iDMC 
Independent Data Monitoring Committee 
IEC 
Independent Ethics Committee 
IFN-γ 
interferon gamma 
Ig 
immunoglobulin 
IgA 
immunoglobulin A 
IgG 
immunoglobulin G  
IgM 
immunoglobulin M 
IL-2, -6, -10 
interleukin 2, 6, 10 
IND 
Investigational New Drug  
INR 
international normalized ratio 
IRB 
Institutional Review Board 
IRR 
infusion-related reaction 
IRT 
interactive response technology 
ITT 
intent-to-treat 
IV 
intravenous(ly) 
LDH 
lactate dehydrogenase 
MCH 
mean corpuscular hemoglobin  
MCV 
mean corpuscular volume 
MERS 
Middle East respiratory syndrome 
NEWS2 
National Early Warning Score 2 
NCI CTCAE 
National Cancer Institute Common Terminology Criteria for Adverse Events 
NOAEL 
no-observed adverse effect level 
O2 
oxygen 
PBMC 
peripheral blood mononuclear cell 
PCR 
polymerase chain reaction 
PD 
pharmacodynamics 
PD1 
programmed cell death 1 receptor  
PE 
polyethylene 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 11 of 114 
Version 003 
Abbreviation  
Definition 
PES 
polyethersulfone 
PK 
pharmacokinetic(s) 
PO 
by mouth (orally) 
PO/PE 
polyolefin/polyethylene 
PT 
prothrombin time 
PVC 
polyvinylchloride 
RBC 
red blood cell 
RBD 
receptor binding domain 
RNA 
ribonucleic acid 
RSV 
Respiratory Syncytial Virus 
SAE 
serious adverse event 
SARS 
severe acute respiratory syndrome 
SARS-CoV-2 
severe acute respiratory syndrome coronavirus 2 
SCD 
sickle cell disease 
SoA 
schedule of activities 
SOB 
shortness of breath 
SOC 
standard of care 
SpO2 
oxygen saturation 
SUSAR 
suspected unexpected serious adverse reactions 
TNF-α 
tumor necrosis factor alpha 
ULN 
upper limit of normal 
US/USA 
United States of America 
USP 
United States Pharmacopeia 
WBC 
white blood cell 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 12 of 114 
Version 003 
1. 
PROTOCOL SUMMARY 
1.1. 
SYNOPSIS 
Name of Sponsor: Corvus Pharmaceuticals, Inc. 
Investigational Product: CPI-006 
Title of Study: Phase 3, Randomized, Placebo Controlled, Double-blind, Multicenter, 
Stratified Study of CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in 
Mild to Moderately Symptomatic Hospitalized Covid-19 Patients 
Phase of Development: 3 
Number of Participants: Approximately 1000 evaluable participants for an estimated total 
of 330 evaluable participants per treatment group 
Study Centers: Multicenter 
Study Objectives and Endpoints:  
Objectives 
Endpoints 
Primary 
 
• 
To compare the proportion of participants alive 
and respiratory failure free during the 28 days 
after dosing with CPI-006 plus SOC versus 
placebo plus SOC in hospitalized participants 
with mild to moderately symptomatic Covid-19 
infection 
• 
Proportion of participants who are alive and free 
from respiratory deterioration during the 28 days 
after dosing defined as follows per the 8-point 
ordinal scale (Appendix 6): 
o Deterioration to Categories 6, 7, or 8 for a 
participant who entered the trial at Categories 4 
or 5  
o Deterioration to Categories 7 or 8 for a 
participant who entered the trial at Category 6 
Key Secondary 
 
• 
To compare the time to recovery of CPI-006 plus 
SOC versus placebo plus SOC in hospitalized 
participants with mild to moderately symptomatic 
Covid-19 infection 
• 
Time to recovery during the 28 days after dosing. 
Day of recovery is defined as the first day on 
which the participant satisfies 1 of the following 
3 categories from the 8-point ordinal scale 
(Appendix 6): 1) Not hospitalized, no limitations 
on activities.; 2) Not hospitalized, limitation on 
activities and/or requiring home oxygen; 3) 
Hospitalized, not requiring supplemental oxygen 
- no longer requires ongoing medical care. 
• 
To compare the time to clinical improvement of 
CPI-006 plus SOC versus placebo plus SOC in 
hospitalized participants with mild to moderately 
symptomatic Covid-19 infection 
• 
Time to clinical improvement (≥ 2 points 
improvement in the 8-point ordinal scale) during 
the 28 days after dosing 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 13 of 114 
Version 003 
Objectives 
Endpoints 
• 
To compare the mortality rate due to any cause 
during the 28 days after dosing with CPI-006 plus 
SOC versus placebo plus SOC in hospitalized 
participants with mild to moderately symptomatic 
Covid-19 infection 
• 
Proportion of participants who died during the 
28 days after dosing  
Supportive Secondary  
 
• 
To compare the change from baseline in the level 
of antibodies targeting the RBD of SARS-CoV-2  
• 
Change from baseline level of IgG targeting the 
RBD at Days 7, 14, 21, and 28 
• 
To compare the time to improvement of Covid-
19-attributable symptoms including fever, cough, 
sore throat, headache, muscle pain, and shortness 
of breath 
• 
Time to resolution of  all Covid-19 attributable 
symptoms (see Appendix 8) including fever, 
cough, sore throat, headache, muscle pain, and/or 
shortness of breath reported at baseline to score of 
none or mild during the 28 days after dosing 
• 
To compare the clinical status of CPI-006 plus 
SOC versus placebo plus SOC in hospitalized 
participants with mild to moderately symptomatic 
Covid-19 infection 
• 
Change in clinical status, defined by the change in 
the 8-point ordinal scale from baseline at Days 3, 
7, 14, 21, and 28 
• 
To compare the percentage of participants with 
clinical improvement with CPI-006 plus SOC 
versus placebo plus SOC in hospitalized 
participants with mild to moderately symptomatic 
Covid-19 infection 
• 
Percentage of participants with clinical 
improvement (≥ 2 points improvement in the 
8-point ordinal scale) at Days 3, 7, 14, 21, and 28  
• 
To compare the change from baseline in the level 
of antibodies targeting the RBD of SARS-CoV-2 
• 
Change from baseline level of IgM targeting the 
RBD at Days 7, 14, 21, and 28 
• 
To compare the change from baseline in the 
SARS-CoV-2 viral load 
• 
Change from baseline in the SARS-CoV-2 viral 
load at Days 3, 7, 14, 21, and 28 
• 
To compare time to PCR negativity, and 
percentage of participants with PCR negative of 
CPI-006 plus SOC versus placebo plus SOC in 
hospitalized participants with mild to moderately 
symptomatic Covid-19 infection 
• 
Time to PCR negativity during the 28 days after 
dosing 
• 
Percentage of participants with PCR negative at 
Days 7, 14, 21, and 28 
• 
To compare the change from Baseline in NEWS2 
of CPI-006 plus SOC versus placebo plus SOC in 
hospitalized participants with mild to moderately 
symptomatic Covid-19 infection 
• 
Change from Baseline in NEWS2 at Days 3 and 
7, Day of Discharge, and Day 28.                             
NEWS2 (Appendix 7) consists of: Physiological 
Parameters: respiration rate (per minute), SpO2 
Scale 1 (%), SpO2 Scale 2 (%), use of air or 
oxygen, systolic blood pressure (mmHg), pulse 
(per minute), consciousness, and temperature (°C) 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 14 of 114 
Version 003 
Objectives 
Endpoints 
• 
To compare the medical interventions/procedures 
during the 28 days after dosing of CPI-006 plus 
SOC versus placebo plus SOC in hospitalized 
participants with mild to moderately symptomatic 
Covid-19 infection 
• 
Rate and duration of mechanical ventilation (days 
receiving invasive or non-invasive mechanical 
ventilation during the 28 days after dosing) 
• 
Rate and duration of any supplemental oxygen (if 
applicable) in days during the 28 days after dosing 
• 
Rate and duration of invasive mechanical 
ventilation (if applicable) in days during the 28 
days after dosing 
• 
Rate and duration (if applicable) in days of non-
invasive ventilation/ high flow oxygen devices 
during the 28 days after dosing 
• 
Oxygenation free days during the 28 days after 
dosing 
• 
Rate of rehospitalization during the 28 days after 
dosing 
• 
To compare the safety of CPI-006 plus SOC 
versus placebo plus SOC in hospitalized 
participants with mild to moderately symptomatic 
Covid-19 infection 
• 
Incidence, type, and severity of 
treatment -emergent adverse events of CPI-006 
plus SOC compared to placebo plus SOC assessed 
by NCI CTCAE v 5.0 

CPI-006-003 
Corvus Pharmaceuticals, Inc. 
Protocol 
CONFIDENTIAL 
Page 15 of 114 
Version 003 
Objectives 
Endpoints 
Exploratory 
•
To compare changes from baseline in Covid-19-
related lab assessments of CPI-006 plus SOC
versus placebo plus SOC in hospitalized
participants with mild to moderately symptomatic
Covid-19 infection
•
Hematology, chemistry, CRP, and ferritin
assessments on Days 1, 3, 5, 7, 14, 21, 28 (while
hospitalized); Day of Discharge; and Day 28
(return to clinic if discharged)
•
PT, INR, aPTT, fibrinogen, and D-dimer on
Days 1, 3, 5, 7, 14, 21, 28 (while hospitalized),
and Day of Discharge
•
Change from baseline level of IgA targeting the
RBD at Days 7, 14, 21, and 28
•
Changes in IgG, IgM, or IgA antibodies targeting
other SARS-CoV-2 antigens including (but not
limited to) spike, nucleocapsid, and membrane
proteins
•
Change from baseline in the frequency and
function of memory B cells in the peripheral
blood at Days 14 and 28
•
Changes from baseline in the frequency or
function of memory/effector T cells in the
peripheral blood at Days 14 and 28
•
B cell receptor repertoire analysis at baseline,
Day 14, and Day 28
•
Systemic cytokine and chemokine levels at
baseline and Days 7 (while hospitalized), Day of
Discharge, and Day 28
•
Neutralizing antibody levels on Days 1 and 28
using a biochemical ELISA, a pseudovirus
neutralization assay, and a PRNT50 live virus
assay
•
Change from baseline level of IgG and IgM
targeting the RBD at Days 56, 84, and 168
•
To characterize the pharmacokinetics of CPI-006
in hospitalized participants with Covid-19
infection
•
PK characteristics including covariate analysis to
determine which variables, if any, influence
exposure of CPI-006
Abbreviations:  aPTT = activated partial thromboplastin time; CRP = C-reactive protein; ELISA = enzyme-
linked immunosorbent assay; IgA = immunoglobulin A; IgG = immunoglobulin G; IgM = immunoglobulin M; 
INR = international normalized ratio; NCI CTCAE = National Cancer Institute Common Terminology Criteria 
for Adverse Events; NEWS2 = National Early Warning Score 2; PCR = polymerase chain reaction; PK = 
pharmacokinetic; RBD =  receptor binding domain; PT = prothrombin time; SARS-CoV-2 = severe acute 
respiratory syndrome coronavirus 2; SOC = standard of care; SpO2 = oxygen saturation. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 16 of 114 
Version 003 
Study Design: 
This is a Phase 3, randomized, 3-arm, placebo controlled, double-blind, multicenter, stratified 
study of CPI-006 plus standard of care (SOC) versus placebo plus SOC in mild to moderately 
symptomatic hospitalized adult (≥ 18 years) participants with Covid-19. Covid-19 disease 
will be confirmed by polymerase chain reaction (PCR) or antigen testing for SARS-CoV-2. 
Approximately 1000 participants will be randomized at a 1:1:1 ratio to the 3 treatment arms 
and stratified by the following factors: 
• Region of the world (North America [US and Canada] vs. Latin America vs. 
Europe/Middle East/Africa).   
• Age (< 65 vs. ≥ 65) 
• Comorbidities (0 vs. at least 1) based on the following list: 
o Chronic lung disease (e.g., emphysema and chronic bronchitis, idiopathic 
pulmonary fibrosis, chronic obstructive pulmonary disease [COPD], or cystic 
fibrosis) or moderate to severe asthma 
o Significant cardiac disease (e.g., heart failure, coronary artery disease, 
congenital heart disease, cardiomyopathies, and pulmonary hypertension) 
o Obesity (body mass index ≥ 30 kg/m2) 
o Diabetes (Type 1, Type 2, or gestational) 
o Liver disease 
o Chronic kidney disease (CKD) 
o Sickle cell disease (SCD) 
o Organ transplantation 
o Cancer 
CPI-006 will be administered at a dose of 2 mg/kg (Treatment A - maximum dose of 
200 mg) or 1 mg/kg (Treatment B - maximum dose of 100 mg) intravenously (IV) on Day 1. 
A placebo will be given at the same schedule as the active drug for participants who receive 
the control (Treatment C). Participants, investigators, and Corvus will be blinded to the 
treatment allocation. All participants will receive supportive care according to the SOC of the 
trial hospital. If a hospital has a written policy or guideline, participants will receive 
treatment (including remdesivir, tocilizumab, steroids, convalescent plasma, anti-SARS-
CoV-2 monoclonal antibodies, or any other approved treatment) per those guidelines at the 
discretion of the investigator. Chloroquine/hydroxychloroquine are not allowed as SOC. 
Participation in any other investigational treatment during the first 28 days after 
randomization will not be allowed unless the investigator, in consult with the Corvus medical 
monitor, feels medical necessity and that such participation would not affect the integrity of 
this trial.  
After the participant’s initial eligibility is established and informed consent has been 
obtained, the study site must enroll the participant into the study by logging in to an 
interactive response technology (IRT) system to obtain the participant number. Every 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 17 of 114 
Version 003 
participant that signs the informed consent form (ICF) must be assigned with a participant 
number in IRT. Specific instructions for using IRT will be provided to the investigational site 
in the IRT Manual. The investigator or designee will register the participant for enrollment 
by following the enrollment procedures established by Corvus. 
All participants will undergo a series of efficacy, safety, and laboratory assessments. 
Participants will be assessed daily during their hospitalization. Participants’ clinical status 
based on the 8-point ordinal scale, the National Early Warning Score 2 (NEWS2), Covid-19 
related signs/symptoms, and safety laboratory tests will be recorded every day while 
hospitalized including day of discharge from the hospital. Discharged participants will be 
asked to attend post- hospitalization study assessments at Days 14, 21, and 28, if discharged 
before any of these assessments were completed. Severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) PCR test will be obtained on Days 1, 7, 14, 21, and 28 while 
hospitalized; and on day of discharge (if discharged prior to Day 28) and will be tested 
locally. Samples will be collected for viral load that will be assessed at a central lab. Anti-
SARS-CoV-2 antibody samples will be collected to assessed at a central lab on Day 1 before 
dosing, and on Days 7, 14, 21, and 28 if a participant remains hospitalized as well as the day 
of hospital discharge. For participants who are discharged before Day 14, 21 and 28, a 
sample will be collected on day of discharge as well as the post-hospitalization sample 
collection on Days 14, 21, and 28 that are not collected during the hospital stay. Participants 
who consent separately to the optional assessments for anti-SARS-CoV-2 serum antibody 
tests will be asked to attend post-hospitalization assessments on Days 56, 84, and 168. 
An iDMC will be formed to monitor safety and efficacy of the study treatment at 
pre-specified timepoints including futility and interim analysis timepoints. The iDMC will 
review the unblinded safety data from the first 60 participants after completion of the Day 28 
assessments. Subsequent iDMC reviews will occur when approximately 120, 250, 400, 600, 
and 800 participants have completed the Day 28 assessments. The analysis with 250 and 600 
participants will be a futility evaluation. Safety and efficacy data will be analyzed for the 
iDMC review at both interim analyses.   
Study enrollment will be paused after the first 60 participants are enrolled. Enrollment will 
only be re-initiated following iDMC recommendation. For the second iDMC review, when 
120 participants are enrolled, the study enrollment will not be paused. For the review of the 
futility analysis (~250 participants), study enrollment will also be paused at that time. 
Enrollment will only be re-initiated following iDMC recommendation. The study will not be 
paused for enrollment for the subsequent reviews after the futility analysis. However, the 
iDMC may request a pause in enrollment at any time during the study based on the safety 
and efficacy data. 
The protocol team will review blinded pools of AE/SAE data every 2 weeks. If there are a 
significant number of unexpected AEs, the iDMC will be asked to review unblinded safety 
and efficacy data in an ad hoc meeting.  

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 18 of 114 
Version 003 
Eligibility: Hospitalized mild to moderately symptomatic Covid-19 patients. Participants 
may have controlled pre-existing conditions such as cancer and diabetes. All participants will 
receive standard care for Covid-19. 
Test Product, Dose and Administration: CPI-006 single dose at either 1 mg/kg or 2 mg/kg 
given by IV infusion over 10-15 minutes. 
Rationale:  
CPI-006 is a humanized immunoglobulin G (IgG) fragment crystallizable (Fc) receptor 
binding deficient monoclonal antibody that activates B cells leading to the production of 
immunoglobulin M (IgM) and IgG antibodies (Luke et al, 2019b). In vivo administration to 
patients with cancer has shown rapid and temporary redistribution in circulating B cells with 
return of memory B cell phenotype. Immune markers demonstrate activation of B cells, 
expression of CD69 and increases in human leukocyte antigen – DR isotype (HLA-DR) 
expression. Molecular studies of the B cell receptor (BCR) in treated patients have 
demonstrated that CPI-006 stimulates the generation of B cell clones with new BCRs. These 
findings indicate that CPI-006 is activating B cells, causing their trafficking to lymphoid 
tissues and potentially their further differentiation into antibody producing cells. Further 
studies in patients with cancer have demonstrated production of anti-tumor antibodies in 
some patients. The high anti-SARS-CoV-2 titer seen in a patient with Covid-19 following 
treatment with CPI-006 for lung cancer are supportive of the hypothesis that CPI-006 may 
enhance anti-viral antibody response. CPI-006 is therefore under development for Covid-19 
since neutralizing antibodies and the generation of immune memory are critical for 
eliminating infections with severe acute respiratory syndrome (SARS) and Middle East 
respiratory syndrome (MERS) coronaviruses. In the ongoing Phase 1 CPI-006-002 study, 
27 participants with mild to moderate Covid-19 have received a single dose of CPI-006 at 
doses ranging from 0.3 mg/kg to 5 mg/kg. CPI-006 was well tolerated with no treatment 
related AEs or dose-limiting toxicities (DLTs) reported. IgG and IgM antibody titers 
measured against the SARS-CoV-2 spike protein and/or receptor binding domain (RBD) 
increased in all evaluable participants within 7 days of a single infusion of low doses of 
CPI-006 and were sustained over time. Similar results were observed in anti-SARS-CoV-2 
immunoglobulin A (IgA) titers. This increase in antibody titers provides the rationale to 
develop CPI-006 for treatment of Covid-19. This Phase 3 study evaluates clinical benefit, 
safety, and the anti-SARS-CoV-2 antibody production in participants who are hospitalized 
with mild to moderately symptomatic Covid-19 treated with CPI-006. Treatment with 
CPI-006 may also result in prolonged immunity to SARS-CoV-2 and related viruses 
(Willingham et al., 2020).  
Overall Design: 
This is a randomized, placebo controlled, double-blind, multicenter, stratified study of 
CPI-006 plus SOC versus placebo plus SOC in mild to moderately symptomatic hospitalized 
participants with Covid-19. An iDMC will monitor safety, efficacy, and conduct of the study. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 19 of 114 
Version 003 
All participants will be followed for 28 days for production of anti-SARS-CoV-2 antibodies 
followed by an optional period of 5 months. While in the hospital, participants will receive 
standard of care monitoring including vital signs every 4-6 hours, or per institutional 
guidelines and safety assessments. Safety and other disease assessments will be conducted at 
Days 3, 7, 14, 21, and 28. Discharged participants will be asked to attend post- 
hospitalization study assessments at Days 14, 21, and 28, if discharged before any of these 
assessments were completed. 
Treatment Groups and Duration: 
Participants meeting study entry criteria will be randomized in a 1:1:1 ratio to receive either 
Treatment A (CPI-006 2 mg/kg plus SOC) or Treatment B (CPI-006 1mg/kg plus SOC) or 
Treatment C (placebo plus SOC). Participants randomized to Treatment A will receive a 
single dose of CPI-006 at 2 mg/kg given by IV infusion plus SOC (maximum dose of 
200 mg). Participants randomized to Treatment B will receive a single dose of CPI-006 at 
1 mg/kg given by IV infusion plus SOC (maximum dose of 100 mg). A placebo will be given 
at the same schedule as the active drug for participants randomized to Treatment C. All 
participants will be managed per physician using best SOC for Covid-19 patients. No dose 
modifications will be allowed. 
Statistical Methods:  
Statistical Hypothesis for the Primary and Key Secondary Endpoints  
Five hypotheses will be tested for the comparison of Treatment A to Treatment C (Treatment 
A Hypotheses Family). The first 3 hypotheses are to test the superiority of Treatment A over 
Treatment C in terms of the primary endpoint and the first and second secondary endpoints in 
the priority as they are listed in the Objectives and Endpoints module above. The fourth 
hypothesis is to test non-inferiority of Treatment A relative to Treatment C in terms of the 
ratio of Treatment A mortality over Treatment C mortality. If non-inferiority is established, 
then the fifth hypothesis will be tested for the superiority of Treatment A over Treatment C in 
terms of the mortality ratio.   
The same 5 hypotheses will be tested for the comparison of Treatment B to Treatment C 
(Treatment B Hypotheses Family). 
The overall one-sided Type-I error rate α=0.025 is initially equally split for the Treatment A 
Family and Treatment B Family for testing the 5 hypotheses within a treatment family. A 
parallel gatekeeping strategy with multiplicity adjustment is designed to control the overall 
Type I error rate α at the one-sided 0.025 level for testing the hypotheses in the 2 families. 
The 5 hypotheses are arranged in the hierarchical order described above for statistical testing 
within each treatment family. The details of the gatekeeping strategy and stepwise testing 
procedures are presented in Appendix 11. 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 20 of 114 
Version 003 
Sample Size 
Approximately 1000 hospitalized participants with mild to moderately symptomatic 
Covid-19 will be enrolled. The participants will be randomized in a 1:1:1 ratio between 
Treatment A, Treatment B, and Treatment C within each of the strata defined by: 
• Region of the world (North America [US and Canada] vs. Latin America vs. 
Europe/Middle East/Africa). 
• Age (< 65 vs. ≥ 65) 
• Comorbidities (0 vs. at least 1) based on the following list: 
o Chronic lung disease (e.g., emphysema and chronic bronchitis, idiopathic 
pulmonary fibrosis, COPD, or cystic fibrosis) or moderate to severe asthma 
o Significant cardiac disease (e.g., heart failure, coronary artery disease, 
congenital heart disease, cardiomyopathies, and pulmonary hypertension) 
o Obesity (body mass index ≥ 30 kg/m2) 
o Diabetes (Type 1, Type 2, or gestational) 
o Liver disease 
o CKD 
o SCD 
o Organ transplantation 
o Cancer 
With approximately 330 participants per treatment arm, there would be an approximately 
80% power to show a statistically significant superiority of Treatment A over Treatment C in 
the proportion of participants alive and free from respiratory deterioration during the 28 days 
after dosing at a 1-sided α level of 0.0125 when the true proportion of Treatment A is 92% 
and that of Treatment C is 84%. The same sample size and power statement also holds for the 
comparison between Treatment B and C.  
Populations for Analyses 
For purposes of analyses, the following populations are defined in Table 1. 
Table 1 
Population Definitions 
Population 
Description 
Intent-to-treat (ITT) 
All participants who are randomized into the study and analyzed 
according to treatment assigned at randomization.  
Efficacy 
All participants who receive any amount of study drug (CPI-006 or 
placebo) and have post-baseline efficacy assessment based on the 
8-point ordinal scale. The participants will be analyzed according to 
the treatment actually received.  
Safety 
All participants who receive any amount of study treatment 
(CPI-006, placebo, or SOC). 
Pharmacokinetic 
All participants who receive CPI-006 and had at least 
1 post-treatment blood sample collected 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 21 of 114 
Version 003 
 
Statistical Design 
Two formal interim analyses are planned for this study. The first interim analysis is a 
non‑binding futility analysis and will be performed when approximately 250 of participants 
have been enrolled into the study with 28 days of follow-up time. Safety and efficacy will be 
analyzed for futility evaluation.   
The second interim analysis is also a non-binding futility and efficacy analysis and will be 
performed when approximately 600 of participants have been enrolled and with 28 days of 
follow-up time. Comparison between Treatment A and C, and between Treatment B and C, 
with respect to the primary and key secondary efficacy endpoints will be performed.  
At both interim analyses, unblinded analyses will be provided by a separate unblinded 
statistician to the iDMC for making futility assessment.   
As part of the second interim analysis, Corvus may request the iDMC to assess the primary 
efficacy endpoint and its conditional power of establishing a significant treatment effect at 
the final analysis based on the interim data. The total sample size of the study may be 
increased with the recommendation by iDMC. The sample size adaptation plan and increase 
rule will be detailed in the statistical analysis plan and provided to the regulatory authority 
before the first interim analysis. 
The primary analysis of the study is the final analysis. Safety and efficacy analyses will be 
performed when all the participants of the study have completed the Day 28 assessments.  
   

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 22 of 114 
Version 003 
1.2. 
SCHEMA 
Figure 1 Study Schematic 
 
 
IV = intravenous; R = randomization 
 
1.3. 
SCHEDULE OF ACTIVITIES (SOA) 
For the schedule of activities, please see Appendix 1, Table 6. 
2. 
INTRODUCTION 
2.1. 
STUDY RATIONALE 
CPI-006 is a humanized immunoglobulin G (IgG) fragment crystallizable (Fc) receptor 
binding deficient monoclonal antibody that activates B cells leading to the production of 
immunoglobulin M (IgM) and IgG antibodies (Luke et al, 2019b). In vivo administration to 
patients with cancer has shown rapid and temporary redistribution in circulating B cells with 
return of memory B cell phenotype. Immune markers demonstrate activation of B cells, 
expression of CD69 and increases in human leukocyte antigen – DR isotype (HLA-DR) 
expression. Molecular studies of the B cell receptor (BCR) in treated patients have 
demonstrated that CPI-006 stimulates the generation of B cell clones with new BCRs. These 
findings indicate that CPI-006 is activating B cells, causing their trafficking to lymphoid 
tissues and potentially their further differentiation into antibody producing cells. Further 
studies in patients with cancer have demonstrated production of anti-tumor antibodies in 
some patients. The high anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) titer seen in a patient with Covid-19 following treatment with CPI-006 for lung cancer are 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 23 of 114 
Version 003 
supportive of the hypothesis that CPI-006 may enhance anti-viral antibody response. CPI-006 
is therefore under development for Covid-19 since neutralizing antibodies and the generation 
of immune memory are critical for eliminating infections with severe acute respiratory 
syndrome (SARS) and Middle East respiratory syndrome (MERS) coronaviruses. In the 
ongoing Phase 1 CPI-006-002 study, 27 participants with mild to moderate Covid-19 have 
received a single dose of CPI-006 at doses ranging from 0.3 mg/kg to 5 mg/kg. CPI-006 was 
well tolerated with no treatment related AEs or dose-limiting toxicities (DLTs) reported. IgG 
and IgM antibody titers measured against the SARS-CoV-2 spike protein and/or receptor 
binding domain (RBD) increased in all evaluable participants within 7 days of a single 
infusion of low doses of CPI-006 and were sustained over time. Similar results were 
observed in anti-SARS-CoV-2 immunoglobulin A (IgA) titers. This increase in antibody 
titers provides the rationale to develop CPI-006 for treatment of Covid-19. This Phase 3 
study evaluates clinical benefit, safety, and the anti-SARS-CoV-2 antibody production in 
participants who are hospitalized with mild to moderately symptomatic Covid-19 treated 
with CPI-006. Treatment with CPI-006 may also result in prolonged immunity to SARS-
CoV-2 and related viruses (Willingham et al., 2020). 
The Covid-19 pandemic is not yet under control and there is fear that infections could spread 
and/or recur in a seasonal manner, even if controlled now or with vaccination efforts. There 
is also the possibility of viral mutation or emergence of other virulent coronaviruses. Based 
on encouraging preliminary data, CPI-006 may improve the magnitude, duration, and 
diversity of antibody responses to SARS-CoV-2 and improve clinical outcome. It also may 
result in prolonged immunity to SARS-CoV-2, its variants, and related coronaviruses. It is 
also possible that experience gained with treating Covid-19 with CPI-006 could be applied to 
treatment of other infectious diseases including future viral pandemics, and potential use in 
conjunction with vaccination of healthy participants. 
2.2. 
BACKGROUND 
Since its emergence in Hubei province, China in December of 2019, the novel coronavirus 
(2019-nCoV, Covid-19) has become a global health crisis (Wu et al, 2020; Chan et al, 2020). 
There is an urgent need for therapies that can improve survival, clinical outcomes, and reduce 
the requirements for intensive supportive care and prolonged hospitalization (Huang et al, 
2020). There are efforts underway to re-purpose direct acting antivirals targeting the 
ribonucleic acid (RNA)-dependent RNA polymerase including remdesivir and favipiravir 
both of which are being actively studied in multiple clinical trials. Similarly, inhibitors of the 
virally encoded proteases are being evaluated. To compliment therapeutic approaches there is 
an intense effort underway to develop vaccines. A number of approaches to vaccine 
development have begun clinical trials or are planned. To support vaccine strategies, there is 
a growing understanding of the key viral/host interaction required for viral entry and 
replication (Du et al, 2009). Indeed, it is increasingly clear that the virally encoded spike 
protein binds to angiotensin converting enzyme 2 (ACE2) on target cells to facilitate entry 
and replication. The spike protein is a multidomain viral envelop glycoprotein which 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 24 of 114 
Version 003 
contains a receptor binding domain (RBD) in subunit 1 of the spike protein (Wrapp et al, 
2020). This RBD directly interacts with N-terminal domain of ACE2. This interaction is 
absolutely required and initiates a sequence of steps leading to efficient viral infection. Thus, 
antibodies that disrupt this key interaction may be effective in viral neutralization and 
clearance. A recent publication from Zhang and colleagues have identified neutralizing 
antibodies from 8 Covid-19 infected patients that bind to the RBD of the spike protein and 
are neutralizing (Yuan et al, 2020). This provides evidence that neutralizing antibody 
responses to SARS-CoV-2 are possible and may provide clinical benefit in patients with 
Covid-19 and protection from disease in healthy subjects. Indeed, the U.S. Food and Drug 
Administration (FDA) has given emergency use authorization for the use of Covid-19 
Convalescent Plasma (CCP) and monoclonal antibodies for the treatment of Covid-19. 
Clinical studies with CCP suggest that higher titers of neutralizing antibody provide superior 
clinical benefit to recipients (Joyner et al, 2020; Rasheed et al 2020). These findings support 
the value of anti-viral antibodies in eradicating viral infection in patients, lessening disease 
severity, improving clinical course and potentially reducing transmission.  
CD73 is an adhesion molecule that was initially found to be important for lymphocyte 
trafficking and T cell activation (Resta & Thompson, 1997). It also functions as an 
ectoenzyme that converts adenosine monophosphate (AMP) to immunosuppressive 
adenosine. Several companies are developing anti-CD73 antibodies to inhibit production of 
adenosine and thereby augment immune response in patients with cancer. These antibodies 
have been designed primarily to block enzymatic activity. Corvus has designed a novel 
anti-CD73 antibody with agonistic, immunomodulatory properties that binds CD73 resulting 
in activation of immune cells such as B cells, and results in antibody production in vitro 
(Luke et al, 2019a). This antibody, CPI-006, is under investigation in a Phase 1b trial 
(NCT03454451) in advanced cancer as monotherapy and in combination with other 
immunotherapies such as anti- programmed cell death 1 receptor (PD1). Over 90 participants 
have received doses of this antibody ranging from 1 mg/kg to 24 mg/kg given IV every 
21 days. Treatment has been safe and tolerable, with chills and rigor seen during antibody 
infusion, that are managed by premedication with acetaminophen and diphenhydramine. 
CPI-006 is a humanized FcγR binding-deficient monoclonal antibody. In vitro studies have 
revealed binding to CD73 and direct effects on B cells, morphologic transformation to 
plasmablasts and induction of IgM and IgG secretion (Luke et al, 2019b). In vivo 
administration to patients with cancer has shown rapid and temporary drop in circulating 
B cells with return of memory B cell phenotype. Immune markers demonstrate activation of 
B cells, expression of CD69 and increases in HLA-DR expression. Molecular studies of the 
BCR in treated patients have demonstrated that CPI-006 stimulates the generation of B cell 
clones with new BCRs. These findings indicate that CPI-006 is activating B cells, causing 
their trafficking to lymphoid tissues and potentially their further differentiation into antibody 
producing cells. Further studies in patients with cancer have demonstrated production of 
anti-tumor antibodies in some patients.  

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 25 of 114 
Version 003 
CPI-006 is under investigation in a Phase 1 trial (NCT04464395) in mild to moderately 
symptomatic hospitalized Covid-19 patients. The results from the study (CPI-006-002) 
shows IgG and IgM antibody titers measured against the SARS-CoV-2 spike protein and/or 
receptor binding domain (RBD) increased in all evaluable participants within 7 days of a 
single infusion of low doses of CPI-006 and were sustained overtime. Similar results were 
observed in anti-SARS-CoV-2 IgA titers. In participants receiving 0.3 mg/kg CPI-006, all 
4 evaluable participants achieved high IgG titers to spike protein that were sustained for at 
least 84 days after onset of symptoms. In these participants, IgM titers peaked at 14 days and 
remained elevated at the last measured timepoint of 84 days. Similar kinetics were seen in 
antibody responses to RBD. At doses above 0.3 mg/kg, durable high titers of IgG and IgM to 
spike protein and RBD were achieved out to 84 days for the 1.0 mg/kg and 3.0 mg/kg 
cohorts, and 28 days for the 5.0 mg/kg cohort in the ongoing study. Peak titers increased 
from 0.3 mg/kg to 1.0 mg/kg CPI-006 but did not appear to increase for all isotypes toward 
each antigen from 1.0 mg/kg to 3.0 mg/kg or from 3.0 mg/kg to 5.0 mg/kg at the evaluable 
time points. An increase of IgG titer toward spike protein was observed from 1.0 mg/kg to 
3.0 mg/kg at Day 28. High and durable neutralizing titers were observed in subjects where 
ID50 values up to 23,000 were measured using a functional pseudovirus neutralizing antibody 
assay. Neutralizing titers were observed to persist at least 84 days following onset of 
symptoms in the ongoing trial. Immunophenotyping of peripheral blood mononuclear cells 
(PBMCs) at baseline and at 14, 28, or 56 days after treatment provided preliminary evidence 
that CPI-006 increased the frequency of memory B cells in 7 evaluated participants. An 
increased frequency of memory/effector CD4POS and CD8POS T cells was also observed in 
5 (CD4POS) and 6 (CD8POS) evaluable participants. CPI-006 has been well tolerated in 
participants with Covid-19 in this study. No DLTs or treatment-related AEs have been 
reported in the study. The AEs reported in the study were due to the underlying Covid-19 or 
comorbidities. 
In this Phase 3, randomized, 3-arm, placebo controlled, double-blind, multicenter, stratified 
study of CPI-006 plus standard of care (SOC) versus placebo plus SOC in mild to moderately 
symptomatic hospitalized participants with Covid-19. Approximately 1000 participants will 
be randomized in a 1:1:1 fashion to receive Treatment A (CPI-006 at 2 mg/kg plus SOC) or 
Treatment B (CPI-006 at 1 mg/kg plus SOC) or Treatment C (matching placebo plus SOC). 
Standard of care will be per institutional guidelines. Corvus will assess if administering 
CPI-006 to participants with Covid-19 along with SOC can lead to clinical benefit and 
enhance humoral immune response to the SARS-CoV-2. The production of neutralizing 
antibodies would be expected to shorten disease interval and improve clinical outcome, and 
treatment is expected to be safe. Therefore, CPI-006 treatment is expected to have a positive 
benefit/risk profile (see Section 2.4.1).  
2.3. 
CPI-006 NONCLINICAL EVALUATION 
CPI-006 recognizes and binds human CD73 with high affinity (KD values of 0.64–7.1 nM), 
inhibits CD73 catalytic activity (mean concentration required for 50% inhibition [IC50] 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 26 of 114 
Version 003 
values of 2.1 nM and 4.0 nM for human and cynomolgus monkey CD73), and has 
downstream biological effects on T cells as evidenced by restoration of CD3+ T cell 
proliferation in the presence of AMP. CPI-006 also binds to and inhibits cynomolgus monkey 
CD73, but not mouse or rat CD73, supporting the use of cynomolgus monkeys for studies of 
the pharmacokinetics (PK) and toxicology of CPI-006. 
Complete CD73 occupancy on CD8+ T cells in peripheral blood samples from cynomolgus 
monkeys by CPI-006 was observed at all doses of CPI-006. Complete CD73 occupancy was 
also observed in the axillary lymph nodes, indicating successful solid tissue penetration by 
CPI-006 with full coverage at least 24 hours after the final dose. 
An in vitro cytokine release assay was conducted with CPI-006 to evaluate the potential for 
CPI-006 to induce an immune response resulting in production of multiple cytokines 
(cytokine storm). The results demonstrated that CPI-006 did not directly induce cytokine 
(interferon gamma [IFN-γ], interleukin 2 [IL-2], interleukin 6 [IL-6], interleukin 10 [IL-10], 
and tumor necrosis factor alpha [TNF-α]) release from fresh human PBMCs at 0.1-10 µg/mL 
of CPI-006. 
Safety of CPI-006 was evaluated in male and female cynomolgus monkeys in two toxicity 
studies. In the first, a dose range finding study, CPI-006 was administered over 15-minutes 
by IV infusion at doses up to 120 mg/kg CPI-006, weekly (5 doses) for 31 days. The second, 
was a Good Laboratory Practice (GLP)-compliant toxicity study in which doses up to 
100 mg/kg CPI-006 were administered by IV infusion over 60 minutes, weekly (5 doses) for 
28 days. Toxicokinetics, safety pharmacology, and local tolerance assessments were built 
into the GLP compliant toxicity study. CPI-006 administered by IV infusion was well 
tolerated in both studies up to, and including, the highest doses administered. No definitive 
CPI-006-related changes were observed in the animals. No-observed adverse effect levels 
(NOAEL) were the highest doses administered, 120 mg/kg and 100 mg/kg CPI-006. 
Additional nonclinical information is provided in the Investigational Brochure for CPI-006. 
2.4. 
SUMMARY OF CLINICAL EXPERIENCE WITH CPI-006 
In CPI-006-001 oncology study, CPI-006 has been administered as a single agent and in 
combination with ciforadenant (an A2a receptor antagonist), and /or pembrolizumab (a 
blocking anti-PD-1 antibody). CPI-006 has been well tolerated when administered every 
3 weeks as monotherapy and in combination with ciforadenant and/or pembrolizumab.  
As of 20 Oct 2020, 35 participants have been treated with CPI-006 (every 3 weeks) 
monotherapy at doses up to 24 mg/kg, and no maximum tolerated dose was established. The 
most common adverse reactions were infusion related reactions (IRRs), primarily chills and 
rigors. These IRRs were non-serious, mild to moderate in severity (Grade 1-2), transient and 
did not lead to discontinuation. The IRRs have been observed during (or immediately after) 
Cycle 1, Day 1 and are uncommon at subsequent infusions of CPI-006. To mitigate the risk 
of IRRs, premedication with diphenhydramine (50 mg orally [PO]) and acetaminophen 500–

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 27 of 114 
Version 003 
1000 mg PO (or equivalents) was required prior to infusion of CPI-006 at Cycle 1, Day 1 and 
has shown a decreased rate and intensity of IRRs.  
As of 29 Dec 2020, in the ongoing Phase 1 CPI-006-002 study, 27 hospitalized participants 
with mild to moderate Covid-19 have received a single dose of CPI-006 at doses ranging 
from 0.3 mg/kg to 5 mg/kg with follow-up data. CPI-006 was well tolerated. IRRs have not 
been observed with CPI-006 infusion. No DLTs or treatment related AEs have been reported. 
The safety data in this Phase 1 study is reviewed on an ongoing basis by an Independent Data 
Monitoring Committee (iDMC).  
2.4.1. 
Benefit/Risk Assessment 
This study proposes to administer single doses of CPI-006 to hospitalized mild or moderately 
symptomatic participants with Covid-19.  
Study treatment will be administered in the hospital and participants will be monitored 
closely. CD73 is expressed on endothelial cells and it is possible that negative effects or 
exacerbation of disease could be seen in participants with Covid-19. However, data from the 
GLP general toxicity study did not show any CPI-006 related changes in coagulation 
parameters (Section 4.3). Data from 27 participants with Covid-19 in the CPI-006-002 study 
did not indicate any effect of CPI-006 on systemic inflammatory response or coagulopathy. 
In addition, data from over 90 participants in study CPI-006-001 in participants with cancer 
did not show any CPI-006 related systemic inflammatory response or coagulopathy. The 
participant follow-up and monitoring involve routine procedures not associated with 
significant health risk. The benefit of therapy to participants who receive Treatment A or 
Treatment B is the development of neutralizing antibodies which could lead to more rapid 
clinical improvement, avoidance of complications of Covid-19 disease, and the potential for 
longer lasting immunity.  
Participants enrolled in Treatment C will receive standard of care (SOC) per institutional 
guidelines. The participant follow-up and monitoring involve routine procedures not 
associated with significant health risk. Overall data will be used to assess any difference 
between the participants who receive Treatment A, Treatment B, and Treatment C in terms of 
clinical outcome and anti-SARS-CoV-2 levels. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 28 of 114 
Version 003 
3. 
OBJECTIVES AND ENDPOINTS  
Objectives 
Endpoints 
Primary 
 
• 
To compare the proportion of participants alive 
and respiratory failure free during the 28 days 
after dosing with CPI-006 plus SOC versus 
placebo plus SOC in hospitalized participants 
with mild to moderately symptomatic Covid-19 
infection 
• 
Proportion of participants who are alive and free 
from respiratory deterioration during the 28 days 
after dosing defined as follows per the 8-point 
ordinal scale (Appendix 6): 
o Deterioration to Categories 6, 7, or 8 for a 
participant who entered the trial at Categories 4 
or 5  
o Deterioration to Categories 7 or 8 for a 
participant who entered the trial at Category 6 
Key Secondary 
 
• 
To compare the time to recovery of CPI-006 plus 
SOC versus placebo plus SOC in hospitalized 
participants with mild to moderately symptomatic 
Covid-19 infection 
• 
Time to recovery during the 28 days after dosing. 
Day of recovery is defined as the first day on 
which the participant satisfies 1 of the following 
3 categories from the 8-point ordinal scale 
(Appendix 6): 1) Not hospitalized, no limitations 
on activities.; 2) Not hospitalized, limitation on 
activities and/or requiring home oxygen; 3) 
Hospitalized, not requiring supplemental oxygen 
- no longer requires ongoing medical care. 
• 
To compare the time to clinical improvement of 
CPI-006 plus SOC versus placebo plus SOC in 
hospitalized participants with mild to moderately 
symptomatic Covid-19 infection 
• 
Time to clinical improvement (≥ 2 points 
improvement in the 8-point ordinal scale) during 
the 28 days after dosing 
• 
To compare the mortality rate due to any cause 
during the 28 days after dosing with CPI-006 plus 
SOC versus placebo plus SOC in hospitalized 
participants with mild to moderately symptomatic 
Covid-19 infection 
• 
Proportion of participants who died during the 
28 days after dosing  
Supportive Secondary  
 
• 
To compare the change from baseline in the level 
of antibodies targeting the RBD of SARS-CoV-2  
• 
Change from baseline level of IgG targeting the 
RBD at Days 7, 14, 21, and 28 
• 
To compare the time to improvement of Covid-
19-attributable symptoms including fever, cough, 
sore throat, headache, muscle pain, and shortness 
of breath 
• 
Time to resolution of  all Covid-19 attributable 
symptoms (see Appendix 8) including fever, 
cough, sore throat, headache, muscle pain, and/or 
shortness of breath reported at baseline to score of 
none or mild during the 28 days after dosing 
• 
To compare the clinical status of CPI-006 plus 
SOC versus placebo plus SOC in hospitalized 
participants with mild to moderately symptomatic 
Covid-19 infection 
• 
Change in clinical status, defined by the change in 
the 8-point ordinal scale from baseline at Days 3, 
7, 14, 21, and 28 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 29 of 114 
Version 003 
Objectives 
Endpoints 
• 
To compare the percentage of participants with 
clinical improvement with CPI-006 plus SOC 
versus placebo plus SOC in hospitalized 
participants with mild to moderately symptomatic 
Covid-19 infection 
• 
Percentage of participants with clinical 
improvement (≥ 2 points improvement in the 
8-point ordinal scale) at Days 3, 7, 14, 21, and 28  
• 
To compare the change from baseline in the level 
of antibodies targeting the RBD of SARS-CoV-2 
• 
Change from baseline level of IgM targeting the 
RBD at Days 7, 14, 21, and 28 
• 
To compare the change from baseline in the 
SARS-CoV-2 viral load 
• 
Change from baseline in the SARS-CoV-2 viral 
load at Days 3, 7, 14, 21, and 28 
• 
To compare time to PCR negativity, and 
percentage of participants with PCR negative of 
CPI-006 plus SOC versus placebo plus SOC in 
hospitalized participants with mild to moderately 
symptomatic Covid-19 infection 
• 
Time to PCR negativity during the 28 days after 
dosing 
• 
Percentage of participants with PCR negative at 
Days 7, 14, 21, and 28 
• 
To compare the change from Baseline in NEWS2 
of CPI-006 plus SOC versus placebo plus SOC in 
hospitalized participants with mild to moderately 
symptomatic Covid-19 infection 
• 
Change from Baseline in NEWS2 at Days 3 and 
7, Day of Discharge, and Day 28.                             
NEWS2 (Appendix 7) consists of: Physiological 
Parameters: respiration rate (per minute), SpO2 
Scale 1 (%), SpO2 Scale 2 (%), use of air or 
oxygen, systolic blood pressure (mmHg), pulse 
(per minute), consciousness, and temperature (°C) 
• 
To compare the medical interventions/procedures 
during the 28 days after dosing of CPI-006 plus 
SOC versus placebo plus SOC in hospitalized 
participants with mild to moderately symptomatic 
Covid-19 infection 
• 
Rate and duration of mechanical ventilation (days 
receiving invasive or non-invasive mechanical 
ventilation during the 28 days after dosing) 
• 
Rate and duration of any supplemental oxygen (if 
applicable) in days during the 28 days after dosing 
• 
Rate and duration of invasive mechanical 
ventilation (if applicable) in days during the 28 
days after dosing 
• 
Rate and duration (if applicable) in days of non-
invasive ventilation/ high flow oxygen devices 
during the 28 days after dosing 
• 
Oxygenation free days during the 28 days after 
dosing 
• 
Rate of rehospitalization during the 28 days after 
dosing 
• 
To compare the safety of CPI-006 plus SOC 
versus placebo plus SOC in hospitalized 
participants with mild to moderately symptomatic 
Covid-19 infection 
• 
Incidence, type, and severity of 
treatment -emergent adverse events of CPI-006 
plus SOC compared to placebo plus SOC assessed 
by NCI CTCAE v 5.0 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 30 of 114 
Version 003 
Objectives 
Endpoints 
Exploratory  
 
• 
To compare changes from baseline in Covid-19-
related lab assessments of CPI-006 plus SOC 
versus placebo plus SOC in hospitalized 
participants with mild to moderately symptomatic 
Covid-19 infection 
  
• 
Hematology, chemistry, CRP, and ferritin 
assessments on Days 1, 3, 5, 7, 14, 21, 28 (while 
hospitalized); Day of Discharge; and Day 28 
(return to clinic if discharged) 
• 
PT, INR, aPTT, fibrinogen, and D-dimer on 
Days 1, 3, 5, 7, 14, 21, 28 (while hospitalized), 
and Day of Discharge 
• 
Change from baseline level of IgA targeting the 
RBD at Days 7, 14, 21, and 28 
• 
Changes in IgG, IgM, or IgA antibodies targeting 
other SARS-CoV-2 antigens including (but not 
limited to) spike, nucleocapsid, and membrane 
proteins 
• 
Change from baseline in the frequency and 
function of memory B cells in the peripheral 
blood at Days 14 and 28 
• 
Changes from baseline in the frequency or 
function of memory/effector T cells in the 
peripheral blood at Days 14 and 28 
• 
B cell receptor repertoire analysis at baseline, 
Day 14, and Day 28 
• 
Systemic cytokine and chemokine levels at 
baseline and Days 7 (while hospitalized), Day of 
Discharge, and Day 28 
• 
Neutralizing antibody levels on Days 1 and 28 
using a biochemical ELISA, a pseudovirus 
neutralization assay, and a PRNT50 live virus 
assay 
• 
Change from baseline level of IgG and IgM 
targeting the RBD at Days 56, 84, and 168 
• 
To characterize the pharmacokinetics of CPI-006 
in hospitalized participants with Covid-19 
infection  
• 
PK characteristics including covariate analysis to 
determine which variables, if any, influence 
exposure of CPI-006 
Abbreviations:  aPTT = activated partial thromboplastin time; CRP = C-reactive protein; ELISA = enzyme-
linked immunosorbent assay; IgA = immunoglobulin A; IgG = immunoglobulin G; IgM = immunoglobulin M; 
INR = international normalized ratio; NCI CTCAE = National Cancer Institute Common Terminology Criteria 
for Adverse Events; NEWS2 = National Early Warning Score 2; PCR = polymerase chain reaction; PK = 
pharmacokinetic; RBD =  receptor binding domain; PT = prothrombin time; SARS-CoV-2 = severe acute 
respiratory syndrome coronavirus 2; SOC = standard of care; SpO2 = oxygen saturation. 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 31 of 114 
Version 003 
4. 
STUDY DESIGN 
4.1. 
OVERALL DESIGN 
This is a Phase 3, randomized, 3-arm, placebo controlled, double-blind, multicenter, stratified 
study of CPI-006 plus SOC versus placebo plus SOC in mild to moderately symptomatic 
hospitalized adult (≥ 18 years) participants with Covid-19. Covid-19 disease will be 
confirmed by polymerase chain reaction (PCR) or antigen testing for SARS-CoV-2. 
Approximately 1000 participants will be randomized at a 1:1:1 ratio to the 3 treatment arms 
and stratified by the following factors: 
• Region of the world (North America [US and Canada] vs. Latin America vs. 
Europe/Middle East/Africa)   
• Age (< 65 vs. ≥ 65) 
• Comorbidities (0 vs. at least 1) based on the following list: 
o Chronic lung disease (e.g., emphysema and chronic bronchitis, idiopathic 
pulmonary fibrosis, chronic obstructive pulmonary disease [COPD], or cystic 
fibrosis) or moderate to severe asthma 
o Significant cardiac disease (e.g., heart failure, coronary artery disease, 
congenital heart disease, cardiomyopathies, and pulmonary hypertension) 
o Obesity (body mass index ≥ 30 kg/m2) 
o Diabetes (Type 1, Type 2, or gestational) 
o Liver disease 
o Chronic kidney disease (CKD) 
o Sickle cell disease (SCD) 
o Organ transplantation 
o Cancer 
CPI-006 will be administered at a dose of 2 mg/kg (Treatment A – maximum dose of 
200 mg) or 1 mg/kg (Treatment B – maximum dose of 100 mg) intravenously (IV) on Day 1. 
A placebo will be given at the same schedule as the active drug for participants who receive 
the control (Treatment C). Participants, investigators, and Corvus will be blinded to the 
treatment allocation. All participants will receive supportive care according to the SOC of the 
trial hospital. If a hospital has a written policy or guideline, participants will receive 
treatment (including remdesivir, tocilizumab, steroids, convalescent plasma, anti-SARS-
CoV-2 monoclonal antibodies, or any other approved treatment) per those guidelines at the 
discretion of the investigator. Chloroquine/hydroxychloroquine are not allowed as SOC. 
Participation in any other investigational treatment during the first 28 days after 
randomization will not be allowed unless the investigator, in consult with the Corvus medical 
monitor, feels medical necessity and that such participation would not affect the integrity of 
this trial.  
After the participant’s initial eligibility is established and informed consent has been 
obtained, the study site must enroll the participant into the study by logging in to an 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 32 of 114 
Version 003 
interactive response technology (IRT) system to obtain the participant number. Every 
participant that signs the informed consent form (ICF) must be assigned with a participant 
number in IRT. Specific instructions for using IRT will be provided to the investigational site 
in the IRT Manual. The investigator or designee will register the participant for enrollment 
by following the enrollment procedures established by Corvus. 
All participants will undergo a series of efficacy, safety, and laboratory assessments. 
Participants will be assessed daily during their hospitalization. Participants’ clinical status 
based on the 8-point ordinal scale, the NEWS2, Covid-19 related signs/symptoms, and safety 
laboratory tests will be recorded every day while hospitalized including day of discharge 
from the hospital. Discharged participants will be asked to attend post- hospitalization study 
assessments at Days 14, 21, and 28, if discharged before any of these assessments were 
completed. SARS-CoV-2 PCR test will be obtained on Days 1, 7, 14, 21, and 28 while 
hospitalized; and on day of discharge (if discharged prior to Day 28) and will be tested 
locally. Samples will be collected for viral load that will be assessed at a central lab. Anti-
SARS-CoV-2 antibody samples will be collected to assessed at a central lab on Day 1 before 
dosing, and on Days 7, 14, 21, and 28 if the participant remains hospitalized as well as the 
day of hospital discharge. For participants who are discharged before Day 14, 21 and 28, a 
sample will be collected on day of discharge as well as the post-hospitalization sample 
collection on Days 14, 21, and 28 that are not collected during the hospital stay. Participants 
who consent separately to the optional assessments for anti-SARS-CoV-2 serum antibody 
tests will be asked to attend post-hospitalization assessments on Days 56, 84, and 168.  
An iDMC will be formed to monitor safety and efficacy of the study treatment at pre-
specified timepoints including futility and interim analysis timepoints. The iDMC will review 
the unblinded safety data from the first approximately 60 participants after completion of the 
Day 28 assessments. Subsequent iDMC reviews will occur when approximately 120, 250, 
400, 600, and 800 participants have completed the Day 28 assessments. The analysis with 
250 and 600 participants are the interim analyses for futility evaluation. Safety and efficacy 
data will be analyzed for the iDMC review at both interim analyses. Study enrollment will be 
paused after the first 60 participants are enrolled. Enrollment will only be re-initiated 
following iDMC recommendation. For the second iDMC review, when 120 participants are 
enrolled, the study enrollment will not be paused. For the review of the futility analysis 
(~250 participants), study enrollment will also be paused at that time. Enrollment will only 
be re-initiated following iDMC recommendation. The study will not be paused for 
enrollment for the subsequent reviews after the futility analysis. However, the iDMC may 
request a pause in enrollment at any time during the study based on the safety and efficacy 
data. 
The protocol team will review blinded pools of AE/SAE data every 2 weeks. If there are a 
significant number of unexpected AEs, the iDMC will be asked to review unblinded safety 
and efficacy data in an ad hoc meeting. Further details on the iDMC are provided in 
Section 9.2.8. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 33 of 114 
Version 003 
4.2. 
SCIENTIFIC RATIONALE FOR STUDY DESIGN 
CPI-006 activates B cells in vitro leading to B cell differentiation and secretion of 
immunoglobulins. Studies in patients with cancer have demonstrated differentiation of 
B cells into plasmablasts, trafficking from blood and return of memory B cells to blood. The 
in vitro and in vivo effects indicate that CPI-006 stimulates B cell differentiation, antigen 
driven clonal selection and differentiation into antibody producing cells. Novel anti-tumor 
antibodies have been produced in some treated patients with cancer. B cell receptor 
molecular studies have demonstrated the emergence of novel B cell clones in the blood of 
CPI-006 treated patients with cancer. No changes in total serum immunoglobulins have been 
seen to date (Willingham et al., 2020). It is believed that the activation of B cells and 
enhancement of antibody production will lead to a more robust humoral immune response to 
SARS-CoV-2 and provide clinical benefits such as shorter disease duration, less disease 
severity, fewer complications, and greater long-term immunity.  
In Study CPI-006-002 (in mild to moderate hospitalized participants with Covid-19), IgG and 
IgM antibody titers measured against the SARS-CoV-2 spike protein and/or RBD increased 
in all evaluable participants within 7 days of a single infusion of low doses of CPI-006 and 
were sustained over time. Similar results were observed in anti-SARS-CoV-2 IgA titers. No 
correlation between duration of Covid-19 symptoms and pre-treatment serum antibody levels 
has been observed in participants. Fourteen of 22 evaluable participants had low 
pre-treatment antibody titers despite relatively long durations of symptoms in some 
participants. In participants receiving 0.3 mg/kg CPI-006, all 4 evaluable participants 
achieved high IgG titers to spike protein that were sustained for at least 84 days after onset of 
symptoms. In these participants, IgM titers peaked at 14 days and remained elevated at the 
last measured timepoint of 84 days. Similar kinetics were seen in antibody responses to RBD. 
At doses above 0.3 mg/kg, durable high titers of IgG and IgM to spike protein and RBD were 
achieved out to 84 days for the 1.0 mg/kg and 3.0 mg/kg cohorts, and 28 days for the 
5.0 mg/kg cohort in the ongoing study. Peak titers increased from 0.3 mg/kg to 1.0 mg/kg 
CPI-006 but did not appear to increase for all isotypes toward each antigen from 1.0 mg/kg to 
3.0 mg/kg or from 3.0 mg/kg to 5.0 mg/kg at the evaluable time points. An increase of IgG 
titer toward spike protein was observed from 1.0 mg/kg to 3.0 mg/kg at Day 28. High and 
durable neutralizing titers were observed in subjects where ID50 values up to 23,000 were 
measured using a functional pseudovirus neutralizing antibody assay. Neutralizing titers were 
observed to persist at least 84 days following onset of symptoms in the ongoing trial. No 
changes in total serum immunoglobulins have been seen to date. 
4.3. 
JUSTIFICATION FOR DOSE 
Two active doses of CPI-006, 1.0 mg/kg up to a maximum dose of 100 mg or 2.0 mg/kg up 
to a maximum dose of 200 mg, were selected based on safety, PD, and PK parameters. Safety 
is summarized in the CPI-006 Investigational Brochure and in Section 2.3 and Section 2.4.  

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 34 of 114 
Version 003 
In the GLP general toxicity study in cynomolgus monkeys, CPI-006 was administered by 
60-minute IV infusion once weekly for 5 consecutive weeks at dose levels of 10, 30, or 
100 mg/kg, followed by a 28-day recovery period. CPI-006 doses of up to 100 mg/kg/week 
(5 total doses) were well tolerated. CD73 is expressed weakly on endothelial cells. No 
CPI-006-related changes in hematologic coagulation parameters, which included 
prothrombin time (PT) activated partial thromboplastin time (aPTT), or fibrinogen, occurred 
during the study. The NOAEL was the highest dose administered, 100 mg/kg/week, 
corresponding to maximum drug concentration in serum or plasma (Cmax) of 3,560 and 
3,280 μg/mL and AUC from the start of infusion to 169 hours after the start of infusion 
(AUC(0-169)) of 167,000 and 186,000 hr•μg/mL, for males and females, respectively. The Cmax 
and AUC from time zero to the time of the last quantifiable concentration (AUClast) for the 
GLP repeat dose cynomolgus monkey toxicity study are 60 and 66 times higher, respectively, 
than the Cmax and AUClast after a single administration of 3 mg/kg to humans in the CPI-006-
001 study. Safety margins are anticipated to be even greater for the 1 mg/kg and 2 mg/kg 
doses selected for the subject protocol. 
In clinical study CPI-006-001, 93 participants with advanced cancers received repeated IV 
infusions ranging from 1 mg/kg to 24 mg/kg CPI-006 once every 3 weeks until disease 
progression. CPI-006 was administered as a single agent or in combination with other 
oncology therapies. No DLTs were observed for CPI-006 at doses below 24 mg/kg in the 
dose escalation portion of the study. A DLT was observed in a single participant who 
received 24 mg/kg CPI-006 (Grade 3 hyponatremia in a participant with NSCLC who had a 
history of hyponatremia). The 24 mg/kg cohort was expanded, and no more DLTs were 
reported. Thus, a maximum tolerated dose was not established, and the 24 mg/kg cohort was 
defined as maximum administered dose per protocol. 
A covariate analysis was performed using serum CPI-006 levels, participant demographics, 
vital signs, laboratory values, and concomitant medications data from 93 participants who 
received 1-24 mg/kg CPI-006 in the CPI-006-001 study. Clearance was strongly associated 
with participant body weight, indicating a body weight-adjusted dose is preferred over a 
fixed dose. CPI-006 showed non-linear PK and modeling with clearance being a linear 
function of dose. The fit of the model to the data was excellent. Area under the curve (AUC) 
after a dose of 24 mg/kg is 453-fold higher than the AUC after a dose of 1 mg/kg and it is 
estimated to be 31-fold higher than the area under the serum concentration-time curve (AUC) 
after a dose of 2 mg/kg. The serum CPI-006 concentration 30 minutes after infusion was not 
modeled for a dose of 2 mg/kg, but the geometric mean 30-minute serum CPI-006 
concentration after administration of 24 mg/kg was 11.6 times higher than after 
administration of 3 mg/kg, and 40.2 times higher than after administration of 1 mg/kg, 
indicating a more than dose proportional increase in Cmax over the range of doses.  
In clinical study CPI-006-002, a single dose, dose escalation study, 27 participants 
hospitalized for mild to moderate Covid-19 symptoms were treated with a single IV infusion 
of CPI-006 ranging from 0.3 mg/kg to 5.0 mg/kg in combination with SOC. CPI-006 was 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 35 of 114 
Version 003 
well tolerated in all participants with no DLTs or treatment-related AEs reported in the study. 
Safety was monitored in the study by an iDMC.  
The preliminary geometric mean 30-minute serum CPI-006 concentrations in study CPI-006-
002 (n = 3 per cohort) for the 0.3 mg/kg, 1.0 mg/kg, and 3.0 mg/kg cohorts are 1.9 µg/mL, 
9.3 µg/mL, and 56.4 µg/mL, respectively. The 30-minute serum CPI-006 concentrations are 
similar to those for samples collected from the corresponding 1 mg/kg and 3 mg/kg cohorts 
at the same time in the CPI-006-001 oncology study. CPI-006 is rapidly cleared from serum 
and is undetectable (serum concentration < 50 ng/mL) 1-7 days after a 1 mg/kg IV infusion 
or 14-21 days after a 3 mg/kg infusion. In CPI-006-002, the relationship between clearance 
and weight was less well defined; however, there was a small statistical preference for a 
model in which clearance was weight-proportional, presumably because of fewer subject for 
whom PK data are available and the larger variability in this group of participants. 
Serum IgG and IgM antibody titers against the SARS-CoV-2 spike protein and/or RBD 
increased in all evaluable participants in CPI-006-002 within 7 days of a single infusion of 
CPI-006. Similar results were observed in serum anti-SARS-CoV-2 IgA titers. No correlation 
between duration of Covid-19 symptoms and pre-treatment serum antibody levels was 
observed in these participants. Thirteen of 17 evaluable participants had low pre-CPI-006 
infusion antibody titers despite relatively long durations of symptoms in some participants. In 
participants receiving 0.3 mg/kg CPI-006, all 4 evaluable participants achieved high IgG 
titers to spike protein that were sustained for at least 84 days after onset of symptoms. In 
these participants, IgM titers peaked at 14 days and remained elevated at the last measured 
timepoint of 84 days. Similar kinetics were observed in antibody responses to the RBD. At 
doses higher than 0.3 mg/kg, durable high titers of IgG and IgM to spike protein and RBD 
were achieved for at least 84 days, 56 days, and 28 days for the 1.0 mg/kg, 3.0 mg/kg, and 
5.0 mg/kg cohorts, respectively. Peak serum anti-SARS-CoV-2 titers increased from 
0.3 mg/kg to 1.0 mg/kg CPI-006 but did not appear to increase from 1.0 mg/kg to 5.0 mg/kg 
at the evaluable time points suggesting that the peak pharmacodynamic effect occurred in the 
range of 1.0-3.0 mg/kg CPI-006. In addition, the duration of sustained high antibody titers 
appeared optimum in the 1.0 mg/kg-3.0 mg/kg cohorts and was not improved at 5.0 mg/kg. 
Immunophenotyping of peripheral blood from participants enrolled in clinical study CPI-
006-001 demonstrated that doses greater than 1 mg/kg are sufficient to activate B cells, 
resulting in a temporary redistribution to lymphoid tissues and corresponding increase in the 
frequency of memory B cells returning to circulation. A similar increase in the frequency of 
memory B cells was observed in Covid-19 patients tested in the CPI-006-002 trial, including 
participants receiving 0.3 mg/kg CPI-006. In vitro, CPI-006 induced B cell activation is 
dose-dependent with concentrations of 1 μg/mL achieving near maximal induction of CD69. 
This initial activation leads to a morphologic transformation of B cells into plasmablasts and 
secretion of IgM and IgG in vitro. These levels of CPI-006 also result in increased expression 
of various markers involved in antigen presentation e.g. HLA-DR, CD86. A dose of 1 mg/kg 
is sufficient to sustain CPI-006 serum concentrations above 1 µg/ml for up to 48 hours and a 
dose of 2 mg/kg to sustain CPI-006 serum concentrations up to 1 week. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 36 of 114 
Version 003 
In summary, a dose of 1 mg/kg appeared to be sufficient to achieve the maximum level of 
IgG and IgM anti-SARS-CoV-2 titers in serum. Immunophenotyping of peripheral blood in 
participants from CPI-006-001 suggested that a higher dose may be required to activate 
B cells, resulting in a temporary redistribution to lymphoid tissues and corresponding 
increase in the frequency of memory B cells returning to circulation. Thus, a dose of 2 mg/kg 
was selected for investigation. 
4.4. 
END OF STUDY DEFINITION 
A participant in this study is considered to have completed the study if he/she has completed 
all study visits including Day 28 study assessments. The study visits beyond Day 28 will be 
optional for exploratory endpoint of antibody levels at Days 56, 84, and 168.   
The end of the study is defined as the date that the last expected study visit is completed for 
all participants.  
5. 
STUDY POPULATION 
5.1. 
INCLUSION CRITERIA 
1. Participants must be ≥ 18 years of age at the time of signing the informed consent.  
2. Confirmed positive by PCR or antigen test for SARS-CoV-2 with sample collection 
≤ 10 days prior to the day of randomization. PCR is the preferred method; however 
other tests for SARS-CoV-2 are allowed if authorized for use in the country. 
3. Covid-19 illness of any duration of symptoms. 
4. Participant capable of understanding the study and giving informed consent. 
Participant capable of signing and dating the written ICF. Participant must understand 
and agree to comply with planned study procedures for the duration of the study. The 
study visits beyond Day 28 will be optional and require a separate consent.  
5. Hospitalized for Covid-19 illness for ≤ 5 days with mild to moderate Covid-19 
symptoms, including: 
- 
Mild: Symptoms of Covid-19 including fever, rhinorrhea, mild cough, sore 
throat, headache, muscle pain, malaise but not requiring supplemental oxygen 
- 
Moderate: Lower respiratory symptoms: shortness of breath (SOB) or signs of 
pneumonia or lung infiltrates based on X-ray or computed tomography (CT) 
scan < 50% present 
And  
Meets the criteria for: 
- 
Category 4 - Hospitalized, not requiring supplemental oxygen - requiring 
ongoing medical care (Covid-19 related or otherwise) OR 
- 
Category 5 - Hospitalized, requiring supplemental oxygen, OR 
- 
Category 6 - Hospitalized, on non-invasive ventilation or high flow oxygen 
devices per 8-point ordinal scale (see Appendix 6).   

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 37 of 114 
Version 003 
6. Adequate organ function, as defined by: 
- 
CBC: ANC >1000/mm3, platelets>75,000mm3, Hgb >9 gm/100 cc 
- 
Calculated creatinine clearance based on ideal body weight per 
Cockcroft-Gault formula or 24-hour urine ≥ 30 mL/min 
- 
Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤ 5 × 
upper limit of normal (ULN) 
- 
D-dimer < 10,000 ng/mL 
7. Eligible participants of child-bearing age (male or female) must agree to use adequate 
contraception for a total of 6 weeks after study treatment administration 
(Appendix 5). Female participants or the female partners of male participants who 
become pregnant during the study or within the protocol-specified period after their 
last CPI-006 administration should immediately inform their treating physicians. 
5.2. 
EXCLUSION CRITERIA 
1. Signs of acute respiratory distress syndrome (ARDS) or respiratory failure 
necessitating mechanical ventilation at the time of screening (and randomization) or 
anticipated impending need for mechanical ventilation. 
2. History of severe chronic respiratory disease and requirement for long-term oxygen 
therapy. 
3. Any uncontrolled active systemic infection or hemodynamic instability requiring 
admission to an intensive care unit (ICU).  
4. Participants with malignant tumor receiving treatment, or other serious systemic 
diseases affecting life expectancy within 29 days of Screening. 
5. Receipt of cancer chemotherapy or immunomodulatory drugs including (but not 
limited to) biologics such as anti-CD20, anti-TNF, anti-IL6, anti-IL6 receptor; 
alkylating agents (e.g., cyclophosphamide); antimetabolites (e.g., azathioprine); or 
chronic corticosteroid use equivalent to prednisone >10 mg/day, during preceding 2 
months. 
Note: Steroids for treatment of Covid-19 are acceptable. 
6. Convalescent plasma (CCP) or anti-SARS-CoV-2 monoclonal antibodies 
administered less than 24 hours prior to randomization. Participants must have 
recovered from any adverse events related to CCP treatment. Received chloroquine or 
hydroxychloroquine within last 7 days or during the study. 
7. Patients who are participating in other clinical trials including participants in an 
extended access program.  
8. Active deep vein thrombosis or pulmonary embolism as confirmed by the investigator 
within last 6 months.  
9. Anticipated discharge from the hospital or transfer to another hospital which is not a 
study site within 48 hours of admission as confirmed by the investigator. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 38 of 114 
Version 003 
10. Any active uncontrolled co-morbid disease that might interfere with study conduct or 
interpretation of findings. 
11. Known to be positive for HIV or positive test for chronic HBV infection (defined as 
positive hepatitis B surface antigen [HbsAg]) or positive test for hepatitis C antibody. 
12. Pregnancy or breast feeding.  
13. Persons under legal protection or currently incarcerated. 
5.3. 
LIFESTYLE CONSIDERATIONS 
Blood, sperm, and ova donations are restricted for at least 6 weeks after CPI-006 
administration. 
5.3.1. 
Meals and Dietary Restrictions 
No dietary restrictions. 
5.3.2. 
Activity 
No required restrictions. 
5.4. 
SCREEN FAILURES 
Screen failures are defined as participants who consent to participate in the clinical study but 
are not subsequently randomized. Reasons for screen failure will be recorded.  
6. 
STUDY TREATMENT 
Study treatment is defined as any investigational treatment(s), marketed product(s), placebo, 
or medical device(s) intended to be administered to a study participant according to the study 
protocol. 
6.1. 
STUDY TREATMENT ADMINISTERED 
A summary of study treatment information is provided in Table 2. 
Table 2 
Study Treatment 
Study Treatment Name: 
CPI-006 Injection, 
200 mg/20 mL  
CPI-006 Placebo 
Dosage formulation:  
10 mg/mL with 20 mM 
histidine, 9 % sucrose, 0.01 % 
(w/v) polysorbate 80, pH 5.5. 
(5% Dextrose Injection, USP [5% dextrose 
(glucose)a]) 
Unit dose strength (s) 
200 mg / 20 mL (10 mg/mL) 
5% Dextrose 
Route of administration 
IV  
IV  

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 39 of 114 
Version 003 
Doseb 
Treatment Group A: 2 mg/kg 
up to a maximum of 200 mg  
-or-  
Treatment Group B: 1 mg/kg 
up to a maximum of 100 mg 
Treatment Group C: 
Placebo (no CPI-006) 
Dosing instructions: 
IV Infusion over 10-15 
minutes, on Day 1 followed by 
infusion line flush with 5% 
Dextrose Injection, USP (5% 
dextrose [glucose]). CPI-006 
Injection is diluted with 5% 
Dextrose Injection, USP (5% 
dextrose [glucose]). 
IV Infusion over 10-15 minutes, on Day 1 
followed by infusion line flush with 5% 
Dextrose Injection, USP (5% dextrose 
[glucose]).  
Packaging and labeling 
  
Study Treatment will be 
provided in a sterile, single-use 
vial with a rubber stopper and a 
blue cap. One vial is packaged 
inside a carton. Each vial will 
be labeled as required per 
country requirement. 
Not Applicable 
Manufacturer 
Manufactured for Corvus 
Pharmaceuticals, Inc. by Vetter 
Development Services USA, 
Inc. 
Placebo will be purchased by the clinical 
institution from commercial vendors 
approved by that institution 
Abbreviations: IV = intravenous; US/USA = United States of America; USP= United States Pharmacopeia 
a 5% Dextrose Injection, USP will be used at clinical sites within the United States; similar sterile, low-
endotoxin grades of 5% dextrose (glucose) that are commercially available and meet local or compendial laws 
and regulations may be substituted outside of the US. 
b The CPI-006 dose for participants who weigh more than 100 kg will be limited to a fixed dose of 200 mg in 
the 2 mg/kg dose group (Treatment A), or a fixed dose of 100 mg for the 1 mg/kg dose group (Treatment B). 
 
6.2. 
STUDY TREATMENT: 
PREPARATION/HANDLING/STORAGE/ACCOUNTABILITY 
1. The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study treatments received, and any 
discrepancies are reported and resolved before use of the study treatment. 
2. Only participants enrolled in the study may receive study treatment, and only 
authorized site staff may supply or administer study treatment. All study treatment 
must be stored in a secure, environmentally controlled, and monitored (manual or 
automated) area in accordance with the labeled storage conditions with access limited 
to the investigator and authorized site staff. 
3. The unblinded site staff preparing the study treatment is responsible for study 
treatment accountability, log of receipt, inventory, reconciliation, dispensing, return 
of study treatment, destruction of study treatment and record maintenance (i.e., 
receipt, reconciliation, and final disposition records). The study treatment logs and 
records must be kept current and blinded from others (e.g. investigators, site staff, 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 40 of 114 
Version 003 
participants, Sponsor and contract research organization (CRO) staff with oversight 
of study conduct). Study treatment logs must be kept in a secure location with access 
limited only to the unblinded staff members. 
4. Further guidance and information for the final disposition of unused study treatments 
are provided in the Pharmacy Manual. 
6.2.1. 
Handling and Storage 
6.2.1.1. 
CPI-006 Injection 
CPI-006 Injection is provided as a sterile solution in a single use vial that delivers up to 200 
mg of active ingredient in 20 mL (10 mg/mL). CPI-006 vials will be stored at 2°C to 8°C and 
protected from direct light. Excursions up to 25°C are allowed up to 3 days. Refer to the 
product labeling for product storage. 
The prepared CPI-006 can be stored at 2°C to 8°C for up to 24 hours and/or stored at room 
temperature (15°C to 25°C) for up to 6 hours, including the infusion time. Avoid shaking the 
prepared CPI-006.   
Do not freeze CPI-006 vials or diluted CPI-006 infusion solution. 
6.2.1.2. 
Placebo 
The placebo, 5% Dextrose Injection, USP will be purchased by each clinical site within the 
United States. Either 5% Dextrose Injection, USP or a similar sterile, low-endotoxin grade of 
5% dextrose (glucose) that is commercially available and meets local or compendial laws and 
regulations may be substituted outside of the US. The placebo should be handled and stored 
according to manufacturer’s specifications. 
The prepared placebo can be stored at 2°C to 8°C for up to 24 hours and/or stored at room 
temperature (15°C to 25°C) for up to 6 hours, including the infusion time. Avoid shaking the 
prepared placebo.   
Do not freeze the placebo. 
6.2.2. 
Preparation and Dispensing  
Refer to the Pharmacy Manual for detailed instructions on how to prepare study treatment for 
administration. Study treatment will be prepared using aseptic techniques and dispensed by 
an appropriately qualified and experienced member of the study staff (e.g., pharmacist, 
pharmacy assistant, or pharmacy technician) who is unblinded to study treatment (see 
blinding plan in the pharmacy manual). The identity of the study treatment should not be 
revealed by markings on labels or the infusion bag or infusion set except for a blinded 
randomization code. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 41 of 114 
Version 003 
CPI-006 infusion will be prepared using aseptic techniques by withdrawing the appropriate 
amount of CPI-006 Injection, 10 mg/mL from a vial into a sterile syringe. The contents of the 
syringe will be emptied into a sterile polyolefin/polyethylene (PO/PE) or polyvinyl chloride 
(PVC) infusion bag and diluted with 5% Dextrose Injection, USP or equivalent grade of 5% 
dextrose (glucose). Apply gentle mixing by inverting the IV bag; avoid shaking the IV bag. 
Placebo will be prepared using aseptic techniques. The placebo infusion is 5% Dextrose 
Injection, USP or equivalent grade of 5% dextrose (glucose) in a sterile polyolefin/ 
polyethylene (PE) or polyvinyl chloride (PVC) infusion bag. After it is prepared, the placebo 
can be stored at 2°C to 8°C for up to 24 hours and/or stored at room temperature (15°C to 
25°C) for up to 6 hours, including the infusion time. Avoid shaking the prepared placebo. 
6.2.3. 
Administration 
Administration of study treatment will be performed by an appropriately qualified, Good 
Clinical Practice (GCP)-trained, and infusion-experienced member of the study staff (e.g., 
physician, nurse, physician’s assistant, nurse practitioner, pharmacist, or medical assistant) as 
allowed by local, state, and institutional guidance. Site staff administering the study 
treatment will be blinded to the treatment (active or placebo) being administered. Participants 
will receive a single dose of study treatment by IV infusion on Day 1 of the study. Study 
treatment must be infused through an in-line filter. Infusion lines should be made of PO/PE 
or PVC, equipped with a 0.2 µm or 0.22 µm in-line polyethersulfone (PES) filter. 
The infusion should be administered via a port as close to the participant’s vein as possible to 
ensure that the full dose is administered in the allotted time. The total infusion time from start 
of infusion to completion of infusion will be 10-15 minutes. As soon as the infusion is 
complete, the infusion line used for the study treatment will be flushed with the greater of the 
priming volume of the infusion set or 30 mL of 5% Dextrose Injection, USP or equivalent 
grade of 5% dextrose (glucose) solution. The same infusion rate used for the study treatment 
infusion will be used for the flush.   
Infusion reactions are possible, thus appropriate drugs and medical equipment to treat acute 
infusion reactions must be immediately available and study personnel must be trained to 
recognize and treat infusion reactions. Premedication with diphenhydramine 50 mg PO (or 
equivalent dose of antihistamine) or diphenhydramine 25–50 mg IV and acetaminophen 500–
1000 mg PO (or equivalent dose of analgesic) prior to infusion of CPI‑006/placebo is 
recommended for participants who are not receiving steroids for treatment of Covid‑19. Oral 
premedication should be administered 30-60 minutes prior to the start of the CPI‑006/placebo 
infusion. IV diphenhydramine should be administered 15-30 minutes prior to the start of the 
CPI‑006/placebo infusion. 
Study treatment administration details will be recorded on the CRF and will include at a 
minimum: participant number, infusion start time and stop time, interruption stop and restart 
times, flush start and stop times. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 42 of 114 
Version 003 
6.2.4. 
Management of Infusion Reactions 
Any CPI-006-associated infusion reactions should also be managed as shown in Table 3. 
Table 3 
CPI-006 Infusion-Related Reaction Management Guidelines 
NCI CTCAE Grade 
Treatment 
Grade 1 
Mild reaction; infusion 
interruption not indicated; 
treatment not indicated 
  
  
  
  
  
  
Reduce infusion rate (e.g., from 10 mL/min to 5 mL/min) or 
stop infusion rate as medically indicated. 
  
Provide supportive care. Increase monitoring of vital signs as 
medically indicated. 
  
If symptoms do not improve within 1 hour, provide medical 
treatment until the participant is deemed medically stable in the 
opinion of the investigator.  
  
If infusion is stopped and symptoms resolve within 2 hours. 
CPI-006 infusion may be restarted at 25%-50% of the original 
infusion rate (e.g., from 10 mL/min to 5 mL/min). 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 43 of 114 
Version 003 
NCI CTCAE Grade 
Treatment 
Grade 2 
Requires therapy or infusion 
interruption but responds 
promptly to symptomatic 
treatment (e.g., antihistamines, 
NSAIDs, narcotics, IV fluids); 
prophylactic medications 
indicated for ≤ 24 hours 
  
  
  
  
Reduce infusion rate (e.g., from 10 mL/min to 5 mL/min) or 
stop infusion rate as medically indicated. 
  
Additional appropriate medical therapy may include but is not 
limited to: 
– IV fluids 
– Antihistamines 
– NSAIDs 
– Acetaminophen 
– Narcotics 
– Corticosteroids 
  
Increase monitoring of vital signs as medically indicated until 
the participant is deemed medically stable in the opinion of the 
investigator. 
  
If symptoms have not subsided or worsen with reduced infusion 
rate, stop infusion. 
  
If infusion is stopped and symptoms resolve within 2 hours. 
CPI-006 infusion may be restarted at 25%-50% of the original 
infusion rate (e.g. from 10 mL/min to 5 mL/min). 
  
Otherwise, if symptoms do not resolve, dosing will be held until 
symptoms resolve, and the participant should be premedicated 
for the next scheduled dose. 
  
Participants who develop Grade 2 toxicity with premedication 
and do not have symptom resolution within 2 hours of medical 
treatment should be permanently discontinued from further 
study drug treatment. 
  

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 44 of 114 
Version 003 
NCI CTCAE Grade 
Treatment 
Grade 3 
Prolonged (i.e., not rapidly 
responsive to symptomatic 
medication and/or brief 
interruption of infusion); 
recurrence of symptoms following 
initial improvement; 
hospitalization indicated for other 
clinical sequelae (e.g., renal 
impairment, pulmonary infiltrates) 
  
Stop Infusion. 
Additional appropriate medical therapy may include but is not 
limited to: 
– Epinephrinea 
– IV fluids 
– Antihistamines 
– NSAIDs 
– Acetaminophen 
– Corticosteroids 
– Narcotics 
– Oxygen 
– Vasopressors 
  
Grade 4 
Life-threatening; pressor or 
ventilator support indicated 
  
Stop Infusion. 
Additional appropriate medical therapy may include but is not 
limited to: 
- 
Epinephrinea 
- 
IV fluids 
- 
Antihistamines 
- 
NSAIDs 
- 
Acetaminophen 
- 
Narcotics 
- 
Oxygen 
- 
Vasopressors 
- 
Corticosteroids 
Increase monitoring of vital signs as medically indicated until 
the participant is deemed medically stable in the opinion of the 
investigator. 
 
Hospitalization may be indicated. 
Participant is permanently discontinued from further study drug 
treatment. 
Abbreviations: : IV = intravenous; NSAID = nonsteroidal anti-inflammatory drug. 
a In cases of anaphylaxis, epinephrine should be used immediately. 
6.3. 
Measures to Minimize Bias: Randomization and Blinding  
6.3.1. 
Randomization 
All participants will be randomized to Treatment A, Treatment B, or Treatment C in a 1:1:1 
ratio using an Interactive Response Technology (IRT). Before the study is initiated, the 
log-in information & directions for the IRT will be provided to each site. 
Participants will receive a single IV administration of study treatment on Day 1 of the study.   
Returned study treatment should not be redispensed to any participants. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 45 of 114 
Version 003 
6.3.2. 
Blinding 
This is an observer blinded design, so investigators, site staff (except the unblinded pharmacy 
personnel preparing the study treatment), participants, Sponsor, and CRO staff with oversight 
of study conduct will remain blinded to treatment allocation throughout the course of the 
study. The IRT will provide the unblinded pharmacist(s) the randomized treatment arm 
assignment to be allocated to the participant at the administration visit. Routines for this will 
be described in the IRT user manual that will be provided to each study site. 
CPI-006 Injection is a clear colorless solution and will remain clear and colorless when 
diluted in 5% Dextrose Injection, USP or equivalent grade of 5% dextrose (glucose) solution. 
At full concentration, CPI-006 is slightly more viscous than water and may create minimal 
foam if vigorously shaken. Once diluted, CPI-006 is not visually distinguishable from the 
5% Dextrose Injection, USP placebo. 
To maintain the blind, an otherwise uninvolved staff member (e.g. pharmacist, pharmacy 
assistant, or pharmacy technician) will prepare and dispense the study treatment for 
administration such that the identity (active or placebo) of the treatment is blinded to all other 
site staff responsible for administration and study conduct throughout the study. The 
unblinded personnel are responsible for study treatment preparation and accountability only 
and will not participate in any other aspect of the study. The unblinded personnel will 
endeavor to ensure that there are no differences in time taken to dispense following 
randomization or preparation that might reveal the identity of the study treatment to 
investigators, site staff, participants, Sponsor, and CRO staff.  
In the event of a Quality Assurance audit, the auditor(s) will be allowed access to unblinded 
study treatment records at the site(s) to verify that randomization/dispensing has been done 
accurately. 
6.3.3. 
Procedures for Unblinding 
The IRT will be programmed with blind-breaking instructions. In case of an emergency, the 
investigator has the sole responsibility for determining if unblinding of a participant’s 
treatment assignment is warranted. Participant safety must always be the first consideration 
in making such a determination. If the investigator decides that unblinding is warranted, the 
investigator should make every effort to contact the Sponsor prior to unblinding a 
participant’s treatment assignment unless this could delay emergency treatment of the 
participant. If a participant’s treatment assignment is unblinded, the Sponsor must be notified 
within 24 hours after breaking the blind. The date and reason that the blind was broken must 
be recorded in the source documentation and case report form, as applicable. 
6.4. 
Study Treatment Compliance 
Investigational Product will be administered on a single occasion by the investigator or 
qualified designee to participants who are hospitalized. Randomization code, treatment 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 46 of 114 
Version 003 
volume, start and stop times for the study treatment infusion, flush volume, and start and stop 
times for the flush will be accurately recorded in the CRF. 
The study site is responsible for ensuring that participants comply with the specified study 
windows. If a participant misses a visit, every effort should be made to contact the participant 
and complete a visit within the defined visit window (Appendix 1 Schedule of Activities). If 
a participant does not complete a visit within the specified time, the visit will be classified as 
a missed visit and the participant will continue with subsequent scheduled study visits. All 
safety requirements of the missed visit will be captured and included in the subsequent visit 
(e.g. clinical laboratory testing, and immunologic testing, as applicable). 
6.5. 
CONCOMITANT THERAPY 
Investigators may prescribe any concomitant medications, procedures, or treatments deemed 
necessary to provide adequate supportive care except for those listed in Section 6.5.3.   
Any medication or vaccine (including influenza vaccine and Covid-19 vaccine, which are 
both allowed concomitant medications), over-the-counter or prescription medicines, 
vitamins, and/or herbal supplements that the participant is receiving at the time of enrollment 
or receives during the study must be recorded along with: 
• Reason for use 
• Dates of administration including start and end dates 
• Dosage information including dose and frequency 
6.5.1. 
Rescue Medicine 
The study site will supply infusion reaction rescue medication that will be obtained locally by 
the clinical site. The following rescue medications may be used: 
• Antihistamine such as diphenhydramine administered PO or IV according to standard 
practices at the clinical institution for treating infusion related reactions 
• Analgesics such as acetaminophen administered PO or IV according to standard 
practices at the clinical institution for treating infusion related reactions 
• Corticosteroids administered according to standard practices at the site/hospital for 
treating infusion related reactions 
• The date and time of rescue medication administration as well as the name and 
dosage regimen of the rescue medication must be recorded in the CRF 
6.5.2. 
Permitted Concomitant Therapy 
The following concomitant medications and vaccinations are allowed and will be recorded in 
the CRF: 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 47 of 114 
Version 003 
• Therapies that are either approved or accepted as standard of care therapies for 
Covid-19 per site/institutional guidelines (e.g., remdesivir, tocilizumab, steroids, 
convalescent plasma, anti-SARS-CoV-2 monoclonal antibodies)  
• Prophylactic or therapeutic anticoagulation  
• Supportive care for management of Covid-19 symptoms and complications 
• It is recommended that participants who are not being treated with steroids for 
Covid‑19 be premedicated with diphenhydramine 50 mg PO (or equivalent dose of 
antihistamine) or diphenhydramine 25–50 mg IV and acetaminophen 500–1000 mg 
PO (or equivalent dose of analgesic) prior to infusion of CPI-006/placebo (see 
Section 6.2.3). 
The medical monitor should be contacted if there are any questions regarding concomitant or 
prior therapy. 
6.5.3. 
Prohibited Concomitant Therapy 
The following medications are prohibited and the Sponsor must be notified if a participant 
receives any of these prohibited medications. The use of the following concomitant 
medications, however, will not definitively require withdrawal of the participant from the 
study but may determine a participant’s evaluability in the per-protocol analysis set. 
If a participant receives a prohibited concomitant medication, the investigator in consultation 
with the medical monitor will evaluate any potential impact on receipt of the study 
intervention based on time the medication was administered, the medication’s pharmacology 
and pharmacokinetics, and whether the medication will compromise the participant’s safety 
or interpretation of the data.  
The following concomitant medications are prohibited:  
• Chloroquine or hydroxychloroquine 
• Cancer chemotherapy or immunomodulatory drugs for management of medical 
conditions or comorbidities other than Covid-19, including (but not limited to) 
biologics such as anti-CD20, anti-TNF, anti-IL6, anti-IL6 receptor; alkylating agents 
(e.g., cyclophosphamide); antimetabolites (e.g., azathioprine); or chronic 
corticosteroid use equivalent to prednisone >10 mg/day, during preceding 2 months. 
• Investigational medication or device (other than protocol-mandated study treatment) 
is prohibited within 30 days prior to initiation of study treatment and throughout the 
study unless the investigator, in consult with the Corvus medical monitor, feels 
medical necessity and that such participation would not affect the integrity of this 
trial. 
The medical monitor should be contacted if there are any questions regarding concomitant 
therapies. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 48 of 114 
Version 003 
6.6. 
Dose Modification 
No dose modifications for CPI-006 are allowed. 
6.7. 
Study Treatment After the End of the Study 
No study treatment will be provided to study participants at the end of the study. 
7. 
DISCONTINUATION OF STUDY TREATMENT AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL 
• Participant or participant’s physician may elect to discontinue their participation in 
the study at any time. Reasons for withdrawal will be recorded on the CRF. 
• All randomized participants will be followed for 28 days.  
• Participants who consent to optional follow-up visits will be followed for 168 days. 
7.1. 
DISCONTINUATION OF STUDY TREATMENT 
A single dose of CPI-006/placebo is administered only on Day 1 for participants, thus there is 
no discontinuation from study treatment unless the participant does not receive full dose due 
to toxicity during the infusion. Standard of care will be administered to all participants at the 
discretion of the investigator per institutional guidelines.  
7.2. 
PARTICIPANT DISCONTINUATION/WITHDRAWAL FROM THE 
STUDY 
• A participant may withdraw from the study at any time at his/her own request or may 
be withdrawn at any time at the discretion of the investigator for safety, behavioral, 
compliance, or administrative reasons. 
• If the participant withdraws consent for disclosure of future information, the Sponsor 
may retain and continue to use any data collected before such a withdrawal of 
consent. 
• If a participant withdraws from the study, he/she may request destruction of any 
samples taken and not tested, and the investigator must document this in the site study 
records. 
7.3. 
LOST TO FOLLOW-UP 
• A participant will be considered lost to follow-up if he or she repeatedly fails to 
return for scheduled visits and is unable to be contacted by the study site. 
• The following actions must be taken if a participant fails to return to the clinic for a 
required study visit: 
o The site must attempt to contact the participant and reschedule the missed visit 
as soon as possible and counsel the participant on the importance of 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 49 of 114 
Version 003 
maintaining the assigned visit schedule and ascertain whether or not the 
participant wishes to and/or should continue in the study. 
o Before a participant is deemed lost to follow-up, the investigator or designee 
must make every effort to regain contact with the participant (where possible, 
3 telephone calls and, if necessary, a certified letter to the participant’s last 
known mailing address or local equivalent methods). These contact attempts 
should be documented in the participant’s medical record. 
o Should the participant continue to be unreachable, he/she will be considered to 
have withdrawn from the study. 
8. 
STUDY ASSESSMENTS AND PROCEDURES  
Study procedures and their timing are summarized in the SoA (Appendix 1). Protocol 
waivers or exemptions are not allowed. Adherence to the study design requirements, 
including those specified in the SoA, is essential and required for study conduct. 
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility or record reasons for 
screening failure, as applicable. 
Procedures conducted as part of the participant’s routine clinical management (e.g., blood 
count) and obtained before signing of the ICF may be utilized for screening or baseline 
purposes provided the procedures met the protocol-specified criteria and were performed 
within the time frame defined in the SoA (Appendix 1). 
Hospitalized participants will receive daily monitoring and testing while in the hospital 
including routine vital sign monitoring and labs per institutional standards. Once discharged, 
participants will be asked to attend post- hospitalization study visits as described in 
Section 4.1.  
Follow-up visits after discharge could include, but are not limited to, clinic visits, outpatient 
hospital visits, home health visits or telehealth, depending on local or institutional standards. 
If no other method of follow-up is feasible, home visits may be used. 
Study assessments will utilize local labs and procedures at the clinical sites except for the key 
secondary endpoint, anti-SARS-CoV-2 antibody levels and various exploratory endpoints 
such as neutralizing antibody levels and peripheral blood immunophenotyping which will be 
assessed by the central lab. Other exploratory endpoints such as BCR repertoire analysis and 
systemic cytokine/chemokine analysis will be performed by external vendors outside of the 
central lab. Results of tests conducted at central lab, are not considered as critical to the 
management of Covid-19 in participants and will not be reported to the investigator or 
participant. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 50 of 114 
Version 003 
The anti-RBD IgG level will be measured using an electrochemiluminescent immunoassay 
on serum specimens stored at -20°C. The method is based on reactivity to immunogenic viral 
protein where a recombinant form of viral RBD antigen is absorbed to the surface of a 
96-well microtiter plate. Participant serum will be dispensed to the wells where antibodies 
recognizing the antigen are allowed to react before removal of unbound immunoglobulin 
from the wells. Anti-RBD IgG bound to the viral protein will be detected using standard 
enzyme-linked immunosorbent assay (ELISA) techniques. 
Immediate safety concerns should be discussed with the Sponsor directly upon occurrence or 
awareness to determine if the participant should continue or discontinue study treatment 
regardless of SoA assessments. Repeat or unscheduled samples may be taken for safety 
reasons or for technical issues with the samples. 
8.1. 
SCREENING  
Screening assessments and procedures are detailed in Appendix 1, Table 6. 
8.2. 
STUDY ASSESSMENTS AND PROCEDURES  
Study assessments and procedures are detailed in Appendix 1, Table 6.  
8.3. 
EFFICACY ASSESSMENTS 
The following assessments will also be performed for all participants at the time points 
described in the SoA (Appendix 1, Table 6): 
• Covid-19 Symptoms Assessment – Covid-19-attributable symptoms including fever, 
cough, sore throat, headache, muscle pain, and/or shortness of breath (Appendix 8) 
• 8-point Ordinal Scale Assessment (Appendix 6) 
• SARS-CoV-2 viral load 
• PCR negativity 
• NEWS2 Assessment (Appendix 7) 
• Anti-RBD antibody titers will be measured in sera collected at the time points 
described in the SoA (Appendix 1, Table 6). Collection of the predose timepoint is 
critical for subsequent analysis. The assays will measure IgM, IgG and IgA levels 
targeting the RBD for key and additional secondary endpoints using the 
electrochemiluminescent immunoassay. The assays will be conducted at a centralized 
testing facility using validated methods.  
• A viral PCR test by nasal swab will be obtained to demonstrate a negative test and 
viral load. Participants with positive PCR or antigen tests will have repeat PCR tests 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 51 of 114 
Version 003 
on subsequent visits until a negative test. This test will be conducted by the clinical 
lab at the investigator sites.  
• Exploratory measurements will be conducted at Sponsor’s research laboratories or 
through use of outside vendors including immunophenotyping analysis, immune cell 
functional assays, BCR repertoire analysis, systemic cytokine/chemokine analysis, 
and, anti-SARS-CoV-2 antibody characterization, and anti-viral neutralization assays. 
• Clinical assessments will include time to clinical improvement, time to resolution of 
the Covid-19 attributable symptoms, change in clinical status, rate of participants 
with clinical improvement, time to discharge, requirement for ICU, requirement for 
mechanical ventilation, duration of mechanical ventilation, oxygenation free days 
during the 28 days after dosing, and incidence and duration of new O2 use during the 
study. 
8.4. 
PHARMACOKINETIC AND PHARMACODYNAMIC ASSESSMENTS 
Serum samples will be collected from each participant enrolled in the study for measurement 
of serum concentrations of CPI-006 as specified in the SoA (Appendix 1, Table 6). A 
maximum of 4 additional samples may be collected at time points during the study if 
warranted and agreed upon between the investigator and the Sponsor. Instructions for the 
collection and handling of biological samples will be provided by the Sponsor. 
The actual collection date and time (24-hour clock time) for each sample will be recorded. 
Samples will be used to evaluate the PK of CPI-006. Each serum sample will be divided into 
3 aliquots (1 each for PK, backup, and for potential analysis of anti-drug antibodies [ADA], 
and/or neutralizing antibodies [refer to Section 8.7.1 Immunogenicity Assessments]). 
Samples collected for analyses of serum CPI-006 concentration may also be used to evaluate 
safety or efficacy aspects related to concerns arising during or after the study. 
At visits during which serum samples for the determination of PK, backup, ADA, and/or 
neutralizing antibodies of CPI-006 will be taken, one sample of sufficient volume can be 
used. 
Drug concentration information that may unblind the study will not be reported to 
investigative sites or blinded personnel until the study has been unblinded. 
Any changes in the timing or addition of time points, up to 4 time points, for any planned 
study assessments must be documented and approved by the relevant study team member and 
then archived in the Sponsor and site study files, but will not constitute a protocol 
amendment. The Institutional Review Board (IRB)/Independent Ethics Committee (IEC) will 
be informed of any safety issues that require alteration of the safety monitoring scheme or 
amendment of the ICF. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 52 of 114 
Version 003 
8.5. 
SAFETY ASSESSMENTS 
The following assessments will also be performed for all participants at the time points 
described in the SoA (Appendix 1, Table 6): 
• Incidence, type, and severity of AEs and SAEs assessed by NCI CTCAE v 5.0 to 
compare safety of CPI-006 plus SOC to placebo plus SOC.  
• Safety assessments will be made using local lab testing (Appendix 3) for hematology, 
chemistry, coagulation, inflammatory markers and serum quantitative 
immunoglobulins. 
• Routine physical exams. 
• Vital signs (pulse rate, blood pressure, respiratory rate, temperature and blood oxygen 
saturation) including at start, at conclusion and at approximately 2 hours after 
completion of the CPI-006/placebo infusion.  
8.6. 
ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS 
The definitions of an AE or SAE can be found in Appendix 4. 
AEs will be reported by the participant (or, when appropriate, by a caregiver, or surrogate). 
The investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible for 
following up AEs that are serious, considered related to the study treatment or study 
procedures, or that caused the participant to discontinue the administration of  CPI-006/ 
placebo, or the study (see Section 7). 
8.6.1. 
Time Period and Frequency for Collecting AE and SAE Information 
After informed consent has been obtained but prior to initiation of study treatment, only 
SAEs caused by protocol-mandated procedures (e.g., study related procedures, 
discontinuation of medications) should be reported (see Appendix 4).  
After initiation of study treatment, all AEs and SAEs will be reported until completion of the 
study at Day 28.  
Medical occurrences that begin before the start of study treatment but after obtaining 
informed consent will be recorded on the Medical History/Current Medical Conditions 
section of the CRF, not the AE section. 
All SAEs will be recorded and reported to the Sponsor or designee within 24 hours, as 
indicated in Appendix 4. The investigator will submit any updated SAE data to the Sponsor 
within 24 hours of it being available. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 53 of 114 
Version 003 
For participants with worsening of Covid-19, the clinical event(s) that mark the worsening 
should be reported as AE or an SAE (see definitions in Appendix 4). Investigators are not 
obligated to actively seek AEs or SAEs outside clinical practice after conclusion of the study 
participation. However, if the investigator learns of any SAE, including a death, at any time 
after a participant has been discharged from the study, and he/she considers the event to be 
reasonably related to the study treatment or study participation, the investigator must 
promptly notify the Sponsor. 
The method of recording, evaluating, and assessing causality of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Appendix 4. 
8.6.2. 
Method of Detecting AEs and SAEs 
The investigator is responsible for ensuring that all AEs are recorded on the Adverse Event 
CRF and reported to the Sponsor in accordance with instructions provided in this section and 
in Appendix 4. 
For each AE recorded on the Adverse Event CRF, the investigator assesses seriousness, 
severity, and causality as per Appendix 4. 
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about AE 
occurrences. 
Reporting requirements for SAEs can be found in Appendix 4. 
8.6.3. 
Follow-up of AEs and SAEs 
After the initial AE/SAE report, the investigator is required to proactively follow each 
participant at subsequent visits/contacts. All SAEs (as defined in Appendix 4), will be 
followed until resolution, stabilization, the event is otherwise explained, or the participant is 
lost to follow-up (as defined in Section 7.3). Further information on follow-up procedures is 
given in Appendix 4. 
8.6.4. 
Regulatory Reporting Requirements for SAEs 
• Prompt notification by the investigator to the Sponsor of a SAE is essential so that 
legal obligations and ethical responsibilities towards the safety of participants and the 
safety of a study treatment under clinical investigation are met. 
• The Sponsor has a legal responsibility to notify both the local regulatory authority 
and other regulatory agencies about the safety of a study treatment under clinical 
investigation. The Sponsor will comply with country-specific regulatory requirements 
relating to safety reporting to the regulatory authority, IRB/IEC, and investigators. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 54 of 114 
Version 003 
• Investigator safety reports must be prepared for suspected unexpected serious adverse 
reactions (SUSAR) according to local regulatory requirements and Sponsor policy 
and forwarded to investigators as necessary. 
• An investigator who receives an investigator safety report describing a SAE or other 
specific safety information (e.g., summary or listing of SAEs) from the Sponsor will 
review and then file it along with the Investigational Brochure and will notify the 
IRB/IEC, if appropriate according to local requirements. 
8.7. 
BIOMARKERS  
Serum at baseline and at specified times will be stored at -20°C for use in various serology 
studies which include: 
Supportive Secondary Endpoints 
• Measurement of anti-RBD IgG, IgM, and IgA levels.  
Exploratory Endpoints 
• Measurement of neutralizing antibody levels that block association of viral RBD and 
human ACE2 assessed in a biochemical ELISA. 
• Measurement of neutralizing antibody levels that block infection assessed in a 
pseudovirus assay, and in a live virus assay 
• Changes in IgG, IgM, or IgA antibodies targeting other SARS-CoV-2 antigens 
including (but not limited to) spike, nucleocapsid, and membrane proteins. 
• Additional exploratory serum assays may be conducted with extra serum not required 
for primary analysis. 
Peripheral blood collected at baseline and at specified times will be analyzed while fresh or 
processed into PBMCs and cryopreserved for use in various studies including: 
• Immunophenotyping using flow cytometry to evaluate the frequency of memory 
B cells and memory/effector T cells 
• Functional B and T cell assays to evaluate ex vivo immune responses to SARS-CoV-
2 antigens compared to controls. 
• BCR repertoire analysis to evaluate effects of CPI-006 on B cell clonality and 
antibody isotype switching 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 55 of 114 
Version 003 
8.7.1. 
Immunogenicity Assessments 
Antibodies to CPI-006 may be evaluated in serum samples collected from participants 
according to the SoA. These samples may be tested by the Sponsor or Sponsor’s designee. 
Serum samples may be screened for antibodies binding to CPI-006 and the titer of confirmed 
positive samples will be reported. Other analyses may be performed to verify the stability of 
antibodies to CPI-006 and/or further characterize the immunogenicity of CPI-006 
The detection and characterization of antibodies to CPI-006 will be performed using a 
validated assay method by or under the supervision of the Sponsor. All samples collected for 
detection of antibodies to study treatment may also be evaluated for CPI-006 serum 
concentration to enable interpretation of the antibody data. Antibodies may be further 
characterized and/or evaluated for their ability to neutralize the activity of the study 
treatment(s). Samples may be stored for a maximum of 5 years (or according to local 
regulations) following the last participant’s last visit for the study at a facility selected by the 
Sponsor to enable further analysis of immune responses to CPI-006. 
9. 
STATISTICAL CONSIDERATIONS 
9.1. 
SAMPLE SIZE DETERMINATION 
Approximately 1000 hospitalized participants with mild to moderately symptomatic 
Covid-19 will be enrolled. The participants will be randomized in a 1:1:1 ratio between 
Treatment A, Treatment B and Treatment C (approximately 330 per arm) within each of the 
strata defined by: 
• Region of the world (North America [(US and Canada] vs. Latin America vs. 
Europe/Middle East/Africa). 
• Age (< 65 vs. ≥ 65) 
• Comorbidities (0 vs. at least 1) based on the following list: 
o Chronic lung disease (e.g., emphysema and chronic bronchitis, idiopathic 
pulmonary fibrosis, COPD, or cystic fibrosis) or moderate to severe asthma 
o Significant cardiac disease (e.g., heart failure, coronary artery disease, 
congenital heart disease, cardiomyopathies, and pulmonary hypertension) 
o Obesity (body mass index ≥ 30 kg/m2) 
o Diabetes (Type 1, Type 2, or gestational) 
o Liver disease 
o CKD 
o SCD 
o Organ transplantation 
o Cancer 
With approximately 330 participants per treatment arm, there would be an approximately 
80% power to show a statistically significant superiority of Treatment A over Treatment C in 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 56 of 114 
Version 003 
the proportion of participants alive and free from respiratory deterioration during the 28 days 
after dosing at a 1-sided α level of 0.0125 when the true proportion of Treatment A is 92% 
and that of Treatment C is 84%. The same sample size and power statement also holds for the 
comparison between Treatment B and C.  
9.2. 
STATISTICAL ANALYSES 
The Statistical Analysis Plan (SAP) will be developed and finalized before the first interim 
analysis (the futility analysis, see Section 9.2.7) and will describe the study populations to be 
included in the analyses. This section is a summary of the planned statistical analyses of the 
primary and key secondary endpoints.  
9.2.1. 
POPULATION FOR ANALYSES 
For purposes of analyses, the following populations are defined in Table 4. 
Table 4 
Population Definitions 
Population 
Description 
Intent-to-treat (ITT) 
All participants who are randomized into the study and analyzed 
according to treatment assigned at randomization.  
Efficacy 
All participants who receive any amount of study drug (CPI-006 
or placebo) and have post-baseline efficacy assessment based on 
the 8-point ordinal scale. The participants will be analyzed 
according to the treatment actually received.  
Safety 
All participants who receive any amount of study treatment 
(CPI-006, placebo, or SOC). 
Pharmacokinetic 
All participants who receive CPI-006 and had at least 
1 post-treatment blood sample collected 
Abbreviations: ITT = intent-to-treat;  SOC = standard of care 
9.2.2. 
General Approach 
Unless otherwise specified, the following general analysis will be performed. Continuous 
variables will be summarized using the following descriptive statistics: number of observed 
values, mean, standard deviation, median, and minimum and maximum. Categorical 
variables will be summarized using frequencies and percentages. Time-to-event variables, 
when appropriate, will be summarized by the median with 95% confidence intervals (CI) and 
the 25% and 75% quartiles. Kaplan-Meier curves will be provided. The baseline value for 
analysis variable is the last measurement before administration of study treatments. 
In addition to the analyses specified below for the key estimands, the primary and key 
secondary endpoints will be summarized with univariate analyses including point estimates 
and associated confidence intervals by treatment group. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 57 of 114 
Version 003 
9.2.3. 
Demographic and Participant Characteristics 
Demographic information such as age, gender, race, body weight, and participant 
characteristics such as baseline disease severity, symptoms, and comorbidities will be listed 
and summarized. 
9.2.4. 
Efficacy Analyses 
Table 5 
Efficacy Endpoints 
 
Endpoints 
Primary  
The primary efficacy endpoint is the proportion of participants who are alive and free from 
respiratory deterioration during the 28 days after dosing defined as follows per the 8-point 
ordinal scale (Appendix 6):   
• Deterioration to Categories 6, 7, or 8 for a participant who entered the trial at Categories 4 
or 5    
• Deterioration to Categories 7 or 8 for a participant who entered the trial at Category 6 
 
Secondary 
Key Secondary Endpoints:  
• 
Time to recovery during the 28 days after dosing. Day of recovery is defined as the first 
day on which the participant satisfies 1 of the following 3 categories from the 8-point 
ordinal scale (Appendix 6):  
o Not hospitalized, no limitations on activities. 
o Not hospitalized, limitation on activities and/or requiring home oxygen;  
o Hospitalized, not requiring supplemental oxygen – no longer requires 
ongoing medical care. 
• 
Time clinical improvement (≥ 2 points improvement in the 8-point ordinal scale) during 
the 28 days after dosing. 
• 
Proportion of participants who died during the 28 days after dosing. 
 
Supportive Secondary Endpoints:  
• 
Change from baseline level of IgG targeting the RBD at Days 7, 14, 21, and 28. 
• 
Time to resolution of all Covid-19 attributable symptoms (see Appendix 8) including 
fever, cough, sore throat, headache, muscle pain, and/or shortness of breath reported at 
baseline to score of none or mild during the 28 days after dosing 
• 
Change in in clinical status, defined by the change in the 8-point ordinal scale from 
baseline at Days 3, 7, 14, 21, and 28. 
• 
Percentage of participants with clinical improvement (≥ 2 points improvement in the 8-
point ordinal scale) at Days 3, 7, 14, 21, and 28.  
• 
Change from baseline level of IgM targeting the RBD at Days 7, 14, 21, and 28. 
• 
Change from baseline in the SARS-CoV-2 viral load at Days 3, 7, 14, 21, and 28.  
• 
Time to PCR negativity during the 28 days after dosing 
• 
Percentage of participants with PCR negative at Days 7, 14, 21, and 28 
• 
Change from Baseline in NEWS2 at Days 3 and 7, Day of Discharge, and Day 28. 
NEWS2 (Appendix 7) consists of: Physiological Parameters: respiration rate (per minute), 
SpO2 Scale 1 (%), SpO2 Scale 2 (%), use of air or oxygen, systolic blood pressure 
(mmHg), pulse (per minute), consciousness, and temperature (°C).  
• 
Rate and duration of mechanical ventilation (days receiving invasive or non-invasive 
mechanical ventilation during the 28 days after dosing) 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 58 of 114 
Version 003 
• 
Rate and duration of any supplemental oxygen (if applicable) in days during the 28 days 
after dosing 
• 
Rate and duration of invasive mechanical ventilation (if applicable) in days during the 28 
days after dosing 
• 
Rate and duration (if applicable) in days of non-invasive ventilation/ high flow oxygen 
devices during the 28 days after dosing 
• 
Oxygenation free days during the 28 days after dosing 
• 
Rate of rehospitalization during the 28 days after dosing 
Exploratory 
• 
Hematology, chemistry, CRP, and ferritin assessments on Days 1, 3, 5, 7, 14, 21, 28 
(while hospitalized); Day of Discharge; and Day 28 (return to clinic if discharged) 
• 
PT, INR, aPTT, fibrinogen, and D-dimer on Days 1, 3, 5, 7, 14, 21, 28 (while 
hospitalized), and Day of Discharge 
• 
Change from baseline level of IgA targeting the RBD at Days 7, 14, 21, and 28 
• 
Changes in IgG, IgM, or IgA antibodies targeting other SARS-CoV-2 antigens including 
(but not limited to) spike, nucleocapsid, and membrane proteins 
• 
Change from baseline in the frequency and function of memory B cells in the peripheral 
blood at Days 14 and 28 
• 
Changes from baseline in the frequency or function of memory/effector T cells in the 
peripheral blood at Days 14 and 28 
• 
B cell receptor repertoire analysis at baseline, Day 14, and Day 28 
• 
Systemic cytokine and chemokine levels at baseline and Days 7 (while hospitalized), Day 
of Discharge, and Day 28 
• 
Neutralizing antibody levels on Days 1 and 28 using a biochemical ELISA, a pseudovirus 
neutralization assay, and a PRNT50 live virus assay 
• 
Change from baseline level of IgG and IgM targeting the RBD at Days 56, 84, and 168 
All efficacy analyses will be performed based on the ITT population, with appropriate 
estimands that include strategies to address potential intercurrent events (ICE). Three 
possible ICEs have been identified for this trial within the 28-day study duration after 
randomization. They are: all-cause death (ICE-1), receiving life-saving procedures including 
ICU admission (ICE-2), and all other intercurrent events (ICE-3) (receiving investigational or 
non-approved treatments intended for treatment of Covid-19 at the time of randomization, 
incomplete study dosing/infusion, usage of prohibited medications, early study 
discontinuation, etc.). See the description and details of possible types of intercurrent event in 
Appendix 9 (Table 11). 
9.2.4.1. 
Analysis of Primary and Key Secondary Efficacy Endpoints 
Estimands for the primary and key secondary endpoints are defined and presented in detail in 
Appendix 9 (Table 12). 
9.2.4.1.1. 
Analysis of Primary Endpoint: Estimand 1 
For the primary endpoint, Estimand 1a (main estimand) will be defined as a hybrid 
estimand, which combines two strategies for handling intercurrent events. The intercurrent 
event of death (ICE-1) is part of the composite endpoint, and all other intercurrent events will 
be addressed with the treatment policy strategy (ICH E9 [R1] Addendum 2017). The primary 
analysis will be based on a logistic regression model adjusted for the stratification factors 
(region of the world, age, and presence of comorbidities) (Ge et al. 2011). The potential-

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 59 of 114 
Version 003 
outcome framework will be applied to compute population-level estimates of the proportions 
of participants alive and free from respiratory deterioration during the 28 days after dosing in 
the 2 treatment groups. The treatment effect will be assessed by the difference between 
Treatment A (or B) and Treatment C at the population level. Confidence interval with 
appropriate confidence level for the difference between treatments will also be provided. 
Further details of the potential outcome framework are provided in Appendix 10. 
Estimand 1b is a sensitivity analysis for the primary endpoint. The intercurrent event of 
death (ICE-1) and receiving life-saving procedures including ICU admission (ICE-2) will be 
a part of the composite endpoint. All other intercurrent events (ICE-3) will be addressed with 
the treatment policy strategy. In this analysis, ICE-1 and ICE-2 will be considered equivalent 
in analysis. In other words, a participant will be considered as a treatment failure equivalent 
to death if the participant receives life-saving procedures. Ge’s method will be used for this 
sensitivity analysis. Details regarding receiving life-saving procedures will be provided in the 
SAP. 
Other Sensitivity analyses which are based on control-based imputation and delta-adjusted 
imputation (tipping point), will be conducted as part of the proposed estimand framework. 
The missing 8-point ordinal scale assessments after baseline for participants with ICE-2 or 
ICE-3 will be imputed. For the control-based imputation, imputation for all treatment groups 
will be informed by participants in the control group with the ICE’s who have outcomes 
collected after the ICE. For the delta-adjusted imputation, imputation will be informed by the 
participants in the respective treatment group with ICE’s who have outcomes collected after 
the ICE. For each imputation method, the estimated treatment effects and associated standard 
errors from the individual completed data sets will be combined using Rubin’s rules to 
produce a single inferential statement (treatment effect, standard error and p-value). A 
detailed description of the sensitivity analyses will be provided in the SAP. 
9.2.4.1.2. 
Analysis of Secondary Endpoints: Estimand 2, 3, and 4 
For the key secondary endpoints time to recovery (Estimand 2) and time to clinical 
improvement (Estimand 3), Kaplan-Meier estimates will be presented by treatment group. 
Overall homogeneity of  the distribution functions of time to recovery as well as time to 
clinical improvement between Treatment A (or B) and Treatment C will be tested using log-
rank method with adjustment for stratification (region of the world, age, and presence of 
comorbidities). Participants hospitalized beyond Day 28 or experiencing death due to all 
causes prior to or on Day 28 will be censored at Day 28. Participants withdrawing consent 
and not achieving the endpoint will be censored at their last day in the study up to Day 28. 
Sensitivity analysis for time to recovery (Estimand 2) and time to clinical improvement 
(Estimand 3) will be carried out using Restricted Mean Survival Time (RMST) method. The 
RMST of time to the event (with cutoff at Day 28) will be estimated by treatment group 
using the Kaplan-Meier method. Participants hospitalized beyond Day 28 or experiencing 
death prior to or on Day 28 will be censored at Day 28. Participants withdrawing consent and 
not achieving the endpoint will be censored at their last day in the study up to Day 28. The 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 60 of 114 
Version 003 
difference in RMST between two compared groups will be tested using a two-sample t-test. 
Further details of the sensitivity analyses including descriptive statistics by RMST will be 
provided in the SAP. 
The cumulative mortality rate over the 28 day period from dosing (Estimand 4) will be 
estimated with time to death of participants in each treatment group using Kaplan-Meier 
methods. The absolute difference in the log-transformed estimated mortality rate will be 
calculated between Treatment A (or B) and Treatment C. A multiplicity adjusted 2-sided CI 
(97.5% or 95%, depending on the multiplicity adjustment) will be obtained for this difference 
in log-transformed mortality rates, using a variance for this difference being the sum of the 
variances of the two compared treatment groups obtained using Greenwood’s formula. 
Results will be anti-logged to give the estimated ratio of the cumulative mortality rates 
through day 28 (Treatment A [or B] relative to Treatment C) and its associated multiplicity 
adjusted CI. The CI will be used to assess the non-inferiority of Treatment A (or B) in 
comparison to Treatment C against the non-inferiority margin of 1.3. If the upper limit of the 
anti-logged CI of the mortality ratio of Treatment A (or B) relative to Treatment C is below 
1.3, then that treatment would be established as non-inferior to Treatment C. Appendix 13 
contains a summary of a simulation study overviewing the operating characteristics of the 
test for non-inferiority relative to the 1.3 testing boundary. 
If Treatment A (or B) is established as non-inferior to Treatment C, then that treatment will 
be tested for superiority against Treatment C. The test of superiority will compare the upper 
limit of the anti-logged CI of the mortality ratio of Treatment A (or B) relative to Treatment 
C to 1.0. If it is less than 1.0 then Treatment A (or B) would be established as superior to 
Treatment C. Further details of the tests for non-inferiority and superiority in mortality will 
be provided in the SAP. 
9.2.4.1.3. 
Statistical Hypotheses for the Primary and Key Secondary Endpoints 
The following hypotheses are defined for the comparisons between Treatment A and 
Treatment C - Treatment A Hypotheses Family: 
Null Hypothesis HAi: Treatment A is not superior to Treatment C with respect to endpoint i  
versus 
H'Ai: 
Treatment A is superior to Treatment C with respect to endpoint i, 
where i = 1 for the primary endpoint “proportion of participants alive and free from 
respiratory deterioration during the 28 days after dosing”; 
i = 2 for the secondary endpoint “time to recovery during the 28 days after dosing”; 
i = 3 for the secondary endpoint “time to clinical improvement by at least 2 points 
during the 28 days after dosing”; 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 61 of 114 
Version 003 
Null Hypothesis HA4: Treatment A is inferior to Treatment C with respect to the secondary 
endpoint “mortality rate over the 28 days after dosing”. 
versus 
H'A4: Treatment A is non-inferior to Treatment C with respect to the secondary endpoint 
 
“mortality rate over the 28 days after dosing”. 
 
Null Hypothesis HA5: Treatment A is not superior to Treatment C with respect to the 
secondary endpoint “mortality rate over the 28 days after dosing”. 
versus 
H'A5: Treatment A is superior to Treatment C with respect to the secondary endpoint 
 
“mortality rate over the 28 days after dosing”. 
The same hypotheses HBi versus H'Bi , for the endpoints indicated by i = 1, 2, 3, 4, and 5 will 
be tested for the comparison between Treatment B and C - Treatment B Hypotheses Family. 
9.2.4.1.4. 
Parallel Gatekeeping Procedure for Testing Hypotheses 
The overall one-sided Type-I error rate α=0.025 is initially equally split for the Treatment A 
Family and Treatment B Family for testing the 5 hypotheses within a treatment family. A 
parallel gatekeeping strategy with multiplicity adjustment is designed to control the overall 
Type I error rate α at the one-sided 0.025 level for testing the hypotheses in the 2 families. 
The 5 hypotheses are arranged in the hierarchical order described above for statistical testing 
within each treatment family. The details of the gatekeeping strategy and stepwise testing 
procedures are presented in Appendix 11. 
9.2.5. 
Supportive Secondary and Exploratory Endpoints 
Analysis methodologies for the supportive secondary endpoints and exploratory endpoints 
will be described in the SAP, including the analyses for PK, pharmacodynamic (PD), and 
biomarkers, before database lock.  
9.2.6. 
Safety Analyses 
The safety analyses will include all participants in the Safety Population. 
Safety will be assessed through summaries of AEs (including SAEs), changes in laboratory 
test results, physical examination findings, and vital signs. 
AEs will be coded using the current version of Medical Dictionary for Regulatory Activities 
(MedDRA, Version 23.0) to categorize each AE by System Organ Class and Preferred Term. 
The number of participants who experienced at least 1 AE; treatment-related AE; severe 
(Grade 3 or higher) AE, SAE; and the number of participants withdrawn from treatment due 
to AEs will be summarized. The incidence of AEs will be presented overall, by System 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 62 of 114 
Version 003 
Organ Class and Preferred Term, by intensity (based on National Cancer Institute Common 
Terminology Criteria for Adverse Events [NCI CTCAE], Version 5), by severity, by 
relationship to study treatment or if treatment-emergent, and by treatment. Individual listings 
of AEs will be provided. Study treatment related AEs will be listed individually. 
Laboratory tests will be listed and summarized for each test. Lab values will be graded 
according to the NCI-CTCAE criteria and summarized. 
Deaths and related information will be listed. 
9.2.7. 
Interim and Final Analyses 
Two formal interim analyses are planned for this study. The first interim analysis is a 
non‑binding futility analysis and will be performed when approximately 250 of participants 
have been enrolled into the study with 28 days of follow-up time. Safety and efficacy will be 
analyzed for futility evaluation. 
The second interim analysis is a non-binding futility and efficacy analysis and will be 
performed when approximately 600 of participants have been enrolled with 28 days of 
follow-up time. Comparison between Treatment A and C, and between Treatment B and C, 
with respect to the primary and key secondary efficacy endpoints will be performed at this 
interim analysis.   
At both interim analyses, unblinded analyses will be provided by a separate unblinded 
statistician to the iDMC for making futility assessment.   
As part of the second interim analysis, Corvus may request the iDMC to assess the primary 
efficacy endpoint and its conditional power of establishing a significant treatment effect at 
the final analysis based on the interim data. The total sample size of the study may be 
increased with the recommendation by iDMC. The sample size adaptation plan and increase 
rule will be detailed in the statistical analysis plan and provided to the regulatory authority 
before the first interim analysis. 
The primary analysis of the study is the final analysis. Safety and efficacy analyses will be 
performed when all the participants of the study have completed the Day 28 assessments.  
9.2.7.1. 
Efficacy Stopping Criteria  
The following non-binding efficacy stopping criteria will be applied for the two interim 
analyses after approximately 250 and 600 participants are enrolled: 
• At the first interim analysis, stop enrollment if the z-score is ≤ -0.4. 
• At the second interim analysis, stop enrollment if the z-score is ≤ 1.2. 
The efficacy stopping criteria applies independently to either or both Treatment A and/or B 
when compared to Treatment C. The z-score is the standardized difference of Treatment A 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 63 of 114 
Version 003 
(or B) minus Treatment C with respect to the primary efficacy endpoint. Further details 
regarding the efficacy stopping criteria are provided in Appendix 12. 
9.2.8. 
Independent Data Monitoring Committee (iDMC) 
An iDMC will be formed to monitor safety and efficacy of the study treatment at pre-
specified timepoints including futility and interim analysis timepoints. The iDMC will review 
the unblinded safety data from the first 60 participants after completion of the Day 28 
assessments. Subsequent iDMC reviews will occur when approximately 120, 250, 400, 600, 
and 800 participants have completed the Day 28 assessments. The analysis with 250 and 600 
participants are the interim analyses for futility evaluation., Safety and efficacy data will be 
analyzed for the iDMC review for futility evaluation.  
Study enrollment will be paused after the first 60 participants are enrolled. Enrollment will 
only be re-initiated following iDMC recommendation. For the second iDMC review, when 
120 participants are enrolled, the study enrollment will not be paused. For the review of the 
first futility analysis (~250 participants), study enrollment will also be paused at that time. 
Enrollment will only be re-initiated following iDMC recommendation. The study will not be 
paused for enrollment for the subsequent reviews after the first futility analysis. However, the 
iDMC may request a pause in enrollment at any time during the study based on the safety 
and efficacy data. In addition, the iDMC is available for ad hoc reviews for safety concerns. 
The protocol team will review blinded pools of AE/SAE data every 2 weeks. If there are a 
significant number of unexpected AEs, the iDMC will be asked to review unblinded safety 
and efficacy data in an ad hoc meeting.  
iDMC membership includes: 
• Three clinicians experienced in care/management of Covid-19 and an unblinded 
independent statistician (all voting members) 
9.2.8.1. 
Safety Stopping Criteria 
The following safety stopping criteria will be applied for the two safety assessments (after 60 
and 120 participants are enrolled) and at the time of the futility analysis after 250 participants 
are enrolled: 
• Grade 5 AEs in the active arms ≥20% compared to placebo. 
• Grade 3-4 AEs in the active arms ≥20% compared to placebo. 
The iDMC may recommend stopping at any time for safety concerns. The IDMC will make 
the determination based on review of unblinded safety and efficacy data.  
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 64 of 114 
Version 003 
10. 
REFERENCES 
Bretz F, Maurer W, Brannath W, Posch M. A graphical approach to sequentially rejective multiple 
test procedures. Statistics in medicine. 2009;28(4):586-604. 
Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel 
coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020 
Feb 15;395(10223):514-523. 
Dmitrienko A, D'Agostino Sr R. Traditional multiplicity adjustment methods in clinical trials. 
Statistics in Medicine. 2013;32(29):5172-218. 
Du L, He Y, Zhou Y, et al. The spike protein of SARS-CoV –- a target for vaccine and therapeutic 
development. Nat Rev Microbiol. 2009 Mar;7(3):226-36. 
European Medicines Agency. ICH E9 (R1) addendum on estimands and sensitivity analysis in 
clinical trials to the guideline on statistical principles for clinical trials – Addendum – Step 5. 
2017 Jul. 
Ge M, Durham LK, Meyer RD, et al. Covariate-adjusted difference in proportions from clinical trials 
using logistic regression and weighted risk differences. Drug information journal: DIJ/Drug 
Information Association. 2011 Jul;45(4):481-93. 
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in 
Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. 
Joyner MJ, Senefeld JW, Klassen SA, et al. Effect of convalescent plasma on mortality among 
hospitalized patients with Covid-19: initial three-month experience. MedRxiv. 2020. 
Luke JJ, Merchan J; Harshman L, et al. Immunobiology and clinical activity of CPI-006, an anti-
CD73 antibody with immunomodulating properties in a Phase 1/1b trial in advanced cancers. J. 
Immunother. Cancer 2019b Nov;7(suppl.1) 282. 
Luke JJ, Powderly JD, Merchan JR, et al. Immunobiology, preliminary safety, and efficacy of CPI-
006, an anti-CD73 antibody with immune modulating activity, in a phase 1 trial in advanced 
cancers. J. Clin. Oncol. 2019a 37(15 suppl.). 
Rasheed AM, Ftak DF, Hashim HA, et al. The therapeutic effectiveness of Convalescent plasma 
therapy on treating Covid-19 patients residing in respiratory care units in hospitals in Baghdad, 
Iraq. medRxiv. 2020. 
Resta R, Thompson LF. T cell signaling through CD73. Cell Signal. 1997 Feb;9(2):131-9. 
Royal College of Physicians. National early warning score (NEWS) 2. Standardising the assessment 
of acute-illness severity in the NHS. 2017. 
Willingham SB, Criner G, Hill C, et al. Characterization and Phase 1 Trial of a B Cell Activating 
Anti-CD73 Antibody for the Immunotherapy of Covid-19. medRxiv. 2020. 
World Health Organization. Coronavirus disease 2019 (Covid-19): situation report, 72. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 65 of 114 
Version 003 
Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion 
conformation. Science. 2020 Mar 13;367(6483):1260-1263. 
Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. 
Nature. 2020 Apr; 580(7803):E7. 
Yuan M, Wu NC, Zhu X, et al. A highly conserved cryptic epitope in the receptor-binding domains of 
SARS-CoV-2 and SARS-CoV. Science. 2020 Apr 3. pii: eabb7269 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 66 of 114 
Version 003 
APPENDIX 1 
SCHEDULE OF ACTIVITIES 
Table 6 
Schedule of Activities 
Procedure 
Screening 
(up to 3 
days before 
Day 1) a 
Day 1 
Day 2 to X 
(during 
hospital 
stay)b 
Day 7 (if 
participant 
remains in 
the 
hospital)c 
Day of 
Hospital 
Discharge c 
Day 7 (if 
participant 
is 
discharged 
from 
hospital)d 
Day 
14c, d, e 
Day 
21c, d, e 
Early 
Termination 
D28d 
Optional 
Assessment 
Day 
56d 
Day 
84d 
Day 
168d 
Informed Consent 
X 
 
 
 
 
 
 
 
 
 
 
 
Inclusion and Exclusion Criteria 
X 
 
 
 
 
 
 
 
 
 
 
 
Demography 
X 
 
 
 
 
 
 
 
 
 
 
 
Physical Examination 
X 
 
 
 
 
 
 
 
 
 
 
 
Limited Physical Exam 
 
X 
X 
X 
X 
 
 
 
X 
 
 
 
Medical History  
X 
 
 
 
 
 
 
 
 
 
 
 
Covid-19 Symptoms Assessmentf 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
 
National Early Warning Score 2 Assessment 
X 
X 
X 
X 
X 
 
 
 
X 
 
 
 
8-point Ordinal Scale Assessment  
X 
X 
X 
X 
X 
 
Xg 
Xg 
X 
 
 
 
Vital Signsh 
X 
X 
X 
X 
X 
 
 
 
X 
 
 
 
Hematology Paneli 
X 
X 
X 
X 
X 
 
 
 
X 
 
 
 
Chemistry Panelj 
X 
X 
X 
X 
X 
 
 
 
X 
 
 
 
Serum Quantitative Immunoglobulinsj 
X 
X 
 
 
X 
 
 
 
X 
 
 
 
Serum Ferritin 
X 
X 
X 
X 
X 
 
 
 
X 
 
 
 
Coagulation Test (PT, aPTT, INR) 
X 
X 
X 
X 
X 
 
 
 
X 
 
 
 
D-dimer 
X 
X 
X 
X 
X 
 
 
 
X 
 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 67 of 114 
Version 003 
Procedure 
Screening 
(up to 3 
days before 
Day 1) a 
Day 1 
Day 2 to X 
(during 
hospital 
stay)b 
Day 7 (if 
participant 
remains in 
the 
hospital)c 
Day of 
Hospital 
Discharge c 
Day 7 (if 
participant 
is 
discharged 
from 
hospital)d 
Day 
14c, d, e 
Day 
21c, d, e 
Early 
Termination 
D28d 
Optional 
Assessment 
Day 
56d 
Day 
84d 
Day 
168d 
Fibrinogen 
X 
X 
X 
X 
X 
 
 
 
X 
 
 
 
Pregnancy Testk 
X 
 
 
 
 
 
 
 
X 
 
 
 
SARS-CoV-2 PCR Testl 
X 
X 
 
X 
X 
 
 
 
 
 
 
 
Viral load sample (for Central Lab) 
 
X 
Xm 
X 
X 
 
X 
X 
X 
 
 
 
Influenza and RSV PCR Test 
X 
 
 
 
 
 
 
 
 
 
 
 
C-Reactive Protein   
X 
X 
X 
X 
X 
 
 
 
X 
 
 
 
Anti-SARS-CoV-2 Serum Antibody Test 
Blood Sample (Central Lab)n 
 
Xn 
(pre-dose) 
 
X 
X 
 
X 
X 
X 
(X) 
(X) 
(X) 
Exploratory Biomarker Blood Samples  
 
Xo 
 
 
X 
 
X 
 
X 
 
 
 
PKn and Immunogenicity Serum Samples 
See Table 7 for details 
Treatment Administration 
 
X 
 
 
 
 
 
 
 
 
 
 
Adverse Event Reviewp 
 
<=====================================================================> 
 
 
 
Serious Adverse Event Reviewp 
<===============================================================================> 
 
 
 
Concomitant Medication Review  
<===============================================================================> 
 
 
 
Covid-19 Medical Intervention Reviewq 
<===============================================================================> 
 
 
 
NOTE: Procedures indicated with parentheses “(X)” are conditional. Refer to the appropriate footnote for details. 
Abbreviations: AE = adverse event; aPTT = activated partial thromboplastin time; CBC = complete blood count; CRP = C-reactive protein; INR = international 
normalized ratio; LDH = lactate dehydrogenase; NEWS2 = National Early Warning Score 2 Assessment; PCR = polymerase chain reaction; PK = pharmacokinetic; 
PT = prothrombin time; RSV = Respiratory Syncytial Virus; SAE = serious adverse event; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2. 
a 
Screening and Day 1 testing can be combined, providing they are separated by less than 24 hours from the time of dosing and there are no signs of changes in the 
participant’s status. Clinical lab tests as defined in Appendix 3 performed within 24 hours prior to consent will be acceptable for screening. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 68 of 114 
Version 003 
b 
Participants will be monitored daily while in the hospital for a minimum of 48 hours after study treatment administration. Participants will be monitored with vital 
signs including blood oxygen saturation every 4-6 hours or per institutional standards. Laboratory assessment will be taken daily or per institutional standards and 
should include but are not limited to hematology panel, chemistries, ferritin, CRP, LDH, D-dimer, fibrinogen, PT, aPTT and INR. Participants’ clinical status based 
on the 8-point ordinal scale, the NEWS2, Covid-19 related signs/symptoms, and safety laboratory tests will be recorded every day while hospitalized including day 
of discharge from the hospital.   
c 
All participants will have samples collected for viral load, anti-SARS-CoV-2 serum antibody test, and exploratory biomarkers on day of discharge. Discharged 
participants will be asked to attend post- hospitalization study assessments at Days 14, 21, and 28, if discharged before any of these assessments were completed. 
Participants who are discharged before Day 7, do not need a Day 7 sample collection but will be assessed for Covid-19 symptoms. 
d  
Day 7 can be ± 1 day, Day 14, and Day 21 can be ± 2 days, Day 28 can be + 7 days. Day 56, Day 84, and Day 168 can be ± 5 days. 
e 
All efforts should be made to have the blood draws and exams done and assessments completed. When needed a telemedicine or home health visit can replace a 
clinical visit for the post-hospitalization visits.  
f 
Assessment of Covid-19 symptoms (per Appendix 8) should happen daily during the hospital stay. In the post- hospitalization setting, assessment of symptoms 
should happen on Day 7 (for those discharged before Day 7), Day 14, Day 21 and Day 28. Day 7, Day 14, and Day 21 assessments can be a telemedicine or phone 
call visit. 
g 
If the participant is hospitalized, the assessment should be conducted in the hospital. If discharged and participant is at home, assessment may be conducted over the 
phone. 
h 
Vital signs includes pulse, blood pressure, temperature, respiratory rate, and oxygen saturation by pulse oximeter. Height and weight collected at screening only. On 
Day 1 vital signs will be collected pre-dose, at completion of treatment administration (at the end of the flush) (+ 15 minute window), and 2 hours post-dose 
(± 15 minutes window).  
i 
Hematology panel should include the parameters detailed in protocol Appendix 3. 
j 
Chemistry panel should include the parameters detailed in protocol Appendix 3 and serum quantitative immunoglobulins (Screening, Day 1, day of discharge and 
Day 28). 
k 
Pregnancy test (serum or urine) for women of child-bearing potential only (Appendix 5). 
l 
Participants must have a confirmed positive PCR or antigen test for SARS-CoV-2 within 10 days of randomization (screening sample). PCR test will also be 
obtained on Days 1 and 7, while hospitalized; and on day of discharge (if discharged prior to Day 28) and will be tested locally. 
m 
Viral load sample to be collected on Day 3 while hospitalized as well as Day 1 (pre-dose), Day of discharge, Day 7 (if hospitalized), 14, 21 and 28. 
n 
Anti-SARS-CoV-2 serum antibody test blood sample to be collected pre-dose administration. Anti-SARS-CoV-2 serum antibody samples will be collected to be 
assessed at a central lab on Day 1 before dosing, and on Days 7, 14, 21, and 28 if participant remains hospitalized as well as the day of hospital discharge. For 
participants who are discharged before Day 14, 21 and 28, a sample will be collected on day of discharge as well as the post-hospitalization sample collection on 
Days 14, 21, and 28 that are not collected during the hospital stay. Participants who consent separately to the optional assessments for anti-SARS-CoV-2 serum 
antibody tests will be asked to attend post-hospitalization assessments on Days 56, 84, and 168. 
o  
Exploratory biomarker samples on Day 1 will be collected pre-dose.  
p 
After informed consent has been obtained but prior to initiation of study treatment, only SAEs caused by protocol-mandated procedures will be reported. After 
initiation of study treatment, all AEs and SAEs will be reported until completion of the study at Day 28.  
q 
Review of medical interventions/ procedures for management of Covid-19 such as intubation, ventilation, and supplemental oxygen and rehospitalization. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 69 of 114 
Version 003 
 
Table 7 
PK, ADA, and Neutralizing Antibody Sampling Schedule 
 
Samplea 
Collection Timepoint 
PK Variance 
ADA and Neutralizing Antibody Only 
1 
pre-dose 
-1 hour-0 hours 
 
X (collected as part of PK) 
2 
0.5 hours 
± 5 min 
 
3 
2 hours 
± 30 min 
 
4 
4 hours 
± 30 min 
 
5 
8 hours 
± 2 hours 
 
6 
24 hours 
± 6 hours 
 
7 
48 hours 
± 8 hours 
 
8 
Day 28 
 
 
X 
Abbreviation: ADA = anti-drug antibodies; min = minutes; PK = pharmacokinetics  
a Time post CPI-006 infusion and line flush except for pre-dose sample  
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 70 of 114 
Version 003 
APPENDIX 2 
REGULATORY, ETHICAL, AND STUDY OVERSIGHT CONSIDERATIONS 
REGULATORY AND ETHICAL CONSIDERATIONS 
• This study will be conducted in accordance with the protocol and with the following: 
o Consensus ethical principles derived from international guidelines including 
the Declaration of Helsinki and Council for International Organizations of 
Medical Sciences (CIOMS) International Ethical Guidelines 
o Applicable International Council for Harmonisation (ICH) Good Clinical 
Practice (GCP) Guidelines 
o Applicable laws and regulations 
• The protocol, protocol amendments, ICF, Investigator Brochure, and other relevant 
documents (e.g., advertisements) must be submitted to an IRB/IEC by the investigator 
and reviewed and approved by the IRB/IEC before the study is initiated. 
• Any amendments to the protocol will require IRB/IEC approval before 
implementation of changes made to the study design, except for changes necessary to 
eliminate an immediate hazard to study participants.  
• In accordance with applicable laws and regulations, protocols and any substantial 
amendments to the protocol will require health authority approval prior to initiation 
except for changes necessary to eliminate an immediate hazard to study participants. 
• The investigator will be responsible for the following: 
o Providing written summaries of the status of the study to the IRB/IEC 
annually or more frequently in accordance with the requirements, policies, and 
procedures established by the IRB/IEC 
o Notifying the IRB/IEC of SAEs or other significant safety findings as required 
by IRB/IEC procedures 
o Providing oversight of the conduct of the study at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 
536/2014 for clinical studies (if applicable), and all other applicable local 
regulations 
FINANCIAL DISCLOSURE 
Investigators and sub-investigators will provide the Sponsor with sufficient, accurate 
financial information as requested to allow the Sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate regulatory authorities. 
Investigators are responsible for providing information on financial interests during the study 
and for 1 year after completion of the study. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 71 of 114 
Version 003 
INFORMED CONSENT PROCESS 
• The investigator or his/her representative will explain the nature of the study to the 
participant and answer all questions regarding the study. 
• Participants must be informed that their participation is voluntary. Participants will be 
required to sign a statement of informed consent that meets the requirements of 
21 CFR 50, local regulations, ICH guidelines, and privacy and data protection 
requirements, where applicable, and the IRB/IEC or study center. 
• The medical record must include a statement that written informed consent was 
obtained before the participant was enrolled in the study and the date the written 
consent was obtained. The authorized person obtaining the informed consent must 
also sign the ICF. 
• Participants must be re-consented to the most current version of the ICF(s) during 
their participation in the study. 
• A copy of the ICF(s) must be provided to the participant. 
The ICF will address the use of remaining mandatory samples. The investigator or authorized 
designee will explain to each participant the objectives of the exploratory research. 
Participants will be told that they are free to refuse to participate and may withdraw their 
consent at any time and for any reason during the storage period. A separate consent will be 
required to document a participant's agreement to allow any remaining specimens to be used 
for exploratory research. Participants who decline to participate in this optional research will 
not provide this separate consent. 
Sites will be allowed to use all processes approved by their IRB to ensure safety of staff and 
patients from Covid-19, while maintaining appropriate consent procedures for the duration of 
this study. 
DATA PROTECTION 
• Participants will be assigned a unique identifier by the Sponsor. Any participant 
records or datasets that are transferred to the Sponsor will contain the identifier only; 
participant names or any information which would make the participant identifiable 
will not be transferred. 
• The participant must be informed that his/her personal study-related data will be used 
by the Sponsor in accordance with local data protection law. The level of disclosure 
must also be explained to the participant who will be required to give consent for 
their data to be used as described in the informed consent. 
• The participant must be informed that his/her medical records may be examined by 
Clinical Quality Assurance auditors or other authorized personnel appointed by the 
Sponsor, by appropriate IRB/IEC members, and by inspectors from regulatory 
authorities. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 72 of 114 
Version 003 
COMMITTEES STRUCTURE 
The objectives of the iDMC are to evaluate interim clinical and safety data to protect 
participant welfare and to provide recommendations regarding study conduct. Details of 
iDMC responsibilities and procedures are specified in the iDMC charter.  
DISSEMINATION OF CLINICAL STUDY DATA 
Clinical Study Reports, periodic safety reports, and clinical study summary reports will be 
disclosed after review by regulatory authorities. This includes access to CSRs from studies 
with negative outcomes and from terminated development programs. 
Company-sponsored study information and tabular study results will be posted on the US 
National Institutes of Health’s website www.ClinicalTrials.gov and other publicly accessible 
sites. 
Publication planning and other activities related to non-promotional, peer-reviewed 
publications will be conducted to ensure the scientific integrity and credibility of publication 
activities performed by or on behalf of the company. The granting of access to analyzable 
datasets from clinical studies should be through a secure system, following an independent 
assessment of the scientific merit of a rigorously defined research question from a third party. 
DATA QUALITY ASSURANCE 
• All participant data relating to the study will be recorded on printed or electronic CRF 
unless transmitted to the Sponsor or designee electronically (e.g., laboratory data). 
The investigator is responsible for verifying that data entries are accurate and correct 
by physically or electronically signing the CRF. 
• The investigator must maintain accurate documentation (source data) that supports 
the information entered in the CRF. 
• The investigator must permit study-related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents. 
• Monitoring details describing strategy (e.g., risk-based initiatives in operations and 
quality such as Risk Management and Mitigation Strategies and Analytical Risk-
Based Monitoring), methods, responsibilities, and requirements, including handling 
of noncompliance issues and monitoring techniques (central, remote, or on-site 
monitoring) are provided in the Clinical Monitoring Plan. 
• The Sponsor or designee is responsible for the data management of this study 
including quality checking of the data. 
• The Sponsor assumes accountability for actions delegated to other individuals (e.g., 
Contract Research Organizations). 
• Study monitors will perform ongoing CRF verification to confirm that data entered 
into the CRF by authorized site personnel are accurate and complete; that the safety 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 73 of 114 
Version 003 
and rights of participants are being protected; and that the study is being conducted in 
accordance with the currently approved protocol and any other study agreements, 
ICH GCP, and all applicable regulatory requirements. 
• U.S. FDA regulations (21 CFR §312.62[c]) and the ICH Guideline for GCP 
(Section 4.9 of the guideline) require that records and documents pertaining to the 
conduct of this study and the distribution of investigational drug, including CRFs, 
consent forms, laboratory test results, and medication inventory records, must be 
retained by the Principal Investigator for 2 years after the last marketing application 
approval or after at least 2 years have elapsed since formal discontinuation of clinical 
development of the investigational product. All state and local laws for retention of 
records also apply. No records may be transferred to another location or party without 
written notification to the Sponsor. 
SOURCE DOCUMENTS 
• Source documents provide evidence for the existence of the participant and 
substantiate the integrity of the data collected. Source documents are filed at the 
investigator’s site. 
• Data reported on the CRF or entered in the CRF that are transcribed from source 
documents must be consistent with the source documents or the discrepancies must be 
explained. The investigator may need to request previous medical records or transfer 
records, depending on the study. Also, current medical records must be available. 
• Definition of what constitutes source data can be found in the study monitoring plan. 
STUDY TERMINATION 
Potential reasons for closing the study include: 
• Unsatisfactory subject enrollment 
• Potentially unacceptable risk to study subjects 
• Decision to modify clinical development plan 
• Decision by the regulatory authority 
In the event of a decision to close the study, the Sponsor will promptly inform the 
investigator and the IRB/IEC and provide them with a detailed explanation of the reason for 
closure. The Sponsor and investigator will ensure that the safety of the subjects is protected 
and that IRB/IEC reporting continues per the requirements of the IRB/IEC and applicable 
local laws or requirements. 
SITE CLOSURE 
The Sponsor or designee reserves the right to close a study site at any time for any reason at 
the sole discretion of the Sponsor. Potential reasons for closing a site include: 
• Investigator noncompliance 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 74 of 114 
Version 003 
• Unsatisfactory subject recruitment and enrollment 
• Lack of adherence to protocol procedures, the requirements of the IRB/IEC or local 
health authorities, the Sponsor’s procedures, or GCP guidelines 
• Lack of evaluable and/or complete data 
• Potentially unacceptable risk to study subjects 
• Decision by the regulatory authority 
Study sites will be closed upon study completion. A study site is considered closed when all 
required documents and study supplies have been collected or confirmed as destroyed and a 
study-site closure visit has been performed. 
The investigator may initiate study-site closure at any time, provided there is reasonable 
cause and sufficient notice is given in advance of the intended termination. 
PUBLICATION POLICY 
• The results of this study may be published or presented at scientific meetings. If this 
is foreseen, the investigator agrees to submit all manuscripts or abstracts to the 
Sponsor before submission. This allows the Sponsor to protect proprietary 
information and to provide comments. 
• The Sponsor will comply with the requirements for publication of study results. In 
accordance with standard editorial and ethical practice, the Sponsor will generally 
support publication of multicenter studies only in their entirety and not as individual 
site data. In this case, a coordinating investigator will be designated by mutual 
agreement. 
• Authorship will be determined by mutual agreement and in line with International 
Committee of Medical Journal Editors authorship requirements. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 75 of 114 
Version 003 
APPENDIX 3 
CLINICAL LABORATORY TESTS 
• Protocol-specific requirements for inclusion or exclusion of participants are detailed 
in Section 5 of the protocol. 
• Additional tests may be performed at any time during the study as determined 
necessary by the investigator or required by local regulations. 
 
Table 8 
Protocol-Required Safety Laboratory Assessments 
Chemistry 
Hematology 
Serum 
Quantitative 
Immunoglobulins 
Inflammatory 
Biomarkers 
Coagulation 
Testing 
BUN (Blood Urea 
Nitrogen) 
Platelet Count 
IgA 
C-reactive protein 
PT 
Potassium 
RBC Count 
IgG 
Ferritin 
aPTT 
Creatinine 
Hemoglobin 
IgM 
 
INR 
Sodium 
Hematocrit 
 
 
D-dimer 
Glucose 
RBC (Red Blood 
Cell) indices: 
    MCV 
    MCH 
    % Reticulocytes 
 
 
Fibrinogen 
Calcium 
 
 
 
Bilirubin (total & direct) 
 
 
 
Protein (total) 
 
 
 
LDH (Lactate 
Dehydrogenase) 
WBC count 
(White Blood Cell) 
with differential: 
    Neutrophils 
    Lymphocytes 
    Monocytes 
    Eosinophils 
    Basophils 
 
 
 
AST 
 
 
 
ALT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: ALT = alanine aminotransferase; aPTT = activated partial thromboplastin time; AST = aspartate 
aminotransferase; IgA = immunoglobulin A; IgG = immunoglobulin G; IgM = immunoglobulin M; 
INR = international normalized ratio; LDH = lactate dehydrogenase; MCH = mean corpuscular 
hemoglobin; MCV = mean corpuscular volume; PT = prothrombin time; RBC = red blood cell. 
 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 76 of 114 
Version 003 
APPENDIX 4 
ADVERSE EVENTS: DEFINITIONS AND PROCEDURES FOR RECORDING, 
EVALUATING, FOLLOW-UP, AND REPORTING 
DEFINITION OF AE 
AE Definition 
• An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated 
with the use of study treatment, whether or not considered related to the study treatment. 
• NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory 
finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. 
 
Events Meeting the AE Definition 
• Any abnormal laboratory test results (hematology or clinical chemistry) or other safety assessments (e.g., 
ECG, radiological scans, vital signs measurements), including those that worsen from baseline, is 
accompanied by clinical symptoms, results in a change in study treatment (e.g., dosage modification, 
treatment interruption, or treatment discontinuation), results in a medical treatment (e.g., potassium 
supplementation for hypokalemia) or a change in concomitant therapy, considered clinically significant in 
the medical and scientific judgment of the investigator (i.e., not related to progression of underlying 
disease). 
• 
Exacerbation of a chronic or intermittent pre-existing condition including either an increase in 
frequency and/or intensity of the condition. 
• 
New conditions detected or diagnosed after study treatment administration even though it may have 
been present before the start of the study. 
o 
Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction. 
o 
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study treatment 
or a concomitant medication. Overdose per se will not be reported as an AE/SAE unless it is 
an intentional overdose taken with possible suicidal/self-harming intent. Such overdoses 
should be reported regardless of sequelae.  
• For worsening of Covid-19 symptoms, the clinical event(s) that mark the worsening should be reported as 
AE or an SAE.   
• If a clinically significant laboratory abnormality is a sign of a disease or syndrome (e.g., alkaline 
phosphatase and bilirubin 5 x ULN associated with cholestasis), only the diagnosis (i.e., cholestasis) 
should be recorded on the Adverse Event CRF.  
• Exacerbation of a chronic or intermittent pre-existing condition including either an increase in frequency 
and/or intensity of the condition. 
• Deaths that occur within 28 days after study treatment (CPI-006) should be reported as an SAE.  
• New conditions detected or diagnosed after study treatment administration even though it may have been 
present before the start of the study. 
• "Lack of efficacy" or "failure of expected pharmacological action" per se will not be reported as an AE or 
SAE. Such instances will be captured in the efficacy assessments. However, the signs, symptoms, and/or 
clinical sequelae resulting from lack of efficacy will be reported as AE or SAE if they fulfill the definition 
of an AE or SAE. 
 
 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 77 of 114 
Version 003 
 
Events NOT Meeting the AE Definition 
• Any clinically significant abnormal laboratory findings or other abnormal safety assessments which are 
associated with the underlying disease, unless judged by the investigator to be more severe than expected 
for the participant’s condition. 
• Medical or surgical procedure (e.g., endoscopy, appendectomy): the condition that leads to the procedure 
is the AE. 
• Situations in which an untoward medical occurrence did not occur (social and/or convenience admission to 
a hospital). 
• Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present or detected at the start 
of the study that do not worsen. 
 
DEFINITION OF SAE 
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (e.g., hospitalization for signs/symptoms of the progression of disease 
under study). Hospitalization or ICU admissions due to Covid-19, worsening of Covid-19 in 
the 28 days during this study, or pulmonary conditions attributable to Covid-19 infection are 
considered efficacy-related endpoints. Therefore, Covid-19-related hospitalization or ICU 
admission is excluded from this definition. 
A SAE is defined as any untoward medical occurrence that, at any dose: 
a. Results in death 
b. Is life-threatening 
The term 'life-threatening' in the definition of 'serious' refers to an event in which the participant was at risk of 
death at the time of the event. It does not refer to an event, which hypothetically might have caused death, if it 
were more severe. 
c. 
Requires inpatient hospitalization or prolongation of existing hospitalization 
Any adverse event that causes prolonged hospitalization should be documented and reported as a 
serious adverse event (per the definition of serious adverse event). 
 
• 
For this study, the subjects will be hospitalized for Covid-19 treatment so initial hospitalization will 
not be considered as an SAE. Complications that occur during hospitalization are AEs/SAEs. If a 
complication prolongs hospitalization (or requires admission to ICU) or fulfills any other serious 
criteria, the event is serious.  
 
An event that leads to hospitalization under the following circumstances should not be reported as an 
adverse event or a serious adverse event: 
• 
Hospitalization for respite care 
• 
Planned hospitalization required by the protocol (e.g., for the Covid-19 treatment). 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 78 of 114 
Version 003 
d. Results in persistent disability/incapacity 
• 
The term disability means a substantial disruption of a person’s ability to conduct normal life 
functions. 
• 
This definition is not intended to include experiences of relatively minor medical significance such as 
uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (e.g., sprained 
ankle) which may interfere with or prevent everyday life functions but do not constitute a substantial 
disruption. 
e. 
Is a congenital anomaly/birth defect 
f. 
Other situations 
• 
Medical or scientific judgment should be exercised in deciding whether SAE reporting is appropriate 
in other situations such as important medical events that may not be immediately life-threatening or 
result in death or hospitalization but may jeopardize the participant or may require medical or surgical 
treatment to prevent 1 of the other outcomes listed in the above definition. These events should 
usually be considered serious. 
• 
Examples of such events include invasive or malignant cancers, intensive treatment in an emergency 
room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in 
hospitalization, or development of drug dependency or drug abuse. 
 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 79 of 114 
Version 003 
RECORDING AND FOLLOW-UP OF AE AND/OR SAE 
AE and SAE Recording 
• 
When an AE/SAE occurs, it is the responsibility of the investigator to review all documentation (e.g., 
hospital progress notes, laboratory reports, and diagnostics reports) related to the event. 
• 
The investigator will then record all relevant AE/SAE information in the CRF. 
• 
It is not acceptable for the investigator to send photocopies of the participant’s medical records to 
Sponsor in lieu of completion of the AE/SAE CRF page. 
• 
There may be instances when copies of medical records for certain cases are requested by Sponsor. In 
this case, all participant identifiers, with the exception of the participant number, will be redacted on 
the copies of the medical records before submission to Sponsor. 
• 
The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or 
other clinical information. Whenever possible, the diagnosis (not the individual signs/symptoms) will 
be documented as the AE/SAE. However, if a constellation of signs and/or symptoms cannot be 
medically characterized as a single diagnosis or syndrome at the time of reporting, each individual 
event should be recorded on the Adverse Event CRF. If a diagnosis is subsequently established, all 
previously reported AEs based on signs and symptoms should be nullified and replaced by 1 AE 
report based on the single diagnosis, with a starting date that corresponds to the starting date of the 
first symptom of the eventual diagnosis. 
 
Adverse Events That Are Secondary to Other Events 
In general, AEs that are secondary to other events (e.g., cascade events or clinical sequelae) should be 
identified by their primary cause, with the exception of severe or serious secondary events. A medically 
significant secondary AE that is separated in time from the initiating event should be recorded as an 
independent event on the Adverse Event CRF. For example: 
• 
If vomiting results in mild dehydration with no additional treatment in a healthy adult, only vomiting 
should be reported on the CRF 
• 
If vomiting results in severe dehydration, both events should be reported separately on the CRF 
• 
If a severe gastrointestinal hemorrhage leads to renal failure, both events should be reported 
separately on the CRF 
• 
If dizziness leads to a fall and consequent fracture, all 3 events should be reported separately on the 
CRF 
• 
If neutropenia is accompanied by an infection, both events should be reported separately on the CRF 
All AEs should be recorded separately on the Adverse Event CRF if it is unclear as to whether the events are 
associated. 
 
Persistent or Recurrent Adverse Events 
A persistent AE is one that extends continuously, without resolution, between patient or participant evaluation 
timepoints. Such events should be recorded with each severity change on the Adverse Event CRF. The initial 
severity (intensity or grade) of the event will be recorded at the time the event is first reported, with each 
subsequent change in severity recorded on the same AE CRF with the exception of a non-serious event 
becoming serious. If the event becomes serious, it should be reported to the Sponsor immediately (i.e., no more 
than 24 hours after learning that the event became serious.). A new AE should be recorded as serious in the 
CRF with the date the event became serious recorded as the start date and completing all data fields related to 
SAEs.  
• 
A recurrent AE is one that resolves between patient or participant evaluation timepoints and 
subsequently recurs. Each recurrence of an AE should be recorded as a separate event on the Adverse 
Event CRF. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 80 of 114 
Version 003 
 
 
Assessment of Intensity 
The guidelines outlined below will be used for assessing the severity of AEs. The severity/intensity of AEs and 
SAEs will be graded based upon the participant’s symptoms according to the NCI CTCAE v5. 
AEs that are not defined in the NCI CTCAE v5 should be evaluated for severity/intensity according to the 
following scale: 
Table 9 
Assessment of Severity of Adverse Events 
Grade 
Severity 
1 
Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or treatment 
not indicated 
2 
Moderate; minimal, local, or non-invasive treatment indicated; or limiting age-appropriate 
instrumental activities of daily living a 
3 
Severe or medically significant, but not immediately life-threatening; hospitalization or 
prolongation of hospitalization indicated; disabling; or limiting self-care activities of daily 
living.b,c An AE that is assessed as severe should not be confused with a SAE. Severe is a 
category utilized for rating the intensity of an event; and both AEs and SAEs can be assessed 
as severe. 
An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe. 
 
4 
Life-threatening consequences or urgent treatment indicated d 
5 
Death related to AE d 
a 
Instrumental activities of daily living refer to preparing meals, shopping for groceries or clothes, using the 
telephone, managing money, etc. 
b 
Examples of self-care activities of daily living include bathing, dressing and undressing, feeding oneself, 
using the toilet, and taking medications, as performed by participants who are not bedridden. 
c 
If an event is assessed as a “significant medical event,” it must be reported as an SAE per the definition of 
SAE in (see section above). 
d 
Grade 4 and 5 events must be reported as SAEs per the definition of SAE (see section above). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 81 of 114 
Version 003 
Assessment of Causality 
• 
The investigator is obligated to assess the relationship between study treatment and occurrence of 
each AE/SAE. 
• 
A "reasonable possibility" of a relationship conveys that there are facts, evidence, and/or arguments to 
suggest a causal relationship, rather than a relationship cannot be ruled out. 
• 
The investigator will use clinical judgment to determine the relationship. 
• 
Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, as well 
as the temporal relationship of the event to study treatment administration will be considered and 
investigated. 
• 
The investigator will also consult the Investigational Brochure (IB) and/or Product Information, for 
marketed products, in his/her assessment. 
• 
For each AE/SAE, the investigator must document in the medical notes that he/she has reviewed the 
AE/SAE and has provided an assessment of causality. 
• 
There may be situations in which an SAE has occurred, and the investigator has minimal information 
to include in the initial report to Sponsor. However, it is very important that the investigator always 
make an assessment of causality for every event before the initial transmission of the SAE data to 
Sponsor. 
• 
The investigator may change his/her opinion of causality in light of follow-up information and send 
an SAE follow-up report with the updated causality assessment. 
• 
The causality assessment is one of the criteria used when determining regulatory reporting 
requirements. 
 
Follow-up of AEs and SAEs 
• 
Treatment related AEs and SAEs should be followed up until resolution or until the AE is stable. 
• 
The investigator is obligated to perform or arrange for the conduct of supplemental measurements 
and/or evaluations as medically indicated or as requested by Sponsor to elucidate the nature and/or 
causality of the AE or SAE as fully as possible. This may include additional laboratory tests or 
investigations, histopathological examinations, or consultation with other health care professionals. 
• 
If a participant dies during participation in the study or during a recognized follow-up period, the 
investigator will provide Sponsor with a copy of any post-mortem findings including histopathology. 
• 
New or updated information will be recorded in the originally completed CRF. 
• 
The investigator will submit any updated SAE data to the Sponsor within 24 hours of receipt of the 
information. 
 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 82 of 114 
Version 003 
REPORTING OF SAES 
SAE Reporting to Corvus via an Electronic Data Collection Tool 
The primary mechanism for reporting an SAE to Corvus will be the electronic data 
collection tool. 
If the electronic system is unavailable for more than 24 hours, then the site will use the 
paper SAE data collection tool (see next section). 
The site will enter the SAE data into the electronic system as soon as it becomes available. 
After the study is completed at a given site, the electronic data collection tool will be taken 
off-line to prevent the entry of new data or changes to existing data. 
If a site receives a report of a new SAE from a study participant or receives updated data 
on a previously reported SAE after the electronic data collection tool has been taken 
off-line, then the site can report this information on a paper SAE form (see next section) or 
to the medical monitor by telephone or email. 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 83 of 114 
Version 003 
SAE Reporting via Paper Report Forms 
The primary mechanism for reporting an SAE to Sponsor will be through EDC. If EDC is down or not 
available, then the paper SAE report form can be used for SAE reporting. 
 
Events That Occur Prior to the Study Treatment Initiation 
After informed consent has been obtained but prior to initiation of study treatment (non-treatment emergent), 
only SAEs caused by protocol-mandated procedures should be reported in EDC using the EDC SAE form. 
Investigators should record all case details that can be gathered immediately (i.e., within 24 hours after 
learning of the event) on the Adverse Event CRF and submit the report via the paper report form. All other 
non-treatment emergent AEs should be reported in the Medical History CRF. 
 
Events That Occur after Study Treatment Initiation 
• 
After initiation of study treatment, all AEs and SAEs will be reported for 28 days following stopping 
of study treatment and until participants complete the study. The site will enter the SAE data into the 
EDC SAE report form. 
Adverse Events That Occur after the Adverse Event Reporting Period are described in the following 
section. 
• 
If a site receives a report of a new SAE from a study participant or receives updated data on a 
previously reported SAE, then the site can report this information in EDC (see next section) or to the 
Sponsor’s designee by telephone on the number listed in a section below. 
If EDC is unavailable, then the paper Clinical Trial Serious Adverse Event Form provided to investigators 
should be completed and submitted to the Sponsor or its designee immediately (i.e., no more than 24 hours 
after learning of the event), either by faxing or by scanning and e-mailing the form using the fax number or 
e-mail address provided to investigators below. Please note that email is preferred over fax and phone. 
 
 
 
Note: For Ex-US country-specific safety fax and phone numbers, refer to the study manual. 
• 
In rare circumstances and in the absence of facsimile equipment, notification by telephone is 
acceptable with a copy of the SAE data collection tool sent by overnight mail or courier service. 
• 
Initial notification via telephone does not replace the need for the investigator to complete and sign 
the SAE CRF pages within the designated reporting time frames. 
 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 84 of 114 
Version 003 
APPENDIX 5 
CONTRACEPTIVE GUIDANCE AND COLLECTION OF PREGNANCY 
INFORMATION 
 
DEFINITIONS: 
  
WOMAN OF CHILDBEARING POTENTIAL (WOCBP) AND OF FERTILE MEN 
A woman is considered fertile following menarche and until becoming post-menopausal 
unless permanently sterile (see below). 
1. Women in the following categories are not considered WOCBP 
2. Premenarchal 
a. Premenopausal female with 1 of the following: 
i. Documented hysterectomy 
ii. Documented bilateral salpingectomy 
iii. Documented bilateral oophorectomy 
Note: Documentation can come from the site personnel’s: review of the participant’s medical 
records, medical examination, or medical history interview. 
3. Postmenopausal female 
a. A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. A high follicle stimulating hormone (FSH) level in 
the postmenopausal range may be used to confirm a postmenopausal state in 
women not using hormonal contraception or hormonal replacement therapy 
(HRT). However, in the absence of 12 months of amenorrhea, a single FSH 
measurement is insufficient. 
b. Females on HRT and whose menopausal status is in doubt will be required to 
use one of the non-estrogen hormonal highly effective contraception methods 
if they wish to continue their HRT during the study. Otherwise, they must 
discontinue HRT to allow confirmation of postmenopausal status before study 
enrollment. 
A man is considered fertile after puberty unless permanently sterile by bilateral 
orchidectomy. 
 
CONTRACEPTION GUIDANCE: 
MALE PARTICIPANTS 
Male participants with female partners of childbearing potential are eligible to participate if 
they agree to ONE of the following for 6 weeks after study treatment. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 85 of 114 
Version 003 
• Are abstinent from penile-vaginal intercourse as their usual and preferred lifestyle 
(abstinent on a long term and persistent basis) and agree to remain abstinent. 
• Agree to use a male condom plus partner use of a contraceptive method with a failure 
rate of <1% per year as described in Table 10 of this appendix when having penile-
vaginal intercourse with a woman of childbearing potential who is not currently 
pregnant. 
In addition, male participants must refrain from donating sperm for the duration of the study 
and for 6 weeks after study treatment. 
FEMALE PARTICIPANTS 
Female participants of childbearing potential are eligible to participate if they agree to use a 
highly effective method of contraception consistently and correctly as described in Table 10. 
In addition, female participants must refrain from donating ova for the duration of the study 
and for 6 weeks after study treatment. 
Table 10 
Highly Effective Contraceptive Methodsa 
Highly Effective Contraceptive Methods That Are User Dependent b 
Failure rate of <1% per year when used consistently and correctly. 
Combined (estrogen and progestogen containing) hormonal contraception associated with 
inhibition of ovulation c 
• Oral 
• Intravaginal 
• Transdermal 
Progestogen only hormonal contraception associated with inhibition of ovulation 
• Oral 
• Injectable 
Highly Effective Contraceptive Methods That Are User Independent c 
• Implantable progestogen only hormonal contraception associated with inhibition of 
ovulation c 
• IUD 
• IUS 
• Bilateral tubal occlusion 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 86 of 114 
Version 003 
Vasectomized partner 
A vasectomized partner is a highly effective contraception method provided that the 
partner is the sole male sexual partner of the WOCBP and the absence of sperm has been 
confirmed. If not, an additional highly effective method of contraception should be used. 
Sexual abstinence 
Sexual abstinence is considered a highly effective method only if defined as refraining 
from heterosexual intercourse during the entire period of risk associated with the study 
treatment defined as 6 weeks after receiving study treatment. The reliability of sexual 
abstinence needs to be evaluated in relation to the duration of the study and the preferred 
and usual lifestyle of the participant. 
Abbreviations: IUD = intrauterine device; IUS = intrauterine hormone-releasing system; 
WOCBP = woman of childbearing potential 
a   Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), 
withdrawal (coitus interruptus), spermicides only and lactational amenorrhea method 
(LAM) are not considered acceptable methods of contraception. A male and female 
condom should not be used together as friction between the two can result in either 
product failing. 
b  Typical use failure rates may differ from those when used consistently and correctly. Use 
should be consistent with local regulations regarding the use of contraceptive methods 
for participants participating in clinical studies. 
c    Hormonal contraception may be susceptible to interaction with the study treatment, 
which may reduce the efficacy of the contraceptive method. In this case, two highly 
effective methods of contraception should be utilized during the treatment period and 
for at least 6 weeks corresponding to time needed to eliminate study treatment after the 
last dose of study treatment. Contraception methods with low user dependency should 
preferably be used, in particular when contraception is introduced as a result of 
participation in the clinical trial. 
 
PREGNANCY TESTING: 
• WOCBP should only be included after a negative (urine or serum) pregnancy test at 
screening. 
• Additional pregnancy testing is required at end of study or at early termination (see 
Appendix 1 – Schedule of Activities). 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 87 of 114 
Version 003 
COLLECTION OF PREGNANCY INFORMATION: 
 MALE PARTICIPANTS WITH PARTNERS WHO BECOME PREGNANT 
• The investigator will attempt to collect pregnancy information on any male 
participant’s female partner who becomes pregnant while the male participant is in 
this study.  
• After obtaining the necessary signed informed consent from the pregnant female 
partner directly, the investigator will record pregnancy information on the appropriate 
form and submit it to the Sponsor within 24 hours of learning of the partner’s 
pregnancy. The female partner will also be followed to determine the outcome of the 
pregnancy. Information on the status of the mother and child will be forwarded to the 
Sponsor. Any termination of the pregnancy will be reported regardless of fetal status 
(presence or absence of anomalies) or indication for the procedure.  
FEMALE PARTICIPANTS WHO BECOME PREGNANT 
• The investigator will collect pregnancy information on any female participant who 
becomes pregnant while participating in this study. Information will be recorded on 
the appropriate form and submitted to the Sponsor within 24 hours of learning of a 
participant's pregnancy. The participant will be followed to determine the outcome of 
the pregnancy. The investigator will collect follow-up information on the participant 
and the neonate and the information will be forwarded to the Sponsor. Any 
termination of pregnancy will be reported, regardless of fetal status (presence or 
absence of anomalies) or indication for the procedure. 
• While pregnancy itself is not considered to be an AE or SAE, any pregnancy 
complication or elective termination of a pregnancy will be reported as an AE or 
SAE. A spontaneous abortion is always considered to be an SAE and will be reported 
as such. Any post-study pregnancy related SAE considered reasonably related to the 
study treatment by the investigator will be reported to the Sponsor as described in 
Section 8.6.4. While the investigator is not obligated to actively seek this information 
in former study participants, he or she may learn of an SAE through spontaneous 
reporting. 
 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 88 of 114 
Version 003 
APPENDIX 6 
8-POINT ORDINAL SCALE FOR CLINICAL IMPROVEMENT 
 
1. Not hospitalized, no limitations on activities 
2. Not hospitalized, limitation on activities and/or requiring home oxygen 
3. Hospitalized, not requiring supplemental oxygen - no longer requiring ongoing medical 
care 
4. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care 
(Covid-19 related or otherwise) 
5. Hospitalized, requiring supplemental oxygen 
6. Hospitalized, on non-invasive ventilation or high flow oxygen devices 
7. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane 
oxygenation 
8. Death 
 
 
 
 
 
 
 
 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 89 of 114 
Version 003 
APPENDIX 7 
NEWS2 SCORING SYSTEM 
 
 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 90 of 114 
Version 003 
APPENDIX 8 
EXAMPLE OF AN ASSESSMENT OF 14 COMMON COVID-19-RELATED 
SYMPTOMS: ITEMS AND RESPONSE OPTIONS  
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 91 of 114 
Version 003 
 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 92 of 114 
Version 003 
APPENDIX 9 
INTERCURRENT EVENT (ICE) AND ESTIMAND STRATEGY 
 
Table 11 
Intercurrent Event Types 
Label 
Intercurrent Event Type 
ICE-1 (Death) 
Death from any cause during the 28 days after dose initiation   
ICE-2 (Life-saving procedures 
including ICU admission) 
Any life-saving procedures including ICU admission for any reason during the 
28-day period after dosing. 
ICE-2 (All other events) 
All other events including receiving investigational or non-approved treatments 
intended for treatment of Covid-19 at the time of randomization, incomplete 
study dosing/infusion, usage of prohibited medications, early study 
discontinuation, etc.   
 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 93 of 114 
Version 003 
Table 12 
Primary and Key Secondary Objectives and Estimands with 
Rationale for Strategies to Address Intercurrent Events 
Primary Objective 
Primary Objective 
To compare the proportion of participants alive and free from respiratory 
deterioration during the 28 days after dosing with CPI-006 plus SOC versus 
placebo plus SOC in hospitalized participants with mild to moderately 
symptomatic Covid-19 infection 
Estimand Label 
Estimand 1a (Main Estimand) 
Estimand Description 
Risk difference in the proportions of participants who alive and free from 
respiratory deterioration defined per the 8-point ordinal scale during the 28 
days after dosing with CPI-006 plus SOC versus placebo plus SOC in 
hospitalized participants with mild to moderately symptomatic and virologic-
confirmed COVID-19 infection.  
Target Population 
Mild to moderately symptomatic hospitalized adult (≥ 18 years) participants 
with Covid-19 who meet all inclusion and exclusion criteria  
Endpoint 
Participants who alive and free from respiratory deterioration defined per the 8-
point ordinal scale: 
o 
Deterioration to Categories 6, 7, or 8 for a participant who entered the 
trial at Categories 4 or 5, or 
o 
Deterioration to Categories 7 or 8 for a participant who entered the 
trial at Category 6 
Treatment Condition(s) 
One infusion on Day 1 of CPI-006 at dose of 1 mg/kg or 2 mg/kg, or placebo in 
15 minutes plus SOC per the guideline of the investigation site. 
Population-Level 
Summary 
Risk difference in the proportions of participants of alive and free from 
respiratory deterioration between a CPI-006 dose plus SOC versus placebo plus 
SOC.  
Intercurrent Event 
Strategy:  
(ICEs are described in Table 11.) 
ICE-1 (Death) 
Composite strategy (see ICH E9 (R1) Addendum 2017) 
ICE-2 (Life-saving 
procedures including ICU 
admission) 
Treatment policy strategy (see ICH E9 (R1) Addendum 2017) 
ICE-3 (All other events) 
Treatment policy strategy  

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 94 of 114 
Version 003 
Rationale for Strategies 
The primary estimand is defined as a hybrid estimand, which combines the two 
strategies (composite and treatment policy) for handling the three types of 
intercurrent events. 
 
ICE-1: Death is a part of primary endpoint and is considered treatment failure 
regardless of the outcome from the most recent assessment of the 8-point 
ordinal scale prior to the event.  
 
ICE-2 and 3: Treatment policy strategy will be used for all these intercurrent 
events, meaning that, for the participants who experience the intercurrent 
events, all outcomes collected from the participants after the intercurrent event 
will be used in the analysis. 
 
 
Estimand Label 
Estimand 1b (Sensitivity Analyses) 
Intercurrent Event 
Strategy:  
(ICEs are described in Table 11.) 
ICE-1 (Death) 
Composite strategy 
ICE-2 (Life-saving 
procedures including ICU 
admission) 
Composite strategy 
ICE-3 (All other events) 
Treatment policy strategy 
 
The estimand is defined as a hybrid estimand, which combines the two 
strategies (composite and treatment policy) for handling the three types of 
intercurrent events. 
 
ICE-1: Death is a part of primary endpoint and is considered treatment failure 
regardless of the outcome from the most recent assessment in the 8-point 
ordinal scale prior to the death event.  
 
ICE-2: A participant who receives life-saving procedures including ICU 
admission at any time during the 28 day period after dosing will be considered 
as a treatment failure regardless of the outcome of the assessment based on the 
8-point ordinal scale, as the need of life-saving procedures is likely due to 
clinical deterioration.  
 
ICE-3: Treatment policy strategy will be used for all other intercurrent events, 
meaning that all outcomes collected from the participants experiencing this 
intercurrent event after the intercurrent event will be used in the analysis. 
 
 
Estimand Label 
Estimand 1c (Sensitivity Analyses) 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 95 of 114 
Version 003 
Intercurrent Event 
Strategy:  
(ICEs are described in Table 11.) 
ICE-1 (Death) 
Composite strategy 
ICE-2 (Life-saving  
procedures including ICU 
admission) 
Treatment policy strategy  
ICE-3 (All other events) 
Treatment policy strategy 
Rationale for Strategies 
The sensitivity analysis for the primary estimand will be conducted using a 
control-based imputation and a delta-adjusted imputation (tipping point). 
 
ICE-1: For both control-based and delta-adjusted imputation, the worst 
outcome will be imputed, i.e., treatment failure. 
 
ICE-2 and 3: For the control-based imputation, missing outcomes are imputed 
based on an imputation model informed by participants with ICE-2 or 3 who 
had outcomes collected after the ICE. The imputation model is informed only 
by the participants in the placebo group when imputing for all treatment 
groups. 
 
For the delta-adjusted based imputation, missing outcomes will be imputed 
based on an imputation model informed by participants with ICE-2 or 3 who 
had outcomes collected after the ICE. The probability of an imputed outcome is 
adjusted by adding a pre-defined delta (on the logit scale). Imputation will be 
informed by respective treatment groups. Separate values of the delta parameter 
will be used in the treatment and control groups, giving rise to a two-
dimensional tipping point analysis. 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 96 of 114 
Version 003 
First Key Secondary Objective 
First Key secondary 
objective 
To compare the time to recovery of CPI-006 plus SOC versus placebo plus 
SOC in hospitalized participants with mild to moderately symptomatic Covid-
19 infection.  
Estimand Label 
Estimand 2  
Estimand Description 
Compare distribution of time to recovery during the 28 days after dosing 
between each of CPI-006 plus SOC groups versus placebo plus SOC group in 
hospitalized participants with mild to moderately symptomatic and virologic-
confirmed COVID-19 infection.  
Target Population 
Mild to moderately symptomatic hospitalized adult (≥ 18 years) participants 
with Covid-19 who meet all inclusion and exclusion criteria 
Endpoint 
Time to recovery during the 28 days after dosing where day of recovery is 
defined as the first day on which the participant satisfies 1 of the following 
3 categories from the 8-point ordinal scale (Appendix 6):  1) Not hospitalized, 
no limitations on activities.; 2) Not hospitalized, limitation on activities and/or 
requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen - 
no longer requires ongoing medical care. 
 
Treatment Condition(s) 
One infusion on Day 1 of CPI-006 at dose of 1 mg/kg or 2 mg/kg, or placebo in 
15 minutes, plus SOC per the guideline of the investigation site. 
Population-Level 
Summary 
Compare the distribution of time to recovery between a CPI-006 dose plus 
SOC versus placebo plus SOC within 28 days after dosing.  
ICE-1 (Death) 
Composite strategy  
ICE-2 (Life-saving  
procedures including ICU 
admission) 
Treatment policy strategy  
ICE-3 (All other events) 
Treatment policy strategy  
Rationale for Strategies 
A Treatment policy strategy is used to assess the treatment effect during 28-
days after dosing irrespective of the ICE’s except death as this reflects the 
intended usage in this population. Needing of life-saving procedures would 
impact on and therefore be reflected by the time-to-recovery endpoint. Every 
attempt will be taken to measure the endpoint through 28-day period.  
All-cause death will be considered as non-recovery and censored at Day 28 in 
the Kaplan-Meier estimate and log-rank test.  
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 97 of 114 
Version 003 
Second Key Secondary Objective 
Second Key secondary 
objective 
To compare the time to clinical improvement of CPI-006 plus SOC versus 
placebo plus SOC in hospitalized participants with mild to moderately 
symptomatic Covid-19 infection 
Estimand Label 
Estimand 3  
Estimand Description 
Compare distribution of time to clinical improvement during the 28 days after 
dosing between each of CPI-006 plus SOC groups versus placebo plus SOC 
group in hospitalized participants with mild to moderately symptomatic and 
virologic-confirmed COVID-19 infection.  
Target Population 
Mild to moderately symptomatic hospitalized adult (≥ 18 years) participants 
with Covid-19 who meet all inclusion and exclusion  criteria 
Endpoint 
Time (in days) to clinical improvement (≥ 2 points improvement in the 8-point 
ordinal scale) where clinical improvement is determined by ≥ 2 points 
improvement in the 8-point ordinal scale with no relapsing during the 28 days 
after dosing.  
 
Treatment Condition(s) 
One infusion on Day 1 of CPI-006 at dose of 1 mg/kg or 2 mg/kg, or placebo in 
15 minutes, plus SOC per the guideline of the investigation site. 
Population-Level 
Summary 
Compare the distribution of time to clinical improvement during 28 days study 
after dosing between each CPI-006 dose plus SOC versus placebo plus SOC. 
Intercurrent Event 
Strategy:  
 
ICE-1 (Death) 
Composite strategy  
ICE-2 (Life-saving  
procedures including ICU 
admission) 
Treatment policy strategy  
ICE-3 (All other events) 
Treatment policy strategy  
Rationale for Strategies 
A Treatment policy strategy is used to assess the treatment effect during 28-
days after dosing irrespective of the ICE’s except death as this reflects the 
intended usage in this population. Needing of life-saving procedures would 
impact on and therefore be reflected by the time-to-improvement endpoint. 
Every attempt will be taken to measure the endpoint through 28-day period.  
All-cause death will be considered as non-improvement and censored at Day 28 
in the Kaplan-Meier estimate and log-rank test. 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 98 of 114 
Version 003 
Third Key Secondary Objective 
Third Key secondary 
objective 
Mortality rate over the 28 days after dosing between CPI-006 plus SOC and 
placebo plus SOC in hospitalized participants with mild to moderately 
symptomatic Covid-19 infection 
Estimand Label 
Estimand 4  
Estimand Description 
Ratio in cumulative mortality rates up to 28 days after dosing between each of 
CPI-006 plus SOC groups versus placebo plus SOC group in hospitalized 
participants with mild to moderately symptomatic and virologic-confirmed 
COVID-19 infection.  
Target Population 
Mild to moderately symptomatic hospitalized adult (≥ 18 years) participants 
with Covid-19 who meet all inclusion and exclusion  criteria 
Endpoint 
The event is all-cause death up to 28 days after dosing. Time (in days) to death 
will be defined as from the study dose infusion day to date of death through 
Day 28.  
 
Treatment Condition(s) 
One infusion on Day 1 of CPI-006 at dose of 1 mg/kg or 2 mg/kg, or placebo in 
15 minutes, plus SOC per the guideline of the investigation site. 
Population-Level 
Summary 
Ratio in cumulative mortality rates during the 28 days after dosing between 
each CPI-006 dose plus SOC group versus placebo plus SOC group. 
Intercurrent Event 
Strategy  
 
ICE-1 (Death) 
Composite strategy  
ICE-2 (Life-saving  
procedures including ICU 
admission) 
Treatment policy strategy  
ICE-3 (All other events) 
Treatment policy strategy  
Rationale for Strategies 
The cumulative mortality rate is the endpoint. Treatment policy strategy will be 
used to estimate the treatment effect regardless of the other ICEs (ICE-2 and 3). 
This strategy aligns with the Intent-To-Treatment principle.  
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 99 of 114 
Version 003 
APPENDIX 10 
EFFICACY ANALYSIS FOR THE PRIMARY ENDPOINT 
The primary endpoint is the proportion of participants alive and free from respiratory 
deterioration during the 28 days after dosing. The endpoint will be analyzed using the 
method described in (Ge et al. 2011). This method computes a population-level estimate for 
the treatment difference (i.e., difference in the proportions of patients alive and free of 
respiratory failure during the 28 days after dosing) and incorporates adjustment for the 
stratification factors. 
The method is based on a logistic regression model. To define this model, consider the 𝑖𝑖th 
participant, 𝑖𝑖= 1, … , 𝑛𝑛, where 𝑛𝑛 is the total number of participants in the trial, and let 𝑦𝑦𝑖𝑖 
denote the binary outcome for the primary endpoint, i.e., alive and free of respiratory 
deterioration during the 28 days with 1 to denote alive and free of respiratory deterioration, 
and 0 for otherwise. The treatment indicator for the 𝑖𝑖th patient will be denoted by 𝑡𝑡𝑖𝑖, where 
𝑡𝑡𝑖𝑖= 0 corresponds to the control arm, Treatment C, and 𝑡𝑡𝑖𝑖= 1 corresponds to the treatment 
arm, Treatment A (or B). Finally, the vector of stratification factors for the 𝑖𝑖th patient (age, 
presence of comorbidities, and region of the world) will be denoted by 𝒙𝒙𝑖𝑖. The logistic 
regression model is given by  
logit 𝑝𝑝𝑖𝑖= 𝛽𝛽1 + 𝛽𝛽2𝑡𝑡𝑖𝑖+ 𝜷𝜷3
′ 𝒙𝒙𝑖𝑖, 
where 𝑝𝑝𝑖𝑖= 𝑃𝑃(𝑦𝑦𝑖𝑖= 1) is the probability of being alive and free of respiratory deterioration of 
participant 𝑖𝑖, 𝛽𝛽1 is the control effect, 𝛽𝛽2 is the treatment effect, 𝜷𝜷3 is the vector of model 
parameters corresponding to the stratification factors and the prime denotes transposition of 
𝜷𝜷3. 
After the model has been fitted to the data, the model parameters will be estimated. The 
estimates are denoted by 𝛽𝛽̂1, 𝛽𝛽̂2 and 𝜷𝜷෡3, respectively. The two potential outcomes will be 
computed from the model for each patient. These outcomes represent the outcome 
probabilities for the 𝑖𝑖th patient if this patient had been assigned to the control or CPI-006 
arm: 
𝑝𝑝𝑖𝑖0 = 𝑃𝑃(𝑦𝑦𝑖𝑖= 1|𝑡𝑡𝑖𝑖= 0) = (1 + exp (−𝛽𝛽̂1 −𝜷𝜷෡3
′ 𝒙𝒙𝑖𝑖))−1, 
𝑝𝑝𝑖𝑖1 = 𝑃𝑃(𝑦𝑦𝑖𝑖= 1|𝑡𝑡𝑖𝑖= 1) = (1 + exp (−𝛽𝛽̂1 −𝛽𝛽̂2 −𝜷𝜷෡3
′ 𝒙𝒙𝑖𝑖))−1. 
The population-level estimate for the treatment difference is defined as 
𝑑𝑑= 𝑛𝑛−1 ∑
𝑝𝑝𝑖𝑖1
𝑛𝑛
𝑖𝑖=1
−𝑛𝑛−1 ∑
𝑝𝑝𝑖𝑖0
𝑛𝑛
𝑖𝑖=1
. 
The standard error of 𝑑𝑑, SE(𝑑𝑑), will be estimated using the delta method (Ge et al. 2011, 
Appendix A).   
The test statistics  𝑑𝑑/ SE(𝑑𝑑) is asymptotically distributed as the standard normal distribution. 
The hypothesis HA1 (Protocol 9.2.4.1.3.) will be rejected if the value of 𝑑𝑑/ SE(𝑑𝑑) is above 
z(1-α)  where α = 0.025 or 0.0125 depending on the multiplicity adjustment of the gatekeeping 
procedure. Here z(1-α) denotes the quantile of the standard normal distribution above which 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 100 of 114 
Version 003 
the probability (area under the curve) equals to α. Same testing criteria will be applied for 
HB1. The confidence interval of 𝑑𝑑 will be provided by 𝑑𝑑± Z(1-α) SE(𝑑𝑑). 
 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 101 of 114 
Version 003 
APPENDIX 11 
GATEKEEPING STRATEGY FOR TESTING HYPOTHESES 
1. STATISTICAL HYPOTHESES 
The following hypotheses are defined for the comparisons between Treatment A (CPI-006 at 
a dose of 2 mg/kg plus SOC) and Treatment C (placebo plus SOC) - Treatment A Family: 
Null Hypothesis HAi: Treatment A is not superior to Treatment C with respect to endpoint i  
versus 
H'Ai: 
Treatment A is superior to Treatment C with respect to endpoint i, 
where i = 1 for the primary endpoint “proportion of participants alive and free from 
respiratory deterioration during the 28 days after dosing”; 
i = 2 for the secondary endpoint “time to recovery during the 28 days after dosing”; 
i = 3 for the secondary endpoint “time to clinical improvement by at least 2 points 
during the 28 days after dosing”; 
 
Null Hypothesis HA4: Treatment A is inferior to Treatment C with respect to the secondary 
endpoint “mortality rate over the 28 days after dosing”. 
versus 
H'A4: Treatment A is non-inferior to Treatment C with respect to the secondary endpoint 
 
“mortality rate over the 28 days after dosing”. 
Null Hypothesis HA5: Treatment A is not superior to Treatment C with respect to the 
secondary endpoint “mortality rate over the 28 days after dosing”. 
versus 
H'A5: Treatment A is superior to Treatment C with respect to the secondary endpoint 
 
“mortality rate over the 28 days after dosing”. 
The same hypotheses will be tested for the comparison between Treatment B and C - 
Treatment B Family: HBi versus H'Bi , where i = 1, 2, 3, 4, and 5. 
2. PARALLEL GATEKEEPING PROCEDURE FOR TESTING HYPOTHESES 
A multiplicity adjustment strategy is designed to control the study level overall Type I error 
rate α at a one-sided 0.025 for the hypotheses in Treatment A and B families defined above 
and illustrated using Bretz’s graphical method (Bretz et al., 2009). Note that the five null 
hypotheses are arranged in a hierarchical order within the hypothesis family of each 
treatment. This multiplicity adjustment is aligned with the logical restrictions among the ten 
null hypotheses, i.e., a hypothesis in a given treatment family can be tested only if all 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 103 of 114 
Version 003 
o gB34 = ε'; 
o gB45 = 1;  
o gA3B1 = 1 - ε; 
o gB3A1 = 1 - ε';  
o gA5B4 = 1; 
o gB5A4 = 1;  
The transition parameters determine the fraction of the local α level that is to be 
allocated to a designated hypothesis in case the prior hypothesis in the same family is 
rejected. 
• The values of ε and ε' are dependent on the Step (see below) at which the hypotheses 
are rejected. Note that as indicated in Figure 2, the choice of transition parameters 
ensures that the hypotheses HA4 and HB4 will be tested only if HA3 and HB3 are both 
rejected, or, in other words, only if the hypotheses HAi and HBi, i=1, 2, and 3 are all 
rejected.  
In details, the multiplicity adjustment strategy will be implemented using the following serial 
testing algorithm (Dmitrienko and D’Agostino, 2013). The algorithm follows the hierarchical 
order and is defined as follows: 
• Step 1: Test the hypotheses HA1 and HB1 each at the α = 0.0125 level.   
o Proceed to Step 2 if at least one hypothesis is rejected at this step.  
o Otherwise, stop the test procedure. 
• Step 2: Test the hypotheses HA2 and/or HB2 each at the α = 0.0125 level if HA1 and/or 
HB1, respectively, is/are rejected at Step 1.   
o Proceed to Step 3 if at least one hypothesis is rejected at this step.  
o Otherwise, stop the test procedure. 
• Step 3: Test the hypotheses HA3 and/or HB3 each at the α = 0.0125 level if HA2 and/or 
HB2, respectively, is/are rejected at Step 2.   
o Proceed to Step 4 if only one hypothesis is rejected.  
o Proceed to Step 5 if both hypotheses are rejected at this step. In this case, set ε 
= ε' = 1, i.e., gA34 = gB34 = 1 and gA3B1 = gB3A1 = 0. 
o Otherwise, stop the test procedure. 
• Step 4:  
o If the hypothesis HA3 is rejected at Step 3 and if any of the hypotheses in the 
Treatment B Family up to Step 3 is not rejected, then return to Step 1 and re-
test all the hypotheses in the Treatment B Family at the full α = 0.025 level 
following the hierarchical order defined in Figure 2. In this case, ε = 0, and 
gA3B1 = 1. If HB3 is rejected as the outcome of re-testing, proceed to Step 5. If 
HB3 is not rejected, stop the testing procedure. 
o Similarly, if the hypothesis HB3 is rejected at Step 3 and if any of the 
hypotheses in the Treatment A Family up to Step 3 is not rejected, then return 
to Step 1 and re-test all the hypotheses in the Treatment A Family at the full α 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 104 of 114 
Version 003 
= 0.025 level following the hierarchical order defined in Figure 2. In this case, 
ε' = 0, and gB3A1 = 1. If HA3 is rejected as the outcome of re-testing, proceed 
to Step 5. If HA3 is not rejected, stop the testing procedure. 
• Step 5: Test the hypotheses HA4 and HB4 each at the α = 0.0125 level.  
o Proceed to Step 6 if at least one hypothesis is rejected at this step.  
o Otherwise, stop the test procedure. 
• Step 6: Test the hypotheses HA5 and/or HB5 each at the α = 0.0125 level if HA4 and/or 
HB4, respectively, is/are rejected at Step 5.  
o Proceed to Step 7 if only one hypothesis is rejected.  
o If both hypotheses are rejected or neither hypothesis is rejected at this step, 
stop the test procedure. 
• Step 7:  
o If the hypothesis HA5 is rejected and if HB5 is not rejected at Step 6, then 
return to Step 5 and re-test the hypotheses HB4 and HB5 at the full α = 0.025 
level following the hierarchical order defined in Figure 2.   
o Similarly, if the hypothesis HB5 is rejected and if HA5 is not rejected at Step 6, 
then return to Step 5 and re-test the hypotheses HA4 and HA5 at the full α = 
0.025 level following the hierarchical order defined in Figure 2.   
o This is the end of the testing procedure. 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 105 of 114 
Version 003 
APPENDIX 12 
FUTILITY CRITERIA AND ITS OPERATING CHARACTERISTICS FOR GO OR 
NO-GO DECISIONS BASED ON EFFICACY DATA AT INTERIM ANALYSES 1 
AND 2 
1. INTRODUCTION 
This document provides a description of the futility criteria and its operating characteristics 
that will guide the Go or No-Go decisions for the study based on the primary efficacy 
endpoint at the interim analyses 1 and 2. The efficacy endpoint is the proportion of 
participants who are alive and free from respiratory deterioration during the 28 days after 
dosing (the Response Rate) (Protocol Section 3. OBJECTIVES AND ENDPOINTS). At each 
interim analysis, the difference between Treatment A (CPI-006 2 mg/kg plus SOC) and 
Treatment C (placebo plus SOC) with respect to the primary efficacy endpoint will be 
evaluated. A Go or No-Go decision will be made by comparing the difference between the 
treatments according to the futility criteria. A similar evaluation will be made to assess the 
difference between Treatment B (CPI-006 1 mg/kg plus SOC) and C. A Go or No-Go 
decision will be made for Treatment B independent of the decision for Treatment A.  
2. SIMULATION STUDY FOR THE FUTILITY CRITERIA BASED ON THE 
PRIMARY EFFICACY ENDPOINT 
The purpose of the simulation study was to determine a set of futility criteria for the study 
and to investigate the operating characteristics of the futility criteria including the estimation 
of the probability of No-Go outcome according to the futility criteria at the interim analyses. 
Extensive simulations were performed based on the primary efficacy endpoint in response 
rate.  Since there was no difference in response rates assumed for Treatment A and B in the 
simulation study, the selected futility criteria and the described operating characteristics 
apply to both Treatment A and B (the Treatment) in comparison to Treatment C (the 
Control). In the simulation study, the response rate for Control was assumed to be 78%, 80%, 
82% and 84%. The 84% for Control was used for the sample size and power assessment for 
the study (Protocol, Section 9.1. SAMPLE SIZE DETERMINATION).  
The response rates of Treatment that were considered as an “inferior treatment”, “ineffective 
treatment”, or “highly effective treatment” in comparison to Control were investigated for the 
performance of the futility criteria. The response rates of Treatment that were investigated for 
the Control rates of 78% and 84% are given in Table 13. The Control rates of 78% and 84% 
represent the range of investigation for the operating characteristics of the futility criteria. 
The simulations for the Control rates of 80% and 82%, being in between 78% and 84%, 
yielded comparable outcomes to these for 78% and 84%, and hence are not provided in this 
document.  

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 106 of 114 
Version 003 
Table 13 
Simulation Scenarios 
Simulation  
Scenarios 
Response Rate for  
Treatment (Difference) vs Control 
Control = 84% 
Control = 78% 
Inferior Treatment 
vs Control 
76%  (-8%) 
70%  (-8%) 
80%  (-4%) 
74%  (-4%) 
Ineffective Treatment 
vs Control 
86% (+2%) 
80% (+2%) 
Highly Effective Treatment 
vs Control 
92%  (+8%) 
86%  (+8%) 
94%  (+10%) 
88%  (+10%) 
3. SIMULATION PROCEDURES 
For each of the above simulation scenarios, 100,000 studies were simulated. Each study was 
simulated in either 1 step (for the study that met the No-Go criteria at Step 1) or 2 steps: 
Step 1:   For each study, 75 “participants” being either a “Responder” or “Non-responder” 
were simulated for Treatment and Control arms from a Bernoulli distribution with the single 
parameter being the Response Rate specified for Treatment or Control as in the above table. 
The difference between Treatment and Control was calculated based on the response rate of 
the treatment arms. The difference was then standardized to a value on the Normal(0,1) scale 
using the formula for the 2-sample binomial test with standard normal approximation: 
 
𝑧𝑧=
(𝑝𝑝̂𝑇𝑇−𝑝𝑝̂𝐶𝐶)
ට𝑝𝑝̂𝑇𝑇(1 −𝑝𝑝̂𝑇𝑇)
𝑛𝑛𝑇𝑇
+ 𝑝𝑝̂𝐶𝐶(1 −𝑝𝑝̂𝐶𝐶)
𝑛𝑛𝐶𝐶
∗ 
* Sample estimates are denoted by the ^ symbol;  𝑝𝑝̂𝑇𝑇, 𝑝𝑝̂𝐶𝐶 are the response rate of Treatment and Control, 𝑛𝑛𝑇𝑇 and 
𝑛𝑛𝐶𝐶 are the number of subjects in Treatment and Control. 
Then the standardized treatment difference was compared to a value pre-determined as the 
“futility threshold” on the Normal(0,1) scale. On the Normal(0,1) scale, negative numbers 
correspond to comparisons that the Treatment response was lower than Control. The larger 
the magnitude of the negative numbers on the Normal(0,1) scale, the worse the 
corresponding Treatment responses are compared to Control. Conversely, positive numbers 
on the Normal(0,1) scale correspond to comparisons that Treatment response was higher than 
Control. The larger the positive numbers on the Normal(0,1) scale, the better the 
corresponding Treatment are compared to Control. The value 0 corresponds to no difference 
between Treatment and Control. 
A simulated study was stopped at Step 1 if the standardized treatment difference is equal to 
or less than the futility threshold indicating that Treatment failed to achieve the level of 
efficacy in response rate compared to Control as defined by the futility threshold at interim 
analysis 1, and therefore the study was discontinued. The probability of No-Go per the 
futility criteria at interim analysis 1 is estimated by the percentage of the simulated studies 
that were stopped out of the 100,000 simulated studies. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 107 of 114 
Version 003 
Step 2: For a simulated study that was not stopped at interim analysis 1 (i.e., that the 
standardized difference between treatment response rates was greater than the futility 
threshold), an additional 125 participants were simulated for each treatment arm from the 
respective Bernoulli distributions, making the total number of participants to be 200 per arm 
for interim analysis 2. Similarly, the standardized treatment difference in response rates was 
calculated and compared to the futility threshold pre-determined for interim analysis 2. The 
study was stopped at interim analysis 2 if the standardized treatment difference is equal to or 
less than the futility threshold. The probability of No-Go at either interim analysis 1 or 2 was 
estimated by the percentage of the simulated studies that were stopped at either interim 
analysis out of the 100,000 simulated studies. 
4. FUTILITY CRITERIA AND OPERATING CHARACTERISTICS BASED ON 
SIMULATION RESULTS 
The futility criteria for interim analyses 1 and 2 were determined based on the simulation 
study, and summarized with the operating characteristics for 2 Control response rates of 84% 
and 78% in Table 14 and Table 15, respectively. Additionally, the Conditional Power (CP) 
assuming that the futility thresholds at interim analyses 1 and 2 are the observed Treatment 
vs Control differences, and assuming the future data would be consistent with the pre-defined 
alternative hypothesis of beneficial effect (Column 2, Table 14 and Table 15) is provided in 
Column 4 in the tables. For example, if at the interim analysis 2 (Table 15), the observed 
response rates are 88.2% vs 84% (z-score 1.2) for Treatment vs Control, then the CP for 
reaching a significance at α = 0.0125 at the end of the study would be 38.6% assuming that 
the actual response rates for Treatment and Control are still 92% vs 84%, respectively. With 
the response rates of 92% vs 84%, based on simulation, there would be approximately 13% 
chance that the study could be stopped for futility at either the interim analysis 1 or 2. 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 108 of 114 
Version 003 
Table 14 
Operating Characteristics of the Futility Stopping Criteria at 
Interim Analysis 1 with 25% Information 
Simulation  
Scenarios 
Response Rate 
for  
Treatment vs 
Control 
Futility Threshold 
on  
N(0,1) Scale for  
No-Go  
at Interim Analysis 
1 
(N=75 per Arm) 
Conditional 
Power (%) at 
Interim Analysis 
1 under the 
Hypotheses in 
Column 2 
Probability (%) 
of   
No-Go  
at Interim 
Analysis 1 
based on 
Simulation 
Inferior Treatment 
vs Control 
76% vs 84% 
-0.4 
(Corresponding to 
81.5% vs 84%) 
2.3E-07 
80.4 
80% vs 84% 
3.5E-05 
61.4 
Ineffective Treatment 
vs Control 
86% vs 84% 
1.4 
24.4 
Highly Effective 
Treatment 
vs Control 
92% vs 84% 
46.5 
2.9 
94% vs 84% 
76.7 
0.8 
  
Inferior Treatment 
vs Control 
70% vs 78% 
-0.4 
(Corresponding to 
75.2% vs 78%) 
6.2E-07 
74.7 
74% vs 78% 
5.6E-05 
55.0 
Ineffective Treatment 
vs Control 
80% vs 78% 
1.1 
24.2 
Highly Effective 
Treatment 
vs Control 
86% vs 78% 
30.6 
5.1 
88% vs 78% 
55.4 
2.3 
Table 15 
Operating Characteristics of the Futility Stopping Criteria at 
Interim Analysis 2 with 60% Information 
Simulation  
Scenarios 
Response Rate 
for  
Treatment vs 
Control 
Futility Threshold 
on  
N(0,1) Scale for  
No-Go  
at Interim Analysis 
2 
(N=200 per Arm) 
Conditional 
Power (%) at 
Interim Analysis 
2 under the 
Hypotheses in 
Column 2 
Probability (%) 
of   
No-Go at  
Interim 
Analyses 1 or 2 
Inferior Treatment 
vs Control 
76% vs 84% 
1.2 
(Corresponding to 
88.2% vs 84%) 
1.2E-04 
99.9 
80% vs 84% 
1.6E-03 
98.6 
Ineffective Treatment 
vs Control 
86% vs 84% 
4.20 
75.8 
Highly Effective 
Treatment 
vs Control 
92% vs 84% 
38.6 
13.0 
94% vs 84% 
60.5 
3.1 
  
Inferior Treatment 
vs Control 
70% vs 78% 
1.2 
(Corresponding to 
82.8% vs 78%) 
1.9E-04 
99.8 
74% vs 78% 
2.3E-03 
98.2 
Ineffective Treatment 
vs Control 
80% vs 78% 
4.7 
77.4 
Highly Effective 
Treatment 
vs Control 
86% vs 78% 
35.1 
22.7 
88% vs 78% 
53.5 
9.8 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 109 of 114 
Version 003 
5. SUMMARY OF RESULTS 
A reasonably broad range of the Response Rate of Control, and the selected Response Rates 
of Treatment that were considered as inferior, ineffective, or highly effective in comparison 
to Control were studied to determine a set of futility stopping criteria by simulations. The 
simulation study supported using -0.4 and 1.2 on the Normal(0,1) scale as the futility 
stopping threshold at interim analyses 1 and 2, respectively. Treatment A or B (or both) 
would be discontinued at the interim analysis 1 or 2 if the standardized difference in response 
rate between Treatment A (or B) and C (A minus C or B minus C) is at or below the 
respective futility threshold at the interim analysis. With the futility thresholds of -0.4 and 1.2 
for the interim analysis 1 and 2, respectively, the probability of No-Go decision at the interim 
analyses is high for an inferior Treatment (55%-80% at interim analysis 1, and >98% at 
interim analysis 2); and is moderate for an ineffective Treatment (24% at interim analysis 1, 
75% at interim analysis 2); and is low (approximately 5% or lower at interim analysis 1, and 
approximately 20% or lower at interim analysis 2) for a highly effective Treatment. The No-
Go probabilities were comparable across all the simulated scenarios as described in 
Section 2. 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 110 of 114 
Version 003 
APPENDIX 13 
OPERATING CHARACTERISTICS OF NON-INFERIORITY TEST FOR 
TREATMENT A (OR B) RELATIVE TO TREATMENT C IN TERMS OF THE 
RATIO OF THE MORTALITY RATES 
1. Introduction 
The cumulative mortality rate over the 28 day period from dosing is a key secondary 
endpoint. Non-inferiority of Treatment A (or B) (Treatment) in comparison with Treatment C 
(Control) will be assessed based on the ratio of Treatment mortality relative to Control 
mortality. A multiplicity adjusted 2-sided confidence interval (CI) (97.5% or 95%, depending 
on the multiplicity adjustment) will be calculated for this ratio (Protocol Section 9.2.4.1.2)  
The CI will be used to assess the non-inferiority of Treatment in comparison to Control 
against the non-inferiority margin of 1.3. If the upper limit of the CI of ratio is equal to or 
less than 1.3, the non-inferiority of Treatment relative to Control is established. 
This appendix provides a description of the operating characteristics of the approach to 
determine the non-inferiority as described above.   
2. Simulation Study for Assessing Non-inferiority 
The purpose of the simulation study was to evaluate the chance for establishing non-
inferiority for a range of mortality rates for Treatment and Control, as well as the chance for 
rejection of non-inferiority, based on the non-inferiority margin of 30%.  
A single parameter exponential distribution was assumed for the time-to-mortality variable of 
interest that would be simulated from the exponential distribution  F(t) = 1 – e-λt . Since the 
mortality endpoint is the cumulative mortality over 28 days, the time variable “t” is fixed at 
28 (days). For each pair of underlying mortality rates of Treatment and Control, 1000 studies 
were simulated. In each study, 330 observations of the time-to-mortality variable for each of 
Treatment and Control were simulated from the treatment specific exponential distribution 
determined by the underlying mortality rates of the treatment groups.   
To be more specific, if a given cumulative mortality rate of Treatment over the 28 days after 
dosing was “x”, then the single parameter λ of the exponential distribution function 
F(t) = 1 – e-λt = x was selected to correspond to the specified mortality rate x at Day 28. 
Similarly, an exponential distribution was derived for the specified Control mortality rate at 
Day 28. Three hundred thirty observations were simulated from these exponential 
distributions up to t = 28 days for each Treatment and Control groups. Simulated mortality 
events exceeding Day 28 were censored at Day 28, thus each simulated random variate 
represents one participant’s observed time-to-mortality outcome through Day 28. The 
cumulative mortality rate of Treatment and Control with the associated variance were 
estimated separately based on the 330 observations using the Kaplan-Meier method. The 
ratio of the Treatment to Control mortality rates at Day 28 and its accompanying variance 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 111 of 114 
Version 003 
were calculated. The CI for this Day 28 mortality ratio with the multiplicity adjusted 
confidence level was calculated following the procedure presented for Estimand 4 in Protocol 
Section 9.2.4.1.2.   
3. Simulation Results 
The simulation outcomes were summarized in Table 16 and Table 17 to describe the 
operating characteristics of the assessment for the non-inferiority of Treatment relative to 
Control based on the ratio of the cumulative mortality of the two groups. 
Table 16 provides the ranges of the underlying mortality rates of the two treatment groups 
with the row headers for Treatment and column headers for Control. The calculated ratio for 
each pair of the underlying mortality rates for Treatment and Control is presented in the body 
of the table. The entries of “1” on a diagonal are the ratios for equal mortality rates of the two 
treatments. The entries being < 1 below the diagonal with entries 1 represent the cases that 
the mortality of Treatment is lower than that of Control; while the entries being > 1 above the 
diagonal represent the cases that the mortality of Treatment is higher than that of Control.  
For each pair of mortality rates of Treatment and Control in Table 16, 1000 studies were 
simulated each with 330 observations of time-to-mortality data for each treatment group 
following the procedure described in Section 2. The Day 28 mortality rate of each treatment 
group was estimated, and a 2-sided CI of the ratio of estimated mortality rates of Treatment 
relative to Control was calculated based on the simulated data of each study. Then the 
percentage of the studies with the upper limit of the CI that were ≤ 1.3 was determined out of 
the total of 1000 studies simulated for this pair of underlying mortality rates. These 
percentages are presented in Table 17. Although the confidence level of the CI’s should be 
determined by the multiplicity adjustment as the non-inferiority would be assessed within the 
gatekeeping procedure, in this simulation the 2-sided confidence level of 97.5% was used for 
the calculation of all the CI’s. 
For example, for the underlying mortality rates of 6% and 8% of Treatment and Control, 
respectively, 97% of the 1000 simulated studies had the upper limit of the CI ≤ 1.3. This 
percentage estimates the probability of establishing non-inferiority of Treatment relative to 
Control for this pair of mortality rates corresponding to its row and column labels.  
The entries highlighted in blue along the diagonal are cases of equal mortality rates between 
Treatment and Control. The values for these cases are reasonably high, indicating that there 
would be sufficient power for non-inferiority to be established for Treatment relative to 
Control. The power for the non-inferiority comparison is trending higher as the mortality rate 
for Treatment is trending lower relative to Control. Conversely, the power for non-inferiority 
is generally low for the cases that the ratio of mortalities of Treatment relative to Control 
exceeds 1.5.  

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 114 of 114 
Version 003 
APPENDIX 14 
PROTOCOL AMENDMENT HISTORY 
 
Table 18  
Document History 
Document History 
Date of Issue 
Version 003 (Amendment 2) 
23-March-2021 
Version 002 (Amendment 1) 
11-January-2021 
Version 001 (Original Protocol) 
06-November-2020 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 1 of 88 
Version 002 
 
 
Protocol 
 
Protocol Title: 
Phase 3, Randomized, Placebo Controlled, Double-blind, 
Multicenter, Stratified Study of CPI-006 Plus Standard of 
Care Versus Placebo Plus Standard of Care in Mild to 
Moderately Symptomatic Hospitalized Covid-19 Patients 
Protocol Number: 
CPI-006-003 
Regulatory Agency 
Identifier Number(s): 
 
EudraCT: 2020‐005305‐54 
Compound Number: 
CPI-006 
Study Phase: 
3 
Sponsor Name: 
Corvus Pharmaceuticals 
Sponsor Address: 
863 Mitten Rd, Suite 102 
Burlingame, CA 94010, USA 
Version Number: 
002 
Date Final: 
11 January 2021 
 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 3 of 88 
Version 002 
INVESTIGATOR SIGNATURE PAGE 
Protocol Title: 
Phase 3, Randomized, Placebo Controlled, Double-blind, Multicenter, 
Stratified Study of CPI-006 Plus Standard of Care Versus Placebo Plus 
Standard of Care in Mild to Moderately Symptomatic Hospitalized 
Covid-19 Patients 
Protocol Number: CPI-006-003 
Version Number: 002 
 
 
 
I have read and understood the current version of the protocol (as listed above). I agree to 
conduct this trial in accordance with International Council for Harmonisation (ICH) Good 
Clinical Practice (GCP), all applicable regulatory requirements, and the general ethical 
principles outlined in the Declaration of Helsinki.  
I agree to ensure that no deviation from, or changes to the protocol will take place without 
prior agreement from Corvus Pharmaceuticals and documented approval from the 
Institutional Review Board (IRB)/Independent Ethics Committee (IEC), except where 
necessary to eliminate an immediate hazard(s) to the trial participants.  
I will ensure that all staff members under my supervision involved in the conduct of this 
study are informed about the protocol and protocol amendments, the investigational products, 
and their study-related duties and functions.  
I agree not to divulge to anyone, either during or after the termination of the study, any 
confidential information acquired regarding the investigational products and processes or 
methods of Corvus. 
 
 
 
 
Investigator Signatory 
Name: 
Title: 
 
Date 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 4 of 88 
Version 002 
TABLE OF CONTENTS 
Page 
1. 
Protocol Summary ............................................................................................ 11 
1.1. 
Synopsis ............................................................................................................ 11 
1.2. 
Schema ............................................................................................................. 21 
1.3. 
Schedule of Activities (SoA) ............................................................................ 21 
2. 
Introduction ...................................................................................................... 21 
2.1. 
Study Rationale ................................................................................................ 21 
2.2. 
Background ...................................................................................................... 22 
2.3. 
CPI-006 Nonclinical Evaluation ...................................................................... 24 
2.4. 
Summary of Clinical Experience with CPI-006 ............................................... 25 
2.4.1. 
Benefit/Risk Assessment .................................................................................. 26 
3. 
Objectives and Endpoints ................................................................................. 27 
4. 
Study Design .................................................................................................... 30 
4.1. 
Overall Design .................................................................................................. 30 
4.2. 
Scientific Rationale for Study Design .............................................................. 32 
4.3. 
Justification for Dose ........................................................................................ 32 
4.4. 
End of Study Definition ................................................................................... 35 
5. 
Study Population .............................................................................................. 35 
5.1. 
Inclusion Criteria .............................................................................................. 35 
5.2. 
Exclusion Criteria ............................................................................................. 36 
5.3. 
Lifestyle Considerations ................................................................................... 37 
5.3.1. 
Meals and Dietary Restrictions ........................................................................ 37 
5.3.2. 
Activity ............................................................................................................. 37 
5.4. 
Screen Failures ................................................................................................. 37 
6. 
Study Treatment ............................................................................................... 37 
6.1. 
Study Treatment Administered ........................................................................ 37 
6.2. 
Study Treatment: Preparation/Handling/Storage/Accountability .................... 38 
6.2.1. 
Handling and Storage ....................................................................................... 39 
6.2.1.1. 
CPI-006 Injection ............................................................................................. 39 
6.2.1.2. 
Placebo ............................................................................................................. 39 
6.2.2. 
Preparation and Dispensing .............................................................................. 39 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 5 of 88 
Version 002 
6.2.3. 
Administration .................................................................................................. 40 
6.2.4. 
Management of Infusion Reactions .................................................................. 41 
6.3. 
Measures to Minimize Bias: Randomization and Blinding .............................. 43 
6.3.1. 
Randomization .................................................................................................. 43 
6.3.2. 
Blinding ............................................................................................................ 44 
6.3.3. 
Procedures for Unblinding ............................................................................... 44 
6.4. 
Study Treatment Compliance ........................................................................... 44 
6.5. 
Concomitant Therapy ....................................................................................... 45 
6.5.1. 
Rescue Medicine .............................................................................................. 45 
6.5.2. 
Permitted Concomitant Therapy ...................................................................... 45 
6.5.3. 
Prohibited Concomitant Therapy ..................................................................... 46 
6.6. 
Dose Modification ............................................................................................ 46 
6.7. 
Treatment After the End of the Study .............................................................. 47 
7. 
Discontinuation of Study Treatment and Participant 
Discontinuation/Withdrawal ............................................................................ 47 
7.1. 
Discontinuation of Study Treatment ................................................................ 47 
7.2. 
Participant Discontinuation/Withdrawal from the Study ................................. 47 
7.3. 
Lost to Follow Up ............................................................................................. 47 
8. 
Study Assessments and Procedures .................................................................. 48 
8.1. 
Screening .......................................................................................................... 49 
8.2. 
Study Assessments and Procedures .................................................................. 49 
8.3. 
Efficacy Assessments ....................................................................................... 49 
8.4. 
Pharmacokinetic and Pharmacodynamic Assessments .................................... 50 
8.5. 
Safety Assessments .......................................................................................... 50 
8.6. 
Adverse Events and Serious Adverse Events ................................................... 51 
8.6.1. 
Time Period and Frequency for Collecting AE and SAE Information ............ 51 
8.6.2. 
Method of Detecting AEs and SAEs ................................................................ 52 
8.6.3. 
Follow-up of AEs and SAEs ............................................................................ 52 
8.6.4. 
Regulatory Reporting Requirements for SAEs ................................................ 52 
8.7. 
Biomarkers ....................................................................................................... 53 
8.7.1. 
Immunogenicity Assessments .......................................................................... 53 
9. 
Statistical Considerations ................................................................................. 54 
9.1. 
Statistical Hypotheses ....................................................................................... 54 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 6 of 88 
Version 002 
9.2. 
Sample Size Determination .............................................................................. 54 
9.3. 
Population for Analyses ................................................................................... 55 
9.4. 
Statistical Analyses ........................................................................................... 55 
9.4.1. 
General Approach ............................................................................................. 55 
9.4.2. 
Demographic and Participant Characteristics .................................................. 56 
9.4.3. 
Efficacy Analyses ............................................................................................. 56 
9.4.4. 
Safety Analyses ................................................................................................ 58 
9.4.5. 
Exploratory Analyses ....................................................................................... 58 
9.4.6. 
Interim Analyses ............................................................................................... 58 
9.4.7. 
Independent Data Monitoring Committee (iDMC) .......................................... 59 
10. 
References ........................................................................................................ 61 
Appendix 1  Schedule of Activities ..................................................................................... 62 
Appendix 2  Regulatory, Ethical, and Study Oversight Considerations .............................. 66 
Appendix 3  Clinical Laboratory Tests ................................................................................ 71 
Appendix 4  Adverse Events: Definitions and Procedures for Recording, Evaluating, 
Follow-up, and Reporting ............................................................................... 72 
Appendix 5  Contraceptive Guidance and Collection of Pregnancy Information ............... 80 
Appendix 6  8-Point Ordinal Scale for Clinical Improvement ............................................ 84 
Appendix 7  NEWS2 Scoring System ................................................................................. 85 
Appendix 8  Example of An Assessment of 14 Common Covid-19-Related Symptoms: 
Items and Response Options ........................................................................... 86 
Appendix 9  Protocol Amendment History .......................................................................... 88 
 
LIST OF TABLES 
Table 1 
Population Definitions................................................................................... 19 
Table 2 
Study Treatment ............................................................................................ 37 
Table 3 
CPI-006 Infusion-Related Reaction Management Guidelines ...................... 41 
Table 4 
Population Definitions................................................................................... 55 
Table 5 
Efficacy Analyses .......................................................................................... 56 
Table 6 
Schedule of Activities ................................................................................... 62 
Table 7 
PK, ADA, and Neutralizing Antibody Sampling Schedule .......................... 65 
Table 8 
Protocol-Required Safety Laboratory Assessments ...................................... 71 
Table 9 
Assessment of Severity of Adverse Events ................................................... 76 
Table 10 
Highly Effective Contraceptive Methodsa .................................................... 81 
Table 11  
Document History ......................................................................................... 88 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 7 of 88 
Version 002 
 
LIST OF FIGURES 
Figure 1 
Study Schematic ............................................................................................ 21 
 
LIST OF APPENDICES 
Appendix 1 
 Schedule of Activities .................................................................................. 62 
Appendix 2 
 Regulatory, Ethical, and Study Oversight Considerations ........................... 66 
Appendix 3 
 Clinical Laboratory Tests ............................................................................. 71 
Appendix 4 
 Adverse Events: Definitions and Procedures for Recording, Evaluating, 
Follow-up, and Reporting ............................................................................ 72 
Appendix 5 
 Contraceptive Guidance and Collection of Pregnancy Information ............ 80 
Appendix 6 
 8-Point Ordinal Scale for Clinical Improvement ......................................... 84 
Appendix 7 
 NEWS2 Scoring System .............................................................................. 85 
Appendix 8 
 Example of An Assessment of 14 Common Covid-19-Related Symptoms: 
Items and Response Options ........................................................................ 86 
Appendix 9 
 Protocol Amendment History....................................................................... 88 
 
 
 
 
 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 8 of 88 
Version 002 
 
LIST OF ABBREVIATIONS 
Abbreviation  
Definition 
ACE2 
angiotensin converting enzyme 2 
ADA 
anti-drug antibodies 
AE 
adverse event 
ALT 
alanine aminotransferase 
AMP 
adenosine monophosphate 
ANC 
absolute neutrophil count 
aPTT 
activated partial thromboplastin time 
ARDS 
acute respiratory distress syndrome 
AST 
aspartate aminotransferase 
AUC 
area under the serum or plasma concentration-time curve 
AUC(0-169) 
AUC from the start of infusion to 169 hours after the start of infusion 
AUClast 
AUC from time zero to the time of the last quantifiable concentration 
BCR 
B cell receptor 
C(0) 
the initial CPI-006 concentration measured 30 minutes after completion of the 
infusion 
CBC 
complete blood count 
CCP 
Covid-19 Convalescent Plasma 
CI 
confidence interval 
CKD 
chronic kidney disease 
Cmax 
maximum drug concentration in serum or plasma 
COPD 
chronic obstructive pulmonary disease 
CRF 
case report form 
CRO 
contract research organization 
CRP 
C-reactive protein 
CT 
computed tomography 
DLT 
dose-limiting toxicity 
ELISA 
enzyme-linked immunosorbent assay 
Fc 
fragment crystallizable 
FDA 
U.S. Food and Drug Administration 
GCP 
Good Clinical Practice 
GLP 
Good Laboratory Practice 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 9 of 88 
Version 002 
Abbreviation  
Definition 
HIPAA 
United States Health Insurance Portability and Accountability Act 
HLA-DR 
human leukocyte antigen – DR isotype  
IC50 
concentration required for 50% inhibition 
ICF 
informed consent form 
ICH 
International Council for Harmonisation 
ICU 
intensive care unit 
iDMC 
Independent Data Monitoring Committee 
IEC 
Independent Ethics Committee 
IFN-γ 
interferon gamma 
Ig 
immunoglobulin 
IgA 
immunoglobulin A 
IgG 
immunoglobulin G  
IgM 
immunoglobulin M 
IL-2, -6, -10 
interleukin 2, 6, 10 
IND 
Investigational New Drug  
INR 
international normalized ratio 
IRB 
Institutional Review Board 
IRR 
infusion-related reaction 
IRT 
interactive response technology 
ITT 
intent-to-treat 
IV 
intravenous(ly) 
LDH 
lactate dehydrogenase 
MCH 
mean corpuscular hemoglobin  
MCV 
mean corpuscular volume 
MERS 
Middle East respiratory syndrome 
NEWS2 
National Early Warning Score 2 
NCI CTCAE 
National Cancer Institute Common Terminology Criteria for Adverse Events 
NOAEL 
no-observed adverse effect level 
O2 
oxygen 
PBMC 
peripheral blood mononuclear cell 
PCR 
polymerase chain reaction 
PD 
pharmacodynamics 
PD1 
programmed cell death 1 receptor  

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 10 of 88 
Version 002 
Abbreviation  
Definition 
PE 
polyethylene 
PES 
polyethersulfone 
PK 
pharmacokinetic(s) 
PO 
by mouth (orally) 
PO/PE 
polyolefin/polyethylene 
PT 
prothrombin time 
PVC 
polyvinylchloride 
RBC 
red blood cell 
RBD 
receptor binding domain 
RNA 
ribonucleic acid 
RSV 
Respiratory Syncytial Virus 
SAE 
serious adverse event 
SARS 
severe acute respiratory syndrome 
SARS-CoV-2 
severe acute respiratory syndrome coronavirus 2 
SCD 
sickle cell disease 
SoA 
schedule of activities 
SOB 
shortness of breath 
SOC 
standard of care 
SpO2 
oxygen saturation 
SUSAR 
suspected unexpected serious adverse reactions 
TNF-α 
tumor necrosis factor alpha 
ULN 
upper limit of normal 
US/USA 
United States of America 
USP 
United States Pharmacopeia 
WBC 
white blood cell 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 11 of 88 
Version 002 
1. 
PROTOCOL SUMMARY 
1.1. 
SYNOPSIS 
Name of Sponsor: Corvus Pharmaceuticals, Inc. 
Investigational Product: CPI-006 
Title of Study: Phase 3, Randomized, Placebo Controlled, Double-blind, Multicenter, 
Stratified Study of CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in 
Mild to Moderately Symptomatic Hospitalized Covid-19 Patients 
Phase of Development: 3 
Number of Participants: Approximately 1000 evaluable participants for an estimated total 
of 330 evaluable participants per treatment group 
Study Centers: Multicenter 
Study Objectives and Endpoints:  
Objectives 
Endpoints 
Primary 
 
• 
To compare the proportion of participants alive 
and respiratory failure free during the 28 days 
after dosing with CPI-006 plus SOC versus 
placebo plus SOC in hospitalized participants 
with mild to moderately symptomatic Covid-19 
infection 
• 
Proportion of participants who are alive and free 
from respiratory deterioration defined as follows 
per the 8-point ordinal scale (Appendix 6): 
o Deterioration to Categories 6, 7, or 8 for a 
participant who entered the trial at Categories 4 
or 5  
o Deterioration to Categories 7 or 8 for a 
participant who entered the trial at Category 6 
Key Secondary 
 
• 
To compare the time to recovery of CPI-006 plus 
SOC versus placebo plus SOC in hospitalized 
participants with mild to moderately symptomatic 
Covid-19 infection 
• 
Time to recovery during the 28 days after dosing. 
Day of recovery is defined as the first day on 
which the participant satisfies 1 of the following 
3 categories from the 8-point ordinal scale 
(Appendix 6): 1) Not hospitalized, no limitations 
on activities.; 2) Not hospitalized, limitation on 
activities and/or requiring home oxygen; 3) 
Hospitalized, not requiring supplemental oxygen 
- no longer requires ongoing medical care. 
• 
To compare the time to clinical improvement of 
CPI-006 plus SOC versus placebo plus SOC in 
hospitalized participants with mild to moderately 
symptomatic Covid-19 infection 
• 
Time to clinical improvement (≥ 2 points 
improvement in the 8-point ordinal scale) 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 12 of 88 
Version 002 
Objectives 
Endpoints 
• 
To compare the change from baseline in the level 
of antibodies targeting the RBD of SARS-CoV-2  
• 
Change from baseline level of IgG targeting the 
RBD at Days 7, 14, 21, and 28 
• 
To compare the time to improvement of Covid-
19-attributable symptoms including fever, cough, 
sore throat, headache, muscle pain, and shortness 
of breath 
• 
Time to resolution of ≥ 50% of the 
Covid-19 -attributable symptoms (see 
Appendix 8) including fever, cough, sore throat, 
headache, muscle pain, and/or shortness of breath 
reported at baseline 
Additional Secondary  
 
• 
To compare the mortality rate due to any cause 
during the 28 days after dosing with CPI-006 plus 
SOC versus placebo plus SOC in hospitalized 
participants with mild to moderately symptomatic 
Covid-19 infection 
• 
Proportion of participants who died during the 
28 days after dosing  
• 
To compare the clinical status of CPI-006 plus 
SOC versus placebo plus SOC in hospitalized 
participants with mild to moderately symptomatic 
Covid-19 infection 
• 
Change in clinical status, defined by the change in 
the 8-point ordinal scale from baseline at Days 3, 
7, Day of Discharge, Days 14, 21, and 28 
• 
To compare the percentage of participants with 
clinical improvement with CPI-006 plus SOC 
versus placebo plus SOC in hospitalized 
participants with mild to moderately symptomatic 
Covid-19 infection 
• 
Percentage of participants with clinical 
improvement (≥ 2 points improvement in the 
8-point ordinal scale) at Days 3, 7, 14, 21, and 28  
• 
To compare the change from baseline in the level 
of antibodies targeting the RBD of SARS-CoV-2 
• 
Change from baseline level of IgM targeting the 
RBD at Days 7, 14, 21, and 28 
• 
To compare the change from baseline in the 
SARS-CoV-2 viral load 
• 
Change from baseline in the SARS-CoV-2 viral 
load at Days 3, 7, 14, 21, and 28 
• 
To compare time to PCR negativity, and 
percentage of participants with PCR negative of 
CPI-006 plus SOC versus placebo plus SOC in 
hospitalized participants with mild to moderately 
symptomatic Covid-19 infection 
• 
Time to PCR negativity 
• 
Percentage of participants with PCR negative at 
Days 7, 14, 21, and 28 
• 
To compare the change from Baseline in NEWS2 
of CPI-006 plus SOC versus placebo plus SOC in 
hospitalized participants with mild to moderately 
symptomatic Covid-19 infection 
• 
Change from Baseline in NEWS2 at Days 3 and 
7, Day of Discharge, and Day 28.                             
NEWS2 (Appendix 7) consists of: Physiological 
Parameters: respiration rate (per minute), SpO2 
Scale 1 (%), SpO2 Scale 2 (%), use of air or 
oxygen, systolic blood pressure (mmHg), pulse 
(per minute), consciousness, and temperature (°C) 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 13 of 88 
Version 002 
Objectives 
Endpoints 
• 
To compare the medical interventions/procedures 
during the 28 days after dosing of CPI-006 plus 
SOC versus placebo plus SOC in hospitalized 
participants with mild to moderately symptomatic 
Covid-19 infection 
• 
Rate of procedures including intubation 
• 
Rate and duration of mechanical ventilation 
• 
Rate and duration of supplemental oxygen, non-
invasive ventilation, or high flow oxygen devices  
• 
Oxygenation free days during the 28 days after 
dosing 
• 
Rate of rehospitalization 
• 
To compare the safety of CPI-006 plus SOC 
versus placebo plus SOC in hospitalized 
participants with mild to moderately symptomatic 
Covid-19 infection 
• 
Incidence, type, and severity of 
treatment -emergent adverse events of CPI-006 
plus SOC compared to placebo plus SOC assessed 
by NCI CTCAE v 5.0 
Exploratory  
 
• 
To compare changes from baseline in Covid-19-
related lab assessments of CPI-006 plus SOC 
versus placebo plus SOC in hospitalized 
participants with mild to moderately symptomatic 
Covid-19 infection 
  
• 
Hematology, chemistry, CRP, and ferritin 
assessments on Days 1, 3, 5, 7, 14, 21, 28 (while 
hospitalized); Day of Discharge; and Day 28 
(return to clinic if discharged) 
• 
PT, INR, aPTT, fibrinogen, and D-dimer on 
Days 1, 3, 5, 7, 14, 21, 28 (while hospitalized), 
and Day of Discharge 
• 
Change from baseline level of IgA targeting the 
RBD at Days 7, 14, 21, and 28 
• 
Changes in IgG, IgM, or IgA antibodies targeting 
other SARS-CoV-2 antigens including (but not 
limited to) spike, nucleocapsid, and membrane 
proteins 
• 
Change from baseline in the frequency and 
function of memory B cells in the peripheral 
blood at Days 14 and 28 
• 
Changes from baseline in the frequency or 
function of memory/effector T cells in the 
peripheral blood at Days 14 and 28 
• 
B cell receptor repertoire analysis at baseline, 
Day 14, and Day 28 
• 
Systemic cytokine and chemokine levels at 
baseline and Days 7 (while hospitalized), Day of 
Discharge, and Day 28 
• 
Neutralizing antibody levels on Days 1 and 28 
using a biochemical ELISA, a pseudovirus 
neutralization assay, and a PRNT50 live virus 
assay 
• 
Change from baseline level of IgG and IgM 
targeting the RBD at Days 56, 84, and 168 
• 
To characterize the pharmacokinetics of CPI-006 
in hospitalized participants with Covid-19 
infection  
• 
PK characteristics including covariate analysis to 
determine which variables, if any, influence 
exposure of CPI-006 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 14 of 88 
Version 002 
Abbreviations:  aPTT = activated partial thromboplastin time; CRP = C-reactive protein; ELISA = enzyme-
linked immunosorbent assay; IgA = immunoglobulin A; IgG = immunoglobulin G; IgM = immunoglobulin M; 
INR = international normalized ratio; NCI CTCAE = National Cancer Institute Common Terminology Criteria 
for Adverse Events; NEWS2 = National Early Warning Score 2; PCR = polymerase chain reaction; PK = 
pharmacokinetic; RBD =  receptor binding domain; PT = prothrombin time; SARS-CoV-2 = severe acute 
respiratory syndrome coronavirus 2; SOC = standard of care; SpO2 = oxygen saturation. 
 
Study Design: 
This is a Phase 3, randomized, 3-arm, placebo controlled, double-blind, multicenter, stratified 
study of CPI-006 plus standard of care (SOC) versus placebo plus SOC in mild to moderately 
symptomatic hospitalized adult (≥ 18 years) participants with Covid-19. Covid-19 disease 
will be confirmed by polymerase chain reaction (PCR) or antigen testing for SARS-CoV-2. 
Approximately 1000 participants will be randomized at a 1:1:1 ratio to the 3 treatment arms 
and stratified by the following factors: 
• Region of the world (North America [US and Canada] vs. Latin America vs. 
Europe/Middle East/Africa).   
• Age (< 65 vs. ≥ 65) 
• Comorbidities (0 vs. at least 1) based on the following list: 
o Chronic lung disease (e.g., emphysema and chronic bronchitis, idiopathic 
pulmonary fibrosis, chronic obstructive pulmonary disease [COPD], or cystic 
fibrosis) or moderate to severe asthma 
o Significant cardiac disease (e.g., heart failure, coronary artery disease, 
congenital heart disease, cardiomyopathies, and pulmonary hypertension) 
o Obesity (body mass index ≥ 30 kg/m2) 
o Diabetes (Type 1, Type 2, or gestational) 
o Liver disease 
o Chronic kidney disease (CKD) 
o Sickle cell disease (SCD) 
o Organ transplantation 
o Cancer 
CPI-006 will be administered at a dose of 2 mg/kg (Treatment A - maximum dose of 
200 mg) or 1 mg/kg (Treatment B - maximum dose of 100 mg) intravenously (IV) on Day 1. 
A placebo will be given at the same schedule as the active drug for participants who receive 
the control (Treatment C). Participants, investigators, and Corvus will be blinded to the 
treatment allocation. All participants will receive supportive care according to the SOC of the 
trial hospital. If a hospital has a written policy or guideline, participants will receive 
treatment (including remdesivir, tocilizumab, steroids, convalescent plasma, anti-SARS-
CoV-2 monoclonal antibodies, or any other approved treatment) per those guidelines at the 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 15 of 88 
Version 002 
discretion of the investigator. Chloroquine/hydroxychloroquine are not allowed as SOC. 
Participation in any other investigational treatment during the first 28 days after 
randomization will not be allowed unless the investigator, in consult with the Corvus medical 
monitor, feels medical necessity and that such participation would not affect the integrity of 
this trial.  
After the participant’s initial eligibility is established and informed consent has been 
obtained, the study site must enroll the participant into the study by logging in to an 
interactive response technology (IRT) system to obtain the participant number. Every 
participant that signs the informed consent form (ICF) must be assigned with a participant 
number in IRT. Specific instructions for using IRT will be provided to the investigational site 
in the IRT Manual. The investigator or designee will register the participant for enrollment 
by following the enrollment procedures established by Corvus. 
All participants will undergo a series of efficacy, safety, and laboratory assessments. 
Participants will be assessed daily during their hospitalization. Participants’ clinical status 
based on the 8-point ordinal scale, the National Early Warning Score 2 (NEWS2), Covid-19 
related signs/symptoms, and safety laboratory tests will be recorded every day while 
hospitalized including day of discharge from the hospital. Discharged participants will be 
asked to attend post- hospitalization study assessments at Days 14, 21, and 28, if discharged 
before any of these assessments were completed. Severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) PCR test will be obtained on Days 1, 7, 14, 21, and 28 while 
hospitalized; and on day of discharge (if discharged prior to Day 28) and will be tested 
locally. Samples will be collected for viral load that will be assessed at a central lab. Anti-
SARS-CoV-2 antibody samples will be collected to assessed at a central lab on Day 1 before 
dosing, and on Days 7, 14, 21, and 28 if a participant remains hospitalized as well as the day 
of hospital discharge. For participants who are discharged before Day 14, 21 and 28, a 
sample will be collected on day of discharge as well as the post-hospitalization sample 
collection on Days 14, 21, and 28 that are not collected during the hospital stay. Participants 
who consent separately to the optional assessments for anti-SARS-CoV-2 serum antibody 
tests will be evaluated on Days 56, 84, and 168. 
An iDMC will be formed to monitor safety and efficacy of the study treatment at 
pre-specified timepoints including futility and interim analysis timepoints. The iDMC will 
review the unblinded safety data from the first 10% (approximately 100) of participants after 
completion of the Day 28 assessments. Subsequent iDMC reviews will occur when 25%, 
40%, 60%, and 80% (approximately 250, 400, 600, and 800, respectively) of participants 
have completed the Day 28 assessments. The analysis with 25% of participants is the first 
interim analysis for futility evaluation, and the analysis with 60% of participants is the 
second interim analysis for both efficacy and futility evaluation.  
Study enrollment will be paused after 10% of the participants are enrolled. Enrollment will 
only be re-initiated following iDMC recommendation. For the second iDMC review, the 
review of the futility analysis, study enrollment will also be paused at this time. Enrollment 
will only be re-initiated following iDMC recommendation.  The study will not be paused for 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 16 of 88 
Version 002 
enrollment for the subsequent reviews after the futility analysis. However, the iDMC may 
request a pause in enrollment at any time during the study based on the safety and efficacy 
data. 
The protocol team will review blinded pools of AE/SAE data every 2 weeks. If there are a 
significant number of unexpected AEs, the iDMC will be asked to review unblinded safety 
and efficacy data in an ad hoc meeting.  
Eligibility: Hospitalized mild to moderately symptomatic Covid-19 patients. Participants 
may have controlled pre-existing conditions such as cancer and diabetes. Participants will 
receive standard care for Covid-19. 
Test Product, Dose and Administration: CPI-006 single dose at either 1 mg/kg or 2 mg/kg 
given by IV infusion over 10-15 minutes. 
Rationale:  
CPI-006 is a humanized immunoglobulin G (IgG) fragment crystallizable (Fc) receptor 
binding deficient monoclonal antibody that activates B cells leading to the production of 
immunoglobulin M (IgM) and IgG antibodies (Luke et al, 2019b). In vivo administration to 
patients with cancer has shown rapid and temporary redistribution in circulating B cells with 
return of memory B cell phenotype. Immune markers demonstrate activation of B cells, 
expression of CD69 and increases in human leukocyte antigen – DR isotype (HLA-DR) 
expression. Molecular studies of the B cell receptor (BCR) in treated patients have 
demonstrated that CPI-006 stimulates the generation of B cell clones with new BCRs. These 
findings indicate that CPI-006 is activating B cells, causing their trafficking to lymphoid 
tissues and potentially their further differentiation into antibody producing cells. Further 
studies in patients with cancer have demonstrated production of anti-tumor antibodies in 
some patients. The high anti-SARS-CoV-2 titer seen in a patient with Covid-19 following 
treatment with CPI-006 for lung cancer are supportive of the hypothesis that CPI-006 may 
enhance anti-viral antibody response. CPI-006 is therefore under development for Covid-19 
since neutralizing antibodies and the generation of immune memory are critical for 
eliminating infections with severe acute respiratory syndrome (SARS) and Middle East 
respiratory syndrome (MERS) coronaviruses. In the ongoing Phase 1 CPI-006-002 study, 
27 participants with mild to moderate Covid-19 have received a single dose of CPI-006 at 
doses ranging from 0.3 mg/kg to 5 mg/kg. CPI-006 was well tolerated with no treatment 
related AEs or dose-limiting toxicities (DLTs) reported. IgG and IgM antibody titers 
measured against the SARS-CoV-2 spike protein and/or receptor binding domain (RBD) 
increased in all evaluable participants within 7 days of a single infusion of low doses of 
CPI-006 and were sustained over time. Similar results were observed in anti-SARS-CoV-2 
immunoglobulin A (IgA) titers. This increase in antibody titers provides the rationale to 
develop CPI-006 for treatment of Covid-19. This Phase 3 study evaluates clinical benefit, 
safety, and the anti-SARS-CoV-2 antibody production in participants who are hospitalized 
with mild to moderately symptomatic Covid-19 treated with CPI-006. Treatment with 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 17 of 88 
Version 002 
CPI-006 may also result in prolonged immunity to SARS-CoV-2 and related viruses 
(Willingham et al., 2020).  
Overall Design: 
This is a randomized, placebo controlled, double-blind, multicenter, stratified study of 
CPI-006 plus SOC versus placebo plus SOC in mild to moderately symptomatic hospitalized 
participants with Covid-19. An iDMC will monitor safety, efficacy, and conduct of the study. 
All participants will be followed for 28 days for production of anti-SARS-CoV-2 antibodies 
followed by an optional period of 5 months. While in the hospital, participants will receive 
standard of care monitoring including vital signs every 4-6 hours, or per institutional 
guidelines and safety assessments. Safety and other disease assessments will be conducted at 
Days 3, 7, 14, 21, and 28. Discharged participants will be asked to attend post- 
hospitalization study assessments at Days 14, 21, and 28, if discharged before any of these 
assessments were completed. 
Treatment Groups and Duration: 
Participants meeting study entry criteria will be randomized in a 1:1:1 ratio to receive either 
Treatment A (CPI-006 2 mg/kg plus SOC) or Treatment B (CPI-006 1mg/kg plus SOC) or 
Treatment C (placebo plus SOC). Participants randomized to Treatment A will receive a 
single dose of CPI-006 at 2 mg/kg given by IV infusion plus SOC (maximum dose of 
200 mg). Participants randomized to Treatment B will receive a single dose of CPI-006 at 
1 mg/kg given by IV infusion plus SOC (maximum dose of 100 mg). A placebo will be given 
at the same schedule as the active drug for participants randomized to Treatment C. All 
participants will be managed per physician using best SOC for Covid-19 patients. No dose 
modifications will be allowed. 
Statistical Methods:  
Hypothesis 
The primary hypothesis is that Treatment A will improve the proportion of participants alive 
and respiratory failure free during the 28 days after dosing based on the 8-point ordinal scale 
in comparison to Treatment C in mild to moderately symptomatic Covid-19 hospitalized 
participants. 
The first secondary hypothesis is that Treatment A will shorten the time to recovery during 
the 28 days after dosing based on the 8-point ordinal scale in comparison to Treatment C in 
mild to moderately symptomatic Covid-19 hospitalized participants. 
The second secondary hypothesis is that Treatment A will shorten the time to clinical 
improvement by at least 2 points during the 28 days after dosing on the 8-point ordinal scale 
in comparison to Treatment C. 
The third secondary hypothesis is that Treatment A will increase the level of IgG targeting 
the RBD of SARS-CoV-2 over Days 7, 14, 21, and 28 more than Treatment C, as measured 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 18 of 88 
Version 002 
by the area under the IgG level curve above the baseline, calculated over Days 1 (the 
baseline), 7, 14, 21, 28, and Day of Discharge. 
The fourth secondary hypothesis is that Treatment A will shorten the time to resolution of 
≥ 50% of the Covid-19-attributable symptoms: fever, cough, sore throat, headache, muscle 
pain, and/or shortness of breath, reported at baseline in comparison to Treatment C.  
The above 5 hypotheses are also applied to the comparison of Treatment B to Treatment C. 
Sample Size 
Approximately 1000 hospitalized participants with mild to moderately symptomatic 
Covid-19 will be enrolled. The participants will be randomized in a 1:1:1 ratio between 
Treatment A, Treatment B, and Treatment C within each of the strata defined by: 
• Region of the world (North America [US and Canada] vs. Latin America vs. 
Europe/Middle East/Africa). 
• Age (< 65 vs. ≥ 65) 
• Comorbidities (0 vs. at least 1) based on the following list: 
o Chronic lung disease (e.g., emphysema and chronic bronchitis, idiopathic 
pulmonary fibrosis, COPD, or cystic fibrosis) or moderate to severe asthma 
o Significant cardiac disease (e.g., heart failure, coronary artery disease, 
congenital heart disease, cardiomyopathies, and pulmonary hypertension) 
o Obesity (body mass index ≥ 30 kg/m2) 
o Diabetes (Type 1, Type 2, or gestational) 
o Liver disease 
o CKD 
o SCD 
o Organ transplantation 
o Cancer 
With approximately 300 participants per treatment arm, there would be an approximately 
85% power to show a statistically significant superiority of Treatment A over Treatment C in 
the proportion of participants alive and respiratory failure free during the 28 days after dosing 
at an overall 1-sided α level of 0.025 when the true proportion of Treatment A is 92% and 
that of Treatment C is 84%. The same sample size and power statement also holds for the 
comparison between Treatment B and C.  
An additional 10% of participants will be enrolled to cover the loss-of-follow-up. 
Populations for Analyses 
For purposes of analyses, the following populations are defined in Table 1. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 19 of 88 
Version 002 
Table 1 
Population Definitions 
Population 
Description 
Intent-to-treat (ITT) 
All participants who are randomized into the study and analyzed 
according to treatment assigned at randomization.  
Efficacy 
All participants who receive any amount of study drug (CPI-006 or 
placebo) and have post-baseline efficacy assessment based on the 
8-point ordinal scale.  The participants will be analyzed according 
to the treatment actually received.  
Safety 
All participants who receive any amount of study treatment 
(CPI-006, placebo, or SOC). 
Pharmacokinetic 
All participants who receive CPI-006 and had at least 
1 post-treatment blood sample collected 
Statistical Methods 
The primary objective of the study is to determine the difference between the 3 treatments in 
time to recovery during the 28 days after dosing.  
Day of recovery is defined as the first day on which the participant satisfies 1 of the 
following 3 categories from the 8-point ordinal scale (See Appendix 6):  1) Not hospitalized, 
no limitations on activities.; 2) Not hospitalized, limitation on activities and/or requiring 
home oxygen; 3) Hospitalized, not requiring supplemental oxygen - no longer requires 
ongoing medical care. 
Statistical Design 
Two formal interim analyses are planned for this study. The first interim analysis is a 
non‑binding futility analysis and will be performed when approximately 25% (250) of 
participants have been enrolled into the study with 28 days of follow-up time. Safety and 
efficacy will be analyzed for futility evaluation.   
The second interim analysis is also a non-binding futility and efficacy analysis and will be 
performed when approximately 60% (600) of participants have completed Day 28 
assessments. Comparison between Treatment A and C, and between Treatment B and C, with 
respect to the primary efficacy endpoint will be made. Should the comparison demonstrate a 
statistically significant superiority of Treatment A over Treatment C, Corvus may file the 
results to regulatory authorities for drug approval. The study will continue its course beyond 
the interim analysis and collect all the planned safety, efficacy, PK, and PD data.  
At both interim analyses, unblinded analyses will be provided by a separate unblinded 
statistician to the iDMC for making the futility decision.   
As part of the second interim analysis, Corvus may request the iDMC to assess the primary 
efficacy endpoint and its conditional power of establishing a significant treatment effect at 
the final analysis based on the interim data. The total sample size of the study may be 
increased with the recommendation by iDMC. The sample size adaptation plan and increase 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 20 of 88 
Version 002 
rule will be detailed in the statistical analysis plan and provided to the regulatory authority 
before the first interim analysis. 
The primary analysis of the study is the final analysis. Safety and efficacy analyses will be 
performed when all the participants of the study have completed the Day 28 assessments.  
The 5 endpoints listed below will be tested according to their hierarchical priority defined as 
they are ordered at both the second interim analysis and final analysis. 
The primary efficacy endpoint, the proportion of participants who are alive and respiratory 
failure free during the 28 days after dosing, as defined above. 
Time to recovery during the 28 days after dosing as defined above by the 8-point ordinal 
scale. 
Time to improvement by at least 2 points on the 8-point ordinal scale during the 28 days after 
dosing. 
The change in the level of IgG targeting RBD of SARS-CoV-2 over Days 7, 14, 21, and 28 
from baseline measured by the area under the IgG level curve above the baseline over 
Days 1, 7, 14, 21, 28 and Day of Discharge. 
The time to resolution of ≥ 50% of the Covid-19-attributable symptoms including fever, 
cough, sore throat, headache, muscle pain, and/or short of breath reported at baseline. 
At the second interim analysis, the superiority of Treatment A over C will be tested with 
respect to the above 5 endpoints following the hierarchical priority.  If all the 5 endpoints 
reach statistical significance, then the superiority of Treatment B over C will be tested with 
respect to the 5 endpoints following the hierarchical priority.  
At the final analysis, the above endpoints which either are not tested or tested but fail to 
reach statistical significance at the interim analysis will be tested following the hierarchical 
priority for the superiority of Treatment A over C, then Treatment B over C.  
For planning purpose for the study, the endpoints would be tested at a 1-sided α of 0.0038 at 
the second interim analysis and tested at a 1-sided α of 0.0238 at the final analysis. The 
α levels are determined by the Lan-DeMets error spending function corresponding to the 
O’Brien-Fleming boundary assuming a 60% information fraction at the interim analysis.  
However, when the interim and final analyses are performed, the actual α levels will be 
determined based on the actual information fraction at the interim analysis.  
The mortality rate due to all causes is also a secondary endpoint of the study and will be 
provided at both interim analyses and final analysis. The 95% 2-sided CI will also be 
calculated for all 3 treatments.   

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 21 of 88 
Version 002 
1.2. 
SCHEMA 
Figure 1 Study Schematic 
 
 
IV = intravenous; R = randomization 
 
1.3. 
SCHEDULE OF ACTIVITIES (SOA) 
For the schedule of activities, please see Appendix 1, Table 6. 
2. 
INTRODUCTION 
2.1. 
STUDY RATIONALE 
CPI-006 is a humanized immunoglobulin G (IgG) fragment crystallizable (Fc) receptor 
binding deficient monoclonal antibody that activates B cells leading to the production of 
immunoglobulin M (IgM) and IgG antibodies (Luke et al, 2019b). In vivo administration to 
patients with cancer has shown rapid and temporary redistribution in circulating B cells with 
return of memory B cell phenotype. Immune markers demonstrate activation of B cells, 
expression of CD69 and increases in human leukocyte antigen – DR isotype (HLA-DR) 
expression. Molecular studies of the B cell receptor (BCR) in treated patients have 
demonstrated that CPI-006 stimulates the generation of B cell clones with new BCRs. These 
findings indicate that CPI-006 is activating B cells, causing their trafficking to lymphoid 
tissues and potentially their further differentiation into antibody producing cells. Further 
studies in patients with cancer have demonstrated production of anti-tumor antibodies in 
some patients. The high anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) titer seen in a patient with Covid-19 following treatment with CPI-006 for lung cancer are 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 22 of 88 
Version 002 
supportive of the hypothesis that CPI-006 may enhance anti-viral antibody response. CPI-006 
is therefore under development for Covid-19 since neutralizing antibodies and the generation 
of immune memory are critical for eliminating infections with severe acute respiratory 
syndrome (SARS) and Middle East respiratory syndrome (MERS) coronaviruses. In the 
ongoing Phase 1 CPI-006-002 study, 27 participants with mild to moderate Covid-19 have 
received a single dose of CPI-006 at doses ranging from 0.3 mg/kg to 5 mg/kg. CPI-006 was 
well tolerated with no treatment related AEs or dose-limiting toxicities (DLTs) reported. IgG 
and IgM antibody titers measured against the SARS-CoV-2 spike protein and/or receptor 
binding domain (RBD) increased in all evaluable participants within 7 days of a single 
infusion of low doses of CPI-006 and were sustained over time. Similar results were 
observed in anti-SARS-CoV-2 immunoglobulin A (IgA) titers. This increase in antibody 
titers provides the rationale to develop CPI-006 for treatment of Covid-19. This Phase 3 
study evaluates clinical benefit, safety, and the anti-SARS-CoV-2 antibody production in 
participants who are hospitalized with mild to moderately symptomatic Covid-19 treated 
with CPI-006. Treatment with CPI-006 may also result in prolonged immunity to SARS-
CoV-2 and related viruses (Willingham et al., 2020). 
The Covid-19 pandemic is not yet under control and there is fear that infections could spread 
and/or recur in a seasonal manner, even if controlled now or with vaccination efforts. There 
is also the possibility of viral mutation or emergence of other virulent coronaviruses. Based 
on encouraging preliminary data, CPI-006 may improve the magnitude, duration, and 
diversity of antibody responses to SARS-CoV-2 and improve clinical outcome. It also may 
result in prolonged immunity to SARS-CoV-2, its variants, and related coronaviruses. It is 
also possible that experience gained with treating Covid-19 with CPI-006 could be applied to 
treatment of other infectious diseases including future viral pandemics, and potential use in 
conjunction with vaccination of healthy participants. 
2.2. 
BACKGROUND 
Since its emergence in Hubei province, China in December of 2019, the novel coronavirus 
(2019-nCoV, Covid-19) has become a global health crisis (Wu et al, 2020; Chan et al, 2020). 
There is an urgent need for therapies that can improve survival, clinical outcomes, and reduce 
the requirements for intensive supportive care and prolonged hospitalization (Huang et al, 
2020). There are efforts underway to re-purpose direct acting antivirals targeting the 
ribonucleic acid (RNA)-dependent RNA polymerase including remdesivir and favipiravir 
both of which are being actively studied in multiple clinical trials. Similarly, inhibitors of the 
virally encoded proteases are being evaluated. To compliment therapeutic approaches there is 
an intense effort underway to develop vaccines. A number of approaches to vaccine 
development have begun clinical trials or are planned. To support vaccine strategies, there is 
a growing understanding of the key viral/host interaction required for viral entry and 
replication (Du et al, 2009). Indeed, it is increasingly clear that the virally encoded spike 
protein binds to angiotensin converting enzyme 2 (ACE2) on target cells to facilitate entry 
and replication. The spike protein is a multidomain viral envelop glycoprotein which 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 23 of 88 
Version 002 
contains a receptor binding domain (RBD) in subunit 1 of the spike protein (Wrapp et al, 
2020). This RBD directly interacts with N-terminal domain of ACE2. This interaction is 
absolutely required and initiates a sequence of steps leading to efficient viral infection. Thus, 
antibodies that disrupt this key interaction may be effective in viral neutralization and 
clearance. A recent publication from Zhang and colleagues have identified neutralizing 
antibodies from 8 Covid-19 infected patients that bind to the RBD of the spike protein and 
are neutralizing (Yuan et al, 2020). This provides evidence that neutralizing antibody 
responses to SARS-CoV-2 are possible and may provide clinical benefit in patients with 
Covid-19 and protection from disease in healthy subjects. Indeed, the U.S. Food and Drug 
Administration (FDA) has given emergency use authorization for the use of Covid-19 
Convalescent Plasma (CCP) and monoclonal antibodies for the treatment of Covid-19. 
Clinical studies with CCP suggest that higher titers of neutralizing antibody provide superior 
clinical benefit to recipients (Joyner et al, 2020; Rasheed et al 2020). These findings support 
the value of anti-viral antibodies in eradicating viral infection in patients, lessening disease 
severity, improving clinical course and potentially reducing transmission.  
CD73 is an adhesion molecule that was initially found to be important for lymphocyte 
trafficking and T cell activation (Resta & Thompson, 1997). It also functions as an 
ectoenzyme that converts adenosine monophosphate (AMP) to immunosuppressive 
adenosine. Several companies are developing anti-CD73 antibodies to inhibit production of 
adenosine and thereby augment immune response in patients with cancer. These antibodies 
have been designed primarily to block enzymatic activity. Corvus has designed a novel 
anti-CD73 antibody with agonistic, immunomodulatory properties that binds CD73 resulting 
in activation of immune cells such as B cells, and results in antibody production in vitro 
(Luke et al, 2019a). This antibody, CPI-006, is under investigation in a Phase 1b trial 
(NCT03454451) in advanced cancer as monotherapy and in combination with other 
immunotherapies such as anti- programmed cell death 1 receptor (PD1). Over 90 participants 
have received doses of this antibody ranging from 1 mg/kg to 24 mg/kg given IV every 
21 days. Treatment has been safe and tolerable, with chills and rigor seen during antibody 
infusion, that are managed by premedication with acetaminophen and diphenhydramine. 
CPI-006 is a humanized FcγR binding-deficient monoclonal antibody. In vitro studies have 
revealed binding to CD73 and direct effects on B cells, morphologic transformation to 
plasmablasts and induction of IgM and IgG secretion (Luke et al, 2019b). In vivo 
administration to patients with cancer has shown rapid and temporary drop in circulating 
B cells with return of memory B cell phenotype. Immune markers demonstrate activation of 
B cells, expression of CD69 and increases in HLA-DR expression. Molecular studies of the 
BCR in treated patients have demonstrated that CPI-006 stimulates the generation of B cell 
clones with new BCRs. These findings indicate that CPI-006 is activating B cells, causing 
their trafficking to lymphoid tissues and potentially their further differentiation into antibody 
producing cells. Further studies in patients with cancer have demonstrated production of 
anti-tumor antibodies in some patients.  

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 24 of 88 
Version 002 
CPI-006 is under investigation in a Phase 1 trial (NCT04464395) in mild to moderately 
symptomatic hospitalized Covid-19 patients. The results from the study (CPI-006-002) 
shows IgG and IgM antibody titers measured against the SARS-CoV-2 spike protein and/or 
receptor binding domain (RBD) increased in all evaluable participants within 7 days of a 
single infusion of low doses of CPI-006 and were sustained overtime. Similar results were 
observed in anti-SARS-CoV-2 IgA titers. In participants receiving 0.3 mg/kg CPI-006, all 
4 evaluable participants achieved high IgG titers to spike protein that were sustained for at 
least 84 days after onset of symptoms. In these participants, IgM titers peaked at 14 days and 
remained elevated at the last measured timepoint of 84 days. Similar kinetics were seen in 
antibody responses to RBD. At doses above 0.3 mg/kg, durable high titers of IgG and IgM to 
spike protein and RBD were achieved out to 84 days for the 1.0 mg/kg and 3.0 mg/kg 
cohorts, and 28 days for the 5.0 mg/kg cohort in the ongoing study. Peak titers increased 
from 0.3 mg/kg to 1.0 mg/kg CPI-006 but did not appear to increase for all isotypes toward 
each antigen from 1.0 mg/kg to 3.0 mg/kg or from 3.0 mg/kg to 5.0 mg/kg at the evaluable 
time points. An increase of IgG titer toward spike protein was observed from 1.0 mg/kg to 
3.0 mg/kg at Day 28. High and durable neutralizing titers were observed in subjects where 
ID50 values up to 23,000 were measured using a functional pseudovirus neutralizing antibody 
assay. Neutralizing titers were observed to persist at least 84 days following onset of 
symptoms in the ongoing trial.  Immunophenotyping of peripheral blood mononuclear cells 
(PBMCs) at baseline and at 14, 28, or 56 days after treatment provided preliminary evidence 
that CPI-006 increased the frequency of memory B cells in 7 evaluated participants. An 
increased frequency of memory/effector CD4POS and CD8POS T cells was also observed in 
5 (CD4POS) and 6 (CD8POS) evaluable participants. CPI-006 has been well tolerated in 
participants with Covid-19 in this study. No DLTs or treatment-related AEs have been 
reported in the study. The AEs reported in the study were due to the underlying Covid-19 or 
comorbidities. 
In this Phase 3, randomized, 3-arm, placebo controlled, double-blind, multicenter, stratified 
study of CPI-006 plus standard of care (SOC) versus placebo plus SOC in mild to moderately 
symptomatic hospitalized participants with Covid-19. Approximately 1000 participants will 
be randomized in a 1:1:1 fashion to receive Treatment A (CPI-006 at 2 mg/kg plus SOC) or 
Treatment B (CPI-006 at 1 mg/kg plus SOC) or Treatment C (matching placebo plus SOC). 
Standard of care will be per institutional guidelines. Corvus will assess if administering 
CPI-006 to participants with Covid-19 along with SOC can lead to clinical benefit and 
enhance humoral immune response to the SARS-CoV-2. The production of neutralizing 
antibodies would be expected to shorten disease interval and improve clinical outcome, and 
treatment is expected to be safe. Therefore, CPI-006 treatment is expected to have a positive 
benefit/risk profile (see Section 2.4.1).  
2.3. 
CPI-006 NONCLINICAL EVALUATION 
CPI-006 recognizes and binds human CD73 with high affinity (KD values of 0.64–7.1 nM), 
inhibits CD73 catalytic activity (mean concentration required for 50% inhibition [IC50] 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 25 of 88 
Version 002 
values of 2.1 nM and 4.0 nM for human and cynomolgus monkey CD73), and has 
downstream biological effects on T cells as evidenced by restoration of CD3+ T cell 
proliferation in the presence of AMP. CPI-006 also binds to and inhibits cynomolgus monkey 
CD73, but not mouse or rat CD73, supporting the use of cynomolgus monkeys for studies of 
the pharmacokinetics (PK) and toxicology of CPI-006. 
Complete CD73 occupancy on CD8+ T cells in peripheral blood samples from cynomolgus 
monkeys by CPI-006 was observed at all doses of CPI-006. Complete CD73 occupancy was 
also observed in the axillary lymph nodes, indicating successful solid tissue penetration by 
CPI-006 with full coverage at least 24 hours after the final dose. 
An in vitro cytokine release assay was conducted with CPI-006 to evaluate the potential for 
CPI-006 to induce an immune response resulting in production of multiple cytokines 
(cytokine storm). The results demonstrated that CPI-006 did not directly induce cytokine 
(interferon gamma [IFN-γ], interleukin 2 [IL-2], interleukin 6 [IL-6], interleukin 10 [IL-10], 
and tumor necrosis factor alpha [TNF-α]) release from fresh human PBMCs at 0.1-10 µg/mL 
of CPI-006. 
Safety of CPI-006 was evaluated in male and female cynomolgus monkeys in two toxicity 
studies. In the first, a dose range finding study, CPI-006 was administered over 15-minutes 
by IV infusion at doses up to 120 mg/kg CPI-006, weekly (5 doses) for 31 days. The second, 
was a Good Laboratory Practice (GLP)-compliant toxicity study in which doses up to 
100 mg/kg CPI-006 were administered by IV infusion over 60 minutes, weekly (5 doses) for 
28 days. Toxicokinetics, safety pharmacology, and local tolerance assessments were built 
into the GLP compliant toxicity study. CPI-006 administered by IV infusion was well 
tolerated in both studies up to, and including, the highest doses administered. No definitive 
CPI-006-related changes were observed in the animals. No-observed adverse effect levels 
(NOAEL) were the highest doses administered, 120 mg/kg and 100 mg/kg CPI-006. 
Additional nonclinical information is provided in the Investigational Brochure for CPI-006. 
2.4. 
SUMMARY OF CLINICAL EXPERIENCE WITH CPI-006 
In CPI-006-001 oncology study, CPI-006 has been administered as a single agent and in 
combination with ciforadenant (an A2a receptor antagonist), and /or pembrolizumab (a 
blocking anti-PD-1 antibody). CPI-006 has been well tolerated when administered every 
3 weeks as monotherapy and in combination with ciforadenant and/or pembrolizumab.  
As of 20 Oct 2020, 35 participants have been treated with CPI-006 (every 3 weeks) 
monotherapy at doses up to 24 mg/kg, and no maximum tolerated dose was established. The 
most common adverse reactions were infusion related reactions (IRRs), primarily chills and 
rigors. These IRRs were non-serious, mild to moderate in severity (Grade 1-2), transient and 
did not lead to discontinuation. The IRRs have been observed during (or immediately after) 
Cycle 1, Day 1 and are uncommon at subsequent infusions of CPI-006. To mitigate the risk 
of IRRs, premedication with diphenhydramine (50 mg orally [PO]) and acetaminophen 500–

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 26 of 88 
Version 002 
1000 mg PO (or equivalents) was required prior to infusion of CPI-006 at Cycle 1, Day 1 and 
has shown a decreased rate and intensity of IRRs.  
As of 29 Dec 2020, in the ongoing Phase 1 CPI-006-002 study, 27 hospitalized participants 
with mild to moderate Covid-19 have received a single dose of CPI-006 at doses ranging 
from 0.3 mg/kg to 5 mg/kg with follow-up data. CPI-006 was well tolerated. IRRs have not 
been observed with CPI-006 infusion. No DLTs or treatment related AEs have been reported. 
The safety data in this Phase 1 study is reviewed on an ongoing basis by an Independent Data 
Monitoring Committee (iDMC).  
2.4.1. 
Benefit/Risk Assessment 
This study proposes to administer single doses of CPI-006 to hospitalized mild or moderately 
symptomatic participants with Covid-19.  
Study treatment will be administered in the hospital and participants will be monitored 
closely. CD73 is expressed on endothelial cells and it is possible that negative effects or 
exacerbation of disease could be seen in participants with Covid-19. However, data from the 
GLP general toxicity study did not show any CPI-006 related changes in coagulation 
parameters (Section 4.3). Data from 27 participants with Covid-19in the CPI-006-002 study 
did not indicate any effect of CPI-006 on systemic inflammatory response or coagulopathy. 
In addition, data from over 90 participants in study CPI-006-001 in participants with cancer 
did not show any CPI-006 related systemic inflammatory response or coagulopathy. The 
participant follow-up and monitoring involve routine procedures not associated with 
significant health risk. The benefit of therapy to participants who receive Treatment A or 
Treatment B is the development of neutralizing antibodies which could lead to more rapid 
clinical improvement, avoidance of complications of Covid-19 disease, and the potential for 
longer lasting immunity.  
Participants enrolled in Treatment C will receive standard of care (SOC) per institutional 
guidelines. The participant follow-up and monitoring involve routine procedures not 
associated with significant health risk. Overall data will be used to assess any difference 
between the participants who receive Treatment A, Treatment B, and Treatment C in terms of 
clinical outcome and anti-SARS-CoV-2 levels. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 27 of 88 
Version 002 
3. 
OBJECTIVES AND ENDPOINTS 
Objectives 
Endpoints 
Primary 
 
• 
To compare the proportion of participants alive 
and respiratory failure free during the 28 days 
after dosing with CPI-006 plus SOC versus 
placebo plus SOC in hospitalized participants 
with mild to moderately symptomatic Covid-19 
infection 
• 
Proportion of participants who are alive and free 
from respiratory deterioration defined as follows 
per the 8-point ordinal scale (Appendix 6): 
o Deterioration to Categories 6, 7, or 8 for a 
participant who entered the trial at Categories 4 
or 5  
o Deterioration to Categories 7 or 8 for a 
participant who entered the trial at Category 6 
Key Secondary 
 
• 
To compare the time to recovery of CPI-006 plus 
SOC versus placebo plus SOC in hospitalized 
participants with mild to moderately symptomatic 
Covid-19 infection 
• 
Time to recovery during the 28 days after dosing. 
Day of recovery is defined as the first day on 
which the participant satisfies 1 of the following 
3 categories from the 8-point ordinal scale 
(Appendix 6):  1) Not hospitalized, no limitations 
on activities.; 2) Not hospitalized, limitation on 
activities and/or requiring home oxygen; 3) 
Hospitalized, not requiring supplemental oxygen - 
no longer requires ongoing medical care. 
• 
To compare the time to clinical improvement of 
CPI-006 plus SOC versus placebo plus SOC in 
hospitalized participants with mild to moderately 
symptomatic Covid-19 infection 
• 
Time to clinical improvement (≥ 2 points 
improvement in the 8-point ordinal scale) 
• 
To compare the change from baseline in the level 
of antibodies targeting the RBD of SARS-CoV-2  
• 
Change from baseline level of IgG targeting the 
RBD at Days 7, 14, 21, and 28 
• 
To compare the time to improvement of Covid-
19-attributable symptoms including fever, cough, 
sore throat, headache, muscle pain, and shortness 
of breath 
• 
Time to resolution of ≥ 50% of the 
Covid-19 -attributable symptoms (see 
Appendix 8) including fever, cough, sore throat, 
headache, muscle pain, and/or shortness of breath 
reported at baseline 
Additional Secondary  
 
• 
To compare the mortality rate due to any cause 
during the 28 days after dosing with CPI-006 plus 
SOC versus placebo plus SOC in hospitalized 
participants with mild to moderately symptomatic 
Covid-19 infection 
• 
Proportion of participants who died during the 
28 days after dosing  
• 
To compare the clinical status of CPI-006 plus 
SOC versus placebo plus SOC in hospitalized 
participants with mild to moderately symptomatic 
Covid-19 infection 
• 
Change in clinical status, defined by the change in 
the 8-point ordinal scale from baseline at Days 3, 
7, Day of Discharge, Days 14, 21, and 28 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 28 of 88 
Version 002 
Objectives 
Endpoints 
• 
To compare the percentage of participants with 
clinical improvement with CPI-006 plus SOC 
versus placebo plus SOC in hospitalized 
participants with mild to moderately symptomatic 
Covid-19 infection 
• 
Percentage of participants with clinical 
improvement (≥ 2 points improvement in the 
8-point ordinal scale) at Days 3, 7, 14, 21, and 28  
• 
To compare the change from baseline in the level 
of antibodies targeting the RBD of SARS-CoV-2 
• 
Change from baseline level of IgM targeting the 
RBD at Days 7, 14, 21, and 28 
• 
To compare the change from baseline in the 
SARS-CoV-2 viral load 
• 
Change from baseline in the SARS-CoV-2 viral 
load at Days 3, 7, 14, 21, and 28 
• 
To compare time to PCR negativity, and 
percentage of participants with PCR negative of 
CPI-006 plus SOC versus placebo plus SOC in 
hospitalized participants with mild to moderately 
symptomatic Covid-19 infection 
• 
Time to PCR negativity 
• 
Percentage of participants with PCR negative at 
Days 7, 14, 21, and 28 
• 
To compare the change from Baseline in NEWS2 
of CPI-006 plus SOC versus placebo plus SOC in 
hospitalized participants with mild to moderately 
symptomatic Covid-19 infection 
• 
Change from Baseline in NEWS2 at Days 3 and 
7, Day of Discharge, and Day 28.                             
NEWS2 (Appendix 7) consists of: Physiological 
Parameters: respiration rate (per minute), SpO2 
Scale 1 (%), SpO2 Scale 2 (%), use of air or 
oxygen, systolic blood pressure (mmHg), pulse 
(per minute), consciousness, and temperature (°C) 
• 
To compare the medical interventions/procedures 
during the 28 days after dosing of CPI-006 plus 
SOC versus placebo plus SOC in hospitalized 
participants with mild to moderately symptomatic 
Covid-19 infection 
• 
Rate of procedures including intubation 
• 
Rate and duration of mechanical ventilation 
• 
Rate and duration of supplemental oxygen, non-
invasive ventilation, or high flow oxygen devices  
• 
Oxygenation free days during the 28 days after 
dosing 
• 
Rate of rehospitalization 
• 
To compare the safety of CPI-006 plus SOC 
versus placebo plus SOC in hospitalized 
participants with mild to moderately symptomatic 
Covid-19 infection 
• 
Incidence, type, and severity of 
treatment-emergent adverse events of CPI-006 
plus SOC compared to placebo plus SOC assessed 
by NCI CTCAE v 5.0 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 29 of 88 
Version 002 
Objectives 
Endpoints 
Exploratory  
 
• 
To compare changes from baseline in Covid-19-
related lab assessments of CPI-006 plus SOC 
versus placebo plus SOC in hospitalized 
participants with mild to moderately symptomatic 
Covid-19 infection 
 
• 
Hematology, chemistry, CRP, and ferritin 
assessments on Days 1, 3, 5, 7, 14, 21, 28 (while 
hospitalized); Day of Discharge; and Day 28 
(return to clinic if discharged) 
• 
PT, INR, aPTT, fibrinogen, and D-dimer on 
Days 1, 3, 5, 7, 14, 21, 28 (while hospitalized), 
and Day of Discharge 
• 
Change from baseline level of IgA targeting the 
RBD at Days 7, 14, 21, and 28 
• 
Changes in IgG, IgM, or IgA antibodies targeting 
other SARS-CoV-2 antigens including (but not 
limited to) spike, nucleocapsid, and membrane 
proteins 
• 
Change from baseline in the frequency and 
function of memory B cells in the peripheral 
blood at Days 14 and 28 
• 
Changes from baseline in the frequency or 
function of memory/effector T cells in the 
peripheral blood at Days 14 and 28 
• 
B cell receptor repertoire analysis at baseline, 
Day 14, and Day 28 
• 
Systemic cytokine and chemokine levels at 
baseline and Days 7 (while hospitalized), Day of 
Discharge, and Day 28 
• 
Neutralizing antibody levels on Days 1 and 28 
using a biochemical ELISA, a pseudovirus 
neutralization assay, and a PRNT50 live virus 
assay 
• 
Change from baseline level of IgG and IgM 
targeting the RBD at Days 56, 84, and 168 
• 
To characterize the pharmacokinetics of CPI-006 
in hospitalized participants with Covid-19 
infection  
• 
PK characteristics including covariate analysis to 
determine which variables, if any, influence 
exposure of CPI-006 
Abbreviations:  aPTT = activated partial thromboplastin time; CRP = C-reactive protein; ELISA = enzyme-
linked immunosorbent assay; IgA = immunoglobulin A; IgG = immunoglobulin G; IgM = immunoglobulin M; 
INR = international normalized ratio; NCI CTCAE = National Cancer Institute Common Terminology Criteria 
for Adverse Events; NEWS2 = National Early Warning Score 2; PCR = polymerase chain reaction; PK = 
pharmacokinetic; RBD =  receptor binding domain; PT = prothrombin time; SARS-CoV-2 = severe acute 
respiratory syndrome coronavirus 2; SOC = Standard of Care; SpO2 = oxygen saturation. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 30 of 88 
Version 002 
4. 
STUDY DESIGN 
4.1. 
OVERALL DESIGN 
This is a Phase 3, randomized, 3-arm, placebo controlled, double-blind, multicenter, stratified 
study of CPI-006 plus SOC versus placebo plus SOC in mild to moderately symptomatic 
hospitalized adult (≥ 18 years) participants with Covid-19. Covid-19 disease will be 
confirmed by polymerase chain reaction (PCR) or antigen testing for SARS-CoV-2. 
Approximately 1000 participants will be randomized at a 1:1:1 ratio to the 3 treatment arms 
and stratified by the following factors: 
• Region of the world (North America [US and Canada] vs. Latin America vs. 
Europe/Middle East/Africa)   
• Age (< 65 vs. ≥ 65) 
• Comorbidities (0 vs. at least 1) based on the following list: 
o Chronic lung disease (e.g., emphysema and chronic bronchitis, idiopathic 
pulmonary fibrosis, chronic obstructive pulmonary disease [COPD], or cystic 
fibrosis) or moderate to severe asthma 
o Significant cardiac disease (e.g., heart failure, coronary artery disease, 
congenital heart disease, cardiomyopathies, and pulmonary hypertension) 
o Obesity (body mass index ≥ 30 kg/m2) 
o Diabetes (Type 1, Type 2, or gestational) 
o Liver disease 
o Chronic kidney disease (CKD) 
o Sickle cell disease (SCD) 
o Organ transplantation 
o Cancer 
CPI-006 will be administered at a dose of 2 mg/kg (Treatment A – maximum dose of 
200 mg) or 1 mg/kg (Treatment B – maximum dose of 100 mg) intravenously (IV) on Day 1. 
A placebo will be given at the same schedule as the active drug for participants who receive 
the control (Treatment C). Participants, investigators, and Corvus will be blinded to the 
treatment allocation. All participants will receive supportive care according to the SOC of the 
trial hospital. If a hospital has a written policy or guideline, participants will receive 
treatment (including remdesivir, tocilizumab, steroids, convalescent plasma, anti-SARS-
CoV-2 monoclonal antibodies, or any other approved treatment) per those guidelines at the 
discretion of the investigator. Chloroquine/hydroxychloroquine are not allowed as SOC. 
Participation in any other investigational treatment during the first 28 days after 
randomization will not be allowed unless the investigator, in consult with the Corvus medical 
monitor, feels medical necessity and that such participation would not affect the integrity of 
this trial.  
After the participant’s initial eligibility is established and informed consent has been 
obtained, the study site must enroll the participant into the study by logging in to an 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 31 of 88 
Version 002 
interactive response technology (IRT) system to obtain the participant number. Every 
participant that signs the informed consent form (ICF) must be assigned with a participant 
number in IRT. Specific instructions for using IRT will be provided to the investigational site 
in the IRT Manual. The investigator or designee will register the participant for enrollment 
by following the enrollment procedures established by Corvus. 
All participants will undergo a series of efficacy, safety, and laboratory assessments. 
Participants will be assessed daily during their hospitalization. Participants’ clinical status 
based on the 8-point ordinal scale, the NEWS2, Covid-19 related signs/symptoms, and safety 
laboratory tests will be recorded every day while hospitalized including day of discharge 
from the hospital. Discharged participants will be asked to attend post- hospitalization study 
assessments at Days 14, 21, and 28, if discharged before any of these assessments were 
completed. SARS-CoV-2 PCR test will be obtained on Days 1, 7, 14, 21, and 28 while 
hospitalized; and on day of discharge (if discharged prior to Day 28) and will be tested 
locally. Samples will be collected for viral load that will be assessed at a central lab. Anti-
SARS-CoV-2 antibody samples will be collected to assessed at a central lab on Day 1 before 
dosing, and on Days 7, 14, 21, and 28 if the participant remains hospitalized as well as the 
day of hospital discharge. For participants who are discharged before Day 14, 21 and 28, a 
sample will be collected on day of discharge as well as the post-hospitalization sample 
collection on Days 14, 21, and 28 that are not collected during the hospital stay. Participants 
who consent separately to the optional assessments for anti-SARS-CoV-2 serum antibody 
tests will be evaluated on Days 56, 84, and 168.  
An iDMC will be formed to monitor safety and efficacy of the study treatment at pre-
specified timepoints including futility and interim analysis timepoints. The iDMC will review 
the unblinded safety data from the first 10% (approximately 100) of participants after 
completion of the Day 28 assessments. Subsequent iDMC reviews will occur when 25%, 
40%, 60%, and 80% (approximately 250, 400, 600, and 800, respectively) of participants 
have completed the Day 28 assessments. The analysis with 25% of participants is the first 
interim analysis for futility evaluation, and the analysis with 60% of participants is the 
second interim analysis for both efficacy and futility evaluation. Safety and efficacy data will 
be analyzed for the iDMC review at both interim analyses. 
Study enrollment will be paused after 10% of the participants are enrolled. Enrollment will 
only be re-initiated following iDMC recommendation. For the second iDMC review, the 
review of the futility analysis, study enrollment will also be paused at this time. Enrollment 
will only be re-initiated following iDMC recommendation.  The study will not be paused for 
enrollment for the subsequent reviews after the futility analysis. However, the iDMC may 
request a pause in enrollment at any time during the study based on the safety and efficacy 
data. 
The protocol team will review blinded pools of AE/SAE data every 2 weeks. If there are a 
significant number of unexpected AEs, the iDMC will be asked to review unblinded safety 
and efficacy data in an ad hoc meeting. Further details on the iDMC are provided in 
Section 9.4.8. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 32 of 88 
Version 002 
4.2. 
SCIENTIFIC RATIONALE FOR STUDY DESIGN 
CPI-006 activates B cells in vitro leading to B cell differentiation and secretion of 
immunoglobulins. Studies in patients with cancer have demonstrated differentiation of 
B cells into plasmablasts, trafficking from blood and return of memory B cells to blood. The 
in vitro and in vivo effects indicate that CPI-006 stimulates B cell differentiation, antigen 
driven clonal selection and differentiation into antibody producing cells. Novel anti-tumor 
antibodies have been produced in some treated patients with cancer. B cell receptor 
molecular studies have demonstrated the emergence of novel B cell clones in the blood of 
CPI-006 treated patients with cancer. No changes in total serum immunoglobulins have been 
seen to date (Willingham et al., 2020). It is believed that the activation of B cells and 
enhancement of antibody production will lead to a more robust humoral immune response to 
SARS-CoV-2 and provide clinical benefits such as shorter disease duration, less disease 
severity, fewer complications, and greater long-term immunity.  
In Study CPI-006-002 (in mild to moderate hospitalized participants with Covid-19), IgG and 
IgM antibody titers measured against the SARS-CoV-2 spike protein and/or RBD increased 
in all evaluable participants within 7 days of a single infusion of low doses of CPI-006 and 
were sustained over time. Similar results were observed in anti-SARS-CoV-2 IgA titers. No 
correlation between duration of Covid-19 symptoms and pre-treatment serum antibody levels 
has been observed in participants. Fourteen of 22 evaluable participants had low 
pre-treatment antibody titers despite relatively long durations of symptoms in some 
participants. In participants receiving 0.3 mg/kg CPI-006, all 4 evaluable participants 
achieved high IgG titers to spike protein that were sustained for at least 84 days after onset of 
symptoms. In these participants, IgM titers peaked at 14 days and remained elevated at the 
last measured timepoint of 84 days. Similar kinetics were seen in antibody responses to RBD. 
At doses above 0.3 mg/kg, durable high titers of IgG and IgM to spike protein and RBD were 
achieved out to 84 days for the 1.0 mg/kg and 3.0 mg/kg cohorts, and 28 days for the 
5.0 mg/kg cohort in the ongoing study. Peak titers increased from 0.3 mg/kg to 1.0 mg/kg 
CPI-006 but did not appear to increase for all isotypes toward each antigen from 1.0 mg/kg to 
3.0 mg/kg or from 3.0 mg/kg to 5.0 mg/kg at the evaluable time points. An increase of IgG 
titer toward spike protein was observed from 1.0 mg/kg to 3.0 mg/kg at Day 28. High and 
durable neutralizing titers were observed in subjects where ID50 values up to 23,000 were 
measured using a functional pseudovirus neutralizing antibody assay. Neutralizing titers were 
observed to persist at least 84 days following onset of symptoms in the ongoing trial. No 
changes in total serum immunoglobulins have been seen to date. 
4.3. 
JUSTIFICATION FOR DOSE 
Two active doses of CPI-006, 1.0 mg/kg up to a maximum dose of 100 mg or 2.0 mg/kg up 
to a maximum dose of 200 mg, were selected based on safety, PD, and PK parameters. Safety 
is summarized in the CPI-006 Investigational Brochure and in Section 2.3 and Section 2.4.  

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 33 of 88 
Version 002 
In the GLP general toxicity study in cynomolgus monkeys, CPI-006 was administered by 
60-minute IV infusion once weekly for 5 consecutive weeks at dose levels of 10, 30, or 
100 mg/kg, followed by a 28-day recovery period. CPI-006 doses of up to 100 mg/kg/week 
(5 total doses) were well tolerated. CD73 is expressed weakly on endothelial cells. No 
CPI-006-related changes in hematologic coagulation parameters, which included 
prothrombin time (PT) activated partial thromboplastin time (aPTT), or fibrinogen, occurred 
during the study. The NOAEL was the highest dose administered, 100 mg/kg/week, 
corresponding to maximum drug concentration in serum or plasma (Cmax) of 3,560 and 
3,280 μg/mL and AUC from the start of infusion to 169 hours after the start of infusion 
(AUC(0-169)) of 167,000 and 186,000 hr•μg/mL, for males and females, respectively. The Cmax 
and AUC from time zero to the time of the last quantifiable concentration (AUClast) for the 
GLP repeat dose cynomolgus monkey toxicity study are 60 and 66 times higher, respectively, 
than the Cmax and AUClast after a single administration of 3 mg/kg to humans in the CPI-006-
001 study.  Safety margins are anticipated to be even greater for the 1 mg/kg and 2 mg/kg 
doses selected for the subject protocol. 
In clinical study CPI-006-001, 93 participants with advanced cancers received repeated IV 
infusions ranging from 1 mg/kg to 24 mg/kg CPI-006 once every 3 weeks until disease 
progression. CPI-006 was administered as a single agent or in combination with other 
oncology therapies. No DLTs were observed for CPI-006 at doses below 24 mg/kg in the 
dose escalation portion of the study. A DLT was observed in a single participant who 
received 24 mg/kg CPI-006 (Grade 3 hyponatremia in a participant with NSCLC who had a 
history of hyponatremia). The 24 mg/kg cohort was expanded, and no more DLTs were 
reported. Thus, a maximum tolerated dose was not established, and the 24 mg/kg cohort was 
defined as maximum administered dose per protocol. 
A covariate analysis was performed using serum CPI-006 levels, participant demographics, 
vital signs, laboratory values, and concomitant medications data from 93 participants who 
received 1-24 mg/kg CPI-006 in the CPI-006-001 study. Clearance was strongly associated 
with participant body weight, indicating a body weight-adjusted dose is preferred over a 
fixed dose. CPI-006 showed non-linear PK and modeling with clearance being a linear 
function of dose. The fit of the model to the data was excellent. Area under the curve (AUC) 
after a dose of 24 mg/kg is 453-fold higher than the AUC after a dose of 1 mg/kg and it is 
estimated to be 31-fold higher than the area under the serum concentration-time curve (AUC) 
after a dose of 2 mg/kg. The serum CPI-006 concentration 30 minutes after infusion was not 
modeled for a dose of 2 mg/kg, but the geometric mean 30-minute serum CPI-006 
concentration after administration of 24 mg/kg was 11.6 times higher than after 
administration of 3 mg/kg, and 40.2 times higher than after administration of 1 mg/kg, 
indicating a more than dose proportional increase in Cmax over the range of doses.  
In clinical study CPI-006-002, a single dose, dose escalation study, 27 participants 
hospitalized for mild to moderate Covid-19 symptoms were treated with a single IV infusion 
of CPI-006 ranging from 0.3 mg/kg to 5.0 mg/kg in combination with SOC. CPI-006 was 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 34 of 88 
Version 002 
well tolerated in all participants with no DLTs or treatment-related AEs reported in the study. 
Safety was monitored in the study by an iDMC.  
The preliminary geometric mean 30-minute serum CPI-006 concentrations in study CPI-006-
002 (n = 3 per cohort) for the 0.3 mg/kg, 1.0 mg/kg, and 3.0 mg/kg cohorts are 1.9 µg/mL, 
9.3 µg/mL, and 56.4 µg/mL, respectively. The 30-minute serum CPI-006 concentrations are 
similar to those for samples collected from the corresponding 1 mg/kg and 3 mg/kg cohorts 
at the same time in the CPI-006-001 oncology study. CPI-006 is rapidly cleared from serum 
and is undetectable (serum concentration < 50 ng/mL) 1-7 days after a 1 mg/kg IV infusion 
or 14-21 days after a 3 mg/kg infusion. In CPI-006-002, the relationship between clearance 
and weight was less well defined; however, there was a small statistical preference for a 
model in which clearance was weight-proportional, presumably because of fewer subject for 
whom PK data are available and the larger variability in this group of participants. 
Serum IgG and IgM antibody titers against the SARS-CoV-2 spike protein and/or RBD 
increased in all evaluable participants in CPI-006-002 within 7 days of a single infusion of 
CPI-006. Similar results were observed in serum anti-SARS-CoV-2 IgA titers. No correlation 
between duration of Covid-19 symptoms and pre-treatment serum antibody levels was 
observed in these participants. Thirteen of 17 evaluable participants had low pre-CPI-006 
infusion antibody titers despite relatively long durations of symptoms in some participants. In 
participants receiving 0.3 mg/kg CPI-006, all 4 evaluable participants achieved high IgG 
titers to spike protein that were sustained for at least 84 days after onset of symptoms. In 
these participants, IgM titers peaked at 14 days and remained elevated at the last measured 
timepoint of 84 days. Similar kinetics were observed in antibody responses to the RBD. At 
doses higher than 0.3 mg/kg, durable high titers of IgG and IgM to spike protein and RBD 
were achieved for at least 84 days, 56 days, and 28 days for the 1.0 mg/kg, 3.0 mg/kg, and 
5.0 mg/kg cohorts, respectively. Peak serum anti-SARS-CoV-2 titers increased from 
0.3 mg/kg to 1.0 mg/kg CPI-006 but did not appear to increase from 1.0 mg/kg to 5.0 mg/kg 
at the evaluable time points suggesting that the peak pharmacodynamic effect occurred in the 
range of 1.0-3.0 mg/kg CPI-006. In addition, the duration of sustained high antibody titers 
appeared optimum in the 1.0 mg/kg-3.0 mg/kg cohorts and was not improved at 5.0 mg/kg. 
Immunophenotyping of peripheral blood from participants enrolled in clinical study CPI-
006-001 demonstrated that doses greater than 1 mg/kg are sufficient to activate B cells, 
resulting in a temporary redistribution to lymphoid tissues and corresponding increase in the 
frequency of memory B cells returning to circulation. A similar increase in the frequency of 
memory B cells was observed in Covid-19 patients tested in the CPI-006-002 trial, including 
participants receiving 0.3 mg/kg CPI-006. In vitro, CPI-006 induced B cell activation is 
dose-dependent with concentrations of 1 μg/mL achieving near maximal induction of CD69. 
This initial activation leads to a morphologic transformation of B cells into plasmablasts and 
secretion of IgM and IgG in vitro. These levels of CPI-006 also result in increased expression 
of various markers involved in antigen presentation e.g. HLA-DR, CD86. A dose of 1 mg/kg 
is sufficient to sustain CPI-006 serum concentrations above 1 µg/ml for up to 48 hours and a 
dose of 2 mg/kg to sustain CPI-006 serum concentrations up to 1 week. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 35 of 88 
Version 002 
In summary, a dose of 1 mg/kg appeared to be sufficient to achieve the maximum level of 
IgG and IgM anti-SARS-CoV-2 titers in serum. Immunophenotyping of peripheral blood in 
participants from CPI-006-001 suggested that a higher dose may be required to activate 
B cells, resulting in a temporary redistribution to lymphoid tissues and corresponding 
increase in the frequency of memory B cells returning to circulation. Thus, a dose of 2 mg/kg 
was selected for investigation. 
4.4. 
END OF STUDY DEFINITION 
A participant in this study is considered to have completed the study if he/she has completed 
all study visits including Day 28 study assessments. The study visits beyond Day 28 will be 
optional for exploratory endpoint of antibody levels at Days 56, 84, and 168.   
The end of the study is defined as the date that the last expected study visit is completed for 
all participants.  
5. 
STUDY POPULATION 
5.1. 
INCLUSION CRITERIA 
1. Participants must be ≥ 18 years of age at the time of signing the informed consent.  
2. Confirmed positive by PCR or antigen test for SARS-CoV-2 within 72 hours before 
randomization. 
3. Onset of symptoms not more than 7 days prior to randomization. 
4. Participant capable of understanding the study and giving informed consent. 
Participant capable of signing and dating the written ICF. Participant must understand 
and agree to comply with planned study procedures for the duration of the study. The 
study visits beyond Day 28 will be optional and require a separate consent.  
5. Hospitalized for Covid-19 illness for ≤72 hours with mild to moderate Covid-19 
symptoms including: 
- 
Mild: Symptoms of Covid-19 including fever, rhinorrhea, mild cough, sore 
throat, headache, muscle pain, malaise but not requiring supplemental oxygen 
- 
Moderate: Lower respiratory symptoms: shortness of breath (SOB) or signs of 
pneumonia or lung infiltrates based on X-ray or computed tomography (CT) 
scan < 50% present 
6. Maintains O2 saturation of at least 93% on room air or supplemental O2, including 
high-flow and non-invasive ventilation at randomization (Categories 4, 5, or 6 per 
8-point ordinal scale; see Appendix 6).   
7. Adequate organ function, as defined by: 
- 
CBC: ANC >1000/mm3, platelets>75,000mm3, Hgb >9 gm/100 cc 
- 
Calculated creatinine clearance based on ideal body weight per 
Cockcroft-Gault formula or 24-hour urine ≥ 30 mL/min 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 36 of 88 
Version 002 
- 
Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤ 5 × 
upper limit of normal (ULN) 
- 
D-dimer < 10,000 ng/mL 
8. Eligible participants of child-bearing age (male or female) must agree to use adequate 
contraception for a total of 6 weeks after study treatment administration 
(Appendix 5). Female participants or the female partners of male participants who 
become pregnant during the study or within the protocol-specified period after their 
last CPI-006 administration should immediately inform their treating physicians. 
5.2. 
EXCLUSION CRITERIA 
1. Signs of acute respiratory distress syndrome (ARDS) or respiratory failure 
necessitating mechanical ventilation at the time of screening (and randomization) or 
anticipated impending need for mechanical ventilation. 
2. History of severe chronic respiratory disease and requirement for long-term oxygen 
therapy. 
3. Any uncontrolled active systemic infection or hemodynamic instability requiring 
admission to an intensive care unit (ICU).  
4. Participants with malignant tumor receiving treatment, or other serious systemic 
diseases affecting life expectancy within 29 days of Screening. 
5. Receipt of cancer chemotherapy or immunomodulatory drugs including (but not 
limited to) biologics such as anti-CD20, anti-TNF, anti-IL6; alkylating agents (e.g., 
cyclophosphamide); antimetabolites (e.g., azathioprine); or chronic corticosteroid use 
equivalent to prednisone >10 gm/day, during preceding 2 months. 
Note: Steroids for treatment of Covid-19 are acceptable. 
6. Patients who are participating in other clinical trials including participants in an 
extended access program.  
7. Active deep vein thrombosis or pulmonary embolism as confirmed by the investigator 
within last 6 months.  
8. Anticipated discharge from the hospital or transfer to another hospital which is not a 
study site within 48 hours of admission as confirmed by the investigator. 
9. Any active uncontrolled co-morbid disease that might interfere with study conduct or 
interpretation of findings. 
10. Known to be positive for HIV or positive test for chronic HBV infection (defined as 
positive hepatitis B surface antigen [HbsAg]) or positive test for hepatitis C antibody. 
11. Convalescent plasma (CCP) or anti-SARS-CoV-2 monoclonal antibodies 
administered less than 24 hours prior to randomization. Participants must have 
recovered from any adverse events related to CCP treatment. Received chloroquine or 
hydroxychloroquine within last 7 days or during the study. 
12. Pregnancy or breast feeding.  

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 37 of 88 
Version 002 
13. Persons under legal protection or currently incarcerated. 
5.3. 
LIFESTYLE CONSIDERATIONS 
Blood, sperm, and ova donations are restricted for at least 6 weeks after CPI-006 
administration. 
5.3.1. 
Meals and Dietary Restrictions 
No dietary restrictions. 
5.3.2. 
Activity 
No required restrictions. 
5.4. 
SCREEN FAILURES 
Screen failures are defined as participants who consent to participate in the clinical study but 
are not subsequently randomized. Reasons for screen failure will be recorded.  
6. 
STUDY TREATMENT 
Study treatment is defined as any investigational treatment(s), marketed product(s), placebo, 
or medical device(s) intended to be administered to a study participant according to the study 
protocol. 
6.1. 
STUDY TREATMENT ADMINISTERED 
A summary of study treatment information is provided in Table 2. 
Table 2 
Study Treatment 
Study Treatment Name: 
CPI-006 Injection, 
200 mg/20 mL  
CPI-006 Placebo 
Dosage formulation:  
10 mg/mL with 20 mM 
histidine, 9 % sucrose, 0.01 % 
(w/v) polysorbate 80, pH 5.5. 
(5% Dextrose Injection, USP [5% dextrose 
(glucose)a]) 
Unit dose strength (s) 
200 mg / 20 mL (10 mg/mL) 
5% Dextrose 
Route of administration 
IV  
IV  
Doseb 
Treatment Group A: 2 mg/kg 
up to a maximum of 200 mg  
-or-  
Treatment Group B: 1 mg/kg 
up to a maximum of 100 mg 
Treatment Group C: 
Placebo (no CPI-006) 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 38 of 88 
Version 002 
Dosing instructions: 
IV Infusion over 10-15 
minutes, on Day 1 followed by 
infusion line flush with 5% 
Dextrose Injection, USP (5% 
dextrose [glucose]). CPI-006 
Injection is diluted with 5% 
Dextrose Injection, USP (5% 
dextrose [glucose]). 
IV Infusion over 10-15 minutes, on Day 1 
followed by infusion line flush with 5% 
Dextrose Injection, USP (5% dextrose 
[glucose]).  
Packaging and labeling 
  
Study Treatment will be 
provided in a sterile, single-use 
vial with a rubber stopper and a 
blue cap. One vial is packaged 
inside a carton. Each vial will 
be labeled as required per 
country requirement. 
Not Applicable 
Manufacturer 
Manufactured for Corvus 
Pharmaceuticals, Inc. by Vetter 
Development Services USA, 
Inc. 
Placebo will be purchased by the clinical 
institution from commercial vendors 
approved by that institution 
Abbreviations: IV = intravenous; US/USA = United States of America; USP= United States Pharmacopeia 
a 5% Dextrose Injection, USP will be used at clinical sites within the United States; similar sterile, low-
endotoxin grades of 5% dextrose (glucose) that are commercially available and meet local or compendial laws 
and regulations may be substituted outside of the US. 
b The CPI-006 dose for participants who weigh more than 100 kg will be limited to a fixed dose of 200 mg in 
the 2 mg/kg dose group (Treatment A), or a fixed dose of 100 mg for the 1 mg/kg dose group (Treatment B). 
 
6.2. 
STUDY TREATMENT: 
PREPARATION/HANDLING/STORAGE/ACCOUNTABILITY 
1. The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study treatments received, and any 
discrepancies are reported and resolved before use of the study treatment. 
2. Only participants enrolled in the study may receive study treatment, and only 
authorized site staff may supply or administer study treatment. All study treatment 
must be stored in a secure, environmentally controlled, and monitored (manual or 
automated) area in accordance with the labeled storage conditions with access limited 
to the investigator and authorized site staff. 
3. The unblinded site staff preparing the study treatment is responsible for study 
treatment accountability, log of receipt, inventory, reconciliation, dispensing, return 
of study treatment, destruction of study treatment and record maintenance (i.e., 
receipt, reconciliation, and final disposition records). The study treatment logs and 
records must be kept current and blinded from others (e.g. investigators, site staff, 
participants, Sponsor and contract research organization (CRO) staff with oversight 
of study conduct). Study treatment logs must be kept in a secure location with access 
limited only to the unblinded staff members. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 39 of 88 
Version 002 
4. Further guidance and information for the final disposition of unused study treatments 
are provided in the Pharmacy Manual. 
6.2.1. 
Handling and Storage 
6.2.1.1. 
CPI-006 Injection 
CPI-006 Injection is provided as a sterile solution in a single use vial that delivers up to 200 
mg of active ingredient in 20 mL (10 mg/mL). CPI-006 vials will be stored at 2°C to 8°C and 
protected from direct light. Excursions up to 25°C are allowed up to 3 days. Refer to the 
product labeling for product storage. 
The prepared CPI-006 can be stored at 2°C to 8°C for up to 24 hours and/or stored at room 
temperature (15°C to 25°C) for up to 6 hours, including the infusion time. Avoid shaking the 
prepared CPI-006.   
Do not freeze CPI-006 vials or diluted CPI-006 infusion solution. 
6.2.1.2. 
Placebo 
The placebo, 5% Dextrose Injection, USP will be purchased by each clinical site within the 
United States. Either 5% Dextrose Injection, USP or a similar sterile, low-endotoxin grade of 
5% dextrose (glucose) that is commercially available and meets local or compendial laws and 
regulations may be substituted outside of the US. The placebo should be handled and stored 
according to manufacturer’s specifications. 
The prepared placebo can be stored at 2°C to 8°C for up to 24 hours and/or stored at room 
temperature (15°C to 25°C) for up to 6 hours, including the infusion time. Avoid shaking the 
prepared placebo.   
Do not freeze the placebo. 
6.2.2. 
Preparation and Dispensing  
Refer to the Pharmacy Manual for detailed instructions on how to prepare study treatment for 
administration. Study treatment will be prepared using aseptic techniques and dispensed by 
an appropriately qualified and experienced member of the study staff (e.g., pharmacist, 
pharmacy assistant, or pharmacy technician) who is unblinded to study treatment (see 
blinding plan in the pharmacy manual). A second staff member will verify the dispensing and 
preparation. The identity of the study treatment should not be revealed by markings on labels 
or the infusion bag or infusion set except for a blinded randomization code. 
CPI-006 infusion will be prepared using aseptic techniques by withdrawing the appropriate 
amount of CPI-006 Injection, 10 mg/mL from a vial into a sterile syringe. The contents of the 
syringe will be emptied into a sterile polyolefin/polyethylene (PO/PE) or polyvinyl chloride 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 40 of 88 
Version 002 
(PVC) infusion bag and diluted with 5% Dextrose Injection, USP or equivalent grade of 5% 
dextrose (glucose). Apply gentle mixing by inverting the IV bag; avoid shaking the IV bag. 
Placebo will be prepared using aseptic techniques. The placebo infusion is 5% Dextrose 
Injection, USP or equivalent grade of 5% dextrose (glucose) in a sterile polyolefin/ 
polyethylene (PE) or polyvinyl chloride (PVC) infusion bag. After it is prepared, the placebo 
can be stored at 2°C to 8°C for up to 24 hours and/or stored at room temperature (15°C to 
25°C) for up to 6 hours, including the infusion time. Avoid shaking the prepared placebo. 
6.2.3. 
Administration 
Administration of study treatment will be performed by an appropriately qualified, Good 
Clinical Practice (GCP)-trained, and infusion-experienced member of the study staff (e.g., 
physician, nurse, physician’s assistant, nurse practitioner, pharmacist, or medical assistant) as 
allowed by local, state, and institutional guidance. Site staff administering the study 
treatment will be blinded to the treatment (active or placebo) being administered. Participants 
will receive a single dose of study treatment by IV infusion on Day 1 of the study.  Study 
treatment must be infused through an in-line filter. Infusion lines should be made of PO/PE 
or PVC, equipped with a 0.2 µm or 0.22 µm in-line polyethersulfone (PES) filter. 
The infusion should be administered via a port as close to the participant’s vein as possible to 
ensure that the full dose is administered in the allotted time. The total infusion time from start 
of infusion to completion of infusion will be 10-15 minutes. As soon as the infusion is 
complete, the infusion line used for the study treatment will be flushed with the greater of the 
priming volume of the infusion set or 30 mL of 5% Dextrose Injection, USP or equivalent 
grade of 5% dextrose (glucose) solution. The same infusion rate used for the study treatment 
infusion will be used for the flush.   
Infusion reactions are possible, thus appropriate drugs and medical equipment to treat acute 
infusion reactions must be immediately available and study personnel must be trained to 
recognize and treat infusion reactions. Premedication with diphenhydramine 50 mg PO (or 
equivalent dose of antihistamine) or diphenhydramine 25–50 mg IV and acetaminophen 500–
1000 mg PO (or equivalent dose of analgesic) prior to infusion of CPI‑006/placebo is 
recommended for participants who are not receiving steroids for treatment of Covid‑19. Oral 
premedication should be administered 30-60 minutes prior to the start of the CPI‑006/placebo 
infusion. IV diphenhydramine should be administered 15-30 minutes prior to the start of the 
CPI‑006/placebo infusion. 
Study treatment administration details will be recorded on the CRF and will include at a 
minimum: participant number, randomization code, infusion start time and stop time, 
interruption stop and restart times, flush start and stop times. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 41 of 88 
Version 002 
6.2.4. 
Management of Infusion Reactions 
Any CPI-006-associated infusion reactions should also be managed as shown in Table 3. 
Table 3 
CPI-006 Infusion-Related Reaction Management Guidelines 
NCI CTCAE Grade 
Treatment 
Grade 1 
Mild reaction; infusion 
interruption not indicated; 
treatment not indicated 
  
  
  
  
  
  
Reduce infusion rate (e.g., from 10 mL/min to 5 mL/min) or 
stop infusion rate as medically indicated. 
  
Provide supportive care. Increase monitoring of vital signs as 
medically indicated. 
  
If symptoms do not improve within 1 hour, provide medical 
treatment until the participant is deemed medically stable in the 
opinion of the investigator.  
  
If infusion is stopped and symptoms resolve within 2 hours. 
CPI-006 infusion may be restarted at 25%-50% of the original 
infusion rate (e.g., from 10 mL/min to 5 mL/min). 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 42 of 88 
Version 002 
NCI CTCAE Grade 
Treatment 
Grade 2 
Requires therapy or infusion 
interruption but responds 
promptly to symptomatic 
treatment (e.g., antihistamines, 
NSAIDs, narcotics, IV fluids); 
prophylactic medications 
indicated for ≤ 24 hours 
  
  
  
  
Reduce infusion rate (e.g., from 10 mL/min to 5 mL/min) or 
stop infusion rate as medically indicated. 
  
Additional appropriate medical therapy may include but is not 
limited to: 
– IV fluids 
– Antihistamines 
– NSAIDs 
– Acetaminophen 
– Narcotics 
– Corticosteroids 
  
Increase monitoring of vital signs as medically indicated until 
the participant is deemed medically stable in the opinion of the 
investigator. 
  
If symptoms have not subsided or worsen with reduced infusion 
rate, stop infusion. 
  
If infusion is stopped and symptoms resolve within 2 hours. 
CPI-006 infusion may be restarted at 25%-50% of the original 
infusion rate (e.g. from 10 mL/min to 5 mL/min). 
  
Otherwise, if symptoms do not resolve, dosing will be held until 
symptoms resolve, and the participant should be premedicated 
for the next scheduled dose. 
  
Participants who develop Grade 2 toxicity with premedication 
and do not have symptom resolution within 2 hours of medical 
treatment should be permanently discontinued from further 
study drug treatment. 
  

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 43 of 88 
Version 002 
NCI CTCAE Grade 
Treatment 
Grade 3 
Prolonged (i.e., not rapidly 
responsive to symptomatic 
medication and/or brief 
interruption of infusion); 
recurrence of symptoms following 
initial improvement; 
hospitalization indicated for other 
clinical sequelae (e.g., renal 
impairment, pulmonary infiltrates) 
  
Stop Infusion. 
Additional appropriate medical therapy may include but is not 
limited to: 
– Epinephrinea 
– IV fluids 
– Antihistamines 
– NSAIDs 
– Acetaminophen 
– Corticosteroids 
– Narcotics 
– Oxygen 
– Vasopressors 
  
Grade 4 
Life-threatening; pressor or 
ventilator support indicated 
  
Stop Infusion. 
Additional appropriate medical therapy may include but is not 
limited to: 
- 
Epinephrinea 
- 
IV fluids 
- 
Antihistamines 
- 
NSAIDs 
- 
Acetaminophen 
- 
Narcotics 
- 
Oxygen 
- 
Vasopressors 
- 
Corticosteroids 
Increase monitoring of vital signs as medically indicated until 
the participant is deemed medically stable in the opinion of the 
investigator. 
 
Hospitalization may be indicated. 
Participant is permanently discontinued from further study drug 
treatment. 
Abbreviations: : IV = intravenous; NSAID = nonsteroidal anti-inflammatory drug. 
a In cases of anaphylaxis, epinephrine should be used immediately. 
6.3. 
Measures to Minimize Bias: Randomization and Blinding  
6.3.1. 
Randomization 
All participants will be randomized to Treatment A, Treatment B, or Treatment C in a 1:1:1 
ratio using an Interactive Response Technology (IRT). Before the study is initiated, the 
log-in information & directions for the IRT will be provided to each site. 
Participants will receive a single IV administration of study treatment on Day 1 of the study.   
Returned study treatment should not be redispensed to any participants. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 44 of 88 
Version 002 
6.3.2. 
Blinding 
This is an observer blinded design, so investigators, site staff (except the unblinded pharmacy 
personnel preparing the study treatment), participants, Sponsor, and CRO staff with oversight 
of study conduct will remain blinded to treatment allocation throughout the course of the 
study. The IRT will provide the unblinded pharmacist(s) the randomized treatment arm 
assignment to be allocated to the participant at the administration visit. Routines for this will 
be described in the IRT user manual that will be provided to each study site. 
CPI-006 Injection is a clear colorless solution and will remain clear and colorless when 
diluted in 5% Dextrose Injection, USP or equivalent grade of 5% dextrose (glucose) solution. 
At full concentration, CPI-006 is slightly more viscous than water and may create minimal 
foam if vigorously shaken. Once diluted, CPI-006 is not visually distinguishable from the 
5% Dextrose Injection, USP placebo. 
To maintain the blind, an otherwise uninvolved staff member (e.g. pharmacist, pharmacy 
assistant, or pharmacy technician) will prepare and dispense the study treatment for 
administration such that the identity (active or placebo) of the treatment is blinded to all other 
site staff responsible for administration and study conduct throughout the study. The 
unblinded personnel are responsible for study treatment preparation and accountability only 
and will not participate in any other aspect of the study. The unblinded personnel will 
endeavor to ensure that there are no differences in time taken to dispense following 
randomization or preparation that might reveal the identity of the study treatment to 
investigators, site staff, participants, Sponsor and CRO staff.  
In the event of a Quality Assurance audit, the auditor(s) will be allowed access to unblinded 
study treatment records at the site(s) to verify that randomization/dispensing has been done 
accurately. 
6.3.3. 
Procedures for Unblinding 
The IRT will be programmed with blind-breaking instructions. In case of an emergency, the 
investigator has the sole responsibility for determining if unblinding of a participant’s 
treatment assignment is warranted. Participant safety must always be the first consideration 
in making such a determination. If the investigator decides that unblinding is warranted, the 
investigator should make every effort to contact the Sponsor prior to unblinding a 
participant’s treatment assignment unless this could delay emergency treatment of the 
participant. If a participant’s treatment assignment is unblinded, the Sponsor must be notified 
within 24 hours after breaking the blind. The date and reason that the blind was broken must 
be recorded in the source documentation and case report form, as applicable. 
6.4. 
Study Treatment Compliance 
Investigational Product will be administered on a single occasion by the investigator or 
qualified designee to participants who are hospitalized. Randomization code, treatment 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 45 of 88 
Version 002 
volume, start and stop times for the study treatment infusion, flush volume, and start and stop 
times for the flush will be accurately recorded in the CRF. 
The study site is responsible for ensuring that participants comply with the specified study 
windows. If a participant misses a visit, every effort should be made to contact the participant 
and complete a visit within the defined visit window (Appendix 1 Schedule of Activities). If 
a participant does not complete a visit within the specified time, the visit will be classified as 
a missed visit and the participant will continue with subsequent scheduled study visits. All 
safety requirements of the missed visit will be captured and included in the subsequent visit 
(e.g. clinical laboratory testing, and immunologic testing, as applicable). 
6.5. 
CONCOMITANT THERAPY 
Investigators may prescribe any concomitant medications, procedures, or treatments deemed 
necessary to provide adequate supportive care except for those listed in Section 6.5.3.   
Any medication or vaccine (including influenza vaccine and Covid-19 vaccine, which are 
both allowed concomitant medications), over-the-counter or prescription medicines, 
vitamins, and/or herbal supplements that the participant is receiving at the time of enrollment 
or receives during the study must be recorded along with: 
• Reason for use 
• Dates of administration including start and end dates 
• Dosage information including dose and frequency 
6.5.1. 
Rescue Medicine 
The study site will supply infusion reaction rescue medication that will be obtained locally by 
the clinical site. The following rescue medications may be used: 
• Antihistamine such as diphenhydramine administered PO or IV according to standard 
practices at the clinical institution for treating infusion related reactions 
• Analgesics such as acetaminophen administered PO or IV according to standard 
practices at the clinical institution for treating infusion related reactions 
• Corticosteroids administered according to standard practices at the site/hospital for 
treating infusion related reactions 
• The date and time of rescue medication administration as well as the name and 
dosage regimen of the rescue medication must be recorded in the CRF 
6.5.2. 
Permitted Concomitant Therapy 
The following concomitant medications and vaccinations are allowed and will be recorded in 
the CRF: 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 46 of 88 
Version 002 
• Therapies that are either approved or accepted as standard of care therapies for 
Covid-19 per site/institutional guidelines (e.g., remdesivir, tocilizumab, steroids, 
convalescent plasma, anti-SARS-CoV-2 monoclonal antibodies)  
• Prophylactic or therapeutic anticoagulation  
• Supportive care for management of Covid-19 symptoms and complications 
• It is recommended that participants who are not being treated with steroids for 
Covid‑19 be premedicated with diphenhydramine 50 mg PO (or equivalent dose of 
antihistamine) or diphenhydramine 25–50 mg IV and acetaminophen 500–1000 mg 
PO (or equivalent dose of analgesic) prior to infusion of CPI-006/placebo (see 
Section 6.2.3). 
The medical monitor should be contacted if there are any questions regarding concomitant or 
prior therapy. 
6.5.3. 
Prohibited Concomitant Therapy 
The following medications are prohibited and the Sponsor must be notified if a participant 
receives any of these prohibited medications. The use of the following concomitant 
medications, however, will not definitively require withdrawal of the participant from the 
study but may determine a participant’s evaluability in the per-protocol analysis set. 
If a participant receives a prohibited concomitant medication, the investigator in consultation 
with the medical monitor will evaluate any potential impact on receipt of the study 
intervention based on time the medication was administered, the medication’s pharmacology 
and pharmacokinetics, and whether the medication will compromise the participant’s safety 
or interpretation of the data.  
The following concomitant medications are prohibited:  
• Chloroquine or hydroxychloroquine 
• Cancer chemotherapy or immunomodulatory drugs including (but not limited to) 
biologics such as anti-CD20, anti-TNF, anti-IL6; alkylating agents (e.g., 
cyclophosphamide); antimetabolites (e.g., azathioprine); or chronic corticosteroid use 
• Investigational medication or device (other than protocol-mandated study treatment) 
is prohibited within 30 days prior to initiation of study treatment and throughout the 
study unless the investigator, in consult with the Corvus medical monitor, feels 
medical necessity and that such participation would not affect the integrity of this 
trial. 
The medical monitor should be contacted if there are any questions regarding concomitant 
therapies. 
6.6. 
Dose Modification 
No dose modifications for CPI-006 are allowed. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 47 of 88 
Version 002 
6.7. 
Study Treatment After the End of the Study 
No study treatment will be provided to study participants at the end of the study. 
7. 
DISCONTINUATION OF STUDY TREATMENT AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL 
• Participant or participant’s physician may elect to discontinue their participation in 
the study at any time. Reasons for withdrawal will be recorded on the CRF. 
• All randomized participants will be followed for 28 days.  
• Participants who consent to optional follow-up visits will be followed for 168 days. 
7.1. 
DISCONTINUATION OF STUDY TREATMENT 
A single dose of CPI-006/placebo is administered only on Day 1 for participants, thus there is 
no discontinuation from study treatment unless the participant does not receive full dose due 
to toxicity during the infusion. Standard of care will be administered to all participants at the 
discretion of the investigator per institutional guidelines.  
7.2. 
PARTICIPANT DISCONTINUATION/WITHDRAWAL FROM THE 
STUDY 
• A participant may withdraw from the study at any time at his/her own request or may 
be withdrawn at any time at the discretion of the investigator for safety, behavioral, 
compliance, or administrative reasons. 
• If the participant withdraws consent for disclosure of future information, the Sponsor 
may retain and continue to use any data collected before such a withdrawal of 
consent. 
• If a participant withdraws from the study, he/she may request destruction of any 
samples taken and not tested, and the investigator must document this in the site study 
records. 
7.3. 
LOST TO FOLLOW-UP 
• A participant will be considered lost to follow-up if he or she repeatedly fails to 
return for scheduled visits and is unable to be contacted by the study site. 
• The following actions must be taken if a participant fails to return to the clinic for a 
required study visit: 
o The site must attempt to contact the participant and reschedule the missed visit 
as soon as possible and counsel the participant on the importance of 
maintaining the assigned visit schedule and ascertain whether or not the 
participant wishes to and/or should continue in the study. 
o Before a participant is deemed lost to follow-up, the investigator or designee 
must make every effort to regain contact with the participant (where possible, 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 48 of 88 
Version 002 
3 telephone calls and, if necessary, a certified letter to the participant’s last 
known mailing address or local equivalent methods). These contact attempts 
should be documented in the participant’s medical record. 
o Should the participant continue to be unreachable, he/she will be considered to 
have withdrawn from the study. 
8. 
STUDY ASSESSMENTS AND PROCEDURES  
Study procedures and their timing are summarized in the SoA (Appendix 1). Protocol 
waivers or exemptions are not allowed. Adherence to the study design requirements, 
including those specified in the SoA, is essential and required for study conduct. 
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility or record reasons for 
screening failure, as applicable. 
Procedures conducted as part of the participant’s routine clinical management (e.g., blood 
count) and obtained before signing of the ICF may be utilized for screening or baseline 
purposes provided the procedures met the protocol-specified criteria and were performed 
within the time frame defined in the SoA. 
Hospitalized participants will receive daily monitoring and testing while in the hospital 
including routine vital sign monitoring and labs per institutional standards. Once discharged, 
participants will be asked to attend post- hospitalization study visits as described in 
Section 4.1.  
Follow-up visits after discharge could include, but are not limited to, clinic visits, outpatient 
hospital visits, home health visits or telehealth, depending on local or institutional standards. 
If no other method of follow-up is feasible, home visits may be used. 
Study assessments will utilize local labs and procedures at the clinical sites except for the key 
secondary endpoint, anti-SARS-CoV-2 antibody levels and various exploratory endpoints 
such as neutralizing antibody levels and peripheral blood immunophenotyping which will be 
assessed by the central lab. Other exploratory endpoints such as BCR repertoire analysis and 
systemic cytokine/chemokine analysis will be performed by external vendors outside of the 
central lab. Results of tests conducted at central lab, are not considered as critical to the 
management of Covid-19 in participants and will not be reported to the investigator or 
participant. 
The anti-RBD IgG level will be measured using an electrochemiluminescent immunoassay 
on serum specimens stored at -20°C. The method is based on reactivity to immunogenic viral 
protein where a recombinant form of viral RBD antigen is absorbed to the surface of a 
96-well microtiter plate. Participant serum will be dispensed to the wells where antibodies 
recognizing the antigen are allowed to react before removal of unbound immunoglobulin 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 49 of 88 
Version 002 
from the wells. Anti-RBD IgG bound to the viral protein will be detected using standard 
enzyme-linked immunosorbent assay (ELISA) techniques. 
Immediate safety concerns should be discussed with the Sponsor directly upon occurrence or 
awareness to determine if the participant should continue or discontinue study treatment 
regardless of SoA assessments. Repeat or unscheduled samples may be taken for safety 
reasons or for technical issues with the samples. 
8.1. 
SCREENING  
Screening assessments and procedures are detailed in Appendix 1, Table 6. 
8.2. 
STUDY ASSESSMENTS AND PROCEDURES  
Study assessments and procedures are detailed in Appendix 1, Table 6.  
8.3. 
EFFICACY ASSESSMENTS 
The following assessments will also be performed for all participants at the time points 
described in the SoA (Appendix 1, Table 6): 
• Covid-19 Symptoms Assessment – Covid-19-attributable symptoms including fever, 
cough, sore throat, headache, muscle pain, and/or shortness of breath (Appendix 8) 
• 8-point Ordinal Scale Assessment (Appendix 6) 
• SARS-CoV-2 viral load 
• PCR negativity 
• NEWS2 Assessment (Appendix 7) 
• Anti-RBD antibody titers will be measured in sera collected at the time points 
described in the SoA (Appendix 1, Table 6). Collection of the predose timepoint is 
critical for subsequent analysis. The assays will measure IgM, IgG and IgA levels 
targeting the RBD for key and additional secondary endpoints using the 
electrochemiluminescent immunoassay. The assays will be conducted at a centralized 
testing facility using validated methods.  
• A viral PCR test by nasal swab will be obtained to demonstrate a negative test and 
viral load. Participants with positive PCR or antigen tests will have repeat PCR tests 
on subsequent visits until a negative test. This test will be conducted by the clinical 
lab at the investigator sites.  
• Exploratory measurements will be conducted at Sponsor’s research laboratories or 
through use of outside vendors including immunophenotyping analysis, immune cell 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 50 of 88 
Version 002 
functional assays, BCR repertoire analysis, systemic cytokine/chemokine analysis, 
and, anti-SARS-CoV-2 antibody characterization, and anti-viral neutralization assays. 
• Clinical assessments will include time to clinical improvement, time to resolution of 
the Covid-19 attributable symptoms, change in clinical status, rate of participants 
with clinical improvement, time to discharge, requirement for ICU, requirement for 
mechanical ventilation, rate of procedures including intubation, duration of 
mechanical ventilation, oxygenation free days in the first 28 days, and incidence and 
duration of new O2 use during the study. 
8.4. 
PHARMACOKINETIC AND PHARMACODYNAMIC ASSESSMENTS 
Serum samples will be collected from each participant enrolled in the study for measurement 
of serum concentrations of CPI-006 as specified in the SoA (Appendix 1, Table 6). A 
maximum of 4 additional samples may be collected at time points during the study if 
warranted and agreed upon between the investigator and the Sponsor. Instructions for the 
collection and handling of biological samples will be provided by the Sponsor. 
The actual collection date and time (24-hour clock time) for each sample will be recorded. 
Samples will be used to evaluate the PK of CPI-006. Each serum sample will be divided into 
3 aliquots (1 each for PK, backup, and for potential analysis of anti-drug antibodies [ADA], 
and/or neutralizing antibodies [refer to Section 8.7.1 Immunogenicity Assessments]). 
Samples collected for analyses of serum CPI-006 concentration may also be used to evaluate 
safety or efficacy aspects related to concerns arising during or after the study. 
At visits during which serum samples for the determination of PK, backup, ADA, and/or 
neutralizing antibodies of CPI-006 will be taken, one sample of sufficient volume can be 
used. 
Drug concentration information that may unblind the study will not be reported to 
investigative sites or blinded personnel until the study has been unblinded. 
Any changes in the timing or addition of time points, up to 4 time points, for any planned 
study assessments must be documented and approved by the relevant study team member and 
then archived in the Sponsor and site study files, but will not constitute a protocol 
amendment. The Institutional Review Board (IRB)/Independent Ethics Committee (IEC) will 
be informed of any safety issues that require alteration of the safety monitoring scheme or 
amendment of the ICF. 
8.5. 
SAFETY ASSESSMENTS 
The following assessments will also be performed for all participants at the time points 
described in the SoA (Appendix 1, Table 6): 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 51 of 88 
Version 002 
• Incidence, type, and severity of AEs and SAEs assessed by NCI CTCAE v 5.0 to 
compare safety of CPI-006 plus SOC to placebo plus SOC.  
• Safety assessments will be made using local lab testing (Appendix 3) for hematology, 
chemistry, coagulation, inflammatory markers and serum quantitative 
immunoglobulins. 
• Routine physical exams. 
• Vital signs (pulse rate, blood pressure, respiratory rate, temperature and blood oxygen 
saturation) including at start, at conclusion and at approximately 2 hours after 
completion of the CPI-006/placebo infusion.  
8.6. 
ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS 
The definitions of an AE or SAE can be found in Appendix 4. 
AEs will be reported by the participant (or, when appropriate, by a caregiver, or surrogate). 
The investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible for 
following up AEs that are serious, considered related to the study treatment or study 
procedures, or that caused the participant to discontinue the administration of  CPI-006/ 
placebo, or the study (see Section 7). 
8.6.1. 
Time Period and Frequency for Collecting AE and SAE Information 
After informed consent has been obtained but prior to initiation of study treatment, only 
SAEs caused by protocol-mandated procedures (e.g., study related procedures, 
discontinuation of medications) should be reported (see Appendix 4).  
After initiation of study treatment, all AEs and SAEs will be reported until completion of the 
study at Day 28.  
Medical occurrences that begin before the start of study treatment but after obtaining 
informed consent will be recorded on the Medical History/Current Medical Conditions 
section of the CRF, not the AE section. 
All SAEs will be recorded and reported to the Sponsor or designee within 24 hours, as 
indicated in Appendix 4. The investigator will submit any updated SAE data to the Sponsor 
within 24 hours of it being available. 
For participants with worsening of Covid-19, the clinical event(s) that mark the worsening 
should be reported as AE or an SAE (see definitions in Appendix 4). Investigators are not 
obligated to actively seek AEs or SAEs outside clinical practice after conclusion of the study 
participation. However, if the investigator learns of any SAE, including a death, at any time 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 52 of 88 
Version 002 
after a participant has been discharged from the study, and he/she considers the event to be 
reasonably related to the study treatment or study participation, the investigator must 
promptly notify the Sponsor. 
The method of recording, evaluating, and assessing causality of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Appendix 4. 
8.6.2. 
Method of Detecting AEs and SAEs 
The investigator is responsible for ensuring that all AEs are recorded on the Adverse Event 
CRF and reported to the Sponsor in accordance with instructions provided in this section and 
in Appendix 4. 
For each AE recorded on the Adverse Event CRF, the investigator assesses seriousness, 
severity, and causality as per Appendix 4. 
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about AE 
occurrences. 
Reporting requirements for SAEs can be found in Appendix 4. 
8.6.3. 
Follow-up of AEs and SAEs 
After the initial AE/SAE report, the investigator is required to proactively follow each 
participant at subsequent visits/contacts. All SAEs (as defined in Appendix 4), will be 
followed until resolution, stabilization, the event is otherwise explained, or the participant is 
lost to follow-up (as defined in Section 7.3). Further information on follow-up procedures is 
given in Appendix 4. 
8.6.4. 
Regulatory Reporting Requirements for SAEs 
• Prompt notification by the investigator to the Sponsor of a SAE is essential so that 
legal obligations and ethical responsibilities towards the safety of participants and the 
safety of a study treatment under clinical investigation are met. 
• The Sponsor has a legal responsibility to notify both the local regulatory authority 
and other regulatory agencies about the safety of a study treatment under clinical 
investigation. The Sponsor will comply with country-specific regulatory requirements 
relating to safety reporting to the regulatory authority, IRB/IEC, and investigators. 
• Investigator safety reports must be prepared for suspected unexpected serious adverse 
reactions (SUSAR) according to local regulatory requirements and Sponsor policy 
and forwarded to investigators as necessary. 
• An investigator who receives an investigator safety report describing a SAE or other 
specific safety information (e.g., summary or listing of SAEs) from the Sponsor will 
review and then file it along with the Investigational Brochure and will notify the 
IRB/IEC, if appropriate according to local requirements. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 53 of 88 
Version 002 
8.7. 
BIOMARKERS  
Serum at baseline and at specified times will be stored at -20°C for use in various serology 
studies which include: 
Key and Additional Secondary Endpoints 
• Measurement of anti-RBD IgG, IgM, and IgA levels.  
Exploratory Endpoints 
• Measurement of neutralizing antibody levels that block association of viral RBD and 
human ACE2 assessed in a biochemical ELISA. 
• Measurement of neutralizing antibody levels that block infection assessed in a 
pseudovirus assay, and in a live virus assay 
• Changes in IgG, IgM, or IgA antibodies targeting other SARS-CoV-2 antigens 
including (but not limited to) spike, nucleocapsid, and membrane proteins. 
• Additional exploratory serum assays may be conducted with extra serum not required 
for primary analysis. 
Peripheral blood collected at baseline and at specified times will be analyzed while fresh or 
processed into PBMCs and cryopreserved for use in various studies including: 
• Immunophenotyping using flow cytometry to evaluate the frequency of memory 
B cells and memory/effector T cells 
• Functional B and T cell assays to evaluate ex vivo immune responses to SARS-CoV-
2 antigens compared to controls. 
• BCR repertoire analysis to evaluate effects of CPI-006 on B cell clonality and 
antibody isotype switching 
8.7.1. 
Immunogenicity Assessments 
Antibodies to CPI-006 may be evaluated in serum samples collected from participants 
according to the SoA. These samples may be tested by the Sponsor or Sponsor’s designee. 
Serum samples may be screened for antibodies binding to CPI-006 and the titer of confirmed 
positive samples will be reported. Other analyses may be performed to verify the stability of 
antibodies to CPI-006 and/or further characterize the immunogenicity of CPI-006 
The detection and characterization of antibodies to CPI-006 will be performed using a 
validated assay method by or under the supervision of the Sponsor. All samples collected for 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 54 of 88 
Version 002 
detection of antibodies to study treatment may also be evaluated for CPI-006 serum 
concentration to enable interpretation of the antibody data. Antibodies may be further 
characterized and/or evaluated for their ability to neutralize the activity of the study 
treatment(s). Samples may be stored for a maximum of 5 years (or according to local 
regulations) following the last participant’s last visit for the study at a facility selected by the 
Sponsor to enable further analysis of immune responses to CPI-006. 
9. 
STATISTICAL CONSIDERATIONS 
9.1. 
STATISTICAL HYPOTHESES 
The primary hypothesis is that Treatment A will improve the proportion of participants alive 
and respiratory failure free during the 28 days after dosing  based on the 8-point ordinal scale 
in comparison to Treatment C in mild to moderately symptomatic Covid-19 hospitalized 
participants. 
The first secondary hypothesis is that Treatment A will shorten the time to recovery during 
the 28 days after dosing based on the 8-point ordinal scale in comparison to Treatment C in 
mild to moderately symptomatic Covid-19 hospitalized participants. 
The second secondary hypothesis is that Treatment A will shorten the time to clinical 
improvement by at least 2 points during the 28 days after dosing on the 8-point ordinal scale 
in comparison to Treatment C. 
The third secondary hypothesis is that Treatment A will increase the level of IgG targeting 
the RBD of SARS-CoV-2 over Days 7, 14, 21, and 28 more than Treatment C, as measured 
by the area under the IgG level curve above the baseline, calculated over Days 1 (the 
baseline), 7, 14, 21, 28, and Day of Discharge. 
The fourth secondary hypothesis is that Treatment A will shorten the time to resolution of 
≥ 50% of the Covid-19-attributable symptoms: fever, cough, sore throat, headache, muscle 
pain, and/or shortness of breath, reported at baseline in comparison to Treatment C.  
The above 5 hypotheses are also applied to the comparison of Treatment B to Treatment C. 
9.2. 
SAMPLE SIZE DETERMINATION 
Approximately 1000 hospitalized participants with mild to moderately symptomatic 
Covid-19 will be enrolled. The participants will be randomized in a 1:1:1 ratio between 
Treatment A, Treatment B and Treatment C (approximately 330 per arm) within each of the 
strata defined by: 
• Region of the world (North America [(US and Canada] vs. Latin America vs. 
Europe/Middle East/Africa). 
• Age (< 65 vs. ≥ 65) 
• Comorbidities (0 vs. at least 1) based on the following list: 
o Chronic lung disease (e.g., emphysema and chronic bronchitis, idiopathic 
pulmonary fibrosis, COPD, or cystic fibrosis) or moderate to severe asthma 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 55 of 88 
Version 002 
o Significant cardiac disease (e.g., heart failure, coronary artery disease, 
congenital heart disease, cardiomyopathies, and pulmonary hypertension) 
o Obesity (body mass index ≥ 30 kg/m2) 
o Diabetes (Type 1, Type 2, or gestational) 
o Liver disease 
o CKD 
o SCD 
o Organ transplantation 
o Cancer 
With approximately 300 participants per treatment arm, there would be an approximately 
85% power to show a statistically significant superiority of Treatment A over Treatment C in 
the proportion of participants alive and respiratory failure free during the 28 days after dosing 
at an overall 1-sided α level of 0.025 when the true proportion of Treatment A is 92% and 
that of Treatment C is 84%.  The same sample size and power statement also holds for the 
comparison between Treatment B and C. An additional 10% of participants will be enrolled 
to cover the loss-of-follow-up. 
9.3. 
POPULATION FOR ANALYSES 
For purposes of analyses, the following populations are defined in Table 4. 
Table 4 
Population Definitions 
Population 
Description 
Intent-to-treat (ITT) 
All participants who are randomized into the study and analyzed 
according to treatment assigned at randomization.  
Efficacy 
All participants who receive any amount of study drug (CPI-006 
or placebo) and have post-baseline efficacy assessment based on 
the 8-point ordinal scale. The participants will be analyzed 
according to the treatment actually received.  
Safety 
All participants who receive any amount of study treatment 
(CPI-006, placebo, or SOC). 
Pharmacokinetic 
All participants who receive CPI-006 and had at least 
1 post-treatment blood sample collected 
9.4. 
STATISTICAL ANALYSES 
The Statistical Analysis Plan (SAP) will be developed and finalized before the first interim 
analysis (the futility analysis, see Section 9.4.6) and will describe the study populations to be 
included in the analyses. This section is a summary of the planned statistical analyses of the 
primary and secondary endpoints.  
9.4.1. 
General Approach 
Unless otherwise specified, the following general analysis will be performed. Continuous 
variables will be summarized using the following descriptive statistics: number of observed 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 56 of 88 
Version 002 
values, mean, standard deviation, median, and minimum and maximum. Categorical 
variables will be summarized using frequencies and percentages. Time-to-event variables, 
when appropriate, will be summarized by the median with 95% confidence intervals (CI) and 
the 25% and 75% quartiles. Kaplan-Meier curves will be provided. The baseline value for 
analysis variable is the last measurement before administration of study treatments. 
9.4.2. 
Demographic and Participant Characteristics 
Demographic information such as age, gender, race, body weight, and participant 
characteristics such as baseline disease severity, symptoms, and comorbidities will be listed 
and summarized. 
9.4.3. 
Efficacy Analyses 
All efficacy analyses will be performed based on the ITT Population.   
Table 5 
Efficacy Analyses 
Endpoint 
Statistical Analysis 
Primary  
The primary efficacy endpoint is the proportion of participants who are alive and free from 
respiratory deterioration during the 28 days after dosing  defined as follows per the 8-point 
ordinal scale (Appendix 6):   
• Deterioration to Categories 6, 7, or 8 for a participant who entered the trial at Categories 4 
or 5  
• Deterioration to Categories 7 or 8 for a participant who entered the trial at Category 6 
The superiority of Treatment A over C with respect to the primary efficacy endpoint will be 
analyzed using the Cochran-Mantel-Haenszel test statistic adjusted by the stratification factors. 
The proportion in each group will also be presented with a 95% confidence interval (CI) using 
the Clopper-Pearson method. The difference in proportions between the two treatments and its 
95% CI for the treatment group comparison will be presented.  
The superiority of Treatment B over C with respect to the primary efficacy endpoint will be 
tested using the same statistical method. 
Secondary 
The following secondary endpoints will be compared between Treatment A and C, and 
between Treatment B and C.  The detailed analysis methods will be described in SAP. 
 
Key Secondary Endpoint:  
• 
Time to recovery during the 28 days after dosing. Day of recovery is defined as the first 
day on which the participant satisfies 1 of the following 3 categories from the 8-point 
ordinal scale:  
o 
Not hospitalized, no limitations on activities. 
o 
Not hospitalized, limitation on activities and/or requiring home oxygen;  
o 
Hospitalized, not requiring supplemental oxygen – no longer requires 
ongoing medical care. 
The superiority of Treatment A over C with respect to this endpoint will be analyzed 
using the log-rank test adjusted by the stratification factors with deaths due to all causes 
censored at Day 28. The superiority of Treatment B over C will be analyzed using the 
same method.  

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 57 of 88 
Version 002 
• 
Time to clinical improvement determined by ≥ 2 points improvement in the 8-point 
ordinal scale during the 28 days after dosing. 
The endpoint will be analyzed by the same method as for the time to recovery. 
• 
The change in the level of IgG targeting RBD of SARS-CoV-2 over Days 7, 14, 21, and 
28 from baseline measured by the area under the IgG level curve above the baseline. 
The endpoint will be analyzed by analysis of variance method adjusted by the 
stratification factors. 
• 
Time to resolution of ≥ 50% of the Covid-19 attributable symptoms including fever, 
cough, sore throat, headache, muscle pain, and/or shortness of breath reported at baseline. 
Explicitly, the resolution of ≥ 50% of symptoms means the resolution of 1 of 1 symptom, 
1 of 2 symptoms, 2 of 3 symptoms, 2 of 4 symptoms, 3 of 5 symptoms, or 3 of 6 
symptoms that are reported at baseline. The endpoint will be analyzed by the same 
method as for the time to recovery. 
Other Secondary Endpoints: 
• 
Mortality rate due to any cause during the 28 days after dosing. 
• 
Change in clinical status, defined by the change in the 8-point ordinal scale from baseline 
at Day of Discharge and Days 3, 7, 14, 21, and 28. 
• 
Percentage of participants with clinical improvement (≥ 2 points improvement in the 
8-point ordinal scale) at Day of Discharge and Days 3, 7, 14, 21, and 28.  
• 
Change from baseline in level of IgM targeting the RBD at Days 7, 14, 21, and 28. 
• 
Change from baseline in the SARS-CoV-2 viral load at Days 7, 14, 21, and 28  
• 
Time to PCR negativity, and percentage of participants with PCR negative at Days 7, 14, 
21, and 28 
• 
Change from Baseline in NEWS2 at Days 3 and 7, Day of Discharge, and Day 28.  
• 
Rate of procedures including intubation. 
• 
Rate and duration of mechanical ventilation. 
• 
Rate and duration of supplemental oxygen, non-invasive ventilation, or high flow oxygen 
devices during the trial 
• 
Oxygenation free days in the first 28 days after dosing  
• 
Rate of rehospitalization 
Exploratory 
• 
Hematology, chemistry, CRP, and ferritin assessments on Days 1, 3, 5, 7, 14, 21, 28 (while 
hospitalized); Day of Discharge; and Day 28 (return to clinic if discharged) 
• 
PT, INR, aPTT, fibrinogen, and D-dimer on Days 1, 3, 5, 7, 14, 21, 28 (while 
hospitalized), and Day of Discharge 
• 
Change from baseline in level of IgA targeting the RBD at Days 7, 14, 21, and 28 
• 
Changes in IgG, IgM, or IgA antibodies targeting other SARS-CoV-2 antigens including 
(but not limited to) trimeric spike, nucleocapsid, and membrane proteins 
• 
Change from baseline in the frequency and function of memory B cells in the peripheral 
blood at Days 14 and 28 
• 
Changes from baseline in the frequency or function of memory/effector T cells in the 
peripheral blood at Days 14 and 28 
• 
B cell receptor repertoire analysis at baseline, Day 14, and Day 28 
• 
Systemic cytokine and chemokine levels at baseline and Days 7 (while hospitalized), Day 
of discharge and Day 28 
• 
Neutralizing antibody levels on Days 1 and 28 using a biochemical ELISA, a pseudovirus 
neutralization assay, and a PRNT50 live virus assay  
• 
Change from baseline level of IgG and IgM targeting the RBD at Days 56, 84 and 168 
• 
PK characteristics including covariate analysis to determine which variables, if any, 
influence exposure of CPI-006 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 58 of 88 
Version 002 
9.4.4. 
Safety Analyses 
The safety analyses will include all participants in the Safety Population. 
Safety will be assessed through summaries of AEs (including SAEs), changes in laboratory 
test results, physical examination findings, and vital signs. 
AEs will be coded using the current version of Medical Dictionary for Regulatory Activities 
(MedDRA, Version 23.0) to categorize each AE by System Organ Class and Preferred Term. 
The number of participants who experienced at least 1 AE; treatment-related AE; severe 
(Grade 3 or higher) AE, SAE; and the number of participants withdrawn from treatment due 
to AEs will be summarized. The incidence of AEs will be presented overall, by System 
Organ Class and Preferred Term, by intensity (based on National Cancer Institute Common 
Terminology Criteria for Adverse Events [NCI CTCAE], Version 5), by severity, by 
relationship to study treatment or if treatment-emergent, and by treatment. Individual listings 
of AEs will be provided. Study treatment related AEs will be listed individually. 
Laboratory tests will be listed and summarized for each test. Lab values will be graded 
according to the NCI-CTCAE criteria and summarized. 
Deaths and related information will be listed. 
9.4.5. 
Exploratory Analyses 
PK, pharmacodynamic (PD), and biomarker exploratory analyses will be described in the 
SAP, finalized before database lock.  
9.4.6. 
Interim and Final Analyses 
Two formal interim analyses are planned for this study. The first interim analysis is a 
non‑binding futility analysis and will be performed when approximately 25% (250) of 
participants have been enrolled into the study with 28 days of follow-up time. Safety and 
efficacy will be analyzed for futility evaluation. 
The second interim analysis is also a non-binding futility and efficacy analysis and will be 
performed when approximately 60% (600) of participants have been enrolled with 28 days of 
follow-up time. Comparison between Treatment A and C, and between Treatment B and C, 
with respect to the efficacy endpoints will be made at this interim analysis. Should the 
comparison demonstrate a statistically significant superiority of Treatment A over 
Treatment C with respect to the primary efficacy endpoint, Corvus may file the results to 
regulatory authorities for drug approval. The study will continue its course beyond the 
interim analysis and collect all the planned safety, efficacy, PK, and PD data.  
At both interim analyses, unblinded analyses will be provided by a separate unblinded 
statistician to the iDMC for making the futility decision.   
As part of the second interim analysis, Corvus may request the iDMC to assess the primary 
efficacy endpoint and its conditional power of establishing a significant treatment effect at 
the final analysis based on the interim data. The total sample size of the study may be 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 59 of 88 
Version 002 
increased with the recommendation by iDMC. The sample size adaptation plan and increase 
rule will be detailed in the statistical analysis plan and provided to the regulatory authority 
before the first interim analysis. 
The primary analysis of the study is the final analysis.  Safety and efficacy analyses will be 
performed when all the participants of the study have completed the Day 28 assessments.  
9.4.7. 
Hierarchical Testing 
The 5 hypotheses listed in Section 9.1 will be tested according to their hierarchical priority 
defined as they are ordered at both the second interim analysis and final analysis. 
At the second interim analysis, the 5 hypotheses for the superiority of Treatment A over C 
will be tested following their hierarchical priority. If the results of the tests for all the 
5 hypotheses reach statistical significance, then the 5 hypotheses for the superiority of 
Treatment B over C will be tested following the hierarchical priority.  
At the final analysis, the hypotheses that are either not tested or tested but fail to reach 
statistical significance for the superiority of Treatment A over C at the interim analysis will 
be tested following the hierarchical priority. If all the hypotheses are tested to be significant, 
then the hypotheses that are either not tested or tested but fail to reach statistical significance 
for the superiority of Treatment B over C at the interim analysis will be tested following the 
hierarchical priority.  
For planning purpose for the study, the hypotheses are tested at a 1-sided α of 0.0038 at the 
second interim analysis and tested at a 1-sided α of 0.0238 at the final analysis. The α levels 
are determined by the Lan-DeMets error spending function corresponding to the 
O’Brien-Fleming boundary assuming a 60% information fraction at the interim analysis. 
However, when the interim and final analyses are performed, the actual α levels will be 
determined based on the actual information fraction at the interim analysis.  
The mortality rate due to all causes during the 28 days after dosing is also a secondary 
endpoint and will be provided at both interim analyses and final analysis. The 95% 2-sided 
CI will also be calculated for all 3 treatments. 
9.4.8. 
Independent Data Monitoring Committee (iDMC) 
An iDMC will be formed to monitor safety and efficacy of the study treatment at pre-
specified timepoints including futility and interim analysis timepoints. The iDMC will review 
the unblinded safety data from the first 10% (approximately 100) of participants after 
completion of the Day 28 assessments. Subsequent iDMC reviews will occur when 25%, 
40%, 60%, and 80% (approximately 250, 400, 600, and 800, respectively) of participants 
have completed the Day 28 assessments. The analysis with 25% of participants is the first 
interim analysis for futility evaluation, and the analysis with 60% of participants is the 
second interim analysis for both efficacy and futility evaluation. Safety and efficacy data will 
be analyzed for the iDMC review at both interim analyses. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 60 of 88 
Version 002 
Study enrollment will be paused after 10% of the participants are enrolled. Enrollment will 
only be re-initiated following iDMC recommendation. For the second iDMC review, the 
review of the futility analysis (first interim analysis), study enrollment will also be paused at 
this time. Enrollment will only be re-initiated following iDMC recommendation. The study 
will not be paused for enrollment for the subsequent reviews after the futility analysis. 
However, the iDMC may request a pause in enrollment at any time during the study based on 
the safety and efficacy data. In addition, the iDMC is available for ad hoc reviews for safety 
concerns. The protocol team will review blinded pools of AE/SAE data every 2 weeks. If 
there are a significant number of unexpected AEs, the iDMC will be asked to review 
unblinded safety and efficacy data in an ad hoc meeting.  
iDMC membership includes: 
• Three clinicians experienced in care/management of Covid-19 and an unblinded 
independent statistician (all voting members) 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 61 of 88 
Version 002 
10. 
REFERENCES 
Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel 
coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020 
Feb 15;395(10223):514-523. 
Du L, He Y, Zhou Y, et al. The spike protein of SARS-CoV –- a target for vaccine and therapeutic 
development. Nat Rev Microbiol. 2009 Mar;7(3):226-36 
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in 
Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. 
Joyner MJ, Senefeld JW, Klassen SA, et al. Effect of convalescent plasma on mortality among 
hospitalized patients with Covid-19: initial three-month experience. MedRxiv. 2020. 
Luke JJ, Merchan J; Harshman L, et al. Immunobiology and clinical activity of CPI-006, an anti-
CD73 antibody with immunomodulating properties in a Phase 1/1b trial in advanced cancers. J. 
Immunother. Cancer 2019b Nov;7(suppl.1) 282. 
Luke JJ, Powderly JD, Merchan JR, et al. Immunobiology, preliminary safety, and efficacy of CPI-
006, an anti-CD73 antibody with immune modulating activity, in a phase 1 trial in advanced 
cancers. J. Clin. Oncol. 2019a 37(15 suppl.). 
Rasheed AM, Ftak DF, Hashim HA, et al. The therapeutic effectiveness of Convalescent plasma 
therapy on treating Covid-19 patients residing in respiratory care units in hospitals in Baghdad, 
Iraq. medRxiv. 2020. 
Resta R, Thompson LF. T cell signaling through CD73. Cell Signal. 1997 Feb;9(2):131-9. 
Royal College of Physicians. National early warning score (NEWS) 2. Standardising the assessment 
of acute-illness severity in the NHS. 2017. 
Willingham SB, Criner G, Hill C, et al. Characterization and Phase 1 Trial of a B Cell Activating 
Anti-CD73 Antibody for the Immunotherapy of Covid-19. medRxiv. 2020. 
World Health Organization. Coronavirus disease 2019 (Covid-19): situation report, 72. 
Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion 
conformation. Science. 2020 Mar 13;367(6483):1260-1263. 
Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. 
Nature. 2020 Apr; 580(7803):E7. 
Yuan M, Wu NC, Zhu X, et al. A highly conserved cryptic epitope in the receptor-binding domains of 
SARS-CoV-2 and SARS-CoV. Science. 2020 Apr 3. pii: eabb7269 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 62 of 88 
Version 002 
APPENDIX 1 
SCHEDULE OF ACTIVITIES 
Table 6 
Schedule of Activities 
Procedure 
Screening 
(up to 3 
days before 
Day 1) a 
Day 1 
Day 2 to X 
(during 
hospital 
stay)b 
Day 7 (if 
participant 
remains in 
the 
hospital)c 
Day of 
Hospital 
Discharge c 
Day 7 (if 
participant 
is 
discharged 
from 
hospital)d 
Day 
14c, d, e 
Day 
21c, d, e 
Early 
Termination 
D28d 
Optional 
Assessment 
Day 
56d 
Day 
84d 
Day 
168d 
Informed Consent 
X 
 
 
 
 
 
 
 
 
 
 
 
Inclusion and Exclusion Criteria 
X 
 
 
 
 
 
 
 
 
 
 
 
Demography 
X 
 
 
 
 
 
 
 
 
 
 
 
Physical Examination 
X 
 
 
 
 
 
 
 
 
 
 
 
Limited Physical Exam 
 
X 
X 
X 
X 
 
 
 
X 
 
 
 
Medical History  
X 
 
 
 
 
 
 
 
 
 
 
 
Covid-19 Symptoms Assessmentf 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
 
National Early Warning Score 2 Assessment 
X 
X 
X 
X 
X 
 
 
 
X 
 
 
 
8-point Ordinal Scale Assessment  
X 
X 
X 
X 
X 
 
Xg 
Xg 
X 
 
 
 
Vital Signsh 
X 
X 
X 
X 
X 
 
 
 
X 
 
 
 
Hematology Paneli 
X 
X 
X 
X 
X 
 
 
 
X 
 
 
 
Chemistry Panelj 
X 
X 
X 
X 
X 
 
 
 
X 
 
 
 
Serum Quantitative Immunoglobulinsj 
X 
X 
 
 
X 
 
 
 
X 
 
 
 
Serum Ferritin 
X 
X 
X 
X 
X 
 
 
 
X 
 
 
 
Coagulation Test (PT, aPTT, INR) 
X 
X 
X 
X 
X 
 
 
 
X 
 
 
 
D-dimer 
X 
X 
X 
X 
X 
 
 
 
X 
 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 63 of 88 
Version 002 
Procedure 
Screening 
(up to 3 
days before 
Day 1) a 
Day 1 
Day 2 to X 
(during 
hospital 
stay)b 
Day 7 (if 
participant 
remains in 
the 
hospital)c 
Day of 
Hospital 
Discharge c 
Day 7 (if 
participant 
is 
discharged 
from 
hospital)d 
Day 
14c, d, e 
Day 
21c, d, e 
Early 
Termination 
D28d 
Optional 
Assessment 
Day 
56d 
Day 
84d 
Day 
168d 
Fibrinogen 
X 
X 
X 
X 
X 
 
 
 
X 
 
 
 
Pregnancy Testk 
X 
 
 
 
 
 
 
 
X 
 
 
 
SARS-CoV-2 PCR Testl 
X 
X 
 
X 
X 
 
 
 
 
 
 
 
Viral load sample (for Central Lab) 
 
X 
Xm 
X 
X 
 
X 
X 
X 
 
 
 
Influenza and RSV PCR Test 
X 
 
 
 
 
 
 
 
 
 
 
 
C-Reactive Protein   
X 
X 
X 
X 
X 
 
 
 
X 
 
 
 
Anti-SARS-CoV-2 Serum Antibody Test 
Blood Sample (Central Lab)n 
 
Xn 
(pre-dose) 
 
X 
X 
 
X 
X 
X 
(X) 
(X) 
(X) 
Exploratory Biomarker Blood Samples  
 
Xo 
 
 
X 
 
X 
 
X 
 
 
 
PKn and Immunogenicity Serum Samples 
See Table 7 for details 
Treatment Administration 
 
X 
 
 
 
 
 
 
 
 
 
 
Adverse Event Reviewp 
 
<=====================================================================> 
 
 
 
Serious Adverse Event Reviewp 
<===============================================================================> 
 
 
 
Concomitant Medication Review  
<===============================================================================> 
 
 
 
Covid-19 Medical Intervention Reviewq 
<===============================================================================> 
 
 
 
NOTE: Procedures indicated with parentheses “(X)” are conditional. Refer to the appropriate footnote for details. 
Abbreviations: AE = adverse event; aPTT = activated partial thromboplastin time; CBC = complete blood count; CRP = C-reactive protein; INR = international 
normalized ratio; LDH = lactate dehydrogenase; NEWS2 = National Early Warning Score 2 Assessment; PCR = polymerase chain reaction; PK = pharmacokinetic; 
PT = prothrombin time; RSV = Respiratory Syncytial Virus; SAE = serious adverse event; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2. 
a 
Screening and Day 1 testing can be combined, providing they are separated by less than 24 hours and there are no signs of changes in the participant’s status. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 64 of 88 
Version 002 
b 
Participants will be monitored daily while in the hospital for a minimum of 48 hours after study treatment administration. Participants will be monitored with vital 
signs including blood oxygen saturation every 4-6 hours or per institutional standards. Laboratory assessment will be taken daily or per institutional standards and 
should include but are not limited to hematology panel, chemistries, ferritin, CRP, LDH, D-dimer, fibrinogen, PT, aPTT and INR. Participants’ clinical status based 
on the 8-point ordinal scale, the NEWS2, Covid-19 related signs/symptoms, and safety laboratory tests will be recorded every day while hospitalized including day 
of discharge from the hospital.   
c 
All participants will have samples collected for viral load, anti-SARS-CoV-2 serum antibody test, and exploratory biomarkers on day of discharge. Discharged 
participants will be asked to attend post- hospitalization study assessments at Days 14, 21, and 28, if discharged before any of these assessments were completed. 
Participants who are discharged before Day 7, do not need a Day 7 sample collection but will be assessed for Covid-19 symptoms. 
d  
Day 7 can be ± 1 day, Day 14, and Day 21 can be ± 2 days, Day 28 can be + 7 days. Day 56, Day 84, and Day 168 can be ± 5 days. 
e 
All efforts should be made to have the blood draws and exams done and assessments completed. When needed a telemedicine or home health visit can replace a 
clinical visit for the post-hospitalization visits.  
f 
Assessment of Covid-19 symptoms (per Appendix 8) should happen daily during the hospital stay. In the post- hospitalization setting, assessment of symptoms 
should happen on Day 7 (for those discharged before Day 7), Day 14, Day 21 and Day 28. Day 7, Day 14, and Day 21 assessments can be a telemedicine or phone 
call visit. 
g 
If the participant is hospitalized, the assessment should be conducted in the hospital. If discharged and participant is at home, assessment may be conducted over the 
phone. 
h 
Vital signs includes pulse, blood pressure, temperature, respiratory rate, and oxygen saturation by pulse oximeter. Height and weight collected at screening only. On 
Day 1 vital signs will be collected pre-dose, at completion of treatment administration (at the end of the flush) (+ 15 minute window), and 2 hours post-dose 
(± 15 minutes window).  
i 
Hematology panel should include the parameters detailed in protocol Appendix 3. 
j 
Chemistry panel should include the parameters detailed in protocol Appendix 3 and serum quantitative immunoglobulins (Screening, Day 1, day of discharge and 
Day 28). 
k 
Pregnancy test (serum or urine) for women of child-bearing potential only (Appendix 5). 
l 
Participants must have a confirmed positive PCR or antigen test for SARS-CoV-2 within 72 hours of randomization (screening sample). PCR test will also be 
obtained on Days 1 and 7, while hospitalized; and on day of discharge (if discharged prior to Day 28) and will be tested locally. 
m 
Viral load sample to be collected on Day 3 while hospitalized as well as day 1 (pre-dose), Day of discharge, Day 7 (if hospitalized), 14, 21 and 28. 
n 
Anti-SARS-CoV-2 serum antibody test blood sample to be collected pre-dose administration. Anti-SARS-CoV-2 serum antibody samples will be collected to be 
assessed at a central lab on Day 1 before dosing, and on Days 7, 14, 21, and 28 if participant remains hospitalized as well as the day of hospital discharge. For 
participants who are discharged before Day 14, 21 and 28, a sample will be collected on day of discharge as well as the post-hospitalization sample collection on 
Days 14, 21, and 28 that are not collected during the hospital stay. Participants who consent separately to the optional assessments for anti-SARS-CoV-2 serum 
antibody tests will be evaluated on Days 56, 84, and 168. 
o  
Exploratory biomarker samples on Day 1 will be collected pre-dose and 4 hours post-dose (± 30 min).  
p 
After informed consent has been obtained but prior to initiation of study treatment, only SAEs caused by protocol-mandated procedures will be reported. After 
initiation of study treatment, all AEs and SAEs will be reported until completion of the study at Day 28.  
q 
Review of medical interventions/ procedures for management of Covid-19 such as intubation, ventilation, and supplemental oxygen and rehospitalization. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 65 of 88 
Version 002 
Table 7 
PK, ADA, and Neutralizing Antibody Sampling Schedule 
 
Samplea 
Collection Timepoint 
PK Variance 
ADA and Neutralizing Antibody Only 
1 
pre-dose 
-1 hour-0 hours 
X (collected as part of PK) 
2 
0.5 hours 
± 5 min 
 
3 
2 hours 
± 30 min 
 
4 
4 hours 
± 30 min 
 
5 
8 hours 
± 2 hours 
 
6 
24 hours 
± 6 hours 
 
7 
48 hours 
± 8 hours 
 
8 
Day 28 
 
X 
Abbreviation: ADA = anti-drug antibodies; min = minutes; PK = pharmacokinetics  
a Time post CPI-006 infusion and line flush except for pre-dose sample  
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 66 of 88 
Version 002 
APPENDIX 2 
REGULATORY, ETHICAL, AND STUDY OVERSIGHT CONSIDERATIONS 
REGULATORY AND ETHICAL CONSIDERATIONS 
• This study will be conducted in accordance with the protocol and with the following: 
o Consensus ethical principles derived from international guidelines including 
the Declaration of Helsinki and Council for International Organizations of 
Medical Sciences (CIOMS) International Ethical Guidelines 
o Applicable International Council for Harmonisation (ICH) Good Clinical 
Practice (GCP) Guidelines 
o Applicable laws and regulations 
• The protocol, protocol amendments, ICF, Investigator Brochure, and other relevant 
documents (e.g., advertisements) must be submitted to an IRB/IEC by the investigator 
and reviewed and approved by the IRB/IEC before the study is initiated. 
• Any amendments to the protocol will require IRB/IEC approval before 
implementation of changes made to the study design, except for changes necessary to 
eliminate an immediate hazard to study participants.  
• In accordance with applicable laws and regulations, protocols and any substantial 
amendments to the protocol will require health authority approval prior to initiation 
except for changes necessary to eliminate an immediate hazard to study participants. 
• The investigator will be responsible for the following: 
o Providing written summaries of the status of the study to the IRB/IEC 
annually or more frequently in accordance with the requirements, policies, and 
procedures established by the IRB/IEC 
o Notifying the IRB/IEC of SAEs or other significant safety findings as required 
by IRB/IEC procedures 
o Providing oversight of the conduct of the study at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 
536/2014 for clinical studies (if applicable), and all other applicable local 
regulations 
FINANCIAL DISCLOSURE 
Investigators and sub-investigators will provide the Sponsor with sufficient, accurate 
financial information as requested to allow the Sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate regulatory authorities. 
Investigators are responsible for providing information on financial interests during the study 
and for 1 year after completion of the study. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 67 of 88 
Version 002 
INFORMED CONSENT PROCESS 
• The investigator or his/her representative will explain the nature of the study to the 
participant and answer all questions regarding the study. 
• Participants must be informed that their participation is voluntary. Participants will be 
required to sign a statement of informed consent that meets the requirements of 
21 CFR 50, local regulations, ICH guidelines, and privacy and data protection 
requirements, where applicable, and the IRB/IEC or study center. 
• The medical record must include a statement that written informed consent was 
obtained before the participant was enrolled in the study and the date the written 
consent was obtained. The authorized person obtaining the informed consent must 
also sign the ICF. 
• Participants must be re-consented to the most current version of the ICF(s) during 
their participation in the study. 
• A copy of the ICF(s) must be provided to the participant. 
The ICF will address the use of remaining mandatory samples. The investigator or authorized 
designee will explain to each participant the objectives of the exploratory research. 
Participants will be told that they are free to refuse to participate and may withdraw their 
consent at any time and for any reason during the storage period. A separate consent will be 
required to document a participant's agreement to allow any remaining specimens to be used 
for exploratory research. Participants who decline to participate in this optional research will 
not provide this separate consent. 
Sites will be allowed to use all processes approved by their IRB to ensure safety of staff and 
patients from Covid-19, while maintaining appropriate consent procedures for the duration of 
this study. 
DATA PROTECTION 
• Participants will be assigned a unique identifier by the Sponsor. Any participant 
records or datasets that are transferred to the Sponsor will contain the identifier only; 
participant names or any information which would make the participant identifiable 
will not be transferred. 
• The participant must be informed that his/her personal study-related data will be used 
by the Sponsor in accordance with local data protection law. The level of disclosure 
must also be explained to the participant who will be required to give consent for 
their data to be used as described in the informed consent. 
• The participant must be informed that his/her medical records may be examined by 
Clinical Quality Assurance auditors or other authorized personnel appointed by the 
Sponsor, by appropriate IRB/IEC members, and by inspectors from regulatory 
authorities. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 68 of 88 
Version 002 
COMMITTEES STRUCTURE 
The objectives of the iDMC are to evaluate interim clinical and safety data to protect 
participant welfare and to provide recommendations regarding study conduct. Details of 
iDMC responsibilities and procedures are specified in the iDMC charter.  
DISSEMINATION OF CLINICAL STUDY DATA 
Clinical Study Reports, periodic safety reports, and clinical study summary reports will be 
disclosed after review by regulatory authorities. This includes access to CSRs from studies 
with negative outcomes and from terminated development programs. 
Company-sponsored study information and tabular study results will be posted on the US 
National Institutes of Health’s website www.ClinicalTrials.gov and other publicly accessible 
sites. 
Publication planning and other activities related to non-promotional, peer-reviewed 
publications will be conducted to ensure the scientific integrity and credibility of publication 
activities performed by or on behalf of the company. The granting of access to analyzable 
datasets from clinical studies should be through a secure system, following an independent 
assessment of the scientific merit of a rigorously defined research question from a third party. 
DATA QUALITY ASSURANCE 
• All participant data relating to the study will be recorded on printed or electronic CRF 
unless transmitted to the Sponsor or designee electronically (e.g., laboratory data). 
The investigator is responsible for verifying that data entries are accurate and correct 
by physically or electronically signing the CRF. 
• The investigator must maintain accurate documentation (source data) that supports 
the information entered in the CRF. 
• The investigator must permit study-related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents. 
• Monitoring details describing strategy (e.g., risk-based initiatives in operations and 
quality such as Risk Management and Mitigation Strategies and Analytical Risk-
Based Monitoring), methods, responsibilities, and requirements, including handling 
of noncompliance issues and monitoring techniques (central, remote, or on-site 
monitoring) are provided in the Clinical Monitoring Plan. 
• The Sponsor or designee is responsible for the data management of this study 
including quality checking of the data. 
• The Sponsor assumes accountability for actions delegated to other individuals (e.g., 
Contract Research Organizations). 
• Study monitors will perform ongoing CRF verification to confirm that data entered 
into the CRF by authorized site personnel are accurate and complete; that the safety 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 69 of 88 
Version 002 
and rights of participants are being protected; and that the study is being conducted in 
accordance with the currently approved protocol and any other study agreements, 
ICH GCP, and all applicable regulatory requirements. 
• U.S. FDA regulations (21 CFR §312.62[c]) and the ICH Guideline for GCP 
(Section 4.9 of the guideline) require that records and documents pertaining to the 
conduct of this study and the distribution of investigational drug, including CRFs, 
consent forms, laboratory test results, and medication inventory records, must be 
retained by the Principal Investigator for 2 years after the last marketing application 
approval or after at least 2 years have elapsed since formal discontinuation of clinical 
development of the investigational product. All state and local laws for retention of 
records also apply. No records may be transferred to another location or party without 
written notification to the Sponsor. 
SOURCE DOCUMENTS 
• Source documents provide evidence for the existence of the participant and 
substantiate the integrity of the data collected. Source documents are filed at the 
investigator’s site. 
• Data reported on the CRF or entered in the CRF that are transcribed from source 
documents must be consistent with the source documents or the discrepancies must be 
explained. The investigator may need to request previous medical records or transfer 
records, depending on the study. Also, current medical records must be available. 
• Definition of what constitutes source data can be found in the study monitoring plan. 
STUDY TERMINATION 
Potential reasons for closing the study include: 
• Unsatisfactory subject enrollment 
• Potentially unacceptable risk to study subjects 
• Decision to modify clinical development plan 
• Decision by the regulatory authority 
In the event of a decision to close the study, the Sponsor will promptly inform the 
investigator and the IRB/IEC and provide them with a detailed explanation of the reason for 
closure. The Sponsor and investigator will ensure that the safety of the subjects is protected 
and that IRB/IEC reporting continues per the requirements of the IRB/IEC and applicable 
local laws or requirements. 
SITE CLOSURE 
The Sponsor or designee reserves the right to close a study site at any time for any reason at 
the sole discretion of the Sponsor. Potential reasons for closing a site include: 
• Investigator noncompliance 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 70 of 88 
Version 002 
• Unsatisfactory subject recruitment and enrollment 
• Lack of adherence to protocol procedures, the requirements of the IRB/IEC or local 
health authorities, the Sponsor’s procedures, or GCP guidelines 
• Lack of evaluable and/or complete data 
• Potentially unacceptable risk to study subjects 
• Decision by the regulatory authority 
Study sites will be closed upon study completion. A study site is considered closed when all 
required documents and study supplies have been collected or confirmed as destroyed and a 
study-site closure visit has been performed. 
The investigator may initiate study-site closure at any time, provided there is reasonable 
cause and sufficient notice is given in advance of the intended termination. 
PUBLICATION POLICY 
• The results of this study may be published or presented at scientific meetings. If this 
is foreseen, the investigator agrees to submit all manuscripts or abstracts to the 
Sponsor before submission. This allows the Sponsor to protect proprietary 
information and to provide comments. 
• The Sponsor will comply with the requirements for publication of study results. In 
accordance with standard editorial and ethical practice, the Sponsor will generally 
support publication of multicenter studies only in their entirety and not as individual 
site data. In this case, a coordinating investigator will be designated by mutual 
agreement. 
• Authorship will be determined by mutual agreement and in line with International 
Committee of Medical Journal Editors authorship requirements. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 71 of 88 
Version 002 
APPENDIX 3 
CLINICAL LABORATORY TESTS 
• Protocol-specific requirements for inclusion or exclusion of participants are detailed 
in Section 5 of the protocol. 
• Additional tests may be performed at any time during the study as determined 
necessary by the investigator or required by local regulations. 
 
Table 8 
Protocol-Required Safety Laboratory Assessments 
Chemistry 
Hematology 
Serum 
Quantitative 
Immunoglobulins 
Inflammatory 
Biomarkers 
Coagulation 
Testing 
BUN (Blood Urea 
Nitrogen) 
Platelet Count 
IgA 
C-reactive protein 
PT 
Potassium 
RBC Count 
IgG 
Ferritin 
aPTT 
Creatinine 
Hemoglobin 
IgM 
 
INR 
Sodium 
Hematocrit 
 
 
D-dimer 
Glucose 
RBC (Red Blood 
Cell) indices: 
    MCV 
    MCH 
    % Reticulocytes 
 
 
Fibrinogen 
Calcium 
 
 
 
Bilirubin (total & direct) 
 
 
 
Protein (total) 
 
 
 
LDH (Lactate 
Dehydrogenase) 
WBC count 
(White Blood Cell) 
with differential: 
    Neutrophils 
    Lymphocytes 
    Monocytes 
    Eosinophils 
    Basophils 
 
 
 
AST 
 
 
 
ALT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: ALT = alanine aminotransferase; aPTT = activated partial thromboplastin time; AST = aspartate 
aminotransferase; IgA = immunoglobulin A; IgG = immunoglobulin G; IgM = immunoglobulin M; 
INR = international normalized ratio; LDH = lactate dehydrogenase; MCH = mean corpuscular 
hemoglobin; MCV = mean corpuscular volume; PT = prothrombin time; RBC = red blood cell. 
 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 72 of 88 
Version 002 
APPENDIX 4 
ADVERSE EVENTS: DEFINITIONS AND PROCEDURES FOR RECORDING, 
EVALUATING, FOLLOW-UP, AND REPORTING 
DEFINITION OF AE 
AE Definition 
• An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated 
with the use of study treatment, whether or not considered related to the study treatment. 
• NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory 
finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. 
 
Events Meeting the AE Definition 
• Any abnormal laboratory test results (hematology or clinical chemistry) or other safety assessments (e.g., 
ECG, radiological scans, vital signs measurements), including those that worsen from baseline, is 
accompanied by clinical symptoms, results in a change in study treatment (e.g., dosage modification, 
treatment interruption, or treatment discontinuation), results in a medical treatment (e.g., potassium 
supplementation for hypokalemia) or a change in concomitant therapy, considered clinically significant in 
the medical and scientific judgment of the investigator (i.e., not related to progression of underlying 
disease). 
• 
Exacerbation of a chronic or intermittent pre-existing condition including either an increase in 
frequency and/or intensity of the condition. 
• 
New conditions detected or diagnosed after study treatment administration even though it may have 
been present before the start of the study. 
o 
Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction. 
o 
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study treatment 
or a concomitant medication. Overdose per se will not be reported as an AE/SAE unless it is 
an intentional overdose taken with possible suicidal/self-harming intent. Such overdoses 
should be reported regardless of sequelae.  
• For worsening of Covid-19 symptoms, the clinical event(s) that mark the worsening should be reported as 
AE or an SAE.   
• If a clinically significant laboratory abnormality is a sign of a disease or syndrome (e.g., alkaline 
phosphatase and bilirubin 5 x ULN associated with cholestasis), only the diagnosis (i.e., cholestasis) 
should be recorded on the Adverse Event CRF.  
• Exacerbation of a chronic or intermittent pre-existing condition including either an increase in frequency 
and/or intensity of the condition. 
• Deaths that occur within 28 days after study treatment (CPI-006) should be reported as an SAE.  
• New conditions detected or diagnosed after study treatment administration even though it may have been 
present before the start of the study. 
• "Lack of efficacy" or "failure of expected pharmacological action" per se will not be reported as an AE or 
SAE. Such instances will be captured in the efficacy assessments. However, the signs, symptoms, and/or 
clinical sequelae resulting from lack of efficacy will be reported as AE or SAE if they fulfill the definition 
of an AE or SAE. 
 
 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 73 of 88 
Version 002 
 
Events NOT Meeting the AE Definition 
• Any clinically significant abnormal laboratory findings or other abnormal safety assessments which are 
associated with the underlying disease, unless judged by the investigator to be more severe than expected 
for the participant’s condition. 
• Medical or surgical procedure (e.g., endoscopy, appendectomy): the condition that leads to the procedure 
is the AE. 
• Situations in which an untoward medical occurrence did not occur (social and/or convenience admission to 
a hospital). 
• Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present or detected at the start 
of the study that do not worsen. 
 
DEFINITION OF SAE 
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (e.g., hospitalization for signs/symptoms of the progression of disease 
under study). Hospitalization or ICU admissions due to Covid-19, worsening of Covid-19 in 
the 28 days during this study, or pulmonary conditions attributable to Covid-19 infection are 
considered efficacy-related endpoints. Therefore, Covid-19-related hospitalization or ICU 
admission is excluded from this definition. 
A SAE is defined as any untoward medical occurrence that, at any dose: 
a. Results in death 
b. Is life-threatening 
The term 'life-threatening' in the definition of 'serious' refers to an event in which the participant was at risk of 
death at the time of the event. It does not refer to an event, which hypothetically might have caused death, if it 
were more severe. 
c. 
Requires inpatient hospitalization or prolongation of existing hospitalization 
Any adverse event that causes prolonged hospitalization should be documented and reported as a 
serious adverse event (per the definition of serious adverse event). 
 
• 
For this study, the subjects will be hospitalized for Covid-19 treatment so initial hospitalization will 
not be considered as an SAE. Complications that occur during hospitalization are AEs/SAEs. If a 
complication prolongs hospitalization (or requires admission to ICU) or fulfills any other serious 
criteria, the event is serious.  
 
An event that leads to hospitalization under the following circumstances should not be reported as an 
adverse event or a serious adverse event: 
• 
Hospitalization for respite care 
• 
Planned hospitalization required by the protocol (e.g., for the Covid-19 treatment). 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 74 of 88 
Version 002 
d. Results in persistent disability/incapacity 
• 
The term disability means a substantial disruption of a person’s ability to conduct normal life 
functions. 
• 
This definition is not intended to include experiences of relatively minor medical significance such as 
uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (e.g., sprained 
ankle) which may interfere with or prevent everyday life functions but do not constitute a substantial 
disruption. 
e. 
Is a congenital anomaly/birth defect 
f. 
Other situations 
• 
Medical or scientific judgment should be exercised in deciding whether SAE reporting is appropriate 
in other situations such as important medical events that may not be immediately life-threatening or 
result in death or hospitalization but may jeopardize the participant or may require medical or surgical 
treatment to prevent 1 of the other outcomes listed in the above definition. These events should 
usually be considered serious. 
• 
Examples of such events include invasive or malignant cancers, intensive treatment in an emergency 
room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in 
hospitalization, or development of drug dependency or drug abuse. 
 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 75 of 88 
Version 002 
RECORDING AND FOLLOW-UP OF AE AND/OR SAE 
AE and SAE Recording 
• 
When an AE/SAE occurs, it is the responsibility of the investigator to review all documentation (e.g., 
hospital progress notes, laboratory reports, and diagnostics reports) related to the event. 
• 
The investigator will then record all relevant AE/SAE information in the CRF. 
• 
It is not acceptable for the investigator to send photocopies of the participant’s medical records to 
Sponsor in lieu of completion of the AE/SAE CRF page. 
• 
There may be instances when copies of medical records for certain cases are requested by Sponsor. In 
this case, all participant identifiers, with the exception of the participant number, will be redacted on 
the copies of the medical records before submission to Sponsor. 
• 
The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or 
other clinical information. Whenever possible, the diagnosis (not the individual signs/symptoms) will 
be documented as the AE/SAE. However, if a constellation of signs and/or symptoms cannot be 
medically characterized as a single diagnosis or syndrome at the time of reporting, each individual 
event should be recorded on the Adverse Event CRF. If a diagnosis is subsequently established, all 
previously reported AEs based on signs and symptoms should be nullified and replaced by 1 AE 
report based on the single diagnosis, with a starting date that corresponds to the starting date of the 
first symptom of the eventual diagnosis. 
 
Adverse Events That Are Secondary to Other Events 
In general, AEs that are secondary to other events (e.g., cascade events or clinical sequelae) should be 
identified by their primary cause, with the exception of severe or serious secondary events. A medically 
significant secondary AE that is separated in time from the initiating event should be recorded as an 
independent event on the Adverse Event CRF. For example: 
• 
If vomiting results in mild dehydration with no additional treatment in a healthy adult, only vomiting 
should be reported on the CRF 
• 
If vomiting results in severe dehydration, both events should be reported separately on the CRF 
• 
If a severe gastrointestinal hemorrhage leads to renal failure, both events should be reported 
separately on the CRF 
• 
If dizziness leads to a fall and consequent fracture, all 3 events should be reported separately on the 
CRF 
• 
If neutropenia is accompanied by an infection, both events should be reported separately on the CRF 
All AEs should be recorded separately on the Adverse Event CRF if it is unclear as to whether the events are 
associated. 
 
Persistent or Recurrent Adverse Events 
A persistent AE is one that extends continuously, without resolution, between patient or participant evaluation 
timepoints. Such events should be recorded with each severity change on the Adverse Event CRF. The initial 
severity (intensity or grade) of the event will be recorded at the time the event is first reported, with each 
subsequent change in severity recorded on the same AE CRF with the exception of a non-serious event 
becoming serious. If the event becomes serious, it should be reported to the Sponsor immediately (i.e., no more 
than 24 hours after learning that the event became serious.). A new AE should be recorded as serious in the 
CRF with the date the event became serious recorded as the start date and completing all data fields related to 
SAEs.  
• 
A recurrent AE is one that resolves between patient or participant evaluation timepoints and 
subsequently recurs. Each recurrence of an AE should be recorded as a separate event on the Adverse 
Event CRF. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 76 of 88 
Version 002 
 
 
Assessment of Intensity 
The guidelines outlined below will be used for assessing the severity of AEs. The severity/intensity of AEs and 
SAEs will be graded based upon the participant’s symptoms according to the NCI CTCAE v5. 
AEs that are not defined in the NCI CTCAE v5 should be evaluated for severity/intensity according to the 
following scale: 
Table 9 
Assessment of Severity of Adverse Events 
Grade 
Severity 
1 
Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or treatment 
not indicated 
2 
Moderate; minimal, local, or non-invasive treatment indicated; or limiting age-appropriate 
instrumental activities of daily living a 
3 
Severe or medically significant, but not immediately life-threatening; hospitalization or 
prolongation of hospitalization indicated; disabling; or limiting self-care activities of daily 
living.b,c An AE that is assessed as severe should not be confused with a SAE. Severe is a 
category utilized for rating the intensity of an event; and both AEs and SAEs can be assessed 
as severe. 
An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe. 
 
4 
Life-threatening consequences or urgent treatment indicated d 
5 
Death related to AE d 
a 
Instrumental activities of daily living refer to preparing meals, shopping for groceries or clothes, using the 
telephone, managing money, etc. 
b 
Examples of self-care activities of daily living include bathing, dressing and undressing, feeding oneself, 
using the toilet, and taking medications, as performed by participants who are not bedridden. 
c 
If an event is assessed as a “significant medical event,” it must be reported as an SAE per the definition of 
SAE in (see section above). 
d 
Grade 4 and 5 events must be reported as SAEs per the definition of SAE (see section above). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 77 of 88 
Version 002 
Assessment of Causality 
• 
The investigator is obligated to assess the relationship between study treatment and occurrence of 
each AE/SAE. 
• 
A "reasonable possibility" of a relationship conveys that there are facts, evidence, and/or arguments to 
suggest a causal relationship, rather than a relationship cannot be ruled out. 
• 
The investigator will use clinical judgment to determine the relationship. 
• 
Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, as well 
as the temporal relationship of the event to study treatment administration will be considered and 
investigated. 
• 
The investigator will also consult the Investigational Brochure (IB) and/or Product Information, for 
marketed products, in his/her assessment. 
• 
For each AE/SAE, the investigator must document in the medical notes that he/she has reviewed the 
AE/SAE and has provided an assessment of causality. 
• 
There may be situations in which an SAE has occurred, and the investigator has minimal information 
to include in the initial report to Sponsor. However, it is very important that the investigator always 
make an assessment of causality for every event before the initial transmission of the SAE data to 
Sponsor. 
• 
The investigator may change his/her opinion of causality in light of follow-up information and send 
an SAE follow-up report with the updated causality assessment. 
• 
The causality assessment is one of the criteria used when determining regulatory reporting 
requirements. 
 
Follow-up of AEs and SAEs 
• 
Treatment related AEs and SAEs should be followed up until resolution or until the AE is stable. 
• 
The investigator is obligated to perform or arrange for the conduct of supplemental measurements 
and/or evaluations as medically indicated or as requested by Sponsor to elucidate the nature and/or 
causality of the AE or SAE as fully as possible. This may include additional laboratory tests or 
investigations, histopathological examinations, or consultation with other health care professionals. 
• 
If a participant dies during participation in the study or during a recognized follow-up period, the 
investigator will provide Sponsor with a copy of any post-mortem findings including histopathology. 
• 
New or updated information will be recorded in the originally completed CRF. 
• 
The investigator will submit any updated SAE data to the Sponsor within 24 hours of receipt of the 
information. 
 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 78 of 88 
Version 002 
REPORTING OF SAES 
SAE Reporting to Corvus via an Electronic Data Collection Tool 
The primary mechanism for reporting an SAE to Corvus will be the electronic data 
collection tool. 
If the electronic system is unavailable for more than 24 hours, then the site will use the 
paper SAE data collection tool (see next section). 
The site will enter the SAE data into the electronic system as soon as it becomes available. 
After the study is completed at a given site, the electronic data collection tool will be taken 
off-line to prevent the entry of new data or changes to existing data. 
If a site receives a report of a new SAE from a study participant or receives updated data 
on a previously reported SAE after the electronic data collection tool has been taken 
off-line, then the site can report this information on a paper SAE form (see next section) or 
to the medical monitor by telephone or email. 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 79 of 88 
Version 002 
SAE Reporting via Paper Report Forms 
The primary mechanism for reporting an SAE to Sponsor will be through EDC. If EDC is down or not 
available, then the paper SAE report form can be used for SAE reporting. 
 
Events That Occur Prior to the Study Treatment Initiation 
After informed consent has been obtained but prior to initiation of study treatment (non-treatment emergent), 
only SAEs caused by protocol-mandated procedures should be reported in EDC using the EDC SAE form. 
Investigators should record all case details that can be gathered immediately (i.e., within 24 hours after 
learning of the event) on the Adverse Event CRF and submit the report via the paper report form. All other 
non-treatment emergent AEs should be reported in the Medical History CRF. 
 
Events That Occur after Study Treatment Initiation 
• 
After initiation of study treatment, all AEs and SAEs will be reported for 28 days following stopping 
of study treatment and until participants complete the study. The site will enter the SAE data into the 
EDC SAE report form. 
Adverse Events That Occur after the Adverse Event Reporting Period are described in the following 
section. 
• 
If a site receives a report of a new SAE from a study participant or receives updated data on a 
previously reported SAE, then the site can report this information in EDC (see next section) or to the 
Sponsor’s designee by telephone on the number listed in a section below. 
If EDC is unavailable, then the paper Clinical Trial Serious Adverse Event Form provided to investigators 
should be completed and submitted to the Sponsor or its designee immediately (i.e., no more than 24 hours 
after learning of the event), either by faxing or by scanning and e-mailing the form using the fax number or 
e-mail address provided to investigators below. Please note that email is preferred over fax and phone. 
 
 
 
Note: For Ex-US country-specific safety fax and phone numbers, refer to the study manual. 
• 
In rare circumstances and in the absence of facsimile equipment, notification by telephone is 
acceptable with a copy of the SAE data collection tool sent by overnight mail or courier service. 
• 
Initial notification via telephone does not replace the need for the investigator to complete and sign 
the SAE CRF pages within the designated reporting time frames. 
 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 80 of 88 
Version 002 
APPENDIX 5 
CONTRACEPTIVE GUIDANCE AND COLLECTION OF PREGNANCY 
INFORMATION 
 
DEFINITIONS: 
  
WOMAN OF CHILDBEARING POTENTIAL (WOCBP) AND OF FERTILE MEN 
A woman is considered fertile following menarche and until becoming post-menopausal 
unless permanently sterile (see below). 
1. Women in the following categories are not considered WOCBP 
2. Premenarchal 
a. Premenopausal female with 1 of the following: 
i. Documented hysterectomy 
ii. Documented bilateral salpingectomy 
iii. Documented bilateral oophorectomy 
Note: Documentation can come from the site personnel’s: review of the participant’s medical 
records, medical examination, or medical history interview. 
3. Postmenopausal female 
a. A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. A high follicle stimulating hormone (FSH) level in 
the postmenopausal range may be used to confirm a postmenopausal state in 
women not using hormonal contraception or hormonal replacement therapy 
(HRT). However, in the absence of 12 months of amenorrhea, a single FSH 
measurement is insufficient. 
b. Females on HRT and whose menopausal status is in doubt will be required to 
use one of the non-estrogen hormonal highly effective contraception methods 
if they wish to continue their HRT during the study. Otherwise, they must 
discontinue HRT to allow confirmation of postmenopausal status before study 
enrollment. 
A man is considered fertile after puberty unless permanently sterile by bilateral 
orchidectomy. 
 
CONTRACEPTION GUIDANCE: 
MALE PARTICIPANTS 
Male participants with female partners of childbearing potential are eligible to participate if 
they agree to ONE of the following  for 6 weeks after study treatment. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 81 of 88 
Version 002 
• Are abstinent from penile-vaginal intercourse as their usual and preferred lifestyle 
(abstinent on a long term and persistent basis) and agree to remain abstinent 
• Agree to use a male condom plus partner use of a contraceptive method with a failure 
rate of <1% per year as described in Table 1 of this appendix when having penile-
vaginal intercourse with a woman of childbearing potential who is not currently 
pregnant. 
In addition, male participants must refrain from donating sperm for the duration of the study 
and for 6 weeks after study treatment. 
FEMALE PARTICIPANTS 
Female participants of childbearing potential are eligible to participate if they agree to use a 
highly effective method of contraception consistently and correctly as described in Table 10. 
In addition, female participants must refrain from donating ova for the duration of the study 
and for 6 weeks after study treatment. 
Table 10 
Highly Effective Contraceptive Methodsa 
Highly Effective Contraceptive Methods That Are User Dependent b 
Failure rate of <1% per year when used consistently and correctly. 
Combined (estrogen and progestogen containing) hormonal contraception associated with 
inhibition of ovulation c 
• Oral 
• Intravaginal 
• Transdermal 
Progestogen only hormonal contraception associated with inhibition of ovulation 
• Oral 
• Injectable 
Highly Effective Contraceptive Methods That Are User Independent c 
• Implantable progestogen only hormonal contraception associated with inhibition of 
ovulationc 
• IUD 
• IUS 
• Bilateral tubal occlusion 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 82 of 88 
Version 002 
Vasectomized partner 
A vasectomized partner is a highly effective contraception method provided that the 
partner is the sole male sexual partner of the WOCBP and the absence of sperm has been 
confirmed. If not, an additional highly effective method of contraception should be used. 
Sexual abstinence 
Sexual abstinence is considered a highly effective method only if defined as refraining 
from heterosexual intercourse during the entire period of risk associated with the study 
treatment defined as 6 weeks after receiving study treatment. The reliability of sexual 
abstinence needs to be evaluated in relation to the duration of the study and the preferred 
and usual lifestyle of the participant. 
Abbreviations: IUD = intrauterine device; IUS = intrauterine hormone-releasing system; 
WOCBP = woman of childbearing potential 
a   Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), 
withdrawal (coitus interruptus), spermicides only and lactational amenorrhea method 
(LAM) are not considered acceptable methods of contraception. A male and female 
condom should not be used together as friction between the two can result in either 
product failing. 
b  Typical use failure rates may differ from those when used consistently and correctly. Use 
should be consistent with local regulations regarding the use of contraceptive methods 
for participants participating in clinical studies. 
c    Hormonal contraception may be susceptible to interaction with the study treatment, 
which may reduce the efficacy of the contraceptive method. In this case, two highly 
effective methods of contraception should be utilized during the treatment period and 
for at least 6 weeks corresponding to time needed to eliminate study treatment after the 
last dose of study treatment. Contraception methods with low user dependency should 
preferably be used, in particular when contraception is introduced as a result of 
participation in the clinical trial. 
 
PREGNANCY TESTING: 
• WOCBP should only be included after a negative (urine or serum) pregnancy test at 
screening 
• Additional pregnancy testing is required at end of study or at early termination (see 
Appendix 1 – Schedule of Activities) 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 83 of 88 
Version 002 
COLLECTION OF PREGNANCY INFORMATION: 
 MALE PARTICIPANTS WITH PARTNERS WHO BECOME PREGNANT 
• The investigator will attempt to collect pregnancy information on any male 
participant’s female partner who becomes pregnant while the male participant is in 
this study.  
• After obtaining the necessary signed informed consent from the pregnant female 
partner directly, the investigator will record pregnancy information on the appropriate 
form and submit it to the Sponsor within 24 hours of learning of the partner’s 
pregnancy. The female partner will also be followed to determine the outcome of the 
pregnancy. Information on the status of the mother and child will be forwarded to the 
Sponsor.  Any termination of the pregnancy will be reported regardless of fetal status 
(presence or absence of anomalies) or indication for the procedure.  
FEMALE PARTICIPANTS WHO BECOME PREGNANT 
• The investigator will collect pregnancy information on any female participant who 
becomes pregnant while participating in this study. Information will be recorded on 
the appropriate form and submitted to the Sponsor within 24 hours of learning of a 
participant's pregnancy. The participant will be followed to determine the outcome of 
the pregnancy. The investigator will collect follow-up information on the participant 
and the neonate and the information will be forwarded to the Sponsor. Any 
termination of pregnancy will be reported, regardless of fetal status (presence or 
absence of anomalies) or indication for the procedure. 
• While pregnancy itself is not considered to be an AE or SAE, any pregnancy 
complication or elective termination of a pregnancy will be reported as an AE or 
SAE. A spontaneous abortion is always considered to be an SAE and will be reported 
as such. Any post-study pregnancy related SAE considered reasonably related to the 
study treatment by the investigator will be reported to the Sponsor as described in 
Section 8.6.4. While the investigator is not obligated to actively seek this information 
in former study participants, he or she may learn of an SAE through spontaneous 
reporting. 
 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 84 of 88 
Version 002 
APPENDIX 6 
8-POINT ORDINAL SCALE FOR CLINICAL IMPROVEMENT 
 
1. Not hospitalized, no limitations on activities 
2. Not hospitalized, limitation on activities and/or requiring home oxygen 
3. Hospitalized, not requiring supplemental oxygen - no longer requiring ongoing medical 
care 
4. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care 
(Covid-19 related or otherwise) 
5. Hospitalized, requiring supplemental oxygen 
6. Hospitalized, on non-invasive ventilation or high flow oxygen devices 
7. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane 
oxygenation 
8. Death 
 
 
 
 
 
 
 
 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 85 of 88 
Version 002 
APPENDIX 7 
NEWS2 SCORING SYSTEM 
 
 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 86 of 88 
Version 002 
APPENDIX 8 
EXAMPLE OF AN ASSESSMENT OF 14 COMMON COVID-19-RELATED 
SYMPTOMS: ITEMS AND RESPONSE OPTIONS  
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 87 of 88 
Version 002 
 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 88 of 88 
Version 002 
APPENDIX 9 
PROTOCOL AMENDMENT HISTORY 
 
Table 11  
Document History 
Document History 
Date of Issue 
Version 002 (Amendment 1) 
11-January-2021 
Version 001 (Original Protocol) 
06-November-2020 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 1 of 85 
Version 001 
Protocol 
 
Protocol Title: 
Phase 3, Randomized, Placebo Controlled, Double-blind, 
Multicenter, Stratified Study of CPI-006 Plus Standard of 
Care Versus Placebo Plus Standard of Care in Mild to 
Moderately Symptomatic Hospitalized Covid-19 Patients 
Protocol Number: 
CPI-006-003 
Regulatory Agency 
Identifier Number(s): 
 
EudraCT: 2020‐005305‐54 
Compound Number: 
CPI-006 
Study Phase: 
3 
Sponsor Name: 
Corvus Pharmaceuticals 
Sponsor Address: 
863 Mitten Rd, Suite 102 
Burlingame, CA 94010 
Version Number: 
001 
Date Final: 
06 November 2020 
 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 3 of 85 
Version 001 
INVESTIGATOR SIGNATURE PAGE 
Protocol Title: 
Phase 3, Randomized, Placebo Controlled, Double-blind, Multicenter, 
Stratified Study of CPI-006 Plus Standard of Care Versus Placebo Plus 
Standard of Care in Mild to Moderately Symptomatic Hospitalized 
Covid-19 Patients 
Protocol Number: CPI-006-003 
Version Number: 001 
 
 
 
I have read and understood the current version of the protocol (as listed above). I agree to 
conduct this trial in accordance with International Council for Harmonisation (ICH) Good 
Clinical Practice (GCP), all applicable regulatory requirements, and the general ethical 
principles outlined in the Declaration of Helsinki.  
I agree to ensure that no deviation from, or changes to the protocol will take place without 
prior agreement from Corvus Pharmaceuticals and documented approval from the 
Institutional Review Board (IRB)/Independent Ethics Committee (IEC), except where 
necessary to eliminate an immediate hazard(s) to the trial participants.  
I will ensure that all staff members under my supervision involved in the conduct of this 
study are informed about the protocol and protocol amendments, the investigational products, 
and their study-related duties and functions.  
I agree not to divulge to anyone, either during or after the termination of the study, any 
confidential information acquired regarding the investigational products and processes or 
methods of Corvus. 
 
 
 
 
Investigator Signatory 
Name: 
Title: 
 
Date 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 4 of 85 
Version 001 
TABLE OF CONTENTS 
Page 
1. 
Protocol Summary ............................................................................................ 11 
1.1. 
Synopsis ............................................................................................................ 11 
1.2. 
Schema ............................................................................................................. 20 
1.3. 
Schedule of Activities (SoA) ............................................................................ 20 
2. 
Introduction ...................................................................................................... 20 
2.1. 
Study Rationale ................................................................................................ 20 
2.2. 
Background ...................................................................................................... 21 
2.3. 
CPI-006 Nonclinical Evaluation ...................................................................... 23 
2.4. 
Summary of Clinical Experience with CPI-006 ............................................... 24 
2.4.1. 
Benefit/Risk Assessment .................................................................................. 25 
3. 
Objectives and Endpoints ................................................................................. 25 
4. 
Study Design .................................................................................................... 28 
4.1. 
Overall Design .................................................................................................. 28 
4.2. 
Scientific Rationale for Study Design .............................................................. 29 
4.3. 
Justification for Dose ........................................................................................ 30 
4.4. 
End of Study Definition ................................................................................... 33 
5. 
Study Population .............................................................................................. 33 
5.1. 
Inclusion Criteria .............................................................................................. 33 
5.2. 
Exclusion Criteria ............................................................................................. 34 
5.3. 
Lifestyle Considerations ................................................................................... 34 
5.3.1. 
Meals and Dietary Restrictions ........................................................................ 35 
5.3.2. 
Activity ............................................................................................................. 35 
5.4. 
Screen Failures ................................................................................................. 35 
6. 
Study Treatment ............................................................................................... 35 
6.1. 
Study Treatment Administered ........................................................................ 35 
6.2. 
Study Treatment: Preparation/Handling/Storage/Accountability .................... 36 
6.2.1. 
Handling and Storage ....................................................................................... 36 
6.2.1.1. 
CPI-006 Injection ............................................................................................. 36 
6.2.1.2. 
Placebo ............................................................................................................. 37 
6.2.2. 
Preparation and Dispensing .............................................................................. 37 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 5 of 85 
Version 001 
6.2.3. 
Administration .................................................................................................. 38 
6.2.4. 
Management of Infusion Reactions .................................................................. 39 
6.3. 
Measures to Minimize Bias: Randomization and Blinding .............................. 41 
6.3.1. 
Randomization .................................................................................................. 41 
6.3.2. 
Blinding ............................................................................................................ 42 
6.3.3. 
Procedures for Unblinding ............................................................................... 42 
6.4. 
Study Treatment Compliance ........................................................................... 42 
6.5. 
Concomitant Therapy ....................................................................................... 43 
6.5.1. 
Rescue Medicine .............................................................................................. 43 
6.5.2. 
Permitted Concomitant Therapy ...................................................................... 43 
6.5.3. 
Prohibited Concomitant Therapy ..................................................................... 44 
6.6. 
Dose Modification ............................................................................................ 44 
6.7. 
Treatment After the End of the Study .............................................................. 44 
7. 
Discontinuation of Study Treatment and Participant 
Discontinuation/Withdrawal ................................................................................................... 45 
7.1. 
Discontinuation of Study Treatment ................................................................ 45 
7.2. 
Participant Discontinuation/Withdrawal from the Study ................................. 45 
7.3. 
Lost to Follow Up ............................................................................................. 45 
8. 
Study Assessments and Procedures .................................................................. 46 
8.1. 
Screening .......................................................................................................... 47 
8.2. 
Study Assessments and Procedures .................................................................. 47 
8.3. 
Efficacy Assessments ....................................................................................... 47 
8.4. 
Pharmacokinetic and Pharmacodynamic Assessments .................................... 48 
8.5. 
Safety Assessments .......................................................................................... 48 
8.6. 
Adverse Events and Serious Adverse Events ................................................... 49 
8.6.1. 
Time Period and Frequency for Collecting AE and SAE Information ............ 49 
8.6.2. 
Method of Detecting AEs and SAEs ................................................................ 50 
8.6.3. 
Follow-up of AEs and SAEs ............................................................................ 50 
8.6.4. 
Regulatory Reporting Requirements for SAEs ................................................ 50 
8.7. 
Biomarkers ....................................................................................................... 51 
8.7.1. 
Immunogenicity Assessments .......................................................................... 51 
9. 
Statistical Considerations ................................................................................. 52 
9.1. 
Statistical Hypotheses ....................................................................................... 52 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 6 of 85 
Version 001 
9.2. 
Sample Size Determination .............................................................................. 52 
9.3. 
Population for Analyses ................................................................................... 53 
9.4. 
Statistical Analyses ........................................................................................... 53 
9.4.1. 
General Approach ............................................................................................. 53 
9.4.2. 
Demographic and Participant Characteristics .................................................. 54 
9.4.3. 
Efficacy Analyses ............................................................................................. 54 
9.4.4. 
Safety Analyses ................................................................................................ 55 
9.4.5. 
Exploratory Analyses ....................................................................................... 55 
9.4.6. 
Interim Analyses ............................................................................................... 56 
9.4.7. 
Independent Data Monitoring Committee (iDMC) .......................................... 57 
10. 
References ........................................................................................................ 58 
Appendix 1  Schedule of Activities ..................................................................................... 59 
Appendix 2  Regulatory, Ethical, and Study Oversight Considerations .............................. 63 
Appendix 3  Clinical Laboratory Tests ................................................................................ 68 
Appendix 4  Adverse Events: Definitions and Procedures for Recording, Evaluating, 
Follow-up, and Reporting ....................................................................................................... 69 
Appendix 5  Contraceptive Guidance and Collection of Pregnancy Information ............... 77 
Appendix 6  8-Point Ordinal Scale for Clinical Improvement ............................................ 81 
Appendix 7  NEWS2 Scoring System ................................................................................. 82 
Appendix 8  Example of An Assessment of 14 Common Covid-19-Related Symptoms: 
Items and Response Options ................................................................................................... 83 
Appendix 9  Protocol Amendment History .......................................................................... 85 
 
LIST OF TABLES 
Table 1 
Population Definitions................................................................................... 18 
Table 2 
Study Treatment ............................................................................................ 35 
Table 3 
CPI-006 Infusion-Related Reaction Management Guidelines ...................... 39 
Table 4 
Population Definitions................................................................................... 53 
Table 5 
Efficacy Analyses .......................................................................................... 54 
Table 6 
Schedule of Activities ................................................................................... 59 
Table 7 
PK, ADA, and Neutralizing Antibody Sampling Schedule .......................... 62 
Table 8 
Protocol-Required Safety Laboratory Assessments ...................................... 68 
Table 9 
Assessment of Severity of Adverse Events ................................................... 73 
Table 10  
Document History ......................................................................................... 85 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 7 of 85 
Version 001 
LIST OF FIGURES 
Figure 1 
Study Schematic ............................................................................................ 20 
 
LIST OF APPENDICES 
Appendix 1 
 Schedule of Activities .................................................................................. 59 
Appendix 2 
 Regulatory, Ethical, and Study Oversight Considerations ........................... 63 
Appendix 3 
 Clinical Laboratory Tests ............................................................................. 68 
Appendix 4 
 Adverse Events: Definitions and Procedures for Recording, Evaluating, 
Follow-up, and Reporting ............................................................................ 69 
Appendix 5 
 Contraceptive Guidance and Collection of Pregnancy Information ............ 77 
Appendix 6 
 8-Point Ordinal Scale for Clinical Improvement ......................................... 81 
Appendix 7 
 NEWS2 Scoring System .............................................................................. 82 
Appendix 8 
 Example of An Assessment of 14 Common Covid-19-Related Symptoms: 
Items and Response Options ........................................................................ 83 
Appendix 9 
 Protocol Amendment History ....................................................................... 85 
 
 
 
 
 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 8 of 85 
Version 001 
 
LIST OF ABBREVIATIONS 
Abbreviation  
Definition 
ACE2 
angiotensin converting enzyme 2 
ADA 
anti-drug antibodies 
AE 
adverse event 
ALT 
alanine aminotransferase 
AMP 
adenosine monophosphate 
ANC 
absolute neutrophil count 
aPTT 
activated partial thromboplastin time 
ARDS 
acute respiratory distress syndrome 
AST 
aspartate aminotransferase 
AUC 
area under the serum or plasma concentration-time curve 
AUC(0-169) 
AUC from the start of infusion to 169 hours after the start of infusion 
AUClast 
AUC from time zero to the time of the last quantifiable concentration 
BCR 
B cell receptor 
C(0) 
the initial CPI-006 concentration measured 30 minutes after completion of the 
infusion 
CBC 
complete blood count 
CCP 
Covid-19 Convalescent Plasma 
CI 
confidence interval 
CKD 
chronic kidney disease 
Cmax 
maximum drug concentration in serum or plasma 
COPD 
chronic obstructive pulmonary disease 
CRF 
case report form 
CRO 
contract research organization 
CRP 
C-reactive protein 
CT 
computed tomography 
DLT 
dose-limiting toxicity 
EAP 
extended access program 
ELISA 
enzyme-linked immunosorbent assay 
Fc 
fragment crystallizable 
FDA 
U.S. Food and Drug Administration 
GCP 
Good Clinical Practice 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 9 of 85 
Version 001 
GLP 
Good Laboratory Practice 
HIPAA 
United States Health Insurance Portability and Accountability Act 
HLA-DR 
human leukocyte antigen – DR isotype  
IC50 
concentration required for 50% inhibition 
ICF 
informed consent form 
ICH 
International Council for Harmonisation 
ICU 
intensive care unit 
iDMC 
Independent Data Monitoring Committee 
IEC 
Independent Ethics Committee 
IFN-γ 
interferon gamma 
Ig 
immunoglobulin 
IgA 
immunoglobulin A 
IgG 
immunoglobulin G  
IgM 
immunoglobulin M 
IL-2, -6, -10 
interleukin 2, 6, 10 
IND 
Investigational New Drug  
INR 
international normalized ratio 
IRB 
Institutional Review Board 
IRR 
infusion-related reaction 
IRT 
interactive response technology 
ITT 
intent-to-treat 
IV 
Intravenous(ly) 
LDH 
lactate dehydrogenase 
MCH 
mean corpuscular hemoglobin  
MCV 
mean corpuscular volume 
MERS 
Middle East respiratory syndrome 
NEWS2 
National Early Warning Score 2 
NCI CTCAE 
National Cancer Institute Common Terminology Criteria for Adverse Events 
NOAEL 
no-observed adverse effect level 
O2 
oxygen 
PBMC 
peripheral blood mononuclear cell 
PCR 
polymerase chain reaction 
PD 
pharmacodynamics 
PD1 
programmed cell death 1 receptor  

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 10 of 85 
Version 001 
PE 
polyethylene 
PES 
polyethersulfone 
PK 
pharmacokinetic(s) 
PO 
by mouth (orally) 
PO/PE 
polyolefin/polyethylene 
PT 
prothrombin time 
PVC 
polyvinylchloride 
RBC 
red blood cell 
RBD 
receptor binding domain 
RNA 
ribonucleic acid 
RSV 
Respiratory Syncytial Virus 
SAE 
serious adverse event 
SARS 
severe acute respiratory syndrome 
SARS-CoV-2 
severe acute respiratory syndrome coronavirus 2 
SCD 
sickle cell disease 
SoA 
schedule of activities 
SOB 
shortness of breath 
SOC 
standard of care 
SpO2 
oxygen saturation 
SUSAR 
suspected unexpected serious adverse reactions 
TNF-α 
tumor necrosis factor alpha 
TTD 
time to death 
ULN 
upper limit of normal 
US/USA 
United States of America 
USP 
United States Pharmacopeia 
WBC 
white blood cell 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 11 of 85 
Version 001 
1. 
PROTOCOL SUMMARY 
1.1. 
SYNOPSIS 
Name of Sponsor: Corvus Pharmaceuticals, Inc. 
Investigational Product: CPI-006 
Title of Study: Phase 3, Randomized, Placebo Controlled, Double-blind, Multicenter, 
Stratified Study of CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in 
Mild to Moderately Symptomatic Hospitalized Covid-19 Patients 
Phase of Development: 3 
Number of Participants: Approximately 620 evaluable participants for an estimated total of 
310 evaluable participants per treatment group 
Study Centers: Multicenter 
Study Objectives and Endpoints:  
Objectives 
Endpoints 
Primary 
 
• 
To compare the time to recovery of CPI-006 plus 
SOC versus placebo plus SOC in hospitalized 
participants with mild to moderately symptomatic 
Covid-19 infection 
• 
Time to recovery during the 28 days after dosing. 
Day of recovery is defined as the first day on 
which the participant satisfies 1 of the following 3 
categories from the 8-point ordinal scale 
(Appendix 6):  1) Not hospitalized, no limitations 
on activities.; 2) Not hospitalized, limitation on 
activities and/or requiring home oxygen; 3) 
Hospitalized, not requiring supplemental oxygen - 
no longer requires ongoing medical care. 
Key Secondary 
 
• 
To compare the time to clinical improvement of 
CPI-006 plus SOC versus placebo plus SOC in 
hospitalized participants with mild to moderately 
symptomatic Covid-19 infection 
• 
Time to clinical improvement (≥ 2 points 
improvement in the 8-point ordinal scale) 
• 
To compare the change from baseline in the level 
of antibodies targeting the RBD of SARS-CoV-2  
• 
Change from baseline level of IgG targeting the 
RBD at Days 7, 14, 21, and 28 
• 
To compare the time to improvement of Covid-
19-attributable symptoms including fever, cough, 
sore throat, headache, muscle pain, and shortness 
of breath 
• 
Time to resolution of ≥ 50% of the 
Covid-19 -attributable symptoms (see 
Appendix 8) including fever, cough, sore throat, 
headache, muscle pain, and/or shortness of breath 
reported at baseline 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 12 of 85 
Version 001 
Additional Secondary  
 
• 
To compare the clinical status of CPI-006 plus 
SOC versus placebo plus SOC in hospitalized 
participants with mild to moderately symptomatic 
Covid-19 infection 
• 
Change in clinical status, defined by the change in 
the 8-point ordinal scale from baseline at Days 3, 
7, Day of Discharge, Days 14, 21, and 28 
• 
To compare the percentage of participants with 
clinical improvement with CPI-006 plus SOC 
versus placebo plus SOC in hospitalized 
participants with mild to moderately symptomatic 
Covid-19 infection 
• 
Percentage of participants with clinical 
improvement (≥ 2 points improvement in the 8-
point ordinal scale) at Days 3, 7, 14, 21, and 28  
• 
To compare the change from baseline in the level 
of antibodies targeting the RBD of SARS-CoV-2 
• 
Change from baseline level of IgM targeting the 
RBD at Days 7, 14, 21 and 28 
• 
To compare the change from baseline in the 
SARS-CoV-2 viral load 
• 
Change from baseline in the SARS-CoV-2 viral 
load at Days 3, 7, 14, 21, and 28 
• 
To compare time to PCR negativity, and 
percentage of participants with PCR negative of 
CPI-006 plus SOC versus placebo plus SOC in 
hospitalized participants with mild to moderately 
symptomatic Covid-19 infection 
• 
Time to PCR negativity 
• 
Percentage of participants with PCR negative at 
Days 7, 14, 21, and 28 
• 
To compare the change from Baseline in NEWS2 
of CPI-006 plus SOC versus placebo plus SOC in 
hospitalized participants with mild to moderately 
symptomatic Covid-19 infection 
• 
Change from Baseline in NEWS2 at Days 3 and 
7, Day of Discharge, and Day 28.                             
NEWS2 consists of: Physiological Parameters: 
respiration rate (per minute), SpO2 Scale 1 (%), 
SpO2 Scale 2 (%), use of air or oxygen, systolic 
blood pressure (mmHg), pulse (per minute), 
consciousness, and temperature (°C) 
• 
To compare the medical interventions/procedures 
including intubation, mechanical ventilation, and 
supplemental O2 use, rehospitalization of CPI-006 
plus SOC versus placebo plus SOC in hospitalized 
participants with mild to moderately symptomatic 
Covid-19 infection 
• 
Rate of procedures including intubation 
• 
Rate and duration of mechanical ventilation 
• 
Rate and duration of supplemental oxygen, non-
invasive ventilation, or high flow oxygen devices 
during the trial 
• 
Oxygenation free days in the first 28 days 
• 
Rehospitalization 
• 
To compare the safety of CPI-006 plus SOC 
versus placebo plus SOC in hospitalized 
participants with mild to moderately symptomatic 
Covid-19 infection 
• 
Incidence, type, and severity of 
treatment -emergent adverse events of CPI-006 
plus SOC compared to placebo plus SOC assessed 
by NCI CTCAE v 5.0 
 
• 
To compare TTD of CPI-006 plus SOC versus 
placebo plus SOC in hospitalized participants 
with mild to moderately symptomatic Covid-19 
infection 
• 
Time to death during the first 28 days 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 13 of 85 
Version 001 
Exploratory  
 
• 
To compare changes from baseline in Covid-19-
related lab assessments of CPI-006 plus SOC 
versus placebo plus SOC in hospitalized 
participants with mild to moderately symptomatic 
Covid-19 infection 
  
• 
Hematology, chemistry, CRP, and ferritin 
assessments on Days 1, 3, 5, 7, 14, 21, 28 (while 
hospitalized); Day of Discharge; and Day 28 
(return to clinic if discharged) 
• 
PT, INR, aPTT, fibrinogen, and D-dimer on Days 
1, 3, 5, 7, 14, 21, 28 (while hospitalized), and Day 
of Discharge 
• 
Change from baseline level of IgA targeting the 
RBD at Days 7, 14, 21, and 28 
• 
Changes in IgG, IgM, or IgA antibodies targeting 
other SARS-CoV-2 antigens including (but not 
limited to) spike, nucleocapsid, and membrane 
proteins 
• 
Change from baseline in the frequency and 
function of memory B cells in the peripheral 
blood at Days 14 and 28 
• 
Changes from baseline in the frequency or 
function of memory/effector T cells in the 
peripheral blood at Days 14 and 28 
• 
B cell receptor repertoire analysis at baseline, Day 
14, and Day 28 
• 
Systemic cytokine and chemokine levels at 
baseline and Days 7 (while hospitalized), Day of 
Discharge, and Day 28 
• 
Neutralizing antibody levels on Days 1 and 28 
using a biochemical ELISA, a pseudovirus 
neutralization assay, and a PRNT50 live virus 
assay 
• 
Change from baseline level of IgG and IgM 
targeting the RBD at Days 56, 84, and 168 
• 
Characterize the pharmacokinetics of CPI-006 in 
hospitalized participants with Covid-19 infection  
• 
PK characteristics including covariate analysis to 
determine which variables, if any, influence 
exposure of CPI-006 
Abbreviations:  aPTT = activated partial thromboplastin time; CRP = C-reactive protein; ELISA = enzyme-
linked immunosorbent assay; IgA = immunoglobulin A; IgG = immunoglobulin G; IgM = immunoglobulin M; 
INR = international normalized ratio; NCI CTCAE = National Cancer Institute Common Terminology Criteria 
for Adverse Events; NEWS2 = National Early Warning Score 2; O2 = oxygen; PCR = polymerase chain 
reaction; PK = pharmacokinetic; RBD =  receptor binding domain; PT = prothrombin time; SARS-CoV-2 = 
severe acute respiratory syndrome coronavirus 2; SOC = Standard of Care; SpO2 = oxygen saturation; TTD = 
time to death 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 14 of 85 
Version 001 
Study Design: 
This is a Phase 3, randomized, placebo controlled, double-blind, multicenter, stratified study 
of CPI-006 plus standard of care (SOC) versus placebo plus SOC in mild to moderately 
symptomatic hospitalized adult (≥ 18 years) Covid-19 patients. Covid-19 disease will be 
confirmed by polymerase chain reaction (PCR) testing. 
Participants will be randomized at a 1:1 ratio to the 2 treatment arms and stratified by the 
following factors: 
• Region of the world (North America vs. Latin America vs. Europe).   
• Age (< 65 vs. ≥ 65) 
• Comorbidities (0 vs. at least 1) based on the following list: 
o Chronic lung disease (e.g., emphysema and chronic bronchitis, idiopathic 
pulmonary fibrosis, chronic obstructive pulmonary disease [COPD], or cystic 
fibrosis) or moderate to severe asthma 
o Significant cardiac disease (e.g., heart failure, coronary artery disease, 
congenital heart disease, cardiomyopathies, and pulmonary hypertension) 
o Obesity (body mass index ≥ 30 kg/m2) 
o Diabetes (Type 1, Type 2, or gestational) 
o Liver disease 
o Chronic kidney disease (CKD) 
o Sickle cell disease (SCD) 
o Organ transplantation 
o Cancer 
CPI-006 will be administered at a dose of 2 mg/kg up to a maximum dose of 200 mg 
intravenously (IV) on Day 1 in the participants randomized to receive treatment (Treatment 
A). A placebo will be given at the same schedule and same volume as the active drug for 
participants to receive the control (Treatment B). Participants, investigators, and Corvus will 
not be aware of the treatment the participants receive. All participants will receive supportive 
care according to the SOC of the trial hospital. If a hospital has a written policy or guideline, 
participants will receive treatment (including remdesivir or any other approved treatment) per 
those guidelines at the discretion of the investigator. Chloroquine/hydroxychloroquine are 
not allowed as SOC. Participation in any other investigational treatment during the first 28 
days after randomization will not be allowed unless the investigator in consult with the 
Corvus medical monitor feels medical necessity and that such participation would not affect 
the integrity of this trial.  
After the participant’s initial eligibility is established and informed consent has been 
obtained, the study site must enroll the participant into the study by logging in to an 
interactive response technology (IRT) system to obtain the participant number. Every 
participant that signs the informed consent form (ICF) must be assigned with a participant 
number in IRT. Specific instructions for using IRT will be provided to the investigational site 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 15 of 85 
Version 001 
in the IRT Manual. The investigator or designee will register the participant for enrollment 
by following the enrollment procedures established by Corvus. 
All participants will undergo a series of efficacy, safety, and laboratory assessments. 
Participants will be assessed daily during their hospitalization. Participants’ clinical status 
based on the 8-point ordinal scale, the National Early Warning Score 2 (NEWS2), Covid-19 
related signs/symptoms, and safety laboratory tests will be recorded every day while 
hospitalized including day of discharge from the hospital. Discharged participants will be 
asked to attend post- hospitalization study assessments at Days 14, 21, and 28, if discharged 
before any of these assessments were completed. Severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) PCR test will be obtained on Days 1, 7, 14, 21, and 28 while 
hospitalized; and on day of discharge (if discharged prior to Day 28) and will be tested 
locally. Samples will be collected for viral load that will be assessed at a central lab. Anti-
SARS-CoV-2 antibody samples will be collected to assessed at a central lab on Day 1 before 
dosing, and on Days 7, 14, 21, and 28 if patient remains hospitalized as well as the day of 
hospital discharge. For participants who are discharged before Day 14, 21 and 28, a sample 
will be collected on day of discharge as well as the posthospitalization sample collection on 
Days 14, 21, and 28 that are not collected during the hospital stay. Participants who consent 
separately to the optional assessments for anti-SARS-CoV-2 serum antibody tests will be 
evaluated on Days 56, 84, and 168. 
An iDMC will be formed to monitor safety and efficacy of the study treatment at pre-
specified timepoints including futility and interim analysis timepoints. The iDMC will review 
the unblinded safety data from the first 50 participants after completion of the Day 28 
assessments. Subsequent iDMC reviews will occur after every 150 participants have 
completed the Day 28 assessments. In addition, the iDMC is available for ad hoc reviews for 
safety concerns. The study will not stop enrollment awaiting these iDMC reviews, although 
the iDMC may recommend temporary or permanent cessation of enrollment based on their 
safety and/or efficacy reviews. The protocol team will review blinded pools of AE/SAE data 
every 2 weeks. If there are a significant number of unexpected AEs, the iDMC will be asked 
to review unblinded safety and efficacy data in an ad hoc meeting.  
Eligibility: Hospitalized mild to moderately symptomatic Covid-19 patients. Participants 
may have preexisting conditions such as cancer and diabetes. Participants will receive 
standard care for Covid-19. 
Test Product, Dose and Administration: CPI-006 single dose at 2 mg/kg given by IV 
infusion over 10-15 minutes. 
Rationale:  
CPI-006 is a humanized immunoglobulin G (IgG) fragment crystallizable (Fc) receptor 
binding deficient monoclonal antibody that activates B cells leading to the production of 
immunoglobulin M (IgM) and IgG antibodies (Luke et al, 2019b). In vivo administration to 
cancer patients has shown rapid and temporary redistribution in circulating B cells with 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 16 of 85 
Version 001 
return of memory B cell phenotype. Immune markers demonstrate activation of B cells, 
expression of CD69 and increases in human leukocyte antigen – DR isotype (HLA-DR) 
expression. Molecular studies of the B cell receptor (BCR) in treated patients has 
demonstrated that CPI-006 stimulates the generation of B cell clones with new BCRs. These 
findings indicate that CPI-006 is activating B cells, causing their trafficking to lymphoid 
tissues and potentially their further differentiation into antibody producing cells. Further 
studies in cancer patients have demonstrated production of anti-tumor antibodies in some 
patients. The high anti-SARS-CoV-2 titer seen in a patient with Covid-19 following 
treatment with CPI-006 for lung cancer are supportive of the hypothesis that CPI-006 may 
enhance anti-viral antibody response. CPI-006 is therefore under development for Covid-19 
since neutralizing antibodies and the generation of immune memory are critical for 
eliminating infections with severe acute respiratory syndrome (SARS) and Middle East 
respiratory syndrome (MERS) coronaviruses. In the ongoing Phase 1 CPI-006-002 study, 20 
participants with mild to moderate Covid-19 have received a single dose of CPI-006 at doses 
ranging from 0.3mg/kg to 5 mg/kg. CPI-006 was well tolerated with no treatment related 
AEs or dose-limiting toxicities (DLTs) reported. IgG and IgM antibody titers measured 
against the SARS-CoV-2 spike protein and/or receptor binding domain (RBD) increased in 
all evaluable patients within 7 days of a single infusion of low doses of CPI-006. Similar 
results were observed in anti-SARS-Cov-2 immunoglobulin A (IgA) titers. This increase in 
antibody titers provides the rationale to develop CPI-006 for treatment of Covid-19. This 
study evaluates clinical benefit, safety, and the anti-SARS-CoV-2 antibody production in 
patients who are hospitalized with mild to moderately symptomatic Covid-19 treated with 
CPI-006. Treatment with CPI-006 may also result in prolonged immunity to SARS-CoV-2 
and related viruses (Willingham et al., 2020).  
Overall Design: 
This is a randomized, placebo controlled, double-blind, multicenter, stratified study of 
CPI-006 plus SOC versus placebo plus SOC in mild to moderately symptomatic hospitalized 
Covid-19 patients. An iDMC will monitor safety, efficacy, and conduct of the study. All 
participants will be followed for 28 days for production of anti-SARS-CoV-2 antibodies 
followed by an optional period of 5 months. While in the hospital, participants will receive 
standard of care monitoring including vital signs every 4-6 hours, or per institutional 
guidelines and safety assessments. Safety and other disease assessments will be conducted at 
Days 3, 7, 14, 21, and 28. Discharged participants will be asked to attend post- 
hospitalization study assessments at Days 14, 21, and 28, if discharged before any of these 
assessments were completed. 
Treatment Groups and Duration: 
Participants meeting study entry criteria will be randomized in a 1:1 ratio to receive either 
Treatment A (CPI-006 plus SOC) or Treatment B (placebo plus SOC). Participants 
randomized to Treatment A will receive a single dose of CPI-006 at 2 mg/kg given by IV 
infusion plus SOC. A placebo will be given at the same schedule and same volume as the 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 17 of 85 
Version 001 
active drug for participants randomized to Treatment B. All participants will be managed per 
physician using best SOC for Covid-19 patients. No dose modifications will be allowed. 
Statistical Methods:  
Hypothesis 
The primary hypothesis is that treatment with CPI-006 plus SOC (Treatment A) will shorten 
the time to recovery during the 28 days after dosing based on the 8-point ordinal scale in 
comparison to placebo plus SOC (Treatment B) in mild to moderately symptomatic Covid-19 
hospitalized participants. 
The first secondary hypothesis is that treatment A will shorten the time to clinical 
improvement by at least 2 points during the 28 days after dosing on the 8-point ordinal scale 
in comparison to treatment B. 
The second secondary hypothesis is that Treatment A will increase the level of IgG targeting 
the RBD of SARS-CoV-2 over Days 7, 14, 21, and 28 more than Treatment B, as measured 
by the area under the IgG level curve above the baseline, calculated over Days 1 (the 
baseline), 7, 14, 21, 28, and Day of Discharge. 
The third secondary hypothesis is that Treatment A will shorten the time to resolution of 
≥ 50% of the Covid-19-attributable symptoms: fever, cough, sore throat, headache, muscle 
pain, and/or shortness of breath, reported at baseline. Explicitly, the resolution of ≥ 50% of 
symptoms means the resolution of 1 of 1 symptom, 1 of 2 symptoms, 2 of 3 symptoms, 2 of 4 
symptoms, 3 of 5 symptoms, or 3 of 6 symptoms that are reported at baseline.  
Sample Size 
Approximately 620 hospitalized participants with mild to moderately symptomatic Covid-19 
will be enrolled. The participants will be randomized in a 1:1 ratio between Treatment A and 
Treatment B within each of the strata defined by: 
• Region of the world (North America vs. Latin America vs. Europe). 
• Age (< 65 vs. ≥ 65) 
• Comorbidities (0 vs. at least 1) based on the following list: 
o Chronic lung disease (e.g., emphysema and chronic bronchitis, idiopathic 
pulmonary fibrosis, COPD, or cystic fibrosis) or moderate to severe asthma 
o Significant cardiac disease (e.g., heart failure, coronary artery disease, 
congenital heart disease, cardiomyopathies, and pulmonary hypertension) 
o Obesity (body mass index ≥ 30 kg/m2) 
o Diabetes (Type 1, Type 2, or gestational) 
o Liver disease 
o CKD 
o SCD 
o Organ transplantation 
o Cancer 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 18 of 85 
Version 001 
With 520 observed recoveries in the 2 treatment groups, there would be an approximately 
83% power to show a statistically significant superiority of Treatment A over Treatment B in 
recovery rate at an overall 1-sided α level of 0.025 when the true recovery rate ratio of 
Treatment A to Treatment B is 1.296, assuming an exponential distribution for time to 
recovery for each treatment.  
With a total of approximately 620 participants, it is estimated that 520 recoveries will be 
observed after 5.5 months assuming that the median time to recovery is 5.4 days and 7 days 
of Treatments A and B, respectively. The all-cause death rate is assumed to be 6% over the 
28-day period. 
 
Populations for Analyses 
For purposes of analyses, the following populations are defined in Table 1. 
Table 1 
Population Definitions 
Population 
Description 
Intent-to-treat (ITT) 
All participants who are randomized into the study. 
Efficacy 
All participants who take at least 1 dose of study treatment (CPI-
006 or placebo) and have at least 1 post-baseline assessment based 
on the 8-point ordinal scale.  
Safety 
All participants who take at least 1 dose of study treatment 
(CPI-006, placebo, or SOC). 
Pharmacokinetic 
All participants who receive CPI-006 and had at least 1 post-
treatment blood sample collected  
Statistical Methods 
The primary objective of the study is to determine the difference between the 2 treatments in 
time to recovery during the 28 days after dosing.  
Day of recovery is defined as the first day on which the participant satisfies 1 of the 
following 3 categories from the 8-point ordinal scale (See Appendix 6):  1) Not hospitalized, 
no limitations on activities.; 2) Not hospitalized, limitation on activities and/or requiring 
home oxygen; 3) Hospitalized, not requiring supplemental oxygen - no longer requires 
ongoing medical care. 
Statistical Design 
Two formal interim analyses are planned for this study. The first interim analysis is a 
non-binding futility analysis when approximately 150 participants have been enrolled into 
the study with 28 days of follow up time. Safety and efficacy will be the focus of the 
evaluation. Unblinded safety and efficacy data will be reviewed by the iDMC. 
The second interim analysis will be performed when approximately 310 (60% of the 520) 
recovery events have been observed in the 2 treatment arms based on the Efficacy 
Population. Comparison between Treatment A and Treatment B with respect to the time to 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 19 of 85 
Version 001 
recovery will be made using a modified version of stratified log-rank test correcting for 
competing risk of all-cause death. Should the comparison demonstrate a statistically 
significant superiority of Treatment A over Treatment B, Corvus may file the results to 
regulatory authorities for drug approval. The study will continue its course beyond the 
interim analysis and collect all the planned safety efficacy, pharmacokinetic (PK), and 
pharmacodynamic (PD) data.  
As part of the second interim analysis, Corvus may request the iDMC to assess the recovery 
rates and the conditional power of the study based on the interim data. The total sample size 
of the study may be increased with the recommendation by iDMC. The sample size 
adaptation plan and increase rule will be detailed in the statistical analysis plan and provided 
to the regulatory authority before the second interim analysis. 
The primary analysis of the study is the final analysis in the time to recovery during the 28 
days after dosing and will be performed when approximately 520 recovery events have been 
observed in the 2 treatment arms based on the ITT Population. Comparison between 
Treatment A and Treatment B with respect to the time to recovery will be made using a 
modified version of stratified log-rank test correcting for competing risk of all-cause death. 
The efficacy stopping boundaries at the second interim and final analyses will be derived 
based on the time and number of recovery events using the Lan-Demets O’Brien and 
Fleming-like α spending function. 
All the enrolled participants will be follow-up to Day 28 and further to the optional visits. 
Corvus may perform the primary analysis when all the enrolled participants have completed 
Day 28 visit and include all participants’ data for the primary analysis, if the iDMC 
recommends doing so at the second interim analysis. In this case, the analysis when 520 
recovery events are observed will not be performed. 
The following are the three key secondary endpoints with their hierarchical priority as 
ordered for statistical testing: 
• Time to improvement by at least two points on the 8-point ordinal scale during the 28 
days after dosing; 
• The change in the level of IgG targeting RBD of SARS-CoV-2 over Days 7, 14, 21, 
and 28 from baseline measured by the area under the IgG level curve above the 
baseline over Days 1, 7, 14, 21, 28 and Day of Discharge; 
• The time to resolution of ≥ 50% of the Covid-19-attributable symptoms including 
fever, cough, sore throat, headache, muscle pain, and/or short of breath reported at 
baseline. 
In the case that a statistical significance is achieved in the time to recovery in comparison of 
Treatments A and B, the three secondary endpoints will be tested according to their 
hierarchical priority. This hierarchical procedure will be applied to the second interim 
analysis and to the final analysis. The α level for the comparison in the secondary endpoints 
will be the same α level as for the comparison in the time to recovery.  

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 20 of 85 
Version 001 
TTD is also a secondary endpoint of the study. TTD will be described at the final analysis 
which will be performed up to 6 months after the primary analysis and will be based on the 
ITT Population. The purpose of the analysis is to show a favorable trend of TTD with 
Treatment A over Treatment B. The Kaplan-Meier product limit curves of TTD and the 2-
sided 95% confidence interval (CI) for the median TTD will be computed for each arm. A 
hazard ratio and a 2-sided 95% CI of the ratio will be estimated using a Cox proportional 
hazards model, with treatment arm as a single covariate, stratified by the stratification 
factors. 
1.2. 
SCHEMA 
Figure 1 
Study Schematic 
 
 
 
 
 
 
 
 
 
 
R = randomization 
 
1.3. 
SCHEDULE OF ACTIVITIES (SOA) 
For the schedule of activities, please see Appendix 1, Table 6. 
2. 
INTRODUCTION 
2.1. 
STUDY RATIONALE 
CPI-006 is a humanized immunoglobulin G (IgG) fragment crystallizable (Fc) receptor 
binding deficient monoclonal antibody that activates B cells leading to the production of 
immunoglobulin M (IgM) and IgG antibodies (Luke et al, 2019b). In vivo administration to 
cancer patients has shown rapid and temporary redistribution in circulating B cells with 
return of memory B cell phenotype. Immune markers demonstrate activation of B cells, 
expression of CD69 and increases in human leukocyte antigen – DR isotype (HLA-DR) 
expression. Molecular studies of the B cell receptor (BCR) in treated patients has 
demonstrated that CPI-006 stimulates the generation of B cell clones with new BCRs. These 
findings indicate that CPI-006 is activating B cells, causing their trafficking to lymphoid 
tissues and potentially their further differentiation into antibody producing cells. Further 
studies in cancer patients have demonstrated production of anti-tumor antibodies in some 
patients. The high anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) titer 
seen in a patient with Covid-19 following treatment with CPI-006 for lung cancer are 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 21 of 85 
Version 001 
supportive of the hypothesis that CPI-006 may enhance anti-viral antibody response. CPI-006 
is therefore under development for Covid-19 since neutralizing antibodies and the generation 
of immune memory are critical for eliminating infections with severe acute respiratory 
syndrome (SARS) and Middle East respiratory syndrome (MERS) coronaviruses. In the 
ongoing Phase 1 CPI-006-002 study, 20 participants with mild to moderate Covid-19 have 
received a single dose of CPI-006 at doses ranging from 0.3mg/kg to 5 mg/kg. CPI-006 was 
well tolerated with no treatment related AEs or dose-limiting toxicities (DLTs) reported. IgG 
and IgM antibody titers measured against the SARS-CoV-2 spike protein and/or receptor 
binding domain (RBD) increased in all evaluable patients within 7 days of a single infusion 
of low doses of CPI-006. Similar results were observed in anti-SARS-Cov-2 
immunoglobulin A (IgA) titers. This increase in antibody titers provides the rationale to 
develop CPI-006 for treatment of Covid-19. This study evaluates clinical benefit, safety, and 
the anti-SARS-CoV-2 antibody production in patients who are hospitalized with mild to 
moderately symptomatic Covid-19 treated with CPI-006. Treatment with CPI-006 may also 
result in prolonged immunity to SARS-CoV-2 and related viruses (Willingham et al., 2020). 
The Covid-19 pandemic is not yet under control and there is fear that infections could spread 
and/or recur in a seasonal manner, even if controlled now. There is also the possibility of 
viral mutation or emergence of other virulent coronaviruses. Vaccines are in development but 
it is not yet clear if such an approach will be effective in controlling Covid-19. Based on 
encouraging preliminary data, CPI-006 may improve the magnitude, duration, and diversity 
of antibody responses to SARS-CoV-2 and improve clinical outcome. It also may result in 
prolonged immunity to SARS-CoV-2, its variants and related coronaviruses. It is also 
possible that experience gained with treating Covid-19 with CPI-006 could be applied to 
treatment of other infectious diseases including future viral pandemics, and potential use in 
conjunction with vaccination of healthy participants. 
2.2. 
BACKGROUND 
Since its emergence in Hubei province, China in December of 2019, the novel coronavirus 
(2019-nCoV, Covid-19) has become a global health crisis (Wu et al, 2020; Chan et al, 2020). 
There is an urgent need for therapies that can improve survival, clinical outcomes, and reduce 
the requirements for intensive supportive care and prolonged hospitalization (Huang et al, 
2020). There are efforts underway to re-purpose direct acting antivirals targeting the 
ribonucleic acid (RNA)-dependent RNA polymerase including remdesivir and favipiravir 
both of which are being actively studied in multiple clinical trials. Similarly, inhibitors of the 
virally encoded proteases are being evaluated. To compliment therapeutic approaches there is 
an intense effort underway to develop vaccines. A number of approaches to vaccine 
development have begun clinical trials or are planned. To support vaccine strategies, there is 
a growing understanding of the key viral/host interaction required for viral entry and 
replication (Du et al, 2009). Indeed, it is increasingly clear that the virally encoded spike 
protein binds to angiotensin converting enzyme 2 (ACE2) on target cells to facilitate entry 
and replication. The spike protein is a multidomain viral envelop glycoprotein which 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 22 of 85 
Version 001 
contains a receptor binding domain (RBD) in subunit 1 of the spike protein (Wrapp et al, 
2020). This RBD directly interacts with N-terminal domain of ACE2. This interaction is 
absolutely required and initiates a sequence of steps leading to efficient viral infection. Thus, 
antibodies that disrupt this key interaction may be effective in viral neutralization and 
clearance. A recent publication from Zhang and colleagues have identified neutralizing 
antibodies from 8 Covid-19 infected patients that bind to the RBD of the spike protein and 
are neutralizing (Yuan et al, 2020). This provides evidence that neutralizing antibody 
responses to SARS-CoV-2 are possible and may provide clinical benefit in patients with 
Covid-19 and protection from disease in healthy subjects. Indeed, the U.S. Food and Drug 
Administration (FDA) has given emergency use authorization for the use of Covid-19 
Convalescent Plasma (CCP) for the treatment of Covid-19. Clinical studies with CCP suggest 
that higher titers of neutralizing antibody provide superior clinical benefit to recipients 
(Joyner et al, 2020; Rasheed et al 2020) These findings support the value of anti-viral 
antibodies in eradicating viral infection in patients, lessening disease severity, improving 
clinical course and potentially reducing transmission.  
CD73 is an adhesion molecule that was initially found to be important for lymphocyte 
trafficking and T cell activation (Resta & Thompson, 1997). It also functions as an 
ectoenzyme that converts adenosine monophosphate (AMP) to immunosuppressive 
adenosine. Several companies are developing anti-CD73 antibodies to inhibit production of 
adenosine and thereby augment immune response in patients with cancer. These antibodies 
have been designed primarily to block enzymatic activity. Corvus has designed a novel anti 
CD73 antibody with agonistic, immunomodulatory properties that binds CD73 resulting in 
activation of immune cells such as B cells, and results in antibody production in vitro (Luke 
et al, 2019a). This antibody, CPI-006, is under investigation in a Phase 1b trial 
(NCT03454451) in advanced cancer as monotherapy and in combination with other 
immunotherapies such as anti- programmed cell death 1 receptor (PD1). Over 90 patients 
have received doses of this antibody ranging from 1mg/kg to 24 mg/kg given IV every 21 
days. Treatment has been safe and tolerable, with chills and rigor seen during antibody 
infusion, that are managed by premedication with acetaminophen and diphenhydramine. 
CPI-006 is a humanized FcγR binding-deficient monoclonal antibody. In vitro studies have 
revealed binding to CD73 and direct effects on B cells, morphologic transformation to 
plasmablasts and induction of IgM and IgG secretion (Luke et al, 2019b). In vivo 
administration to cancer patients has shown rapid and temporary drop in circulating B cells 
with return of memory B cell phenotype. Immune markers demonstrate activation of B cells, 
expression of CD69 and increases in HLA-DR expression. Molecular studies of the BCR in 
treated patients has demonstrated that CPI-006 stimulates the generation of B cell clones with 
new BCRs. These findings indicate that CPI-006 is activating B cells, causing their 
trafficking to lymphoid tissues and potentially their further differentiation into antibody 
producing cells. Further studies in cancer patients have demonstrated production of anti-
tumor antibodies in some patients.  

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 23 of 85 
Version 001 
CPI-006 is under investigation in a Phase1 trial (NCT04464395) in mild to moderately 
symptomatic hospitalized Covid-19 patients. The results from the study (CPI-006-002) 
shows IgG and IgM antibody titers measured against the SARS-CoV-2 spike protein and/or 
receptor binding domain (RBD) increased in all evaluable patients within 7 days of a single 
infusion of low doses of CPI-006. Similar results were observed in anti-SARS-Cov-2 IgA 
titers. In patients receiving 0.3 mg/kg CPI-006, all four evaluable patients achieved high IgG 
titers to spike protein that were sustained for at least 84 days after onset of symptoms. In 
these patients, IgM titers peaked at 14 days and remained elevated at the last measured 
timepoint of 84 days. Similar kinetics were seen in antibody responses to RBD. At doses 
above 0.3 mg/kg, durable high titers of IgG and IgM to spike protein and RBD were achieved 
out to -84 days, 56 days, and 14 days for the 1.0 mg/kg, 3.0 mg/kg and 5.0 mg/kg cohorts, 
respectively in the ongoing study. Peak titers increased from 0.3 mg/kg to 1.0 mg/kg CPI-006 
but did not appear to increase from 1.0 mg/kg to 3.0 mg/kg or from 3.0 mg/kg to 5.0 mg/kg 
at the evaluable time points. Immunophenotying of peripheral blood mononuclear cells 
(PBMCs) at baseline and at 14 -or 18-days after treatment provided preliminary evidence that 
CPI-006 increased the frequency of memory B cells in 2 evaluated patients. An increased 
frequency of memory/effector CD4POS and CD8POS T cells was also observed in 3 evaluable 
patients. CPI-006 has been well tolerated in Covid-19 patients in this study. No DLTs or 
treatment related AEs have been reported in the study. The AEs reported in the study were 
due to the underlying Covid-19 or comorbidities. 
In this Phase 3, randomized, placebo controlled, double-blind, multicenter, stratified study of 
CPI-006 plus standard of care (SOC) versus placebo plus SOC in mild to moderately 
symptomatic hospitalized Covid-19 patients, Corvus will assess if administering CPI-006 to 
Covid-19 patients along with standard of care can lead to clinical benefit and enhance 
humoral immune response to the SARS-CoV-2. The production of neutralizing antibodies 
would be expected to shorten disease interval and improve clinical outcome, and treatment is 
expected to be safe. Therefore, CPI-006 treatment is expected to have a positive benefit/risk 
profile.  
2.3. 
CPI-006 NONCLINICAL EVALUATION 
CPI-006 recognizes and binds human CD73 with high affinity (KD values of 0.64–7.1 nM), 
inhibits CD73 catalytic activity (mean concentration required for 50% inhibition [IC50] 
values of 2.1 nM and 4.0 nM for human and cynomolgus monkey CD73), and has 
downstream biological effects on T cells as evidenced by restoration of CD3+ T cell 
proliferation in the presence of AMP. CPI-006 also binds to and inhibits cynomolgus monkey 
CD73, but not mouse or rat CD73, supporting the use of cynomolgus monkeys for studies of 
the pharmacokinetics (PK) and toxicology of CPI-006. 
Complete CD73 occupancy on CD8+ T cells in peripheral blood samples from cynomolgus 
monkeys by CPI-006 was observed at all doses of CPI-006. Complete CD73 occupancy was 
also observed in the axillary lymph nodes, indicating successful solid tissue penetration by 
CPI-006 with full coverage at least 24 hours after the final dose. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 24 of 85 
Version 001 
An in vitro cytokine release assay was conducted with CPI-006 to evaluate the potential for 
CPI-006 to induce an immune response resulting in production of multiple cytokines 
(cytokine storm). The results demonstrated that CPI-006 did not directly induce cytokine 
(interferon gamma [IFN-γ], interleukin 2 [IL-2], interleukin 6 [IL-6], interleukin 10 [IL-10], 
and tumor necrosis factor alpha [TNF-α]) release from fresh human PBMCs at 0.1-10 µg/mL 
of CPI-006. 
Safety of CPI-006 was evaluated in male and female cynomolgus monkeys in two toxicity 
studies. In the first, a dose range finding study, CPI-006 was administered over 15-minutes 
by IV infusion at doses up to 120 mg/kg CPI-006, weekly (5 doses) for 31 days. The second, 
was a Good Laboratory Practice (GLP)-compliant toxicity study in which doses up to 100 
mg/kg CPI-006 were administered by IV infusion over 60 minutes, weekly (5 doses) for 28 
days. Toxicokinetics, safety pharmacology, and local tolerance assessments were built into 
the GLP compliant toxicity study. CPI-006 administered by IV infusion was well tolerated in 
both studies up to, and including, the highest doses administered. No definitive CPI-006-
related changes were observed in the animals. No-observed adverse effect levels (NOAEL) 
were the highest doses administered, 120 mg/kg and 100 mg/kg CPI-006. Additional 
nonclinical information is provided in the Investigator Brochure for CPI-006. 
2.4. 
SUMMARY OF CLINICAL EXPERIENCE WITH CPI-006 
In CPI-006-001 oncology study, CPI-006 has been administered as a single agent and in 
combination with ciforadenant (an A2a receptor antagonist), and /or pembrolizumab (a 
blocking anti-PD-1 antibody). CPI-006 has been well tolerated when administered every 3 
weeks as monotherapy and in combination with ciforadenant and/or pembrolizumab.  
As of 20 Oct 2020, 35 patients have been treated with CPI-006 (every 3 weeks) monotherapy 
at doses up to 24mg/kg, and no maximum tolerated dose was established. The most common 
adverse reactions were infusion related reactions (IRRs); primarily chills and rigors. These 
IRRs were non-serious, mild to moderate in severity (Grade 1-2), transient and did not lead 
to discontinuation. The IRRs have been observed during (or immediately after) Cycle 1, Day 
1 and are uncommon at subsequent infusions of CPI-006. To mitigate the risk of IRRs, 
premedication with diphenhydramine (50 mg orally [PO]) and acetaminophen 500–1000 mg 
PO (or equivalent) was required prior to infusion of CPI-006 at Cycle 1, Day 1 and has 
shown a decreased rate and intensity of IRRs.  
As of 20 Oct 2020, in the ongoing Phase 1 CPI-006-002 study, 20 hospitalized patients with 
mild to moderate Covid-19 have received a single dose of CPI-006 at doses ranging from 
0.3mg/kg to 5 mg/kg with follow up data. CPI-006 was well tolerated. IRRs have not been 
observed with CPI-006 infusion. No DLTs or treatment related AEs have been reported. The 
safety data in this study is reviewed on an ongoing basis by an Independent Data Monitoring 
Committee (iDMC).  

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 25 of 85 
Version 001 
2.4.1. 
Benefit/Risk Assessment 
This study proposes to administer single doses of CPI-006 to hospitalized mild or moderately 
symptomatic patients with Covid-19.  
Study treatment will be administered in the hospital and participants will be monitored 
closely. CD73 is expressed on endothelial cells and it is possible that negative effects or 
exacerbation of disease could be seen in Covid-19 patients. However, data from the GLP 
general toxicity study did not show any CPI-006 related changes in coagulation parameters 
(Section 4.3). Data from 20 Covid-19 participants in the CPI-006-002 study did not indicate 
any effect of CPI-006 on systemic inflammatory response or coagulopathy. In addition, data 
from over 90 participants in study CPI-006-001 in cancer patients did not show any CPI-006 
related systemic inflammatory response or coagulopathy. The participant follow-up and 
monitoring involve routine procedures not associated with significant health risk. The benefit 
of therapy to participants who receive Treatment A is the development of neutralizing 
antibodies which could lead to more rapid clinical improvement, avoidance of complications 
of Covid-19 disease, and the potential for longer lasting immunity.  
Participants enrolled in Treatment B will receive standard of care (SOC) per institutional 
guidelines. The participant follow-up and monitoring involve routine procedures not 
associated with significant health risk. Overall data will be used to assess any difference 
between the participants who receive Treatment A and Treatment B in terms of clinical 
outcome and anti-SARS-CoV-2 levels. 
3. 
OBJECTIVES AND ENDPOINTS 
Objectives 
Endpoints 
Primary 
 
• 
To compare the time to recovery of CPI-006 plus 
SOC versus placebo plus SOC in hospitalized 
participants with mild to moderately symptomatic 
Covid-19 infection 
• 
Time to recovery during the 28 days after dosing. 
Day of recovery is defined as the first day on 
which the participant satisfies 1 of the following 3 
categories from the 8-point ordinal scale 
(Appendix 6):  1) Not hospitalized, no limitations 
on activities.; 2) Not hospitalized, limitation on 
activities and/or requiring home oxygen; 3) 
Hospitalized, not requiring supplemental oxygen - 
no longer requires ongoing medical care. 
Key Secondary 
 
• 
To compare the time to clinical improvement of 
CPI-006 plus SOC versus placebo plus SOC in 
hospitalized participants with mild to moderately 
symptomatic Covid-19 infection 
• 
Time to clinical improvement (≥ 2 points 
improvement in the 8-point ordinal scale) 
• 
To compare the change from baseline in the level 
of antibodies targeting the RBD of SARS-CoV-2  
• 
Change from baseline level of IgG targeting the 
RBD at Days 7, 14, 21, and 28 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 26 of 85 
Version 001 
• 
To compare the time to improvement of Covid-
19-attributable symptoms including fever, cough, 
sore throat, headache, muscle pain, and shortness 
of breath 
• 
Time to resolution of ≥ 50% of the 
Covid-19 -attributable symptoms (see 
Appendix 8) including fever, cough, sore throat, 
headache, muscle pain, and/or shortness of breath 
reported at baseline 
Additional Secondary  
 
• 
To compare the clinical status of CPI-006 plus 
SOC versus placebo plus SOC in hospitalized 
participants with mild to moderately symptomatic 
Covid-19 infection 
• 
Change in clinical status, defined by the change in 
the 8-point ordinal scale from baseline at Days 3, 
7, Day of Discharge, Days 14, 21, and 28 
• 
To compare the percentage of participants with 
clinical improvement with CPI-006 plus SOC 
versus placebo plus SOC in hospitalized 
participants with mild to moderately symptomatic 
Covid-19 infection 
• 
Percentage of participants with clinical 
improvement (≥ 2 points improvement in the 8-
point ordinal scale) at Days 3, 7, 14, 21, and 28  
• 
To compare the change from baseline in the level 
of antibodies targeting the RBD of SARS-CoV-2 
• 
Change from baseline level of IgM targeting the 
RBD at Days 7, 14, 21 and 28 
• 
To compare the change from baseline in the 
SARS-CoV-2 viral load 
• 
Change from baseline in the SARS-CoV-2 viral 
load at Days 3, 7, 14, 21, and 28 
• 
To compare time to PCR negativity, and 
percentage of participants with PCR negative of 
CPI-006 plus SOC versus placebo plus SOC in 
hospitalized participants with mild to moderately 
symptomatic Covid-19 infection 
• 
Time to PCR negativity 
• 
Percentage of participants with PCR negative at 
Days 7, 14, 21, and 28 
• 
To compare the change from Baseline in NEWS2 
of CPI-006 plus SOC versus placebo plus SOC in 
hospitalized participants with mild to moderately 
symptomatic Covid-19 infection 
• 
Change from Baseline in NEWS2 at Days 3 and 
7, Day of Discharge, and Day 28.                             
NEWS2 consists of: Physiological Parameters: 
respiration rate (per minute), SpO2 Scale 1 (%), 
SpO2 Scale 2 (%), use of air or oxygen, systolic 
blood pressure (mmHg), pulse (per minute), 
consciousness, and temperature (°C) 
• 
To compare the medical interventions/procedures 
including intubation, mechanical ventilation, and 
supplemental O2 use, rehospitalization of CPI-006 
plus SOC versus placebo plus SOC in hospitalized 
participants with mild to moderately symptomatic 
Covid-19 infection 
• 
Rate of procedures including intubation 
• 
Rate and duration of mechanical ventilation 
• 
Rate and duration of supplemental oxygen, non-
invasive ventilation, or high flow oxygen devices 
during the trial 
• 
Oxygenation free days in the first 28 days 
• 
Rehospitalization 
• 
To compare the safety of CPI-006 plus SOC 
versus placebo plus SOC in hospitalized 
participants with mild to moderately symptomatic 
Covid-19 infection 
• 
Incidence, type, and severity of 
treatment -emergent adverse events of CPI-006 
plus SOC compared to placebo plus SOC assessed 
by NCI CTCAE v 5.0 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 27 of 85 
Version 001 
• 
To compare TTD of CPI-006 plus SOC versus 
placebo plus SOC in hospitalized participants 
with mild to moderately symptomatic Covid-19 
infection 
• 
Time to death during the first 28 days 
Exploratory  
 
• 
To compare changes from baseline in Covid-19-
related lab assessments of CPI-006 plus SOC 
versus placebo plus SOC in hospitalized 
participants with mild to moderately symptomatic 
Covid-19 infection 
  
• 
Hematology, chemistry, CRP, and ferritin 
assessments on Days 1, 3, 5, 7, 14, 21, 28 (while 
hospitalized); Day of Discharge; and Day 28 
(return to clinic if discharged) 
• 
PT, INR, aPTT, fibrinogen, and D-dimer on Days 
1, 3, 5, 7, 14, 21, 28 (while hospitalized), and Day 
of Discharge 
• 
Change from baseline level of IgA targeting the 
RBD at Days 7, 14, 21, and 28 
• 
Changes in IgG, IgM, or IgA antibodies targeting 
other SARS-CoV-2 antigens including (but not 
limited to) spike, nucleocapsid, and membrane 
proteins 
• 
Change from baseline in the frequency and 
function of memory B cells in the peripheral 
blood at Days 14 and 28 
• 
Changes from baseline in the frequency or 
function of memory/effector T cells in the 
peripheral blood at Days 14 and 28 
• 
B cell receptor repertoire analysis at baseline, Day 
14, and Day 28 
• 
Systemic cytokine and chemokine levels at 
baseline and Days 7 (while hospitalized), Day of 
Discharge, and Day 28 
• 
Neutralizing antibody levels on Days 1 and 28 
using a biochemical ELISA, a pseudovirus 
neutralization assay, and a PRNT50 live virus 
assay 
• 
Change from baseline level of IgG and IgM 
targeting the RBD at Days 56, 84, and 168 
• 
Characterize the pharmacokinetics of CPI-006 in 
hospitalized participants with Covid-19 infection  
• 
PK characteristics including covariate analysis to 
determine which variables, if any, influence 
exposure of CPI-006 
Abbreviations:  aPTT = activated partial thromboplastin time; CRP = C-reactive protein; ELISA = enzyme-
linked immunosorbent assay; IgA = immunoglobulin A; IgG = immunoglobulin G; IgM = immunoglobulin M; 
INR = international normalized ratio; NCI CTCAE = National Cancer Institute Common Terminology Criteria 
for Adverse Events; NEWS2 = National Early Warning Score 2; O2 = oxygen; PCR = polymerase chain 
reaction; PK = pharmacokinetic; RBD =  receptor binding domain; PT = prothrombin time; SARS-CoV-2 = 
severe acute respiratory syndrome coronavirus 2; SOC = Standard of Care; SpO2 = oxygen saturation; TTD = 
time to death 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 28 of 85 
Version 001 
4. 
STUDY DESIGN 
4.1. 
OVERALL DESIGN 
This is a Phase 3, randomized, placebo controlled, double-blind, multicenter, stratified study 
of CPI-006 plus SOC versus placebo plus SOC in mild to moderately symptomatic 
hospitalized adult (≥ 18 years) Covid-19 patients. Covid-19 disease will be confirmed by 
polymerase chain reaction (PCR) testing. 
Participants will be randomized at a 1:1 ratio to the 2 treatment arms and stratified by the 
following factors: 
• Region of the world (North America vs. Latin America vs. Europe).   
• Age (< 65 vs. ≥ 65) 
• Comorbidities (0 vs. at least 1) based on the following list: 
o Chronic lung disease (e.g., emphysema and chronic bronchitis, idiopathic 
pulmonary fibrosis, chronic obstructive pulmonary disease [COPD], or cystic 
fibrosis) or moderate to severe asthma 
o Significant cardiac disease (e.g., heart failure, coronary artery disease, 
congenital heart disease, cardiomyopathies, and pulmonary hypertension) 
o Obesity (body mass index ≥ 30 kg/m2) 
o Diabetes (Type 1, Type 2, or gestational) 
o Liver disease 
o Chronic kidney disease (CKD) 
o Sickle cell disease (SCD) 
o Organ transplantation 
o Cancer 
CPI-006 will be administered at a dose of 2 mg/kg up to a maximum dose of 200 mg 
intravenously (IV) on Day 1 in the participants randomized to receive treatment (Treatment 
A). A placebo will be given at the same schedule and same volume as the active drug for 
participants to receive the control (Treatment B). Participants, investigators, and Corvus will 
not be aware of the treatment the participants receive. All participants will receive supportive 
care according to the SOC of the trial hospital. If a hospital has a written policy or guideline, 
participants will receive treatment (including remdesivir or any other approved treatment) per 
those guidelines at the discretion of the investigator. Chloroquine/hydroxychloroquine are 
not allowed as SOC. Participation in any other investigational treatment during the first 28 
days after randomization will not be allowed unless the investigator in consult with the 
Corvus medical monitor feels medical necessity and that such participation would not affect 
the integrity of this trial.  
After the participant’s initial eligibility is established and informed consent has been 
obtained, the study site must enroll the participant into the study by logging in to an 
interactive response technology (IRT) system to obtain the participant number. Every 
participant that signs the informed consent form (ICF) must be assigned with a participant 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 29 of 85 
Version 001 
number in IRT. Specific instructions for using IRT will be provided to the investigational site 
in the IRT Manual. The investigator or designee will register the participant for enrollment 
by following the enrollment procedures established by Corvus. 
All participants will undergo a series of efficacy, safety, and laboratory assessments. 
Participants will be assessed daily during their hospitalization. Participants’ clinical status 
based on the 8-point ordinal scale, the NEWS2, Covid-19 related signs/symptoms, and safety 
laboratory tests will be recorded every day while hospitalized including day of discharge 
from the hospital. Discharged participants will be asked to attend post- hospitalization study 
assessments at Days 14, 21, and 28, if discharged before any of these assessments were 
completed. SARS-CoV-2 PCR test will be obtained on Days 1, 7, 14, 21, and 28 while 
hospitalized; and on day of discharge (if discharged prior to Day 28) and will be tested 
locally. Samples will be collected for viral load that will be assessed at a central lab. Anti-
SARS-CoV-2 antibody samples will be collected to assessed at a central lab on Day 1 before 
dosing, and on Days 7, 14, 21, and 28 if patient remains hospitalized as well as the day of 
hospital discharge. For participants who are discharged before Day 14, 21 and 28, a sample 
will be collected on day of discharge as well as the posthospitalization sample collection on 
Days 14, 21, and 28 that are not collected during the hospital stay. Participants who consent 
separately to the optional assessments for anti-SARS-CoV-2 serum antibody tests will be 
evaluated on Days 56, 84, and 168.  
An iDMC will be formed to monitor safety and efficacy of the study treatment at pre-
specified timepoints including futility and interim analysis timepoints. The iDMC will review 
the unblinded safety data from the first 50 participants after completion of the Day 28 
assessments. Subsequent iDMC reviews will occur after every 150 participants have 
completed the Day 28 assessments. In addition, the iDMC is available for ad hoc reviews for 
safety concerns. The study will not stop enrollment awaiting these iDMC reviews, although 
the iDMC may recommend temporary or permanent cessation of enrollment based on their 
safety and/or efficacy reviews. The protocol team will review blinded pools of AE/SAE data 
every 2 weeks. If there are a significant number of unexpected AEs, the iDMC will be asked 
to review unblinded safety and efficacy data in an ad hoc meeting. Further details on the 
iDMC are provided in Section 9.4.7. 
4.2. 
SCIENTIFIC RATIONALE FOR STUDY DESIGN 
CPI-006 activates B cells in vitro leading to B cell differentiation and secretion of 
immunoglobulins. Studies in cancer patients have demonstrated differentiation of B cells into 
plasmablasts, trafficking from blood and return of memory B cells to blood. The in vitro and 
in vivo effects indicate that CPI-006 stimulates B cell differentiation, antigen driven clonal 
selection and differentiation into antibody producing cells. Novel anti-tumor antibodies have 
been produced in some treated cancer patients. B cell receptor molecular studies have 
demonstrated the emergence of novel B cell clones in the blood of CPI-006 treated cancer 
patients. No changes in total serum immunoglobulins have been seen to date 
(Willingham et al., 2020). It is believed that the activation of B cells and enhancement of 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 30 of 85 
Version 001 
antibody production will lead to a more robust humoral immune response to SARS-CoV-2 
and provide clinical benefits such as shorter disease duration, less disease severity, fewer 
complications, and greater long-term immunity.  
In Study CPI-006-002 (in mild moderate hospitalized Covid-19 participants), IgG and IgM 
antibody titers measured against the SARS-CoV-2 spike protein and/or RBD increased in all 
evaluable patients within 7 days of a single infusion of low doses of CPI-006. Similar results 
were observed in anti-SARS-Cov-2 IgA titers. No correlation between duration of Covid-19 
symptoms and pre-treatment serum antibody levels has been observed in patients. Thirteen of 
17 evaluable patients had low pre-treatment antibody titers despite relatively long durations 
of symptoms in some patients. In patients receiving 0.3 mg/kg CPI-006, all four evaluable 
patients achieved high IgG titers to spike protein that were sustained for at least 84 days after 
onset of symptoms. In these patients, IgM titers peaked at 14 days and remained elevated at 
the last measured timepoint of 84 days. Similar kinetics were seen in antibody responses to 
RBD. At doses above 0.3 mg/kg, durable high titers of IgG and IgM to spike protein and 
RBD were achieved out to 84 days, 56 days and 14 days for the 1.0 mg/kg, 3.0 mg/kg and 5.0 
mg/kg cohorts, respectively in the ongoing study. Peak titers increased from 0.3 mg/kg to 1.0 
mg/kg CPI-006 but did not appear to increase from 1.0 mg/kg to 3.0 mg/kg or from 3.0 
mg/kg to 5.0 mg/kg at the evaluable time points. High and durable neutralization titers were 
observed in subjects where values up to 9000 that persist beyond 56 days following onset of 
symptoms were measured using a functional pseudovirus neutralizing antibody assay. No 
changes in total serum immunoglobulins have been seen to date. 
4.3. 
JUSTIFICATION FOR DOSE 
A single dose of 2 mg/kg up to a maximum of 200 mg (2 mg/kg in patients ≥100 kg) was 
selected based on safety, pharmacodynamic, and pharmacokinetic parameters. Safety is 
summarized in the CPI-006 investigator brochure and in Section 2.3 and Section 2.4. In 
clinical study CPI-006-002, 20 patients hospitalized for mild to moderate COVID-19 
symptoms were treated with a single intravenous infusion of CPI-006 ranging from 0.3 
mg/kg to 5.0 mg/kg.  Half of the patients in the study received an infusion of 3 mg/kg or 5 
mg/kg.  CPI-006 was well tolerated in all patients with no DLTs or treatment related AEs 
reported in the study. Safety was monitored in the study by an iDMC. Ninety-three patients 
with advanced cancers enrolled in CPI-006-001 received repeated intravenous infusions of 
CPI-006 once every 3 weeks until disease progression. CPI-006 was administered as a single 
agent, in combination with ciforadenant, Corvus’ experimental adenosine 2A receptor 
antagonist, pembrolizumab, a commercially available anti-PD1 inhibitor, or the triple 
combination of CPI-006, ciforadenant, and pembrolizumab. No dose-limiting toxicities 
(DLTs) were observed for CPI-006 administered as a single agent or in combination at doses 
below 24 mg/kg in the dose escalation portion of the study. A DLT was observed in a single 
patient who received 24 mg/kg CPI-006 (Grade 3 hyponatremia in a NSCLC patient with 
history of hyponatremia). This cohort was further expanded with no more DLTs reported. A 
maximum tolerated dose was not established and after completion of the 24 mg/kg cohort, 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 31 of 85 
Version 001 
this dose was maximum administered dose per protocol. Overall, CPI-006 was well tolerated 
at all doses studied including repeated doses up to 12 times higher than the 2 mg/kg dose.  
A covariate analysis was performed using serum CPI-006 levels, patient demographics, vital 
signs, laboratory values, and concomitant medications data from 93 patients who received 1-
24 mg/kg CPI-006 in the CPI-006-001 oncology study. In CPI-006-001, clearance was 
strongly associated with patient body weight indicating a body weight adjusted dose is 
preferred over a fixed dose.  CPI-006 showed non-linear PK, modeling with clearance being 
a linear function of dose and fit of the model to the data was excellent.  In CPI-006-001, 
AUC after a dose of 24 mg/kg is estimated to be 31-fold higher than the area under the serum 
or plasma concentration-time curve (AUC) after a dose of 2 mg/kg. The serum CPI-006 
concentration 30 minutes after infusion was not modeled for a dose of 2 mg/kg, but the 
geometric mean 30-minute serum CPI-006 concentration after administration of 24 mg/kg 
was 11.6 times higher than after administration of 3 mg/kg. 
The preliminary geometric mean 30-minute serum CPI-006 concentrations in study 
CPI-006-002 (n = 3 per cohort) for the 0.3 mg/kg, 1.0 mg/kg, and 3.0 mg/kg cohorts are 1.9 
µg/mL, 9.3 µg/mL, and 56.4 µg/mL, respectively. The 30-minute serum CPI-006 
concentrations are similar to those for samples collected from the corresponding 1 mg/kg and 
3 mg/kg cohorts at the same time in the CPI-006-001 oncology study. CPI-006 is rapidly 
cleared from serum and is undetectable (serum concentration < 50 ng/mL) 1-7 days after a 
1 mg/kg intravenous infusion or 14-21 days after a 3 mg/kg infusion.  In CPI-006-002, the 
relationship between clearance and weight was less defined (there was a small statistical 
preference for a model in which clearance was weight-proportional), presumably the result of 
the small number of subjects for whom PK data are presently available and larger variability 
in this critically-ill group of patients. 
In the GLP general toxicity study in cynomolgus monkeys, CPI-006 was administered by 60- 
minute IV infusion once weekly for 5 consecutive weeks at dose levels of 10, 30, or 
100 mg/kg, followed by a 28-day recovery period. CPI-006 doses of up to 100 mg/kg/week 
(5 total doses) were well tolerated. CD73 is expressed weakly on endothelial cells. No CPI-
006-related changes in hematologic coagulation parameters, which included prothrombin 
time (PT) activated partial thromboplastin time (aPTT), or fibrinogen, occurred during the 
study. The NOAEL was the highest dose administered, 100 mg/kg/week, corresponding to 
maximum drug concentration in serum or plasma (Cmax) of 3,560 and 3,280 μg/mL and AUC 
from the start of infusion to 169 hours after the start of infusion (AUC(0-169)) of 167,000 and 
186,000 hr•μg/mL, for males and females, respectively. The Cmax and AUC from time zero to 
the time of the last quantifiable concentration (AUClast) for the GLP repeat dose cynomolgus 
monkey toxicity study are 60 and 66 times higher, respectively, than the Cmax and AUClast 
after a single administration of 3 mg/kg to humans in the CPI-006-001 study.  Safety margins 
are anticipated to be at least as high or higher after administration of single dose of 2 mg/kg 
to patients. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 32 of 85 
Version 001 
IgG and IgM antibody titers against the SARS-CoV-2 spike protein and/or RBD increased in 
all evaluable patients in CPI-006-002 within 7 days of a single infusion of CPI-006. Similar 
results were observed in anti-SARS-Cov-2 IgA titers. No correlation between duration of 
Covid-19 symptoms and pre-treatment serum antibody levels was observed in patients. 
Thirteen of 17 evaluable patients had low pre-CPI-006 infusion antibody titers despite 
relatively long durations of symptoms in some patients. In patients receiving 0.3 mg/kg CPI-
006, all four evaluable patients achieved high IgG titers to spike protein that were sustained 
for at least 84 days after onset of symptoms. In these patients, IgM titers peaked at 14 days 
and remained elevated at the last measured timepoint of 84 days. Similar kinetics were 
observed in antibody responses to the RBD. At doses higher than 0.3 mg/kg, durable high 
titers of IgG and IgM to spike protein and RBD were achieved out to 84 days, 56 days and 14 
days for the 1.0 mg/kg, 3.0 mg/kg and 5.0 mg/kg cohorts, respectively in the ongoing study. 
Peak titers increased from 0.3 mg/kg to 1.0 mg/kg CPI-006 but did not appear to increase 
from 1.0 mg/kg to 3.0 mg/kg or from 3.0 mg/kg to 5.0 mg/kg at the evaluable time points, 
suggesting that the peak pharmacodynamic effect occurred in the range of 1.0-3.0 mg/kg 
CPI-006. 
Immunophenotyping of peripheral blood from patients enrolled in clinical study CPI-006-001 
demonstrated that doses greater than 1 mg/kg are sufficient to activate B cells, resulting in a 
temporary redistribution to lymphoid tissues and corresponding increase in the frequency of 
memory B cells returning to circulation. A similar increase in the frequency of memory B 
cells was observed in Covid-19 patients tested in the CPI-006-002 trial, including patients 
receiving 0.3 mg/kg CPI-006. In vitro, CPI-006 induced B cell activation is dose-dependent 
with concentrations of 1 μg/mL achieving near maximal induction of CD69. This initial 
activation leads to a morphologic transformation of B cells into plasmablasts and secretion of 
IgM and IgG in vitro. These levels of CPI-006 also result in increased expression of various 
markers involved in antigen presentation e.g. HLA-DR, CD86. A dose of 1mg/kg is 
sufficient to sustain CPI-006 serum concentrations above 1 ug/ml CPI-006 for 24 to 48 hours 
after administration.   
In summary, A single dose of 2 mg/kg CPI-006 up to a maximum of 200 mg was selected 
based on a good safety profile, maximum pharmacodynamic effect, and good 
pharmacokinetic parameters. This dose is expected to ensure that maximal 
pharmacodynamically active levels of 1µg/ml are achieved.  CPI-006 repeatedly 
administered once every 3 weeks by IV infusion was demonstrated to be well tolerated in 93 
patients in oncology study CPI-006-001 and after a single administration of up to 5 mg/kg to 
20 COVID-19 patients in study CPI-006-002. Clearance decreases with increasing dose and 
is weight proportional in CPI-006-001 and likely CPI-006-002.  CPI-006 clears rapidly in the 
dose-range studied for Covid-19 patients. After a single administration of 3 mg/kg or less, 
serum CPI-006 is undetectable in 3 weeks or less. In CPI-006-002, a dose response in 
pharmacodynamic measures was observed between 0.3 and 1.0 mg/kg and no further 
improvement was observed above 1.0 mg/kg. A dose of 2 mg/kg was selected to ensure 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 33 of 85 
Version 001 
sufficient exposure to CPI-006 for maximum pharmacodynamic effect, rapid clearance, and 
substantial safety margins. 
4.4. 
END OF STUDY DEFINITION 
A participant in this study is considered to have completed the study if he/she has completed 
all study visits including Day 28 study assessments. The study visits beyond Day 28 will be 
optional for exploratory endpoint of antibody levels at Days 56, 84, and 168.   
The end of the study is defined as the date that each participant enrolled in the study 
completes his/her last study visit or discontinues from the study. 
5. 
STUDY POPULATION 
5.1. 
INCLUSION CRITERIA 
1. Participants must be ≥ 18 years of age at the time of signing the informed consent.  
2. Confirmed positive by PCR test for SARS-CoV-2 within 72 hours before 
randomization. 
3. Onset of symptoms not more than 7 days prior to randomization. 
4. Understand and agree to comply with planned study procedures for the duration of 
the study. The study visits beyond Day 28 will be optional and require a separate 
consent.  
5. Hospitalized for Covid-19 illness for ≤72 hours with mild to moderate Covid-19 
symptoms including: 
- 
Mild: Symptoms of Covid-19 including fever, rhinorrhea, mild cough, sore 
throat, headache, muscle pain, malaise but not requiring supplemental oxygen 
- 
Moderate: Lower respiratory symptoms: shortness of breath (SOB) or signs of 
pneumonia or lung infiltrates based on X-ray or computed tomography (CT) 
scan < 50% present 
6. Maintains O2 saturation of at least 93% on room air or supplemental O2 at 
randomization. 
7. Adequate organ function, as defined by: 
- 
CBC: ANC >1000/mm3, platelets>75,000mm3, Hgb>9 gm/100 cc 
- 
Calculated creatinine clearance based on ideal body weight per Cockcroft-
Gault formula or 24-hour urine ≥ 30 mL/min 
- 
Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤ 5 x 
upper limit of normal (ULN) 
- 
D-dimer < 10,000 ng/mL 
8. Eligible participants of child-bearing age (male or female) must agree to use at least 1 
medically accepted method of contraception (e.g., barrier contraceptives [condom, or 
diaphragm with a spermicidal gel], hormonal contraceptives [implants, injectables, 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 34 of 85 
Version 001 
combination oral contraceptives, transdermal patches, or contraceptive rings], or 
intrauterine devices), or agree to abstinence for 6 weeks. Female participants or the 
female partners of male participants who become pregnant during the study or within 
the protocol-specified period after their last CPI-006 administration should 
immediately inform their treating physicians. 
5.2. 
EXCLUSION CRITERIA 
1. Signs of acute respiratory distress syndrome (ARDS) or respiratory failure 
necessitating mechanical ventilation at the time of screening (and randomization) or 
anticipated impending need for mechanical ventilation. 
2. History of severe chronic respiratory disease and requirement for long-term oxygen 
therapy. 
3. Any uncontrolled active systemic infection or hemodynamic instability requiring 
admission to an intensive care unit (ICU).  
4. Patients with malignant tumor receiving treatment, or other serious systemic diseases 
affecting life expectancy within 29 days of Screening. 
5. Receipt of cancer chemotherapy or immunomodulatory drugs including (but not 
limited to) biologics such as anti-CD20, anti-TNF, anti-IL6; alkylating agents (e.g., 
cyclophosphamide); antimetabolites (e.g., azathioprine); or chronic corticosteroid use 
equivalent to prednisone >10 gm/day, during preceding 2 months. 
Note: Steroids for treatment of Covid-19 is acceptable. 
6. Patients who are participating in other clinical trials including participants in an 
extended access program (EAP).  
7. Active deep vein thrombosis or pulmonary embolism as confirmed by the investigator 
within last 6 months.  
8. Anticipated discharge from the hospital or transfer to another hospital which is not a 
study site within 72 hours of admission as confirmed by the investigator. 
9. Any active uncontrolled co-morbid disease that might interfere with study conduct or 
interpretation of findings. 
10. Known to be positive for HIV or positive test for chronic HBV infection (defined as 
positive hepatitis B surface antigen [HBsAg]) or positive test for hepatitis C antibody. 
11. Convalescent plasma (CCP) or anti-SARS-CoV-2 monoclonal antibodies 
administered less than 24 hours prior to randomization. Patient must have recovered 
from any adverse events related to CCP treatment. Received chloroquine or 
hydroxychloroquine within last 7 days or during the study. 
12. Pregnancy or breast feeding.  
5.3. 
LIFESTYLE CONSIDERATIONS 
Blood, sperm, and ova donations are restricted for at least 6 weeks after CPI-006 
administration. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 35 of 85 
Version 001 
5.3.1. 
Meals and Dietary Restrictions 
No dietary restrictions. 
5.3.2. 
Activity 
No required restrictions. 
5.4. 
SCREEN FAILURES 
Screen failures are defined as participants who consent to participate in the clinical study but 
are not subsequently randomized. Reasons for screen failure will be recorded.  
6. 
STUDY TREATMENT 
Study treatment is defined as any investigational treatment (s), marketed product(s), placebo, 
or medical device(s) intended to be administered to a study participant according to the study 
protocol. 
6.1. 
STUDY TREATMENT ADMINISTERED 
A summary of study treatment information is provided in Table 2. 
Table 2 
Study Treatment 
Study Treatment Name: 
CPI-006 Injection, 
200 mg/20 mL  
CPI-006 Placebo 
Dosage formulation:  
10 mg/mL with 20 mM 
histidine, 9 % sucrose, 0.01 % 
(w/v) polysorbate 80, pH 5.5. 
(5% Dextrose Injection, USPa) 
Unit dose strength (s) 
200 mg / 20 mL (10 mg/mL) 
5% Dextrose 
Route of administration 
IV  
IV  
Doseb 
2 mg/kg up to a maximum of 
200 mg 
Placebo (no CPI-006) 
Dosing instructions: 
IV Infusion over 10-15 
minutes, on Day 1 followed by 
infusion line flush with 5% 
Dextrose Injection, USP. 
CPI-006 Injection is diluted 
with 5% Dextrose Injection, 
USP  
IV Infusion over 10-15 minutes, on Day 1 
followed by infusion line flush with 5% 
Dextrose Injection, USP.  
Packaging and labeling 
  
Study Treatment will be 
provided in a sterile, single-use 
vial with a rubber stopper and a 
blue cap. One vial is packaged 
inside a carton. Each vial will 
be labeled as required per 
country requirement. 
Not Applicable 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 36 of 85 
Version 001 
Manufacturer 
Manufactured for Corvus 
Pharmaceuticals, Inc. by Vetter 
Development Services USA, 
Inc. 
Placebo will be purchased by the clinical 
institution from commercial vendors 
approved by that institution 
Abbreviations: IV = intravenous; US/USA = United States of America; USP= United States Pharmacopeia 
a 5% Dextrose Injection, USP will be used at clinical sites within the United States, similar sterile, endotoxin 
free, grades of 5% Dextrose Injection that are commercially available and meet local or compendial laws and 
regulations may be substituted outside of the US. 
b The CPI-006 dose of 2 mg/kg up to a maximum dose of 200 mg, patients who are 100 kg or more will receive 
a dose of 200 mg. 
6.2. 
STUDY TREATMENT: 
PREPARATION/HANDLING/STORAGE/ACCOUNTABILITY 
1. The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study treatments received, and any 
discrepancies are reported and resolved before use of the study treatment. 
2. Only participants enrolled in the study may receive study treatment, and only 
authorized site staff may supply or administer study treatment. All study treatment 
must be stored in a secure, environmentally controlled, and monitored (manual or 
automated) area in accordance with the labeled storage conditions with access limited 
to the investigator and authorized site staff. 
3. The unblinded site staff preparing the study treatment is responsible for study 
treatment accountability, log of receipt, inventory, reconciliation, dispensing, return 
of study treatment, destruction of study treatment and record maintenance (i.e., 
receipt, reconciliation, and final disposition records). The study treatment logs and 
records must be kept current and blinded from others (e.g. investigators, site staff, 
participants, Sponsor and contract research organization (CRO) staff with oversight 
of study conduct). Study treatment logs must be kept in a secure location with access 
limited only to the unblinded staff members. 
4. Further guidance and information for the final disposition of unused study treatments 
are provided in the Pharmacy Manual. 
6.2.1. 
Handling and Storage 
6.2.1.1. 
CPI-006 Injection 
CPI-006 Injection is provided as a sterile solution in a single use vial that delivers 200 mg of 
active ingredient in 20 mL (10 mg/mL). CPI-006 vials will be stored at 2°C to 8°C and 
protected from direct light. Excursions up to 25°C are allowed up to 3 days. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 37 of 85 
Version 001 
The prepared CPI-006 can be stored at 2°C to 8°C for up to 24 hours and/or stored at 
controlled room temperature (20°C to 25°C) for up to 6 hours, including the infusion time. 
Avoid shaking the prepared CPI-006.   
Do not freeze CPI-006 vials or diluted CPI-006 infusion solution. 
6.2.1.2. 
Placebo 
The placebo, 5% Dextrose Injection, USP will be purchased by each clinical site within the 
United States. Either 5% Dextrose Injection, USP or a similar sterile, endotoxin free, grade of 
5% Dextrose Injection that is commercially available and meets local or compendial laws 
and regulations may be substituted outside of the US. The placebo should be handled and 
stored according to manufacturer’s specifications. 
The prepared placebo can be stored at 2°C to 8°C for up to 24 hours and/or stored at 
controlled room temperature (20°C to 25°C) for up to 6 hours, including the infusion time. 
Avoid shaking the prepared placebo.   
Do not freeze the placebo. 
6.2.2. 
Preparation and Dispensing  
Refer to the Pharmacy Manual for detailed instructions on how to prepare study treatment for 
administration. Study treatment will be prepared using aseptic techniques and dispensed by 
an appropriately qualified and experienced member of the study staff (e.g. pharmacist, 
pharmacy assistant, or pharmacy technician) who is unblinded to study treatment (see 
blinding plan in the pharmacy manual). A second staff member will verify the dispensing and 
preparation. The identity of the study treatment should not be revealed by markings on labels 
or the infusion bag or infusion set except for a blinded randomization code. 
CPI-006 infusion will be prepared using aseptic techniques by withdrawing the appropriate 
amount of CPI-006 Injection, 10 mg/mL from a vial into a sterile syringe. The contents of the 
syringe will be emptied into a sterile polyolefin/polyethylene (PO/PE) or polyvinyl chloride 
(PVC) infusion bag and diluted with 5% Dextrose Injection, USP or equivalent grade. Apply 
gentle mixing by inverting the IV bag; avoid shaking the IV bag. 
Placebo will be prepared using aseptic techniques. The placebo infusion is 50 mL to 100 mL 
5% Dextrose Injection, USP, in a sterile polyolefin/polyethylene (PE) or polyvinyl chloride 
(PVC) infusion bag, depending on the patient weight. 
After it is prepared, the placebo can be stored at 2°C to 8°C for up to 24 hours and/or stored 
at controlled room temperature (20°C to 25°C) for up to 6 hours, including the infusion time. 
Avoid shaking the prepared placebo. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 38 of 85 
Version 001 
6.2.3. 
 Administration 
Administration of study treatment will be performed by an appropriately qualified, GCP-
trained, and infusion-experienced member of the study staff (e.g. physician, nurse, 
physician’s assistant, nurse practitioner, pharmacist, or medical assistant) as allowed by 
local, state, and institutional guidance. Site staff administering the study treatment will be 
blinded to the treatment (active or placebo) being administered. Participants will receive a 
single dose of study treatment by IV infusion on Day 1 of the study. The volume of the study 
treatment will be 50-100 mL depending on the dose to be administered. Study treatment must 
be infused through an in-line filter. Infusion lines should be made of PO/PE or PVC, 
equipped with a 0.2 µm or 0.22 µm in-line polyethersulfone (PES) filter. 
The infusion should be administered via a port as close to the participant’s vein as possible to 
ensure that the full dose is administered in the allotted time. The total infusion time from start 
of infusion to completion of infusion will be 10-15 minutes. As soon as the infusion is 
complete, the infusion line used for the study treatment will be flushed with the greater of the 
priming volume of the infusion set or 30 mL of 5% Dextrose Injection, USP. The same 
infusion rate used for the study treatment infusion will be used for the flush.   
Infusion reactions are possible, thus appropriate drugs and medical equipment to treat acute 
infusion reactions must be immediately available and study personnel must be trained to 
recognize and treat infusion reactions. Premedication with diphenhydramine 50 mg PO (or 
equivalent dose of antihistamine) or diphenhydramine 25–50 mg IV and acetaminophen 500–
1000 mg PO (or equivalent dose of analgesic) prior to infusion of CPI‑006/placebo is 
recommended for participants who are not receiving steroids for treatment of Covid‑19. Oral 
premedication should be administered 30-60 minutes prior to the start of the CPI‑006/placebo 
infusion. IV diphenhydramine should be administered 15-30 minutes prior to the start of the 
CPI‑006/placebo infusion. 
Study treatment administration details will be recorded on the CRF and will include at a 
minimum: patient number, randomization code, infusion start time and stop time, interruption 
stop and restart times, flush start and stop times. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 39 of 85 
Version 001 
6.2.4. 
Management of Infusion Reactions 
Any CPI-006-associated infusion reactions should also be managed as shown in Table 3. 
Table 3 
CPI-006 Infusion-Related Reaction Management Guidelines 
NCI CTCAE Grade 
Treatment 
Grade 1 
Mild reaction; infusion 
interruption not indicated; 
treatment not indicated 
  
  
  
  
  
  
Reduce infusion rate (e.g., from 10 mL/min to 5 mL/min) or 
stop infusion rate as medically indicated. 
  
Provide supportive care. Increase monitoring of vital signs as 
medically indicated. 
  
If symptoms do not improve ≥≤ 1 hour, provide medical 
treatment until the participant is deemed medically stable in the 
opinion of the investigator.  
  
If infusion is stopped and symptoms resolve within 2 hours. 
CPI-006 infusion may be restarted at 25%-50% of the original 
infusion rate (e.g., from 10 mL/min to 5 mL/min). 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 40 of 85 
Version 001 
Grade 2 
Requires therapy or infusion 
interruption but responds 
promptly to symptomatic 
treatment (e.g., antihistamines, 
NSAIDs, narcotics, IV fluids); 
prophylactic medications 
indicated for ≤ 24 hours 
  
  
  
  
Reduce infusion rate (e.g., from 10 mL/min to 5 mL/min) or 
stop infusion rate as medically indicated. 
  
Additional appropriate medical therapy may include but is not 
limited to: 
– IV fluids 
– Antihistamines 
– NSAIDs 
– Acetaminophen 
– Narcotics 
– Corticosteroids 
  
Increase monitoring of vital signs as medically indicated until 
the participant is deemed medically stable in the opinion of the 
investigator. 
  
If symptoms have not subsided or worsen with reduced infusion 
rate, stop infusion. 
  
If infusion is stopped and symptoms resolve within 2 hours. 
CPI-006 infusion may be restarted at 25%-50% of the original 
infusion rate (e.g. from 10 mL/min to 5 mL/min). 
  
Otherwise if symptoms do not resolve, dosing will be held until 
symptoms resolve, and the participant should be premedicated 
for the next scheduled dose. 
  
Participants who develop Grade 2 toxicity with premedication 
and do not have symptom resolution within 2 hours of medical 
treatment should be permanently discontinued from further 
study drug treatment. 
  

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 41 of 85 
Version 001 
Grade 3 
Prolonged (i.e., not rapidly 
responsive to symptomatic 
medication and/or brief 
interruption of infusion); 
recurrence of symptoms following 
initial improvement; 
hospitalization indicated for other 
clinical sequelae (e.g., renal 
impairment, pulmonary infiltrates) 
  
Stop Infusion. 
Additional appropriate medical therapy may include but is not 
limited to: 
– Epinephrinea 
– IV fluids 
– Antihistamines 
– NSAIDs 
– Acetaminophen 
– Corticosteroids 
– Narcotics 
– Oxygen 
– Vasopressors 
  
Grade 4 
Life-threatening; pressor or 
ventilator support indicated 
  
Stop Infusion. 
Additional appropriate medical therapy may include but is not 
limited to: 
- 
Epinephrinea 
- 
IV fluids 
- 
Antihistamines 
- 
NSAIDs 
- 
Acetaminophen 
- 
Narcotics 
- 
Oxygen 
- 
Vasopressors 
- 
Corticosteroids 
Increase monitoring of vital signs as medically indicated until 
the participant is deemed medically stable in the opinion of the 
investigator. 
 
Hospitalization may be indicated. 
Participant is permanently discontinued from further study drug 
treatment. 
Abbreviations: : IV = intravenous; NSAID = nonsteroidal anti-inflammatory drug. 
a In cases of anaphylaxis, epinephrine should be used immediately. 
6.3. 
Measures to Minimize Bias: Randomization and Blinding  
6.3.1. 
Randomization 
All participants will be randomized to Treatment A or Treatment B in a 1:1 ratio using an 
Interactive Response Technology (IRT). Before the study is initiated, the log-in information 
& directions for the IRT will be provided to each site. 
Participants will receive a single IV administration of study treatment on Day 1 of the study.   
Returned study treatment should not be re-dispensed to any participants. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 42 of 85 
Version 001 
6.3.2. 
Blinding 
This is an observer blinded design, so investigators, site staff (except the unblinded pharmacy 
personnel preparing the study treatment), participants, Sponsor, and CRO staff with oversight 
of study conduct will remain blinded to treatment allocation throughout the course of the 
study. The IRT will provide the unblinded pharmacist(s) the randomized treatment arm 
assignment to be allocated to the participant at the administration visit. Routines for this will 
be described in the IRT user manual that will be provided to each study site. 
CPI-006 Injection is a clear colorless solution and will remain clear and colorless when 
diluted in 5% Dextrose Injection, USP. At full concentration, CPI-006 is slightly more 
viscous than water and may create minimal foam if vigorously shaken. Once diluted, CPI-
006 is not visually distinguishable from the 5% Dextrose Injection, USP placebo. 
To maintain the blind, an otherwise uninvolved staff member (e.g. pharmacist, pharmacy 
assistant, or pharmacy technician) will prepare and dispense the study treatment for 
administration such that the identity (active or placebo) of the treatment is blinded to all other 
site staff responsible for administration and study conduct throughout the study. The 
unblinded personnel are responsible for study treatment preparation and accountability only 
and will not participate in any other aspect of the study. The unblinded personnel will 
endeavor to ensure that there are no differences in time taken to dispense following 
randomization or preparation that might reveal the identity of the study treatment to 
investigators, site staff, participants, Sponsor and CRO staff.  
In the event of a Quality Assurance audit, the auditor(s) will be allowed access to unblinded 
study treatment records at the site(s) to verify that randomization/dispensing has been done 
accurately. 
6.3.3. 
 Procedures for Unblinding 
The IRT will be programmed with blind-breaking instructions. In case of an emergency, the 
investigator has the sole responsibility for determining if unblinding of a participant’s 
treatment assignment is warranted. Participant safety must always be the first consideration 
in making such a determination. If the investigator decides that unblinding is warranted, the 
investigator should make every effort to contact the Sponsor prior to unblinding a 
participant’s treatment assignment unless this could delay emergency treatment of the 
participant. If a participant’s treatment assignment is unblinded, the Sponsor must be notified 
within 24 hours after breaking the blind. The date and reason that the blind was broken must 
be recorded in the source documentation and case report form, as applicable. 
6.4. 
Study Treatment Compliance 
Investigational Product will be administered on a single occasion by the investigator or 
qualified designee to participants who are hospitalized. Randomization code, treatment 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 43 of 85 
Version 001 
volume, start and stop times for the study treatment infusion, flush volume, and start and stop 
times for the flush will be accurately recorded in the CRF. 
The study site is responsible for ensuring that participants comply with the specified study 
windows. If a participant misses a visit, every effort should be made to contact the participant 
and complete a visit within the defined visit window (Appendix 1 Schedule of Activities). If 
a participant does not complete a visit within the specified time, the visit will be classified as 
a missed visit and the participant will continue with subsequent scheduled study visits. All 
safety requirements of the missed visit will be captured and included in the subsequent visit 
(e.g. clinical laboratory testing, and immunologic testing, as applicable). 
6.5. 
CONCOMITANT THERAPY 
Investigators may prescribe any concomitant medications, procedures, or treatments deemed 
necessary to provide adequate supportive care except for those listed in Section 5.2.   
Any medication or vaccine (including over-the-counter or prescription medicines, vitamins, 
and/or herbal supplements) that the participant is receiving at the time of enrollment or 
receives during the study must be recorded along with: 
• Reason for use 
• Dates of administration including start and end dates 
• Dosage information including dose and frequency 
6.5.1. 
Rescue Medicine 
The study site will supply infusion reaction rescue medication that will be obtained locally by 
the clinical site. The following rescue medications may be used: 
• Antihistamine such as diphenhydramine administered PO or IV according to standard 
practices at the clinical institution for treating infusion related reactions 
• Analgesics such as acetaminophen administered PO or IV according to standard 
practices at the clinical institution for treating infusion related reactions 
• Corticosteroids administered according to standard practices at the site/hospital for 
treating infusion related reactions 
• The date and time of rescue medication administration as well as the name and 
dosage regimen of the rescue medication must be recorded in the CRF 
6.5.2. 
 Permitted Concomitant Therapy 
The following concomitant medications and vaccinations are allowed and will be recorded in 
the CRF: 
• Therapies that are either approved or accepted as standard of care therapies for 
Covid-19 per site/institutional guidelines (e.g. remdesivir, tocilizumab, steroids, 
convalescent plasma, anti-SARS-CoV-2 monoclonal antibodies [see Section 5.3]) 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 44 of 85 
Version 001 
• Prophylactic or therapeutic anticoagulation  
• Supportive care for management of Covid-19 symptoms and complications 
• It is recommended that participants who are not being treated with steroids for 
Covid‑19 be premedicated with diphenhydramine 50 mg PO (or equivalent dose of 
antihistamine) or diphenhydramine 25–50 mg IV and acetaminophen 500–1000 mg 
PO (or equivalent dose of analgesic) prior to infusion of CPI-006/placebo (see 
Section 6.2.3). 
The Medical Monitor should be contacted if there are any questions regarding concomitant or 
prior therapy. 
6.5.3. 
Prohibited Concomitant Therapy 
The following medications are prohibited. and the Sponsor must be notified if a participant 
receives any of these prohibited medications. The use of the following concomitant 
medications, however, will not definitively require withdrawal of the participant from the 
study but may determine a participant's evaluability in the per-protocol analysis set. 
If a participant receives a prohibited concomitant medication, the investigator in consultation 
with the Medical Monitor will evaluate any potential impact on receipt of the study 
intervention based on time the medication was administered, the medication's pharmacology 
and pharmacokinetics, and whether the medication will compromise the participant's safety 
or interpretation of the data.  
The following concomitant medications are prohibited:  
• Chloroquine or hydroxychloroquine 
• Cancer chemotherapy or immunomodulatory drugs including (but not limited to) 
biologics such as anti-CD20, anti-TNF, anti-IL6; alkylating agents (e.g., 
cyclophosphamide); antimetabolites (e.g., azathioprine); or chronic corticosteroid use 
• Investigational medication or device (other than protocol-mandated study treatment) 
is prohibited within 30 days prior to initiation of study treatment and throughout the 
study unless the investigator in consult with the Corvus medical monitor feels 
medical necessity and that such participation would not affect the integrity of this 
trial. 
6.6. 
Dose Modification 
 No dose modifications for CPI-006 are allowed. 
6.7. 
Treatment After the End of the Study 
No study treatment will be provided to study participants at the end of the study. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 45 of 85 
Version 001 
7. 
DISCONTINUATION OF STUDY TREATMENT AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL 
• Participant or participant’s physician may elect to discontinue their participation in 
the study at any time. Reasons for withdrawal will be recorded on the CRF. 
• All randomized participants will be followed for 28 days.  
• Participants who consent to optional follow up visits will be followed for 168 days. 
7.1. 
DISCONTINUATION OF STUDY TREATMENT 
A single dose of CPI-006/placebo is administered on Day 1 only for participants, thus there is 
no discontinuation from study treatment unless patient does not receive full dose due to 
toxicity during the infusion. Standard of care will be administered to both treatments at the 
discretion of the investigator per institutional guidelines.  
7.2. 
PARTICIPANT DISCONTINUATION/WITHDRAWAL FROM THE 
STUDY 
• A participant may withdraw from the study at any time at his/her own request or may 
be withdrawn at any time at the discretion of the investigator for safety, behavioral, 
compliance, or administrative reasons. 
• If the participant withdraws consent for disclosure of future information, the Sponsor 
may retain and continue to use any data collected before such a withdrawal of 
consent. 
• If a participant withdraws from the study, he/she may request destruction of any 
samples taken and not tested, and the investigator must document this in the site study 
records. 
7.3. 
LOST TO FOLLOW UP 
• A participant will be considered lost to follow-up if he or she repeatedly fails to 
return for scheduled visits and is unable to be contacted by the study site. 
• The following actions must be taken if a participant fails to return to the clinic for a 
required study visit: 
o The site must attempt to contact the participant and reschedule the missed visit 
as soon as possible and counsel the participant on the importance of 
maintaining the assigned visit schedule and ascertain whether or not the 
participant wishes to and/or should continue in the study. 
o Before a participant is deemed lost to follow up, the investigator or designee 
must make every effort to regain contact with the participant (where possible, 
3 telephone calls and, if necessary, a certified letter to the participant’s last 
known mailing address or local equivalent methods). These contact attempts 
should be documented in the participant’s medical record. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 46 of 85 
Version 001 
o Should the participant continue to be unreachable, he/she will be considered to 
have withdrawn from the study. 
8. 
STUDY ASSESSMENTS AND PROCEDURES  
Study procedures and their timing are summarized in the SoA (Appendix 1). Protocol 
waivers or exemptions are not allowed. Adherence to the study design requirements, 
including those specified in the SoA, is essential and required for study conduct. 
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility or record reasons for 
screening failure, as applicable. 
Procedures conducted as part of the participant’s routine clinical management (e.g., blood 
count) and obtained before signing of the ICF may be utilized for screening or baseline 
purposes provided the procedures met the protocol-specified criteria and were performed 
within the time frame defined in the SoA. 
Hospitalized participants will receive daily monitoring and testing while in the hospital 
including routine vital sign monitoring and labs per institutional standards. Once discharged, 
participants will be asked to attend post- hospitalization study visits as described in 
Section 4.1.  
Follow up visits after discharge could include, but are not limited to, clinic visits, outpatient 
hospital visits, home health visits or telehealth, depending on local or institutional standards. 
If no other method of follow-up is feasible, home visits may be used. 
Study assessments will utilize local labs and procedures at the clinical sites except for the key 
secondary endpoint, anti-SARS-CoV-2 antibody levels and various exploratory endpoints 
such as neutralizing antibody levels and peripheral blood immunophenotyping which will be 
assessed by the central lab. Other exploratory endpoints such as BCR repertoire analysis and 
systemic cytokine/chemokine analysis will be performed by external vendors outside of the 
central lab. Results of tests conducted at central lab, are not considered as critical to the 
management of Covid-19 in participants and will not be reported to the investigator or 
patient. 
The anti-RBD IgG level will be measured using an electrochemiluminescent immunoassay 
on serum specimens stored at -20°C. The method is based on reactivity to immunogenic viral 
protein where a recombinant form of viral RBD antigen is absorbed to the surface of a 96-
well microtiter plate. Participant serum will be dispensed to the wells where antibodies 
recognizing the antigen are allowed to react before removal of unbound immunoglobulin 
from the wells. Anti-RBD IgG bound to the viral protein will be detected using standard 
enzyme-linked immunosorbent assay (ELISA) techniques. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 47 of 85 
Version 001 
Immediate safety concerns should be discussed with the Sponsor directly upon occurrence or 
awareness to determine if the participant should continue or discontinue study treatment 
regardless of SoA assessments. Repeat or unscheduled samples may be taken for safety 
reasons or for technical issues with the samples. 
8.1. 
SCREENING  
Screening assessments and procedures are detailed in Appendix 1, Table 6. 
8.2. 
STUDY ASSESSMENTS AND PROCEDURES  
Study assessments and procedures are detailed in Appendix 1, Table 6.  
8.3. 
EFFICACY ASSESSMENTS 
The following assessments will also be performed for both treatments at the time points 
described in the SoA (Appendix 1, Table 6): 
• Covid-19 Symptoms Assessment – Covid-19-attributable symptoms including fever, 
cough, sore throat, headache, muscle pain, and/or shortness of breath (Appendix 8) 
• 8-point Ordinal Scale Assessment (Appendix 6) 
• SARS-CoV-2 viral load 
• PCR negativity 
• NEWS2 Assessment (Appendix 7) 
• Anti-RBD antibody titers will be measured in sera collected at the time points 
described in the SoA (Appendix 1, Table 6). Collection of the predose timepoint is 
critical for subsequent analysis. The assays will measure IgM, IgG and IgA levels 
targeting the RBD for key and additional secondary endpoints using the 
electrochemiluminescent immunoassay. The assays will be conducted at a centralized 
testing facility using validated methods.  
• A viral PCR test by nasal swab will be obtained to demonstrate a negative test and 
viral load. Participants with positive PCR tests will have repeat tests on subsequent 
visits until a negative test. This test will be conducted by the clinical lab at the 
investigator sites.  
• Exploratory measurements will be conducted at Sponsor’s research laboratories or 
through use of outside vendors including immunophenotyping analysis, immune cell 
functional assays, BCR repertoire analysis, systemic cytokine/chemokine analysis, 
and, anti-SARS-CoV-2 antibody characterization, and anti-viral neutralization assays. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 48 of 85 
Version 001 
• Clinical assessments will include time to clinical improvement, time to resolution of 
the Covid-19 attributable symptoms, change in clinical status, rate of participants 
with clinical improvement, time to discharge, requirement for ICU, requirement for 
mechanical ventilation, time to death (TTD), rate of procedures including intubation, 
duration of mechanical ventilation, oxygenation free days in the first 28 days, and 
incidence and duration of new O2 use during the study. 
8.4. 
PHARMACOKINETIC AND PHARMACODYNAMIC ASSESSMENTS 
Serum samples will be collected from each patient enrolled in the study for measurement of 
serum concentrations of CPI-006 as specified in the SoA (Appendix 1, Table 6). A maximum 
of 4 additional samples may be collected at time points during the study if warranted and 
agreed upon between the investigator and the Sponsor. Instructions for the collection and 
handling of biological samples will be provided by the Sponsor. 
The actual collection date and time (24-hour clock time) for each sample will be recorded. 
Samples will be used to evaluate the PK of CPI-006. Each serum sample will be divided into 
3 aliquots (1 each for PK, backup, and for potential analysis of anti-drug antibodies [ADA], 
and/or neutralizing antibodies [refer to Section 8.7.1 Immunogenicity Assessments]). 
Samples collected for analyses of serum CPI-006 concentration may also be used to evaluate 
safety or efficacy aspects related to concerns arising during or after the study. 
At visits during which serum samples for the determination of PK, backup, ADA, and/or 
neutralizing antibodies of CPI-006 will be taken, one sample of sufficient volume can be 
used. 
Drug concentration information that may unblind the study will not be reported to 
investigative sites or blinded personnel until the study has been unblinded. 
Any changes in the timing or addition of time points, up to 4 timepoints, for any planned 
study assessments must be documented and approved by the relevant study team member and 
then archived in the Sponsor and site study files, but will not constitute a protocol 
amendment. The IRB/IEC will be informed of any safety issues that require alteration of the 
safety monitoring scheme or amendment of the ICF. 
8.5. 
SAFETY ASSESSMENTS 
The following assessments will also be performed for both treatments at the time points 
described in the SoA (Appendix 1, Table 6): 
• Incidence, type, and severity of AEs and SAEs assessed by NCI CTCAE v 5.0 to 
compare safety of CPI-006 plus SOC to placebo plus SOC.  

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 49 of 85 
Version 001 
• Safety assessments will be made using local lab testing (Appendix 3) for hematology, 
chemistry, coagulation, inflammatory markers and serum quantitative 
immunoglobulins. 
• Routine physical exams. 
• Vital signs (pulse rate, blood pressure, respiratory rate, temperature and blood oxygen 
saturation) including at start, at conclusion and at approximately 2 hours after 
completion of the CPI-006/placebo infusion.  
8.6. 
ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS 
The definitions of an AE or SAE can be found in Appendix 4. 
AE will be reported by the participant (or, when appropriate, by a caregiver, surrogate, or the 
participant’s legally authorized representative). 
The investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible for 
following up AEs that are serious, considered related to the study treatment or study 
procedures, study treatment or that caused the participant to discontinue the administration of  
CPI-006/placebo, or the study (see Section 7). 
8.6.1. 
Time Period and Frequency for Collecting AE and SAE Information 
After informed consent has been obtained but prior to initiation of study treatment, only 
SAEs caused by a protocol-mandated treatment (e.g., study related procedures, 
discontinuation of medications) should be reported (see Appendix 4).  
After initiation of study treatment, all AEs and SAEs will be reported until completion of the 
study at Day 28.  
Medical occurrences that begin before the start of study treatment but after obtaining 
informed consent will be recorded on the Medical History/Current Medical Conditions 
section of the CRF not the AE section. 
All SAEs will be recorded and reported to the Sponsor or designee within 24 hours, as 
indicated in Appendix 4. The investigator will submit any updated SAE data to the Sponsor 
within 24 hours of it being available. 
For participants with worsening of Covid-19, the clinical event (s) that mark the worsening 
should be reported as AE or an SAE (see definitions in Appendix 4). Investigators are not 
obligated to actively seek AE or SAE outside clinical practice after conclusion of the study 
participation. However, if the investigator learns of any SAE, including a death, at any time 
after a participant has been discharged from the study, and he/she considers the event to be 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 50 of 85 
Version 001 
reasonably related to the study treatment or study participation, the investigator must 
promptly notify the Sponsor. 
The method of recording, evaluating, and assessing causality of AE and SAE and the 
procedures for completing and transmitting SAE reports are provided in Appendix 4. 
8.6.2. 
Method of Detecting AEs and SAEs 
The investigator is responsible for ensuring that all AEs are recorded on the Adverse Event 
CRF and reported to the Sponsor in accordance with instructions provided in this section and 
in Appendix 4. 
For each AE recorded on the Adverse Event CRF, the investigator assesses seriousness, 
severity, and causality as per Appendix 4. 
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about AE 
occurrences. 
Reporting requirements for SAEs can be found in Appendix 4. 
8.6.3. 
Follow-up of AEs and SAEs 
After the initial AE/SAE report, the investigator is required to proactively follow each 
participant at subsequent visits/contacts. All SAEs (as defined in Appendix 4), will be 
followed until resolution, stabilization, the event is otherwise explained, or the participant is 
lost to follow-up (as defined in Section 7.3). Further information on follow-up procedures is 
given in Appendix 4. 
8.6.4. 
Regulatory Reporting Requirements for SAEs 
• Prompt notification by the investigator to the Sponsor of a SAE is essential so that 
legal obligations and ethical responsibilities towards the safety of participants and the 
safety of a study treatment under clinical investigation are met. 
• The Sponsor has a legal responsibility to notify both the local regulatory authority 
and other regulatory agencies about the safety of a study treatment under clinical 
investigation. The Sponsor will comply with country-specific regulatory requirements 
relating to safety reporting to the regulatory authority, Institutional Review Boards 
(IRB)/Independent Ethics Committees (IEC), and investigators. 
• Investigator safety reports must be prepared for suspected unexpected serious adverse 
reactions (SUSAR) according to local regulatory requirements and Sponsor policy 
and forwarded to investigators as necessary. 
• An investigator who receives an investigator safety report describing a SAE or other 
specific safety information (e.g., summary or listing of SAEs) from the Sponsor will 
review and then file it along with the Investigator’s Brochure and will notify the 
IRB/IEC, if appropriate according to local requirements. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 51 of 85 
Version 001 
8.7. 
BIOMARKERS  
Serum at baseline and at specified times will be stored at -20°C for use in various serology 
studies which include: 
Key and Additional Secondary Endpoints 
• Measurement of anti-RBD IgG, IgM and IgA levels.  
Exploratory Endpoints 
• Measurement of neutralizing antibody levels that block association of viral RBD and 
human ACE2 assessed in a biochemical ELISA. 
• Measurement of neutralizing antibody levels that block infection assessed in a 
pseudovirus assay, and in a live virus assay 
• Changes in IgG, IgM, or IgA antibodies targeting other SARS-CoV-2 antigens 
including (but not limited to) spike, nucleocapsid, and membrane proteins. 
• Additional exploratory serum assays may be conducted with extra serum not required 
for primary analysis. 
Peripheral blood collected at baseline and at specified times will be analyzed while fresh or 
processed into PBMCs and cryopreserved for use in various studies including: 
• Immunophenotyping using flow cytometry to evaluate the frequency of memory B 
cells and memory/effector T cells 
• Functional B and T cell assays to evaluate ex vivo immune responses to SARS-CoV-
2 antigens compared to controls. 
• BCR repertoire analysis to evaluate effects of CPI-006 on B cell clonality and 
antibody isotype switching 
8.7.1. 
Immunogenicity Assessments 
Antibodies to CPI-006 may be evaluated in serum samples collected from participants 
according to the SoA. These samples may be tested by the Sponsor or Sponsor's designee. 
Serum samples may be screened for antibodies binding to CPI-006 and the titer of confirmed 
positive samples will be reported. Other analyses may be performed to verify the stability of 
antibodies to CPI-006 and/or further characterize the immunogenicity of CPI-006 
The detection and characterization of antibodies to CPI-006 will be performed using a 
validated assay method by or under the supervision of the Sponsor. All samples collected for 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 52 of 85 
Version 001 
detection of antibodies to study treatment may also be evaluated for CPI-006 serum 
concentration to enable interpretation of the antibody data. Antibodies may be further 
characterized and/or evaluated for their ability to neutralize the activity of the study 
treatment(s). Samples may be stored for a maximum of 5 years (or according to local 
regulations) following the last participant’s last visit for the study at a facility selected by the 
Sponsor to enable further analysis of immune responses to CPI-006. 
9. 
STATISTICAL CONSIDERATIONS 
9.1. 
STATISTICAL HYPOTHESES 
The primary hypothesis is that treatment with CPI-006 plus SOC (Treatment A) will shorten 
the time to recovery during the 28 days after dosing based on the 8-point ordinal scale in 
comparison to placebo plus SOC (Treatment B) in mild to moderately symptomatic Covid-19 
hospitalized participants. 
The first secondary hypothesis is that treatment A will shorten the time to clinical 
improvement by at least 2 points during the 28 days after dosing on the 8-point ordinal scale 
in comparison to treatment B. 
The second secondary hypothesis is that Treatment A will increase the level of IgG targeting 
the RBD of SARS-CoV-2 over Days 7, 14, 21, and 28 more than Treatment B, as measured 
by the area under the IgG level curve above the baseline, calculated over Days 1 (the 
baseline), 7, 14, 21, 28, and Day of Discharge. 
The third secondary hypothesis is that Treatment A will shorten the time to resolution of 
≥ 50% of the Covid-19-attributable symptoms: fever, cough, sore throat, headache, muscle 
pain, and/or shortness of breath, reported at baseline. Explicitly, the resolution of ≥ 50% of 
symptoms means the resolution of 1 of 1 symptom, 1 of 2 symptoms, 2 of 3 symptoms, 2 of 4 
symptoms, 3 of 5 symptoms, or 3 of 6 symptoms that are reported at baseline. 
9.2. 
SAMPLE SIZE DETERMINATION 
Approximately 620 hospitalized participants with mild to moderately symptomatic Covid-19 
will be enrolled. The participants will be randomized in a 1:1 ratio between Treatment A and 
Treatment B within each of the strata defined by: 
• Region of the world (North America vs. Latin America vs. Europe). 
• Age (< 65 vs. ≥ 65) 
• Comorbidities (0 vs. at least 1) based on the following list: 
o Chronic lung disease (e.g., emphysema and chronic bronchitis, idiopathic 
pulmonary fibrosis, COPD, or cystic fibrosis) or moderate to severe asthma 
o Significant cardiac disease (e.g., heart failure, coronary artery disease, 
congenital heart disease, cardiomyopathies, and pulmonary hypertension) 
o Obesity (body mass index ≥ 30 kg/m2) 
o Diabetes (Type 1, Type 2, or gestational) 
o Liver disease 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 53 of 85 
Version 001 
o CKD 
o SCD 
o Organ transplantation 
o Cancer 
With 520 observed recoveries in the 2 treatment groups, there would be an approximately 
83% power to show a statistically significant superiority of Treatment A over Treatment B in 
recovery rate at an overall 1-sided α level of 0.025 when the true recovery rate ratio of 
Treatment A to Treatment B is 1.296, assuming an exponential distribution for time to 
recovery for each treatment.  
With a total of approximately 620 participants, it is estimated that 520 recoveries will be 
observed after 5.5 months assuming that the median time to recovery is 5.4 days and 7 days 
of Treatments A and B, respectively. The all-cause death rate is assumed to be 6% over the 
28-day period. 
9.3. 
POPULATION FOR ANALYSES 
For purposes of analyses, the following populations are defined in Table 4. 
Table 4 
Population Definitions 
Population 
Description 
Intent-to-treat (ITT) 
All participants who are randomized into the study. 
Efficacy 
All participants who take at least 1 dose of study treatment (CPI-
006 or placebo) and have at least 1 post-baseline assessment based 
on the 8-point ordinal scale.  
Safety 
All participants who take at least 1 dose of study treatment 
(CPI-006, placebo, or SOC). 
Pharmacokinetic 
All participants who receive CPI-006 and had at least 1 post-
treatment blood sample collected  
 
9.4. 
STATISTICAL ANALYSES 
The SAP will be developed and finalized before the second interim analysis (see Section 
9.4.6) and will describe the study populations to be included in the analyses. This section is a 
summary of the planned statistical analyses of the primary and secondary endpoints.  
9.4.1. 
General Approach 
Unless otherwise specified, the following general analysis will be performed. Continuous 
variables will be summarized using the following descriptive statistics: number of observed 
values, mean, standard deviation, median, and minimum and maximum. Categorical 
variables will be summarized using frequencies and percentages. Time-to-event variables, 
when appropriate, will be summarized by the median with 95% confidence intervals (CI) and 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 54 of 85 
Version 001 
the 25% and 75% quartiles. Kaplan-Meier curves will be provided. The baseline value for 
analysis variable is the last measurement before administration of study treatments. 
9.4.2. 
Demographic and Participant Characteristics 
Demographic information such as age, gender, race, body weight, and participant 
characteristics such as baseline disease severity, symptoms, and comorbidities will be listed 
and summarized. 
9.4.3. 
Efficacy Analyses 
All efficacy analyses will be performed based on the Efficacy Population.   
Table 5 
Efficacy Analyses 
Endpoint 
Statistical Analysis 
Primary  
The primary efficacy endpoint is the time to recovery during the 28 days after dosing. Day 
of recovery is defined as the first day on which the participant satisfies one of the 
following three categories from the eight-point ordinal scale:  
• 
Not hospitalized, no limitations on activities. 
• 
Not hospitalized, limitation on activities and/or requiring home oxygen;  
• 
Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical 
care 
Treatment A and B will be compared by the time to recovery.  
Secondary 
The following endpoints will be compared between Treatment A and B: 
Key Secondary Endpoint: 
• 
Time to clinical improvement determined by ≥ 2 points improvement in the 8-point 
ordinal scale during the 28 days after dosing. 
• 
The change in the level of IgG targeting RBD of SARS-CoV-2 over Days 7, 14, 21, 
and 28 from baseline measured by the area under the IgG level curve above the 
baseline. 
• 
Time to resolution of ≥ 50% of the Covid-19 attributable symptoms including fever, 
cough, sore throat, headache, muscle pain, and/or shortness of breath reported at 
baseline. 
Other Secondary Endpoints 
• 
Change in clinical status, defined by the change in the 8-point ordinal scale from 
baseline at Day of Discharge and Days 3, 7, 14, 21, and 28. 
• 
Percentage of participants with clinical improvement (≥ 2 points improvement in the 
8-point ordinal scale) at Day of Discharge and Days 3, 7, 14, 21, and 28.  
• 
Change from baseline in level of IgM targeting the RBD at Days 7, 14, 21 and 28. 
• 
Change from baseline in the SARS-CoV-2 viral load at Days 7, 14, 21, and 28  
• 
Time to PCR negativity, and percentage of participants with PCR negative at Days 7, 
14, 21, and 28 
• 
Change from Baseline in NEWS2 at Days 3 and 7, Day of Discharge, and Day 28.  
• 
Rate of procedures including intubation. 
• 
Rate and duration of mechanical ventilation. 
• 
Rate and duration of supplemental oxygen, non-invasive ventilation, or high flow 
oxygen devices during the trial 
• 
Oxygenation free days in the first 28 days. 
• 
Time to death during the first 28 days. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 55 of 85 
Version 001 
Exploratory 
• 
Hematology, chemistry, CRP, and ferritin assessments on Days 1, 3, 5, 7, 14, 21, 28 
(while hospitalized); Day of Discharge; and Day 28 (return to clinic if discharged) 
• 
PT, INR, aPTT, fibrinogen, and D-dimer on Days 1, 3, 5, 7, 14, 21, 28 (while 
hospitalized), and Day of Discharge 
• 
Change from baseline in level of IgA targeting the RBD at Days 7, 14, 21, and 28 
• 
Changes in IgG, IgM, or IgA antibodies targeting other SARS-CoV-2 antigens 
including (but not limited to) trimeric spike, nucleocapsid, and membrane proteins 
• 
Change from baseline in the frequency and function of memory B cells in the 
peripheral blood at Days 14 and 28 
• 
Changes from baseline in the frequency or function of memory/effector T cells in the 
peripheral blood at Days 14 and 28 
• 
B cell receptor repertoire analysis at baseline, Day 14, and Day 28 
• 
Systemic cytokine and chemokine levels at baseline and Days 7 (while hospitalized), 
Day of discharge and Day 28 
• 
Neutralizing antibody levels on Days 1 and 28 using a biochemical ELISA, a 
pseudovirus neutralization assay, and a PRNT50 live virus assay  
• 
Change from baseline level of IgG and IgM targeting the RBD at Days 56, 84 and 168 
• 
PK characteristics including covariate analysis to determine which variables, if any, 
influence exposure of CPI-006 
9.4.4. 
Safety Analyses 
The safety analyses will include all participants in the Safety Population. 
Safety will be assessed through summaries of AEs (including SAEs), changes in laboratory 
test results, physical examination findings, and vital signs. 
AEs will be coded using the current version of Medical Dictionary for Regulatory Activities 
(MedDRA, Version 23.0) to categorize each AE by System Organ Class and Preferred Term. 
The number of participants who experienced at least 1 AE; treatment-related AE; severe 
(Grade 3 or higher) AE, SAE; and the number of participants withdrawn from treatment due 
to AEs will be summarized. The incidence of AEs will be presented overall, by System 
Organ Class and Preferred Term, by intensity (based on National Cancer Institute Common 
Terminology Criteria for Adverse Events [NCI CTCAE], Version 5), by severity, by 
relationship to study treatment or if treatment-emergent, and by treatment. Individual listings 
of AEs will be provided. Study treatment related AEs will be listed individually. 
Laboratory tests will be listed and summarized for each test. Lab values will be graded 
according to the NCI-CTCAE criteria and summarized. 
Deaths and related information will be listed. 
9.4.5. 
Exploratory Analyses 
PK, pharmacodynamic (PD), and biomarker exploratory analyses will be described in the 
SAP, finalized before database lock.  

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 56 of 85 
Version 001 
9.4.6. 
Interim Analyses 
Two formal interim analyses are planned for this study. The first interim analysis is a 
non-binding futility analysis when approximately 150 participants have been enrolled into 
the study with 28 days of follow up time. Safety and efficacy will be the focus of the 
evaluation. Unblinded safety and efficacy data will be reviewed by the iDMC. 
The second interim analysis will be performed when approximately 310 (60% of the 520) 
recovery events have been observed in the 2 treatment arms based on the Efficacy 
Population. Comparison between Treatment A and Treatment B with respect to the time to 
recovery will be made using a modified version of stratified log-rank test correcting for 
competing risk of all-cause death. Should the comparison demonstrate a statistically 
significant superiority of Treatment A over Treatment B, Corvus may file the results to 
regulatory authorities for drug approval. The study will continue its course beyond the 
interim analysis and collect all the planned safety efficacy, PK, and PD data.  
As part of the second interim analysis, Corvus may request the iDMC to assess the recovery 
rates and the conditional power of the study based on the interim data. The total sample size 
of the study may be increased with the recommendation by iDMC. The sample size 
adaptation plan and increase rule will be detailed in the statistical analysis plan and provided 
to the regulatory authority before the second interim analysis. 
The primary analysis of the study is the final analysis in the time to recovery during the 28 
days after dosing and will be performed when approximately 520 recovery events have been 
observed in the 2 treatment arms based on the intent-to-treat (ITT) Population. Comparison 
between Treatment A and Treatment B with respect to the time to recovery will be made 
using a modified version of stratified log-rank test correcting for competing risk of all-cause 
death. The efficacy stopping boundaries at the second interim and final analyses will be 
derived based on the time and number of recovery events using the Lan-Demets O’Brien and 
Fleming-like α spending function. 
All the enrolled participants will be followed-up to Day 28 and further to the optional visits. 
Corvus may perform the primary analysis when all the enrolled participants have completed 
the Day 28 visit and include all participants’ data for the primary analysis, if the iDMC 
recommends doing so at the second interim analysis. In this case, the analysis when 520 
recovery events are observed will not be performed. 
The following are the three key secondary endpoints with their hierarchical priority as 
ordered for statistical testing: 
• Time to improvement by at least two points on the 8-point ordinal scale during the 28 
days after dosing; 
• The change in the level of IgG targeting RBD of SARS-CoV-2 over Days 7, 14, 21, 
and 28 from baseline measured by the area under the IgG level curve above the 
baseline over Days 1, 7, 14, 21, 28 and Day of Discharge; 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 57 of 85 
Version 001 
• The time to resolution of ≥ 50% of the Covid-19-attributable symptoms including 
fever, cough, sore throat, headache, muscle pain, and/or short of breath reported at 
baseline. 
In the case that a statistical significance is achieved in the time to recovery in comparison of 
Treatments A and B, the three secondary endpoints will be tested according to their 
hierarchical priority. This hierarchical procedure will be applied to the second interim 
analysis and to the final analysis. The α level for the comparison in the secondary endpoints 
will be the same α level as for the comparison in the time to recovery.  
TTD is also a secondary endpoint of the study. TTD will be described at the final analysis 
which will be performed up to 6 months after the primary analysis and will be based on the 
ITT Population. The purpose of the analysis is to show a favorable trend of TTD with 
Treatment A over Treatment B. The Kaplan-Meier product limit curves of TTD and the 2-
sided 95% confidence interval for the median TTD will be computed for each arm. A hazard 
ratio and a 2-sided 95% confidence interval of the ratio will be estimated using a Cox 
proportional hazards model, with treatment arm as a single covariate, stratified by the 
stratification factors. 
9.4.7. 
Independent Data Monitoring Committee (iDMC) 
An iDMC will be formed to monitor safety and efficacy of the study treatment at pre-
specified timepoints including futility and interim analysis timepoints. The iDMC will review 
the unblinded safety data from the first 50 participants after completion of the Day 28 
assessments. Subsequent iDMC reviews will occur after every 150 participants have 
completed the Day 28 assessments. In addition, the iDMC is available for ad hoc reviews for 
safety concerns. The study will not stop enrollment awaiting these iDMC reviews, although 
the iDMC may recommend temporary or permanent cessation of enrollment based on their 
safety and/or efficacy reviews. The protocol team will review blinded pools of AE/SAE data 
every 2 weeks. If there are a significant number of unexpected AEs, the iDMC will be asked 
to review unblinded safety and efficacy data in an ad hoc meeting.  
iDMC membership includes: 
• Three clinicians experienced in care/management of Covid-19 (voting members) and 
an unblinded non-voting independent statistician 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 58 of 85 
Version 001 
10. 
REFERENCES 
Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel 
coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020 
Feb 15;395(10223):514-523. 
Du L, He Y, Zhou Y, et al. The spike protein of SARS-CoV –- a target for vaccine and therapeutic 
development. Nat Rev Microbiol. 2009 Mar;7(3):226-36 
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in 
Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. 
Joyner MJ, Senefeld JW, Klassen SA, et al. Effect of convalescent plasma on mortality among 
hospitalized patients with Covid-19: initial three-month experience. MedRxiv. 2020. 
Luke JJ, Merchan J; Harshman L, et al. Immunobiology and clinical activity of CPI-006, an anti-
CD73 antibody with immunomodulating properties in a Phase 1/1b trial in advanced cancers. J. 
Immunother. Cancer 2019b Nov;7(suppl.1) 282. 
Luke JJ, Powderly JD, Merchan JR, et al. Immunobiology, preliminary safety, and efficacy of CPI-
006, an anti-CD73 antibody with immune modulating activity, in a phase 1 trial in advanced 
cancers. J. Clin. Oncol. 2019a 37(15 suppl.). 
Rasheed AM, Ftak DF, Hashim HA, et al. The therapeutic effectiveness of Convalescent plasma 
therapy on treating Covid-19 patients residing in respiratory care units in hospitals in Baghdad, 
Iraq. medRxiv. 2020. 
Resta R, Thompson LF. T cell signaling through CD73. Cell Signal. 1997 Feb;9(2):131-9. 
Royal College of Physicians. National early warning score (NEWS) 2. Standardising the assessment 
of acute-illness severity in the NHS. 2017. 
Willingham SB, Criner G, Hill C, et al. Characterization and Phase 1 Trial of a B Cell Activating 
Anti-CD73 Antibody for the Immunotherapy of Covid-19. medRxiv. 2020. 
World Health Organization. Coronavirus disease 2019 (Covid-19): situation report, 72. 
Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion 
conformation. Science. 2020 Mar 13;367(6483):1260-1263. 
Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. 
Nature. 2020 Apr; 580(7803):E7. 
Yuan M, Wu NC, Zhu X, et al. A highly conserved cryptic epitope in the receptor-binding domains of 
SARS-CoV-2 and SARS-CoV. Science. 2020 Apr 3. pii: eabb7269 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 59 of 85 
Version 001 
APPENDIX 1 
SCHEDULE OF ACTIVITIES 
Table 6 
Schedule of Activities 
Procedure 
Screening 
(up to 3 
days before 
Day 1) a 
Day 1 
Day 2 to X 
(during 
hospital 
stay)b 
Day 7 (if 
patient 
remains in 
the 
hospital)c 
Day of 
Hospital 
Discharge c 
Day 7 (if 
patient is 
discharged 
from 
hospital)d 
Day 
14c, d, e 
Day 
21c, d, e 
Early 
Termination 
D28d 
Optional 
Assessment 
Day 
56d 
Day 
84d 
Day 
168d 
Informed Consent 
X 
 
 
 
 
 
 
 
 
 
 
 
Inclusion and Exclusion Criteria 
X 
 
 
 
 
 
 
 
 
 
 
 
Demography 
X 
 
 
 
 
 
 
 
 
 
 
 
Physical Examination 
X 
 
 
 
 
 
 
 
 
 
 
 
Limited Physical Exam 
 
X 
X 
X 
X 
 
 
 
X 
 
 
 
Medical History  
X 
 
 
 
 
 
 
 
 
 
 
 
Covid-19 Symptoms Assessmentf 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
 
National Early Warning Score 2 Assessment 
X 
X 
X 
X 
X 
 
 
 
X 
 
 
 
8-point Ordinal Scale Assessment  
X 
X 
X 
X 
X 
 
Xg 
Xg 
X 
 
 
 
Vital Signsh 
X 
X 
X 
X 
X 
 
 
 
X 
 
 
 
Hematology Paneli 
X 
X 
X 
X 
X 
 
 
 
X 
 
 
 
Chemistry Panelj 
X 
X 
X 
X 
X 
 
 
 
X 
 
 
 
Serum Quantitative Immunoglobulinsj 
X 
X 
 
 
X 
 
 
 
X 
 
 
 
Serum Ferritin 
X 
X 
X 
X 
X 
 
 
 
X 
 
 
 
Coagulation Test (PT, aPTT, INR) 
X 
X 
X 
X 
X 
 
 
 
X 
 
 
 
D-dimer 
X 
X 
X 
X 
X 
 
 
 
X 
 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 60 of 85 
Version 001 
Procedure 
Screening 
(up to 3 
days before 
Day 1) a 
Day 1 
Day 2 to X 
(during 
hospital 
stay)b 
Day 7 (if 
patient 
remains in 
the 
hospital)c 
Day of 
Hospital 
Discharge c 
Day 7 (if 
patient is 
discharged 
from 
hospital)d 
Day 
14c, d, e 
Day 
21c, d, e 
Early 
Termination 
D28d 
Optional 
Assessment 
Day 
56d 
Day 
84d 
Day 
168d 
Fibrinogen 
X 
X 
X 
X 
X 
 
 
 
X 
 
 
 
Pregnancy Testk 
X 
 
 
 
 
 
 
 
X 
 
 
 
SARS-CoV-2 PCR Testl 
X 
X 
 
X 
X 
 
 
 
 
 
 
 
Viral load sample (for Central Lab) 
 
X 
Xm 
X 
X 
 
X 
X 
X 
 
 
 
Influenza and RSV PCR Test 
X 
 
 
 
 
 
 
 
 
 
 
 
C-Reactive Protein   
X 
X 
X 
X 
X 
 
 
 
X 
 
 
 
Anti-SARS-CoV-2 Serum Antibody Test 
Blood Sample (Central Lab)n 
 
Xn 
(pre-dose) 
 
X 
X 
 
X 
X 
X 
(X) 
(X) 
(X) 
Exploratory Biomarker Blood Samples  
 
Xo 
 
 
X 
 
X 
 
X 
 
 
 
PKn and Immunogenicity Serum Samples 
See Table 7 for details 
Treatment Administration 
 
X 
 
 
 
 
 
 
 
 
 
 
Adverse Event Reviewp 
 
<=====================================================================> 
 
 
 
Serious Adverse Event Reviewp 
<===============================================================================> 
 
 
 
Concomitant Medication Review  
<===============================================================================> 
 
 
 
Covid-19 Medical Intervention Reviewq 
<===============================================================================> 
 
 
 
NOTE: Procedures indicated with parentheses “(X)” are conditional. Refer to the appropriate footnote for details. 
Abbreviations: AE = adverse event; aPTT = activated partial thromboplastin time; CBC = complete blood count; CRP = C-reactive protein; INR = international 
normalized ratio; LDH = lactate dehydrogenase; NEWS2 = National Early Warning Score 2 Assessment; PCR = polymerase chain reaction; PK = pharmacokinetic; 
PT = prothrombin time; RSV = Respiratory Syncytial Virus; SAE = serious adverse event; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2. 
a 
Screening and Day 1 testing can be combined, providing they are separated by less than 24 hours and there are no signs of changes in the participant’s status. 
b 
Participants will be monitored daily while in the hospital for a minimum of 48 hours after study treatment administration. Participants will be monitored with vital 
signs including blood oxygen saturation every 4-6 hours or per institutional standards. Laboratory assessment will be taken daily or per institutional standards and 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 61 of 85 
Version 001 
should include but are not limited to hematology panel, chemistries, ferritin, CRP, LDH, D-dimer, fibrinogen, PT, aPTT and INR. Participants’ clinical status based 
on the 8-point ordinal scale, the NEWS2, Covid-19 related signs/symptoms, and safety laboratory tests will be recorded every day while hospitalized including day 
of discharge from the hospital.   
c 
All participants will have samples collected for viral load, anti-SARS-CoV-2 serum antibody test, and exploratory biomarkers on day of discharge. Discharged 
participants will be asked to attend post- hospitalization study assessments at Days 14, 21, and 28, if discharged before any of these assessments were completed. 
Participants who are discharged before Day 7, do not need a Day 7 sample collection but will be assessed for Covid-19 symptoms 
d  
Day 7 can be ± 1 day, Day 14, and Day 21 can be ± 2 days, Day 28 can be ± 3 days. Day 56, Day 84, and Day 168 can be ± 5 days. 
e 
All efforts should be made to have the blood draws and exams done and assessments completed. When needed a telemedicine or home health visit can replace a 
clinical visit for the post-hospitalization visits.  
f 
Assessment of Covid-19 symptoms (per Appendix 8) should happen daily during the hospital stay. In the post- hospitalization setting, assessment of symptoms 
should happen on Day 7 (for those discharged before Day 7), Day 14, Day 21 and Day 28. Day 7, Day 14, and Day 21 assessments can be a telemedicine or phone 
call visit. 
g 
If the patient is hospitalized, the assessment should be conducted in the hospital. If discharged and patient is at home, assessment may be conducted over the phone. 
h 
Vital signs includes pulse, blood pressure, temperature, respiratory rate, and oxygen saturation by pulse oximeter. Height and weight collected at screening only. On 
Day 1 vital signs will be collected pre-dose, at completion of treatment administration (at the end of the flush) (+ 15 minute window), and 2 hours post-dose (± 15 
minutes window).  
i 
Hematology panel should include the parameters detailed in protocol Appendix 3. 
j 
Chemistry panel should include the parameters detailed in protocol Appendix 3 and serum quantitative immunoglobulins (Screening, Day 1, day of discharge and 
Day 28). 
k 
Pregnancy test (serum or urine) for women of child-bearing potential only (Appendix 5). 
l 
Participants must have a confirmed positive test by PCR for SARS-CoV-2 within 72 hours of randomization (screening sample). PCR test will also be obtained on 
Days 1 and 7, while hospitalized; and on day of discharge (if discharged prior to Day 28) and will be tested locally. 
m 
Viral load sample to be collected on Day 3 while hospitalized as well as day 1(pre-dose), Day of discharge, Day 7, 14, 21 and 28. 
n 
Anti-SARS-CoV-2 serum antibody test blood sample to be collected pre-dose administration. Anti-SARS-CoV-2 serum antibody samples will be collected to 
assessed at a central lab on Day 1 before dosing, and on Days 7, 14, 21, and 28 if patient remains hospitalized as well as the day of hospital discharge. For 
participants who are discharged before Day 14, 21 and 28, a sample will be collected on day of discharge as well as the posthospitalization sample collection on 
Days 14, 21, and 28 that are not collected during the hospital stay. Participants who consent separately to the optional assessments for anti-SARS-CoV-2 serum 
antibody tests will be evaluated on Days 56, 84, and 168. 
o  
Exploratory biomarker samples on Day 1 will be collected pre-dose and 4 hours post-dose (± 30 min).  
p 
After informed consent has been obtained but prior to initiation of study treatment, only SAEs caused by a protocol- mandated procedures will be reported. After 
initiation of study treatment, all AEs and SAEs will be reported until completion of the study at Day 28.  
q 
Review of medical interventions/ procedures for management of Covid-19 such as intubation, ventilation, and supplemental oxygen and rehospitalization. 
 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 62 of 85 
Version 001 
 
Table 7 
PK, ADA, and Neutralizing Antibody Sampling Schedule 
 
Samplea 
Collection Timepoint 
Variance 
1 
pre-dose 
-1hour-0 hours 
2 
0.5 hours 
± 5 min 
3 
2 hours 
± 15 min 
4 
4 hours 
± 30 min 
5 
8 hours 
± 2 hours 
6 
24 hours 
± 6 hours 
7 
48 hours 
± 8 hours 
8 
72 hours 
± 8 hours 
9 
96 hours (or time of discharge) 
± 8 hours 
10 
Day 7-9 (or time of discharge) 
11 
Day 14  
± 2 days 
12 
Early Termination Day 28 
± 3 days 
Abbreviations: min = minutes 
a 
Time post CPI-006 infusion and line flush except for pre-dose sample 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 63 of 85 
Version 001 
APPENDIX 2 
REGULATORY, ETHICAL, AND STUDY OVERSIGHT CONSIDERATIONS 
REGULATORY AND ETHICAL CONSIDERATIONS 
• This study will be conducted in accordance with the protocol and with the following: 
o Consensus ethical principles derived from international guidelines including 
the Declaration of Helsinki and Council for International Organizations of 
Medical Sciences (CIOMS) International Ethical Guidelines 
o Applicable International Council for Harmonisation (ICH) Good Clinical 
Practice (GCP) Guidelines 
o Applicable laws and regulations 
• The protocol, protocol amendments, ICF, Investigator Brochure, and other relevant 
documents (e.g., advertisements) must be submitted to an IRB/IEC by the investigator 
and reviewed and approved by the IRB/IEC before the study is initiated. 
• Any amendments to the protocol will require IRB/IEC approval before 
implementation of changes made to the study design, except for changes necessary to 
eliminate an immediate hazard to study participants. 
• The investigator will be responsible for the following: 
o Providing written summaries of the status of the study to the IRB/IEC 
annually or more frequently in accordance with the requirements, policies, and 
procedures established by the IRB/IEC 
o Notifying the IRB/IEC of SAEs or other significant safety findings as required 
by IRB/IEC procedures 
o Providing oversight of the conduct of the study at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 
536/2014 for clinical studies (if applicable), and all other applicable local 
regulations 
FINANCIAL DISCLOSURE 
Investigators and sub-investigators will provide the Sponsor with sufficient, accurate 
financial information as requested to allow the Sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate regulatory authorities. 
Investigators are responsible for providing information on financial interests during the study 
and for 1 year after completion of the study. 
INFORMED CONSENT PROCESS 
• The investigator or his/her representative will explain the nature of the study to the 
participant or his/her legally authorized representative and answer all questions 
regarding the study. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 64 of 85 
Version 001 
• Participants must be informed that their participation is voluntary. Participants or 
their legally authorized representative will be required to sign a statement of informed 
consent that meets the requirements of 21 CFR 50, local regulations, ICH guidelines, 
US Health Insurance Portability and Accountability Act (HIPAA) requirements, 
where applicable, and the IRB/IEC or study center. 
• The medical record must include a statement that written informed consent was 
obtained before the participant was enrolled in the study and the date the written 
consent was obtained. The authorized person obtaining the informed consent must 
also sign the ICF. 
• Participants must be re-consented to the most current version of the ICF(s) during 
their participation in the study. 
• A copy of the ICF(s) must be provided to the participant or the participant’s legally 
authorized representative. 
The ICF will contain a separate section that addresses the use of remaining mandatory 
samples for optional exploratory research. The investigator or authorized designee will 
explain to each participant the objectives of the exploratory research. Participants will be told 
that they are free to refuse to participate and may withdraw their consent at any time and for 
any reason during the storage period. A separate signature will be required to document a 
participant's agreement to allow any remaining specimens to be used for exploratory 
research. Participants who decline to participate in this optional research will not provide this 
separate signature. 
Sites will be allowed to use all processes approved by their IRB to ensure safety of staff and 
patients from Covid-19, while maintaining appropriate consent procedures for the duration of 
this study. 
DATA PROTECTION 
• Participants will be assigned a unique identifier by the Sponsor. Any participant 
records or datasets that are transferred to the Sponsor will contain the identifier only; 
participant names or any information which would make the participant identifiable 
will not be transferred. 
• The participant must be informed that his/her personal study-related data will be used 
by the Sponsor in accordance with local data protection law. The level of disclosure 
must also be explained to the participant. 
• The participant must be informed that his/her medical records may be examined by 
Clinical Quality Assurance auditors or other authorized personnel appointed by the 
Sponsor, by appropriate IRB/IEC members, and by inspectors from regulatory 
authorities. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 65 of 85 
Version 001 
COMMITTEES STRUCTURE 
The objectives of the iDMC are to evaluate interim clinical and safety data to protect 
participant welfare and to provide recommendations regarding study conduct. Details of 
iDMC responsibilities and procedures are specified in the iDMC charter.  
DISSEMINATION OF CLINICAL STUDY DATA 
Clinical Study Reports, periodic safety reports, and clinical study summary reports will be 
disclosed after review by regulatory authorities. This includes access to CSRs from studies 
with negative outcomes and from terminated development programs. 
Company-sponsored study information and tabular study results will be posted on the US 
National Institutes of Health’s website www.ClinTrials.gov and other publicly accessible 
sites. 
Publication planning and other activities related to non-promotional, peer-reviewed 
publications will be conducted to ensure the scientific integrity and credibility of publication 
activities performed by or on behalf of the company. The granting of access to analyzable 
datasets from clinical studies should be through a secure system, following an independent 
assessment of the scientific merit of a rigorously defined research question from a third party 
DATA QUALITY ASSURANCE 
• All participant data relating to the study will be recorded on printed or electronic CRF 
unless transmitted to the Sponsor or designee electronically (e.g., laboratory data). 
The investigator is responsible for verifying that data entries are accurate and correct 
by physically or electronically signing the CRF. 
• The investigator must maintain accurate documentation (source data) that supports 
the information entered in the CRF. 
• The investigator must permit study-related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents. 
• Monitoring details describing strategy (e.g., risk-based initiatives in operations and 
quality such as Risk Management and Mitigation Strategies and Analytical Risk-
Based Monitoring), methods, responsibilities, and requirements, including handling 
of noncompliance issues and monitoring techniques (central, remote, or on-site 
monitoring) are provided in the Clinical Monitoring Plan. 
• The Sponsor or designee is responsible for the data management of this study 
including quality checking of the data. 
• The Sponsor assumes accountability for actions delegated to other individuals (e.g., 
Contract Research Organizations). 
• Study monitors will perform ongoing source data verification to confirm that data 
entered into the CRF by authorized site personnel are accurate, complete, and 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 66 of 85 
Version 001 
verifiable from source documents; that the safety and rights of participants are being 
protected; and that the study is being conducted in accordance with the currently 
approved protocol and any other study agreements, ICH GCP, and all applicable 
regulatory requirements. 
• U.S. Food and Drug Administration (FDA) regulations (21 CFR §312.62[c]) and the 
ICH Guideline for GCP (Section 4.9 of the guideline) require that records and 
documents pertaining to the conduct of this study and the distribution of 
investigational drug, including CRFs, consent forms, laboratory test results, and 
medication inventory records, must be retained by the Principal Investigator for 2 
years after the last marketing application approval or after at least 2 years have 
elapsed since formal discontinuation of clinical development of the investigational 
product. All state and local laws for retention of records also apply. No records may 
be transferred to another location or party without written notification to the Sponsor. 
SOURCE DOCUMENTS 
• Source documents provide evidence for the existence of the participant and 
substantiate the integrity of the data collected. Source documents are filed at the 
investigator’s site. 
• Data reported on the CRF or entered in the CRF that are transcribed from source 
documents must be consistent with the source documents or the discrepancies must be 
explained. The investigator may need to request previous medical records or transfer 
records, depending on the study. Also, current medical records must be available. 
• Definition of what constitutes source data can be found in the study monitoring plan. 
STUDY AND SITE CLOSURE 
The Sponsor designee reserves the right to close the study site or terminate the study at any 
time for any reason at the sole discretion of the Sponsor. Study sites will be closed upon 
study completion. A study site is considered closed when all required documents and study 
supplies have been collected or confirmed as destroyed and a study-site closure visit has been 
performed. 
The investigator may initiate study-site closure at any time, provided there is reasonable 
cause and sufficient notice is given in advance of the intended termination. 
Reasons for the early closure of a study site by the Sponsor or investigator may include but 
are not limited to: 
• Failure of the investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the Sponsor's procedures, or GCP guidelines 
• Inadequate recruitment of participants by the investigator 
• Discontinuation of further study treatment development 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 67 of 85 
Version 001 
PUBLICATION POLICY 
• The results of this study may be published or presented at scientific meetings. If this 
is foreseen, the investigator agrees to submit all manuscripts or abstracts to the 
Sponsor before submission. This allows the Sponsor to protect proprietary 
information and to provide comments. 
• The Sponsor will comply with the requirements for publication of study results. In 
accordance with standard editorial and ethical practice, the Sponsor will generally 
support publication of multicenter studies only in their entirety and not as individual 
site data. In this case, a coordinating investigator will be designated by mutual 
agreement. 
• Authorship will be determined by mutual agreement and in line with International 
Committee of Medical Journal Editors authorship requirements. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 68 of 85 
Version 001 
APPENDIX 3 
CLINICAL LABORATORY TESTS 
• Protocol-specific requirements for inclusion or exclusion of participants are detailed 
in Section 5 of the protocol. 
• Additional tests may be performed at any time during the study as determined 
necessary by the investigator or required by local regulations. 
 
Table 8 
Protocol-Required Safety Laboratory Assessments 
Chemistry 
Hematology 
Serum 
Quantitative 
Immunoglobulins 
Inflammatory 
Biomarkers 
Coagulation 
Testing 
BUN (Blood Urea 
Nitrogen) 
Platelet Count 
IgA 
C-reactive protein 
PT 
Potassium 
RBC Count 
IgG 
Ferritin 
aPTT 
Creatinine 
Hemoglobin 
IgM 
 
INR 
Sodium 
Hematocrit 
 
 
D-dimer 
Glucose 
RBC (Red Blood 
Cell) indices: 
    MCV 
    MCH 
    % Reticulocytes 
 
 
Fibrinogen 
Calcium 
 
 
 
Bilirubin (total & direct) 
 
 
 
Protein (total) 
 
 
 
LDH (Lactate 
Dehydrogenase) 
WBC count 
(White Blood Cell) 
with differential: 
    Neutrophils 
    Lymphocytes 
    Monocytes 
    Eosinophils 
    Basophils 
 
 
 
AST 
 
 
 
ALT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: ALT = alanine aminotransferase; aPTT = activated partial thromboplastin time; AST = aspartate 
aminotransferase; IgA = immunoglobulin A; IgG = immunoglobulin G; IgM = immunoglobulin M; 
INR = international normalized ratio; LDH = lactate dehydrogenase; MCH = mean corpuscular 
hemoglobin; MCV = mean corpuscular volume; PT = prothrombin time; RBC = red blood cell. 
 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 69 of 85 
Version 001 
APPENDIX 4 
ADVERSE EVENTS: DEFINITIONS AND PROCEDURES FOR RECORDING, 
EVALUATING, FOLLOW-UP, AND REPORTING 
DEFINITION OF AE 
AE Definition 
• An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated 
with the use of study treatment, whether or not considered related to the study treatment. 
• NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory 
finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. 
 
Events Meeting the AE Definition 
• Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other safety 
assessments (e.g., ECG, radiological scans, vital signs measurements), including those that worsen from 
baseline, is accompanied by clinical symptoms, results in a change in study treatment (e.g., dosage 
modification, treatment interruption, or treatment discontinuation), results in a medical treatment (e.g., 
potassium supplementation for hypokalemia) or a change in concomitant therapy, considered clinically 
significant in the medical and scientific judgment of the investigator (i.e., not related to progression of 
underlying disease). 
• 
Exacerbation of a chronic or intermittent pre-existing condition including either an increase in 
frequency and/or intensity of the condition. 
• 
New conditions detected or diagnosed after study treatment administration even though it may have 
been present before the start of the study. 
o 
Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction. 
o 
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study treatment 
or a concomitant medication. Overdose per se will not be reported as an AE/SAE unless it is 
an intentional overdose taken with possible suicidal/self-harming intent. Such overdoses 
should be reported regardless of sequelae.  
• For worsening of Covid-19 symptoms, the clinical event (s) that mark the worsening should be reported as 
AE or an SAE.   
• If a clinically significant laboratory abnormality is a sign of a disease or syndrome (e.g., alkaline 
phosphatase and bilirubin 5 x ULN associated with cholestasis), only the diagnosis (i.e., cholestasis) 
should be recorded on the Adverse Event CRF Exacerbation of a chronic or intermittent pre-existing 
condition including either an increase in frequency and/or intensity of the condition. 
• Deaths that occur within 28 days after study treatment (CPI-006) should be reported as an SAE.  
• New conditions detected or diagnosed after study treatment administration even though it may have been 
present before the start of the study. 
• "Lack of efficacy" or "failure of expected pharmacological action" per se will not be reported as an AE or 
SAE. Such instances will be captured in the efficacy assessments. However, the signs, symptoms, and/or 
clinical sequelae resulting from lack of efficacy will be reported as AE or SAE if they fulfil the definition 
of an AE or SAE. 
 
 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 70 of 85 
Version 001 
 
Events NOT Meeting the AE Definition 
• Any clinically significant abnormal laboratory findings or other abnormal safety assessments which are 
associated with the underlying disease, unless judged by the investigator to be more severe than expected 
for the participant’s condition. 
• Medical or surgical procedure (e.g., endoscopy, appendectomy): the condition that leads to the procedure 
is the AE. 
• Situations in which an untoward medical occurrence did not occur (social and/or convenience admission to 
a hospital). 
• Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present or detected at the start 
of the study that do not worsen. 
 
DEFINITION OF SAE 
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (e.g., hospitalization for signs/symptoms of the progression of disease 
under study). Hospitalization or ICU admissions due to Covid-19, worsening of Covid-19 in 
the 28 days during this study, or pulmonary conditions attributable to Covid-19 infection are 
considered efficacy-related endpoints. Therefore, Covid-19-related hospitalization or ICU 
admission is excluded from this definition. 
A SAE is defined as any untoward medical occurrence that, at any dose: 
a. Results in death 
b. Is life-threatening 
The term 'life-threatening' in the definition of 'serious' refers to an event in which the participant was at risk of 
death at the time of the event. It does not refer to an event, which hypothetically might have caused death, if it 
were more severe. 
c. 
Requires inpatient hospitalization or prolongation of existing hospitalization 
Any adverse event that r causes prolonged hospitalization should be documented and reported as a 
serious adverse event (pe the definition of serious adverse event). 
 
• 
For this study, the subjects will be hospitalized for Covid-19 treatment so initial hospitalization will 
not be considered as an SAE. Complications that occur during hospitalization are AEs/SAEs. If a 
complication prolongs hospitalization (or requires admission to ICU) or fulfills any other serious 
criteria, the event is serious.  
 
An event that leads to hospitalization under the following circumstances should not be reported as an 
adverse event or a serious adverse event: 
• 
Hospitalization for respite care 
• 
Planned hospitalization required by the protocol (e.g., for the Covid-19 treatment). 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 71 of 85 
Version 001 
d. Results in persistent disability/incapacity 
• 
The term disability means a substantial disruption of a person’s ability to conduct normal life 
functions. 
• 
This definition is not intended to include experiences of relatively minor medical significance such as 
uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (e.g., sprained 
ankle) which may interfere with or prevent everyday life functions but do not constitute a substantial 
disruption. 
e. 
Is a congenital anomaly/birth defect 
f. 
Other situations 
• 
Medical or scientific judgment should be exercised in deciding whether SAE reporting is appropriate 
in other situations such as important medical events that may not be immediately life-threatening or 
result in death or hospitalization but may jeopardize the participant or may require medical or surgical 
treatment to prevent 1 of the other outcomes listed in the above definition. These events should 
usually be considered serious. 
• 
Examples of such events include invasive or malignant cancers, intensive treatment in an emergency 
room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in 
hospitalization, or development of drug dependency or drug abuse. 
 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 72 of 85 
Version 001 
RECORDING AND FOLLOW-UP OF AE AND/OR SAE 
AE and SAE Recording 
• 
When an AE/SAE occurs, it is the responsibility of the investigator to review all documentation (e.g., 
hospital progress notes, laboratory reports, and diagnostics reports) related to the event. 
• 
The investigator will then record all relevant AE/SAE information in the CRF. 
• 
It is not acceptable for the investigator to send photocopies of the participant’s medical records to 
Sponsor in lieu of completion of the AE/SAE CRF page. 
• 
There may be instances when copies of medical records for certain cases are requested by Sponsor In 
this case, all participant identifiers, with the exception of the participant number, will be redacted on 
the copies of the medical records before submission to Sponsor. 
• 
The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or 
other clinical information. Whenever possible, the diagnosis (not the individual signs/symptoms) will 
be documented as the AE/SAE. However, if a constellation of signs and/or symptoms cannot be 
medically characterized as a single diagnosis or syndrome at the time of reporting, each individual 
event should be recorded on the Adverse Event CRF. If a diagnosis is subsequently established, all 
previously reported AEs based on signs and symptoms should be nullified and replaced by 1 AE 
report based on the single diagnosis, with a starting date that corresponds to the starting date of the 
first symptom of the eventual diagnosis. 
 
Adverse Events That Are Secondary to Other Events 
In general, AEs that are secondary to other events (e.g., cascade events or clinical sequelae) should be 
identified by their primary cause, with the exception of severe or serious secondary events. A medically 
significant secondary AE that is separated in time from the initiating event should be recorded as an 
independent event on the Adverse Event CRF. For example: 
• 
If vomiting results in mild dehydration with no additional treatment in a healthy adult, only vomiting 
should be reported on the CRF 
• 
If vomiting results in severe dehydration, both events should be reported separately on the CRF 
• 
If a severe gastrointestinal hemorrhage leads to renal failure, both events should be reported 
separately on the CRF 
• 
If dizziness leads to a fall and consequent fracture, all 3 events should be reported separately on the 
CRF 
• 
If neutropenia is accompanied by an infection, both events should be reported separately on the CRF 
All AEs should be recorded separately on the Adverse Event CRF if it is unclear as to whether the events are 
associated. 
 
Persistent or Recurrent Adverse Events 
A persistent AE is one that extends continuously, without resolution, between patient or participant evaluation 
timepoints. Such events should be recorded with each severity change on the Adverse Event CRF. The initial 
severity (intensity or grade) of the event will be recorded at the time the event is first reported, with each 
subsequent change in severity recorded on the same AE CRF with the exception of a non-serious event 
becoming serious. If the event becomes serious, it should be reported to the Sponsor immediately (i.e., no more 
than 24 hours after learning that the event became serious.). A new AE should be recorded as serious in the 
CRF with the date the event became serious recorded as the start date and completing all data fields related to 
SAEs.  
• 
A recurrent AE is one that resolves between patient or participant evaluation timepoints and 
subsequently recurs. Each recurrence of an AE should be recorded as a separate event on the Adverse 
Event CRF. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 73 of 85 
Version 001 
 
 
Assessment of Intensity 
The guidelines outlined below will be used for assessing the severity of AEs. The severity/intensity of AEs and 
SAEs will be graded based upon the participant’s symptoms according to the NCI CTCAE v5. 
AEs that are not defined in the NCI CTCAE v5 should be evaluated for severity/intensity according to the 
following scale: 
Table 9 
Assessment of Severity of Adverse Events 
Grade 
Severity 
1 
Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or treatment 
not indicated 
2 
Moderate; minimal, local, or non-invasive treatment indicated; or limiting age-appropriate 
instrumental activities of daily living a 
3 
Severe or medically significant, but not immediately life-threatening; hospitalization or 
prolongation of hospitalization indicated; disabling; or limiting self-care activities of daily 
living.b,c An AE that is assessed as severe should not be confused with a SAE. Severe is a 
category utilized for rating the intensity of an event; and both AEs and SAEs can be assessed 
as severe. 
An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe. 
 
4 
Life-threatening consequences or urgent treatment indicated d 
5 
Death related to AE d 
a 
Instrumental activities of daily living refer to preparing meals, shopping for groceries or clothes, using the 
telephone, managing money, etc. 
b 
Examples of self-care activities of daily living include bathing, dressing and undressing, feeding oneself, 
using the toilet, and taking medications, as performed by participants who are not bedridden. 
c 
If an event is assessed as a “significant medical event,” it must be reported as an SAE per the definition of 
SAE in (see section above). 
d 
Grade 4 and 5 events must be reported as SAEs per the definition of SAE in (see section above). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 74 of 85 
Version 001 
Assessment of Causality 
• 
The investigator is obligated to assess the relationship between study treatment and occurrence of 
each AE/SAE. 
• 
A "reasonable possibility" of a relationship conveys that there are facts, evidence, and/or arguments to 
suggest a causal relationship, rather than a relationship cannot be ruled out. 
• 
The investigator will use clinical judgment to determine the relationship. 
• 
Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, as well 
as the temporal relationship of the event to study treatment administration will be considered and 
investigated. 
• 
The investigator will also consult the Investigator’s Brochure (IB) and/or Product Information, for 
marketed products, in his/her assessment. 
• 
For each AE/SAE, the investigator must document in the medical notes that he/she has reviewed the 
AE/SAE and has provided an assessment of causality. 
• 
There may be situations in which an SAE has occurred, and the investigator has minimal information 
to include in the initial report to Sponsor. However, it is very important that the investigator always 
make an assessment of causality for every event before the initial transmission of the SAE data to 
Sponsor. 
• 
The investigator may change his/her opinion of causality in light of follow-up information and send 
an SAE follow-up report with the updated causality assessment. 
• 
The causality assessment is one of the criteria used when determining regulatory reporting 
requirements. 
 
Follow-up of AEs and SAEs 
• 
Treatment related AEs and SAEs should be followed up until resolution or until the AE is stable. 
• 
The investigator is obligated to perform or arrange for the conduct of supplemental measurements 
and/or evaluations as medically indicated or as requested by Sponsor to elucidate the nature and/or 
causality of the AE or SAE as fully as possible. This may include additional laboratory tests or 
investigations, histopathological examinations, or consultation with other health care professionals. 
• 
If a participant dies during participation in the study or during a recognized follow-up period, the 
investigator will provide Sponsor with a copy of any post-mortem findings including histopathology. 
• 
New or updated information will be recorded in the originally completed CRF. 
• 
The investigator will submit any updated SAE data to the Sponsor within 24 hours of receipt of the 
information. 
 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 75 of 85 
Version 001 
REPORTING OF SAES 
SAE Reporting to Corvus via an Electronic Data Collection Tool 
The primary mechanism for reporting an SAE to Corvus will be the electronic data 
collection tool. 
If the electronic system is unavailable for more than 24 hours, then the site will use the 
paper SAE data collection tool (see next section). 
The site will enter the SAE data into the electronic system as soon as it becomes available. 
After the study is completed at a given site, the electronic data collection tool will be taken 
off-line to prevent the entry of new data or changes to existing data. 
If a site receives a report of a new SAE from a study participant or receives updated data 
on a previously reported SAE after the electronic data collection tool has been taken off-
line, then the site can report this information on a paper SAE form (see next section) or to 
the medical monitor by telephone or email. 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 76 of 85 
Version 001 
SAE Reporting via Paper Report Forms 
The primary mechanism for reporting an SAE to Sponsor will be through EDC. If EDC is down or not 
available, then the paper SAE report form can be used for SAE reporting. 
 
Events That Occur Prior to the Study Treatment Initiation 
After informed consent has been obtained but prior to initiation of study treatment (non-treatment emergent), 
only SAEs caused by a protocol-mandated treatment should be reported in EDC using the EDC SAE form. 
Investigators should record all case details that can be gathered immediately (i.e., within 24 hours after 
learning of the event) on the Adverse Event CRF and submit the report via the paper report form. All other 
non-treatment emergent AEs should be reported in the Medical History CRF. 
 
Events That Occur after Study Treatment Initiation 
• 
After initiation of study treatment, all AEs and SAEs will be reported for 28 days following stopping 
of study treatment and until participants complete the study. The site will enter the SAE data into the 
EDC SAE report form. 
Adverse Events That Occur after the Adverse Event Reporting Period are described in the following 
section. 
• 
If a site receives a report of a new SAE from a study participant or receives updated data on a 
previously reported SAE, then the site can report this information in EDC (see next section) or to the 
Sponsor’s designee by telephone on the number listed in a section below. 
If EDC is unavailable, then the paper Clinical Trial Serious Adverse Event Form provided to investigators 
should be completed and submitted to the Sponsor or its designee immediately (i.e., no more than 24 hours 
after learning of the event), either by faxing or by scanning and e-mailing the form using the fax number or e-
mail address provided to investigators below. Please note that email is preferred over fax and phone. 
 
 
 
Note: For Ex-US country-specific safety fax and phone numbers, refer to the study manual. 
• 
In rare circumstances and in the absence of facsimile equipment, notification by telephone is 
acceptable with a copy of the SAE data collection tool sent by overnight mail or courier service. 
• 
Initial notification via telephone does not replace the need for the investigator to complete and sign 
the SAE CRF pages within the designated reporting time frames. 
 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 77 of 85 
Version 001 
APPENDIX 5 
CONTRACEPTIVE GUIDANCE AND COLLECTION OF PREGNANCY 
INFORMATION 
 
DEFINITIONS: 
  
WOMAN OF CHILDBEARING POTENTIAL (WOCBP) 
A woman is considered fertile following menarche and until becoming post-menopausal 
unless permanently sterile (see below). 
1. Women in the following categories are not considered WOCBP 
2. Premenarchal 
a. Premenopausal female with 1 of the following: 
b. Documented hysterectomy 
c. Documented bilateral salpingectomy 
d. Documented bilateral oophorectomy 
Note: Documentation can come from the site personnel’s: review of the participant’s medical 
records, medical examination, or medical history interview. 
3. Postmenopausal female 
e. A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. A high follicle stimulating hormone (FSH) level in 
the postmenopausal range may be used to confirm a postmenopausal state in 
women not using hormonal contraception or hormonal replacement therapy 
(HRT). However, in the absence of 12 months of amenorrhea, a single FSH 
measurement is insufficient. 
f. Females on HRT and whose menopausal status is in doubt will be required to 
use one of the non-estrogen hormonal highly effective contraception methods 
if they wish to continue their HRT during the study. Otherwise, they must 
discontinue HRT to allow confirmation of postmenopausal status before study 
enrollment. 
  
CONTRACEPTION GUIDANCE: 
MALE PARTICIPANTS 
Male participants with female partners of childbearing potential are eligible to participate if 
they agree to ONE of the following [during the protocol-defined time frame in Section 5.1] 
for six weeks after study treatment. 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 78 of 85 
Version 001 
• Are abstinent from penile-vaginal intercourse as their usual and preferred lifestyle 
(abstinent on a long term and persistent basis) and agree to remain abstinent 
• Agree to use a male condom plus partner use of a contraceptive method with a failure 
rate of <1% per year as described in Table 1 of this appendix when having penile-
vaginal intercourse with a woman of childbearing potential who is not currently 
pregnant. 
In addition, male participants must refrain from donating sperm for the duration of the study 
and for 6 weeks after study treatment. 
Male participants with a pregnant or breastfeeding partner must agree to remain abstinent 
from penile vaginal intercourse or use a male condom during each episode of penile 
penetration during the 28 days of study participation. 
FEMALE PARTICIPANTS 
Female participants of childbearing potential are eligible to participate if they agree to use a 
highly effective method of contraception consistently and correctly as described in Table 1. 
Female participants of childbearing potential are eligible to participate if they agree to use a 
highly effective method of contraception consistently and correctly as described in Table 1. 
Table 1                       Highly Effective Contraceptive Methods 
Highly Effective Contraceptive Methods That Are User Dependent a 
Failure rate of <1% per year when used consistently and correctly. 
Combined (estrogen and progestogen containing) hormonal contraception associated with 
inhibition of ovulation b 
• Oral 
• Intravaginal 
• Transdermal 
Progestogen only hormonal contraception associated with inhibition of ovulation 
• Oral 
• Injectable 
Highly Effective Contraceptive Methods That Are User Independent a 
• Implantable progestogen only hormonal contraception associated with inhibition of 
ovulationb 
• IUD 
• IUS 
• Bilateral tubal occlusion 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 79 of 85 
Version 001 
Vasectomized partner 
A vasectomized partner is a highly effective contraception method provided that the 
partner is the sole male sexual partner of the WOCBP and the absence of sperm has been 
confirmed. If not, an additional highly effective method of contraception should be used. 
Sexual abstinence 
Sexual abstinence is considered a highly effective method only if defined as refraining 
from heterosexual intercourse during the entire period of risk associated with the study 
treatment defined as six weeks after receiving study treatment. The reliability of sexual 
abstinence needs to be evaluated in relation to the duration of the study and the preferred 
and usual lifestyle of the participant. 
Abbreviations: IUD = intrauterine device; IUS = intrauterine hormone-releasing system; 
WOCBP = woman of childbearing potential 
a    Typical use failure rates may differ from those when used consistently and correctly. 
Use should be consistent with local regulations regarding the use of contraceptive 
methods for participants participating in clinical studies. 
b    Hormonal contraception may be susceptible to interaction with the study treatment, 
which may reduce the efficacy of the contraceptive method. In this case, two highly 
effective methods of contraception should be utilized during the treatment period and 
for at least 6 weeks corresponding to time needed to eliminate study treatment after the 
last dose of study treatment. 
   
PREGNANCY TESTING: 
• WOCBP should only be included after a negative (urine or serum) pregnancy test at 
screening 
• Additional pregnancy testing is required at end of study or at early termination (see 
Appendix 1 – Schedule of Activities) 
COLLECTION OF PREGNANCY INFORMATION: 
 MALE PARTICIPANTS WITH PARTNERS WHO BECOME PREGNANT 
• The investigator will attempt to collect pregnancy information on any male 
participant’s female partner who becomes pregnant while the male participant is in 
this study.  
• After obtaining the necessary signed informed consent from the pregnant female 
partner directly, the investigator will record pregnancy information on the appropriate 
form and submit it to the Sponsor within 24 hours of learning of the partner’s 
pregnancy. The female partner will also be followed to determine the outcome of the 
pregnancy. Information on the status of the mother and child will be forwarded to the 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 80 of 85 
Version 001 
Sponsor. Generally, the follow-up will be no longer than 6 to 8 weeks following the 
estimated delivery date. Any termination of the pregnancy will be reported regardless 
of fetal status (presence or absence of anomalies) or indication for the procedure.  
FEMALE PARTICIPANTS WHO BECOME PREGNANT 
• The investigator will collect pregnancy information on any female participant who 
becomes pregnant while participating in this study. Information will be recorded on 
the appropriate form and submitted to the Sponsor within 24 hours of learning of a 
participant's pregnancy. The participant will be followed to determine the outcome of 
the pregnancy. The investigator will collect follow-up information on the participant 
and the neonate and the information will be forwarded to the Sponsor. Generally, 
follow-up will not be required for longer than 6 to 8 weeks beyond the estimated 
delivery date. Any termination of pregnancy will be reported, regardless of fetal 
status (presence or absence of anomalies) or indication for the procedure. 
• While pregnancy itself is not considered to be an AE or SAE, any pregnancy 
complication or elective termination of a pregnancy will be reported as an AE or 
SAE. A spontaneous abortion is always considered to be an SAE and will be reported 
as such. Any post-study pregnancy related SAE considered reasonably related to the 
study treatment by the investigator will be reported to the Sponsor as described in 
Section 8.6.4. While the investigator is not obligated to actively seek this information 
in former study participants, he or she may learn of an SAE through spontaneous 
reporting. 
 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 81 of 85 
Version 001 
APPENDIX 6 
8-POINT ORDINAL SCALE FOR CLINICAL IMPROVEMENT 
 
1. Not hospitalized, no limitations on activities 
2. Not hospitalized, limitation on activities and/or requiring home oxygen 
3. Hospitalized, not requiring supplemental oxygen - no longer requiring ongoing medical 
care 
4. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care 
(COVID19 related or otherwise) 
5. Hospitalized, requiring supplemental oxygen 
6. Hospitalized, on non-invasive ventilation or high flow oxygen devices 
7. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane 
oxygenation 
8. Death 
 
 
 
 
 
 
 
 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 82 of 85 
Version 001 
APPENDIX 7 
NEWS2 SCORING SYSTEM 
 
 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 83 of 85 
Version 001 
APPENDIX 8 
EXAMPLE OF AN ASSESSMENT OF 14 COMMON COVID-19-RELATED 
SYMPTOMS: ITEMS AND RESPONSE OPTIONS  
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 84 of 85 
Version 001 
 
 
 

CPI-006-003 
 
Corvus Pharmaceuticals, Inc. 
Protocol  
 
 
 
CONFIDENTIAL 
Page 85 of 85 
Version 001 
APPENDIX 9 
PROTOCOL AMENDMENT HISTORY 
 
Table 10  
Document History 
Document History 
Date of Issue 
Version 001 (Original Protocol) 
06-November-2020